<SEC-DOCUMENT>0001144204-18-018682.txt : 20180402
<SEC-HEADER>0001144204-18-018682.hdr.sgml : 20180402
<ACCEPTANCE-DATETIME>20180402170007
ACCESSION NUMBER:		0001144204-18-018682
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180402
DATE AS OF CHANGE:		20180402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EYENOVIA, INC.
		CENTRAL INDEX KEY:			0001682639
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				471178401
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38365
		FILM NUMBER:		18729837

	BUSINESS ADDRESS:	
		STREET 1:		8748 TECHNOLOGY WAY
		CITY:			RENO
		STATE:			NV
		ZIP:			89521
		BUSINESS PHONE:		813-766-9539

	MAIL ADDRESS:	
		STREET 1:		8748 TECHNOLOGY WAY
		CITY:			RENO
		STATE:			NV
		ZIP:			89521
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tv488528_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">UNITED
STATES</FONT><BR>
<FONT STYLE="font-size: 12pt">SECURITIES AND EXCHANGE COMMISSION</FONT><BR>
<FONT STYLE="font-size: 10pt">WASHINGTON, DC 20549</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt">FORM 10-K</FONT></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">x</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>ANNUAL REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the fiscal year ended: <U>December
31, 2017</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the transition period from _________________
to ______________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMISSION FILE NUMBER: <U>001-38365</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 22pt"><B>EYENOVIA,
INC.</B></FONT><BR>
<B>(Exact name of Registrant as Specified in Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>DELAWARE</B></FONT></TD>
    <TD STYLE="width: 20%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>47-1178401</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or Other Jurisdiction of<BR>
Incorporation or Organization)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer<BR>
Identification No.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>501 FIFTH AVENUE, SUITE 1404</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>NEW YORK, NY</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>10017</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of Principal Executive Offices)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: <U>(917) 289-1117</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center">Title of each class</TD>
    <TD STYLE="width: 20%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center">Name of each exchange on which registered</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Common Stock, $0.0001 Par Value</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>The Nasdaq Stock Market LLC</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(g) of the Act: none</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Indicate by check mark
if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT>
No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Indicate by check mark
if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT>
No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Indicate by check mark
whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT> No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that
the registrant was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT> No <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Indicate by check mark
if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to
the best of the registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III
of this Form 10-K or any amendment to this Form 10-K. <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company,
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller
reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">Large accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 49%">Accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Non-accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD>Smaller reporting company <FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
news or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT>
No <FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">As of June 30, 2017,
the last business day of the registrant&rsquo;s most recently completed second fiscal quarter, there was no established public
market for the registrant&rsquo;s common stock and, therefore, the registrant cannot calculate the aggregate market value of its
voting and non-voting common stock held by non-affiliates as of such date. The aggregate market value of the voting and non-voting
common stock held by non-affiliates computed by reference to the price at which the common equity was last sold as of March 27,
2018, was approximately $51,000,000. Common stock held by each officer and director and by each person known to the registrant
who owned 10% or more of the outstanding voting and non-voting common stock have been excluded in that such persons may be deemed
to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The number of outstanding
shares of the registrant&rsquo;s common stock was 9,936,771 as of March 27, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DOCUMENTS INCORPORATED BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Portions
of the registrant&rsquo;s definitive Proxy Statement for its 2018 Annual Meeting of Stockholders currently scheduled to be held
on June&nbsp;11, 2018 are incorporated by reference into Part III hereof.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: top; width: 18%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 72%; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><B>Page</B></TD></TR>
<TR>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><A HREF="#a_001"><B>PART I - CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_001">1</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_002">Item 1.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_002">Business</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_002">2</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_003">Item 1A.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_003">Risk Factors</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_003">32</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_004">Item 1B.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_004">Unresolved Staff Comments</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_004">63</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_005">Item 2.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_005">Properties</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_005">63</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_006">Item 3.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_006">Legal Proceedings</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_006">63</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_007">Item 4.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_007">Mine Safety Disclosures</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_007">63</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top"><A HREF="#a_008">PART II</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_008">65</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_009">Item 5.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_009">Market for  Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_009">65</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_010">Item 6.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_010">Selected Financial Data</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_010">66</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_011">Item 7.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_011">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_011">66</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_012">Item 7A.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_012">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_012">72</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_013">Item 8.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_013">Financial Statements and Supplementary Data</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_013">72</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_014">Item 9.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_014">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_014">72</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_015">Item 9A.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_015">Controls and Procedures</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_015">72</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_016">Item 9B.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_016">Other Information</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_016">73</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top"><A HREF="#a_017">PART III</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_017">74</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_018">Item 10.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_018">Directors, Executive Officers, and Corporate Governance</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_018">74</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_019">Item 11.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_019">Executive Compensation</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_019">74</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_020">Item 12.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_020">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_020">74</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_021">Item 13.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_021">Certain Relationships and Related Transactions and Director Independence</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_021">75</A></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_022">Item 14.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_022">Principal Accounting Fees and Services</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_022">75</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="vertical-align: top"><A HREF="#a_023">PART IV</A></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><A HREF="#a_023">76</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; text-indent: 0in"><A HREF="#a_024">Item 15.</A></TD>
    <TD STYLE="vertical-align: top; text-indent: 0in"><A HREF="#a_024">Exhibits and Financial Statement Schedules</A></TD>
    <TD STYLE="vertical-align: bottom; text-align: right; text-indent: 0in"><A HREF="#a_024">76</A></TD></TR>

<TR>
    <TD NOWRAP STYLE="vertical-align: top; padding-left: 0.5in; font-size: 10pt"><A HREF="#item16" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Item 16.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="#item16" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form 10-K Summary</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt; text-align: right"><A HREF="#item16" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">78</FONT></A></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_001"></A>PART I</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This report contains a number of &ldquo;forward-looking
statements.&rdquo; Specifically, all statements other than statements of historical facts included in this report regarding our
financial position, business strategy and plans and objectives of management for future operations are forward-looking statements.
These forward-looking statements are based on the beliefs of management at the time these statements were made, as well as assumptions
made by and information currently available to management. When used in this report and the documents incorporated by reference
herein, the words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;may,&rdquo;
&ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;continue&rdquo; and &ldquo;intend,&rdquo; and words or phrases of similar import,
as they relate to our financial position, business strategy and plans, or objectives of management, are intended to identify forward-looking
statements. These statements reflect our current view with respect to future events and are subject to risks, uncertainties and
assumptions related to various factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should understand that the following
important factors, in addition to those discussed in our periodic reports to be filed with the Securities and Exchange Commission,
or the SEC, under the Securities Exchange Act of 1934, as amended, or the Exchange Act, could affect our future results and could
cause those results to differ materially from those expressed in such forward-looking statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our clinical trials, including two Phase&nbsp;III clinical trials for MicroProst and MicroStat;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to implement our business plan to commercialize our product candidates, if they are approved;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the timing of and our ability to submit applications for, obtain and maintain regulatory approvals for MicroProst, MicroStat,
MicroTears, MicroPine and other product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash on
hand and proceeds of our January 2018 initial public offering, or IPO;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the potential advantages of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the rate and degree of market acceptance and clinical utility of our products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our estimates regarding the potential market opportunity for our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our commercialization, marketing and manufacturing capabilities and strategy;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our intellectual property position;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to identify additional products, product candidates or technologies with significant commercial potential that
are consistent with our commercial objectives;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to attract key personnel;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our estimates regarding expenses, future revenue, timing of any future revenue, capital requirements and needs for additional
financing;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the impact of government laws and regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our competitive position;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments relating to our competitors and our industry;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to maintain and establish collaborations or obtain additional funding;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>general or regional economic conditions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in U.S. generally accepted accounting principles, or GAAP, or in the legal, regulatory and legislative environments
in the markets in which we operate; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups
Act, or the JOBS Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Although we believe that our expectations
(including those on which our forward-looking statements are based) are reasonable, we cannot assure you that those expectations
will prove to be correct. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions
prove incorrect, actual results may vary materially from those described in our forward-looking statements as anticipated, believed,
estimated, expected or intended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except for our ongoing obligations to disclose
material information under the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or any other reason. All subsequent forward-looking statements
attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained
or referred to herein. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this report
and the documents incorporated by reference herein might not occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><A NAME="a_002"></A>Item 1.</TD><TD>Business.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corporate Information</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were organized as a corporation under
the laws of the State of Florida on March&nbsp;12, 2014 under the name &ldquo;PGP Holdings V, Inc.&rdquo; On May&nbsp;5, 2014,
we changed our name to Eyenovia, Inc. On October&nbsp;6, 2014, we reincorporated in the State of Delaware by merging into Eyenovia,
Inc., a Delaware corporation. Our principal executive office is located at 501 Fifth Avenue, Suite 1404, New York, NY 10017, and
our phone number is 917-289-1117. Our website is <I>http://www.eyenoviabio.com</I>. Information contained on, or that can be accessed
through, our website is not incorporated by reference into this report, and you should not consider information on our website
to be part of this report.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This report and all of our filings under
the Exchange Act, including copies of annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K,
and any amendments to those reports, are available free of charge through our website on the date we file those materials with,
or furnish them to, the SEC.&nbsp; Such filings are also available to the public on the internet at the SEC&rsquo;s website at
www.sec.gov.&nbsp; The public may also read and copy any document that we file at the SEC&rsquo;s Public Reference Room located
at 100 F Street, NE, Washington, DC 20549 on official business days during the hours of 10 a.m. to 3 p.m.&nbsp; For further information
on the Public Reference Room, the public is&nbsp;instructed to call the SEC at 1-800-SEC-0300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a clinical stage biopharmaceutical
company developing a pipeline of ophthalmology products utilizing our patented piezo-print technology to deliver micro-therapeutics
topically to the eye. This&nbsp;micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g.&nbsp;conventional
eye droppers that deliver 30&ndash;50 &micro;L) that routinely overdose or under-dose when used in the topical administration of
ophthalmic therapeutics. We believe our micro-therapeutic product candidates may be able to achieve similar pharmacologic effects
as traditional macro-dosing applications while reducing the adverse effects associated with these techniques. We have received
written Food and Drug Administration, or FDA, feedback for our Phase&nbsp;III clinical trials for two of our lead programs: MicroProst,
a novel micro-therapeutic latanoprost formulation for CACG, an indication with no FDA-approved drug treatments; and MicroStat,
a fixed combination of micro-therapeutic phenylephrine-tropicamide formulation for mydriasis, also known as pupil dilation for
use in eye exams. MicroTears, our over-the-counter, or OTC, product candidate for dry eye, will not require Phase&nbsp;III clinical
trials, and we plan to proceed with registration activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All of our product candidates utilize our
patented piezo-print micro-dosing technology to enable the topical delivery of ophthalmic micro-therapeutics. Micro-dosing has
long been the goal for ophthalmic medications because the eye only holds 6&ndash;8 &micro;L of fluid, yet traditional eye drops
overdose the eye with 30&ndash;50 &micro;L of fluid, which frequently leads to adverse side effects such as redness, irritation
and pain, increased risk of certain cardiac and respiratory side effects, as well as inconveniences such as overflow down the cheek
and into the nose through the naso-lacrimal duct or under-dosing in patients that lack motor control to properly use a conventional
eyedropper and thus administer the drops outside the eye. We believe our easy-to-use piezo-print technology may enable patients
to consistently deliver doses of 6&ndash;8 &micro;L of ocular therapeutics, representing maximum eye capacity, and reduce ocular
exposure to preservatives and pharmaceutical ingredients by over 75%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have completed two Phase&nbsp;II clinical
trials, treating more than 110 subjects, with results published in peer-reviewed literature. Applying multiple front-of-the-eye
(the area in front of the lens) formulations in subjects for mydriasis, our piezo-print technology delivered microliter precision
at the volume of the eye&rsquo;s natural tear film capacity of 6&ndash;8 &micro;L, which reduced ocular and systemic drug and preservative
exposure when compared to eye drops, resulting in comparable efficacy and fewer side effects. We believe that these clinical trials
support our advancement into late stage clinical trials through the 505(b)(2) pathway. We intend to use this pathway for future
clinical trials in new indications with significant unmet needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A key feature of our patented technology
is the embedded electronic, smartphone enabled &ldquo;e-health&rdquo; system which we believe is the first-ever intelligent electronic
delivery system for ophthalmic therapies. Our electronic functions are designed to enable patients and physicians to track when
doses are administered to better monitor and improve patient compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following summarizes our product pipeline
and expected milestones:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 23%; border-bottom: Black 1pt solid; text-align: center"><B>Product </B><BR>
<B>Candidate </B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center"><B>Indication </B></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid; text-align: center"><B>Next Expected Milestones </B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">MicroProst</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Chronic Angle Closure Glaucoma</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase&nbsp;III IND H2 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">MicroStat</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Mydriasis (Pupil Dilation)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase&nbsp;III IND H2 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">MicroTears</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Dry Eye</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">OTC Registration H1 2019</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">MicroPine</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Myopia (Near Sightedness)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">Phase&nbsp;III IND H1 2019</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to MicroProst, MicroStat and
MicroTears, we are developing an expanded pipeline of product candidates and are preparing them for late-stage clinical trials.
The first pipeline opportunity is MicroPine, which is a micro-therapeutic formulation of atropine to target myopia (or near sightedness)
progression. Clinical trials conducted to date, as well as a recent technology analysis and review by the American Academy of Ophthalmology,
indicate Level&nbsp;1 (highest) evidence of efficacy for the role of low dose atropine for myopia progression. To date, no therapy
has been possible due to side effects associated with existing macro-dosed drop formulations in the pediatric population using
atropine. We met with the FDA on December&nbsp;15, 2017 to discuss our Phase&nbsp;III trial design for MicroPine. FDA feedback
indicates that we can proceed to Phase&nbsp;III with a primary endpoint of reduction of myopia progression, enrolling children
and adolescents with a three-year follow-up. We have begun development activities for MicroPine with a planned Phase&nbsp;III clinical
trial expected to be initiated in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our management team is a critical component
to the execution of our overall strategy and our business model. We have assembled a team with significant experience in translational
science, drug evaluation, clinical development, regulatory affairs and business development. Our management team is led by our
Chief Executive Officer, Dr.&nbsp;Tsontcho Ianchulev, who has over 15&nbsp;years of experience in public health, life-science and
medical technology covering the spectrum of biotech and med-tech. He is a prolific inventor, innovator, physician-executive and
public health expert who has been at the core of developing medical products and technologies which have transformed the ophthalmic
field and are impacting medical care for hundreds of thousands of patients every year. His intellectual property was a core asset
to WaveTec&rsquo;s (acquired by Alcon) technology for intraoperative aberrometry. While at Genentech, Inc., Dr.&nbsp;Ianchulev
headed the ophthalmology research group and directed the development and the FDA approval of Lucentis, the most successful specialty
biologic in the field of ophthalmology with more than $4&nbsp;billion of annual sales in 2015. Most recently, he headed all clinical
development of Transcend Medical&rsquo;s (acquired by Alcon) micro-stent for glaucoma. Dr.&nbsp;Ianchulev&rsquo;s clinical experience,
combined with development and commercial work in both biopharmaceuticals and medical devices make him ideally suited to lead Eyenovia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to Dr.&nbsp;Ianchulev, the management
team has other professionals with deep engineering, clinical trial, regulatory and commercial experience in ophthalmology. Our
management team is supported by our Board of Directors, which has extensive professional experience in strategic development, executive,
operational and financial leadership in the pharmaceutical and healthcare industries, including several successful ophthalmology
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Strategy </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our goal is to become a leading biopharmaceutical
company focused on developing and commercializing novel therapies for front-of-the-eye conditions by utilizing our micro-therapeutic
piezo-print technology. The key elements of our strategy to achieve this goal are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Establish a portfolio of first-in-class
piezo-print micro-therapeutic products for front-of-the-eye treatments through the 505(b)(2) pathway with the FDA.</I></B>&nbsp;&nbsp;&nbsp;We
are initially focused on developing technology utilizing therapeutic compounds already well-established in the topical treatment
of ophthalmic indications. We believe the 505(b)(2) registration pathway, which reduces development risk compared to new molecular
entity programs, will be available for our initial development pipeline. We believe our pipeline of patented micro-therapeutic
product candidates will be highly differentiated by our improved tolerability and enhanced compliance profile and our late-stage
development programs could lead to New Drug Application, or NDA, submissions in novel indications where the products can have unique
dosing and therapeutic profiles. We believe that this could lead to favorable pricing and reimbursement, and a reduced risk of
generic substitution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Improve clinical outcomes and patient
experiences while providing an improved tolerability profile with our micro-therapeutics.</I></B>&nbsp;&nbsp;&nbsp;We believe our
piezo-print platform will allow for high precision targeted micro-dosing for front-of-the-eye treatments, while eliminating ophthalmic
over-dosing and reducing ocular exposure to toxic preservatives and pharmacologic ingredients by over 75% compared to conventional
eye drop delivery mechanisms. Our clinical trials have demonstrated equivalent biologic activity, improved side effect profile
and enhanced patient experience of our micro-therapeutic approach as compared to conventional eye drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Leverage our electronic, smartphone-enabled
&ldquo;e-health&rdquo; technology to introduce and develop patient-specific compliance monitoring program.</I></B>&nbsp;&nbsp;&nbsp;Our
mobile e-health technology and smart cartridges are designed to track when a patient administers treatments, allowing physicians
to track patient compliance accurately. We believe this may enhance patient compliance and improve compliance monitoring by empowering
patients and physicians with access to dynamic, real-time monitoring and compliance data for a more intelligent, informed and personalized
therapeutic paradigm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Develop micro-therapeutic treatments
for other ophthalmic diseases independently or in collaboration with third parties.</I></B>&nbsp;&nbsp;&nbsp;Our piezo-print technology
is also suitable for new molecular entities. Leveraging our existing platform technology, we plan to continue developing other
micro-therapeutic product candidates for front-of-the-eye diseases that can be administered using our piezo-print technology platform
with mobile e-health technology and smart cartridges either independently or through strategic partnerships with third parties.
We have entered into an exclusive agreement with Senju Pharmaceuticals, a leading ophthalmology company in Japan, for the Asian
development and commercial rights of our therapies and technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>Develop solutions for ophthalmic conditions
with high unmet needs and no approved therapy.</I></B>&nbsp;&nbsp;&nbsp;We will target chronic ophthalmic conditions with a high
unmet medical need. By leveraging our piezo-print micro-dosing technology, we aim to reach conditions where there are no approved
therapies. For example, our MicroPine program which is a micro-formulation of atropine, is intended to slow myopia progression
in the pediatric population. However, there are currently no therapies on the market due to side effects associated with traditional
macro-dosing drop formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Limitations of Conventional Front-of the-Eye Therapies </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our micro-dosing platform technology aims
to address the following issues associated with eye drop-based therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Dosing, administration and waste of medication
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Multiple third party studies have confirmed
the challenges with administering conventional eye drops including overdosing, poor compliance, imprecise dosing, variability in
drop size, and patient difficulty in self-administering. One study in patients experienced in using eye drops undergoing treatment
for glaucoma for at least 6&nbsp;months documented that 9 out of 10 patients were unable to deliver topical treatment correctly
at the end of the 6 month treatment. Patients on average administered almost twice the macro-dose with a range of one to eight
drops (1.8+/-1.2), and 75% of patients risked bottle contamination or potential ocular trauma by having the eye dropper container
touch their eyes. Another larger study in 139 patients demonstrated that the proportion of patients who were able to correctly
deliver therapy on the eye was only 22%&ndash;30%. Other studies have demonstrated similarly that the vast majority of patients
either overdose or do not administer correctly the required therapeutic to the eye, which leads to unnecessary waste of medication,
a problem which is highlighted by recently introduced legislation in the U.S. Senate to address this specific concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Side effects associated with conventional
macro-dose therapies </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Conventional front-of-the-eye therapies
are administered using 100-year-old eye-dropper pipette approaches. Current eye drop therapies consistently overdose the eye with
30&ndash;50 &micro;L of preservatives and pharmaceutical ingredients while the eye only holds 6&ndash;8 &micro;L. Thus, traditional
drops severely overdose the eye, which is associated with many ocular side effects including hyperemia, or increased blood flow
to the eye, redness, discomfort, stinging, blurred vision, burning, itching, excessive tearing, eye pain, iris pigment changes,
foreign body sensation, pigment discoloration, periorbital dermatitis and sunken eye. For some topical medications, there are also
major cardiovascular side effects such as bradycardia and arrhythmia that are caused when medications are absorbed into the circulation
system from overdosing&thinsp;&mdash;&thinsp;both through conjunctiva absorption and when drugs flow into the nose through the
naso-lacrimal duct and are absorbed in the nose or swallowed. For example, phenylephrine can cause cardiovascular adverse reactions
including an increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage. Severe
respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association
with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prostaglandins are a widely-used class of
drugs for glaucoma. However, as shown in the chart below, they present a high risk of ocular irritation and adverse events. We
believe micro-dosing will result in fewer adverse events due to less exposure to the drug and preservatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="41" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Frequencies of Adverse Events (Safety Population)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Latanoprost (n = 136)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Bimatoprost (n = 137)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Travoprost (n = 138)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">n</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No. of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Events</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">n</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No. of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Events</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">n</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No. of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Events</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>P</I></B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Value</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left">Patients with at least one adverse event</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">87</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">64</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">137</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">104</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">75.9</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">95</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">68.8</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">159</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">0.098</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Patients with ocular adverse events</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">162</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.003</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Patients with systemic adverse events</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.933</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Patients with adverse events related to study medications</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68.6</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58.7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.015</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Potential for toxicity </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Many eye medications contain preservatives
(e.g. benzalkonium chloride or BAC) which are toxic to the ocular surface. Cytotoxic assays have confirmed this and showed significant
toxicity proportional to the concentration of BAC and its effects in causing ocular surface disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Another emerging problem with the prostaglandin-class
of medications (e.g. latanoprost, bimatoprost, travoprost) has been the dose-related incidence of orbitopathy (or sunken orbits).
The associations between prostaglandin analogue use and deepening of the upper lid sulci and between prostaglandin analogue use
and loss of inferior periorbital fat were recently confirmed with a 230-fold increased risk of skin tissue shrinking around the
eye.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Solution </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that we are the only company
with clinical stage technology for targeted micro-dosing of ophthalmic investigational therapies. Our solution is based on piezo-print
technology, which is also used for pixel-sharp high-precision ink jet printing. It is miniaturized, optimized for and applied in
ophthalmic delivery to achieve micro-dosing that is many times more precise than conventional eye droppers. Our targeted micro-dosing
delivers doses of 6&ndash;8 &micro;L in a targeted way, directly coating the corneal surface rather than the conjunctiva thus reducing
collateral tissue exposure and focusing on the cornea where 80% of intraocular drug penetration occurs. We believe micro-therapeutic
product candidates reduce greater than 75% of the drug exposure to reduce toxicity, resulting in potentially gentler and more tolerable
treatments. Our micro-therapeutic approach also reduces waste associated with conventional macro-dose drops&thinsp;&mdash;&thinsp;a
problem that has been highlighted by recently introduced legislation in the U.S. Senate to address this specific concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the ophthalmology space, we believe that
our micro-therapeutics will come with first-in-class smart sensing technology for mobile e-health applications and compliance monitoring,
which will be standard with all of our smart cartridges. This technology has the potential to improve compliance and chronic disease
management by tracking each time a patient administers treatment, empowering patients and physicians with access to dynamic, real
time monitoring and compliance data for a more intelligent and personalized therapeutic paradigm. The FDA provided written feedback
that our clinical programs will not be treated as a medical device or as a drug/device combination. All of our programs are treated
as drug development programs because only the drug comes into contact with the eye. Consequently, we do not need a separate FDA
approval for the piezo-print device or to comply with FDA regulations for medical devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our micro-therapeutic solution has been
tested in preclinical models and clinical trials and has been shown to provide many advantages over the current administrations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 44%; padding-bottom: 1pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt 17.6pt; text-indent: -17.6pt"><B>CONVENTIONAL EYE DROPPER
        USING CENTURY-OLD PIPETTE DELIVERY</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt 17.6pt; text-indent: -17.6pt"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt 17.6pt; text-indent: -17.6pt">&times;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overdoses the eye by more than 400%</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt 17.6pt; text-indent: -17.6pt">&times;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Causes overdose-related
        ocular toxicity (drug / preservative / excipient exposure)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt 0.5in; text-indent: -17.6pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hyperemia / red
        eye</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt 0.5in; text-indent: -17.6pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discomfort /
        stinging</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt 0.5in; text-indent: -17.6pt">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Itching</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt 17.6pt; text-indent: -17.6pt">&times;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;50&ndash;80% of
        eye drop applications miss the eye</P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 5%; padding-bottom: 1pt">&#8199;<BR>
&#8199;<BR>
<IMG SRC="tv488528_img1.jpg" ALT=""></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 47%; padding-bottom: 1pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt"><B>EYENOVIA&rsquo;S HIGH-PRECISION PIEZO-PRINT MICRODOSING</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#10003;</FONT>
        Medication delivered directly to the cornea (primary site of ocular drug absorption)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#10003;</FONT>
        Gentle ocular surface microdroplet coating</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#10003;</FONT>
        Less toxicity and drug/preservative exposure</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#10003;</FONT>
        Fewer ocular side effects (redness, stinging)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#10003;</FONT>
        Lower systemic exposure</P></TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Key advantages of our micro-therapeutic platform include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dose reduction</B>:&nbsp;&nbsp;&nbsp;Our micro-droplet delivery
technology achieves precise volumetric control at the microliter level to deliver 6&ndash;8 &micro;L, which is the physiologic
capacity of the tear film compared to the dropper pipette macro-dose of 30&ndash;50 &micro;L which results in overdosing, ocular
toxicity and systemic leaching into the plasma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img2.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Targeted dose instillation</B>:&nbsp;&nbsp;&nbsp;Our piezo-print
technology allows for targeted delivery to the ocular surface and cornea, avoiding the conjunctival cul-de-sac. The micro-jet created
by the piezo-electric vibrations is columnated and focused to provide accurate delivery to the corneal surface where the majority
of ocular penetration occurs. Additionally, our technology includes an LED targeting mechanism to allow proper positioning and
objective alignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img3.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Speed of delivery</B>:&nbsp;&nbsp;&nbsp;Similar to high-precision
ink-jet printing that can deliver pixel-sharp ink printing, we use piezo-electric dispensation. Unlike a simple aerosolized mechanism,
our patented piezo-printing technology achieves micro-droplet ejection control that creates a fast and targeted micro-jet delivery.
We can deliver our micro-therapeutics to the ocular surface in less than 80 milliseconds beating the eye&rsquo;s 100 millisecond
blink reflex.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img4.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Smart electronics</B>:&nbsp;&nbsp;&nbsp;Our smart electronics
and mobile e-health technology are designed to track when a patient administers treatment. This enables physicians to monitor patient
compliance accurately. We believe this technology will improve compliance and chronic disease management by empowering patients
and physicians with access to dynamic, real time monitoring and compliance data for a more intelligent and personalized therapeutic
paradigm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clinical Trial Results </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have a proven platform for the delivery
of micro-therapeutics. Our preclinical and clinical studies suggest that a micro-therapeutic dose of medication delivers clinical
activity comparable to that of a macro-dose delivery via traditional eye drops, but with the advantages of fewer ocular side effects
and less systemic exposure. We can use our platform technology on either new molecular entities, to increase their chances of approval,
or with existing molecular entities in order to improve their safety. We have chosen the latter path for our initial pipeline product
candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To date, we have conducted multiple preclinical
studies and two Phase&nbsp;II clinical trials to validate our piezo-print micro-dose delivery platform. Our micro-dose approach
was studied in preclinical studies to demonstrate pharmacodynamic equivalence of our targeted micro-therapeutic formulations and
to assess whether micro-dosing can achieve comparable biologic activity with its significantly lower levels of drug and preservative
exposure to the ocular tissues. Data from a canine model of glaucoma demonstrated more than 40% intraocular pressure, or IOP, lowering
effect at micro-dose of 8&ndash;9 &micro;L latanoprost. Another independent micro-dose study published in the Journal of Investigative
Ophthalmology and Visual Science in 2014 further demonstrated that 3 &micro;L micro-dose with timolol 0.5% can reduce systemic
plasma levels of the drug by a factor of 17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img5.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IOP Lowering Effect of Micro-Therapeutic
Dose of Latanoprost in Canine Model </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img6.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have completed two Phase&nbsp;II clinical
trials to investigate the pharmacodynamic equivalence and clinical advantages of our micro-therapeutic approach. In these studies,
we examined whether a micro-therapeutic dose of phenylephrine would dilate the eye as compared to a macro-dose with a traditional
eye drop, as well as the side effect incidence of micro-dosing vs. drops. Results of the two Phase&nbsp;II micro-dose clinical
trials suggest that our micro-dose piezo-print technology can deliver equivalent therapeutic activity as conventional eye drop
macro-dosing while reducing the incidence of side effects by reducing by greater than 75% the patient&rsquo;s exposure to preservatives
and active pharmaceutical ingredients, which are the root cause of ocular surface toxicity, and topical and systemic adverse events
associated with topical therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The first clinical trial, which we refer
to as the EYE102 Phase&nbsp;II clinical trial compared the mydriatic pharmacodynamic effect of our micro-dose (7 &micro;L) Phenylephrine
10% versus standard dropper, which delivered 32 &micro;L 10% phenylephrine (4 times our micro-dose of phenylephrine), versus an
eye dropper that delivered 32 &micro;L of phenylephrine 2.5% (same net amount of phenylephrine as our micro-dose). At 75 minute
peak dilation, our micro-dose provided similar mydriatic activity at one quarter of the dose exposure of the dropper with 10% phenylephrine,
and superior activity versus the equal dose exposure via 2.5% phenylephrine drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Pupil
Diameter, Increase from Baseline, mm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img7.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pupil diameter increase from baseline, at
45, 60, and 75 minutes post-administration of PE 2.5%, PE 10%, and EYN- each respectively administered on study Days 1, 7 and 14.
Shown are mean&plusmn;SEM for N=24 eyes of 12 subjects. Colored asterisk at t=75 min indicates significant difference versus comparator
of asterisk color, in this case EYN vs PE 2.5% (p=0.009).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The study was also informative with regard
to systemic drug exposure of topical treatment whereby the micro-dose product candidate demonstrated 35&ndash;40% lower plasma
levels of the drug compared to same concentration macro-dose. There were also significantly fewer ocular adverse events, over macro-dosing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"><B><IMG SRC="tv488528_img8.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the EYE102 Phase&nbsp;II clinical trial,
the same formulation micro-dose also suggested significant improvement in tolerability as compared to conventional eye drops.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="5" STYLE="border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; text-align: center; padding-left: 0"><B>OCULAR ADVERSE EVENTS BY TREATMENT</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 58%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0"><B>Adverse Event Description </B></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; text-align: center; padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 20%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Eye Drop </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>10%</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; text-align: center; padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 20%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYE102 (Micro-</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>dose 10%) </B></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-top: 0; padding-bottom: 0; padding-left: 0">Ocular blurriness </TD>
    <TD STYLE="padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-top: 0; padding-bottom: 0; text-align: center">1</TD>
    <TD STYLE="padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-top: 0; padding-bottom: 0; text-align: center">0</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-top: 0; padding-bottom: 0; padding-left: 0">Ocular burning/stinging/irritation </TD>
    <TD STYLE="padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-top: 0; padding-bottom: 0; text-align: center">4</TD>
    <TD STYLE="padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-top: 0; padding-bottom: 0; text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: #CCEEFF 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0">Ocular dryness </TD>
    <TD STYLE="border-bottom: #CCEEFF 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: #CCEEFF 1pt solid; padding-left: 0; padding-top: 0; padding-bottom: 0; text-align: center">2</TD>
    <TD STYLE="border-bottom: #CCEEFF 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: #CCEEFF 1pt solid; padding-left: 0; padding-top: 0; padding-bottom: 0; text-align: center">0</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-bottom: white 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0"><I>Subtotal by Treatment Group </I></TD>
    <TD STYLE="border-bottom: white 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: white 1pt solid; padding-left: 0; padding-top: 0; padding-bottom: 0; text-align: center">7</TD>
    <TD STYLE="border-bottom: white 1pt solid; padding-top: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: white 1pt solid; padding-left: 0; padding-top: 0; padding-bottom: 0; text-align: center">1</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The other Phase&nbsp;II clinical trial (EYE
103 study) in 103 subjects investigated micro-therapeutics treatment with combination of phenylephrine and tropicamide compared
to conventional eye dropper doses, the results of which were published in the peer-reviewed journal <I>Therapeutic Delivery</I>.
In the study, micro-dosing produced equivalent dilation and 91% of participants preferred micro-dose versus the eyedropper; 6%
preferred the eye dropper and 3% expressed no preference (p &lt; 0.0001). General satisfaction scores were higher with the micro-dose
versus eyedropper (9.8 &plusmn; 0.6 vs 5.8 &plusmn; 3.0). Regarding ocular discomfort, our micro-dose was nearly two times better
than the eyedropper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img9.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At the end of our Phase&nbsp;II clinical
trial, we had a meeting with the FDA and have received guidance on the design and requirements for Phase&nbsp;III development programs
for MicroProst in CACG and MicroStat in mydriasis as well as the requirements for MicroTears for OTC dry eye. Based on this guidance,
we expect to initiate pivotal programs in the second half of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Product Candidates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MicroProst </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MicroProst is our proprietary latanoprost
prostaglandin micro-formulation product candidate being developed for a first-line indication therapy for CACG. Currently, there
are no FDA-approved therapies for CACG, which accounts for 10% of all glaucoma in the U.S. and up to 50% of all glaucoma in China.
If approved, MicroProst would be the first treatment approved for CACG.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Background of Chronic Angle Closure Glaucoma and Market
Opportunity </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">CACG is a well characterized and clinically
diagnosed disease entity, as established by the American Academy of Ophthalmology Preferred Practice Patterns. Similar to the more
prevalent open-angle glaucoma, it is characterized by increased IOP and optic neuropathy. Yet, its pathophysiology is underpinned
by angle closure from peripheral anterior synechiae whereby the iris is occluding the drainage outflow to the trabecular meshwork
in the angle. CACG is separate from acute angle-closure glaucoma which requires immediate intervention. There are more than 581,000
CACG patients in the U.S., as shown below. We conservatively estimate the addressable market at over $700&nbsp;million in the U.S.
alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="13" STYLE="text-align: center"><B>Estimated population with CACG (thousands) by region (95% CI)</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="5" STYLE="text-align: center"><B>Number of CACG cases (thousands) 40&nbsp;years old +</B></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="5">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>% Increase in CACG cases </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>relative to 2010</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 10%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-left: 0.7pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 18%; text-align: center"><FONT STYLE="font-size: 10pt"><B>UK</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-left: 0.7pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 18%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Europe</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-left: 0.7pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 18%; text-align: center"><FONT STYLE="font-size: 10pt"><B>U.S.</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-left: 0.7pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>UK</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Europe</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-left: 0.7pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>U.S.</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2010</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">130 (71&minus;211) </FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">1600 (873&minus;2604)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">581 (309&minus;958)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2015</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">141 (77&minus;229) </FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">1663 (902&minus;2713)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">637 (338&minus;1047)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.6</FONT></TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.9</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">9.5</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2020</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">154 (85&minus;248) </FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">1743 (953&minus;2837)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">687 (372&minus;1124)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19</FONT></TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8.9</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">18.2</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2025</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">160 (89&minus;258) </FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">1831 (1012&minus;2967)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">743 (410&minus;1206)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">23.6</FONT></TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14.5</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27.8</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2030</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">165 (93&minus;265) </FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">1934 (1082&minus;3115)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">812 (457&minus;1304)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">27.5</FONT></TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20.9</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">39.6</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2040</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">188 (108&minus;302) </FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2102 (1198&minus;3344)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">930 (532&minus;1478)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">44.9</FONT></TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">31.4</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">59.9</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2050</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">195 (112&minus;309) </FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">2080 (1208&minus;3285)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">973 (556&minus;1550)</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50.7</FONT></TD>
    <TD NOWRAP STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30</FONT></TD>
    <TD NOWRAP STYLE="padding-left: 0.7pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">67.4</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once angle-closure glaucoma develops, it
is a condition that often requires chronic treatment. The mainstay of glaucoma treatment for both open and angle-closure glaucoma
is IOP lowering with pharmacologic therapy. While IOP lowering pharmacotherapies have been FDA indicated and approved for IOP lowering
in open-angle glaucoma, none have been specifically studied in FDA trials nor indicated for CACG, which is a less prevalent disease.
Despite the unmet need and the fact that over 90% of CACG patients continue to require chronic lifelong IOP lowering therapy, physicians
continue to use off-label treatments without the support of rigorous clinical trials and data. Therapeutic control is particularly
important for CACG patients where it has been well established that optic nerve damage is more IOP-dependent than that of open-angle
glaucoma and CACG patients progress two times more quickly than open-angle glaucoma patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There is strong clinical evidence from multiple
studies as well as a more recent randomized controlled study published in the <I>Archives of Ophthalmology</I> that latanoprost
and timolol cause significant IOP lowering in patients with CACG&thinsp;&mdash;&thinsp;35% and 26% respectively. Even though there
has been no FDA approved therapy, peer-reviewed and published clinical trials demonstrate robust therapeutic effect of latanoprost
in CACG, which is highly informative for our forthcoming Phase&nbsp;III clinical trial. A randomized controlled study in 60 eyes
published in the peer-reviewed journal, <I>Archives of Ophthalmology</I>, shows not only a high level of IOP lowering effect of
8.2 mmHg at 3 month but also superiority to active timolol control which only lowered IOP by 6.1 mmHg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Diumal Variation of Intraocular Pressure (IOP) at Baseline
and After 3 Months of Therapy With Latanoprost and Timolol in 60 Eyes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="7" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B STYLE="font-size: 10pt">Latanoprost </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="7" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B STYLE="font-size: 10pt">Timolol Maleate </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="3" NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="4" NOWRAP STYLE="border-bottom: black 1pt solid; padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B STYLE="font-size: 10pt">Decrease in IOP </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="4" NOWRAP STYLE="border-bottom: black 1pt solid; padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B STYLE="font-size: 10pt">Decrease in IOP </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD COLSPAN="3" NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt">
    <TD NOWRAP STYLE="width: 11%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B STYLE="font-size: 10pt">Time of IOP </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B STYLE="font-size: 10pt">Recording </B></P></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Mean &plusmn; SD</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Baseline</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">IOP, mm</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Hg</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Mean &plusmn;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">SD
        IOP,</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">mm Hg</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Mean &plusmn;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">SD,
        mm</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Hg</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%; border-bottom: black 1pt solid; padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B STYLE="font-size: 10pt">%</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Mean &plusmn;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">SD
        IOP,</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">mm Hg</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Mean &plusmn;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">SD,
        mm</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Hg</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%; border-bottom: black 1pt solid; padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B STYLE="font-size: 10pt">%</B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 9%; border-bottom: black 1pt solid; padding-top: 0; padding-bottom: 0; font-size: 10pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt"><I STYLE="font-size: 10pt">P</I></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-size: 10pt">Value</B></P></TD>
    <TD NOWRAP STYLE="width: 1%; border-bottom: white 1pt solid; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-top: 0; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7&nbsp;AM </FONT></TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.5 &plusmn; 3.1</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14.0 &plusmn; 2.2</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.5 &plusmn; 3.3</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">40.4</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18.3 &plusmn; 3.2</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.2 &plusmn; 3.6</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22.1</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&lt;.01</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt; background-color: White">
    <TD NOWRAP STYLE="padding-top: 0; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10&nbsp;AM </FONT></TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.6 &plusmn; 3.9</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14.6 &plusmn; 2.8</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.0 &plusmn; 4.3</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">40.6</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17.9 &plusmn; 3.6</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.7 &plusmn; 3.5</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">27.2</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&lt;.01</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-top: 0; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1&nbsp;PM </FONT></TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.6 &plusmn; 2.7</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16.2 &plusmn; 2.7</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.4 &plusmn; 3.4</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.4</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17.1 &plusmn; 3.2</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.5 &plusmn; 3.8</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">27.5</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.04</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt; background-color: White">
    <TD NOWRAP STYLE="padding-top: 0; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4&nbsp;PM </FONT></TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.2 &plusmn; 2.7</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15.7 &plusmn; 3.4</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.5 &plusmn; 3.3</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.3</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17.7 &plusmn; 3.9</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.6 &plusmn; 3.7</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.1</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&lt;.01</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-top: 0; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7&nbsp;PM </FONT></TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22.4 &plusmn; 3.1</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15.6 &plusmn; 3.1</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.8 &plusmn; 3.4</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">30.4</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16.9 &plusmn; 3.8</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.6 &plusmn; 3.9</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25.0</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.01</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt; background-color: White">
    <TD NOWRAP STYLE="padding-top: 0; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10&nbsp;PM </FONT></TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.3 &plusmn; 2.9</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15.6 &plusmn; 3.0</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.6 &plusmn; 3.9</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.6</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16.3 &plusmn; 3.4</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.9 &plusmn; 3.6</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">29.6</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">.25</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font-size: 10pt; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-top: 0; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mean </FONT></TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right; font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.4 &plusmn; 2.1</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15.3 &plusmn; 1.8</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8.2 &plusmn; 2.0</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34.9</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17.4 &plusmn; 1.7</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-top: 0; text-align: center; font-size: 10pt; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.1 &plusmn; 1.7</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">26.0</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center; font-size: 10pt; padding-top: 0; padding-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&lt;.01</FONT></TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-top: 0; padding-bottom: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, 72% of patients taking latanoprost
and 43% of patients taking timolol achieved more than 30% IOP lowering from baseline. Similarly, another randomized controlled
study demonstrated an 8.8 mmHg IOP reduction with latanoprost and 5.7 mmHg reduction with timolol in patients with CACG. Data from
these studies not only suggest the biologic therapeutic effect of IOP lowering in CACG but also highlight the undesirable associated
safety profile of macro-dosing such as hyperemia and ocular discomfort which caused significant adverse events in more than 40%
of patients. Based on these studies and the data from the open-angle glaucoma disease therapeutic paradigm, we believe MicroProst
may demonstrate IOP lowering and an improved safety profile for CACG patients in our planned Phase&nbsp;III clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Phase&nbsp;III Clinical Development Program </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subsequent to the completion of our Phase&nbsp;II
clinical trials, we met with the FDA to discuss our Phase&nbsp;III plans for MicroProst. The FDA outlined the necessary clinical
trials for approval, and we are preparing to initiate a Phase&nbsp;III registration program, relying on the 505(b)(2) pathway,
for a first-line therapeutic indication in CACG for MicroProst. If approved, MicroProst will be the first FDA-approved treatment
for CACG. The targeted piezo-print technology will provide micro-dosing (6&ndash;8 &micro;L) of prostaglandin latanoprost directly
to the ocular surface of the cornea, which is the site of the highest intraocular penetration. We believe MicroProst will achieve
similar clinical activity without the adverse effects seen with conventional drops, which overdose the eye with potentially harmful
preservatives and API. This could provide additional opportunities for us to pursue follow-on expanded indications of MicroProst,
such as for the treatment of open-angle glaucoma, where non-micro-therapeutic latanoprost is currently the primary therapeutic
modality.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The MicroProst Phase&nbsp;III program will
consist of two randomized controlled clinical trials in CACG with a 3-month primary end-point consisting of IOP reduction and follow-up
for six&nbsp;months. We plan to commence the clinical trial in the second half of 2018, subject to a pre-IND meeting with the FDA
in early 2018, and estimate 250 patients per clinical trial. If the primary objectives of our Phase&nbsp;III clinical trial are
met, we plan to submit an NDA, for marketing approval of MicroProst for the treatment of CACG in the U.S. We have entered into
a master licensing partnership for all of our micro-therapeutic programs, including our MicroProst program, with Senju Pharmaceuticals
for Asia, including China, Japan and India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MicroStat </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MicroStat is the potentially first-in-class
fixed combination micro-formulation product candidate for mydriasis (eye dilation) intended to facilitate office-based eye examinations
which serve over 80&nbsp;million dilated retina eye exams performed each year in the U.S. MicroStat has been designed to achieve
adequate pupil dilation while reducing unintended side-effects associated with conventional mydriatic agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Background of Mydriasis and Market Opportunity </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are more than 80&nbsp;million topical
mydriatic applications performed every year as a required part of the comprehensive dilated eye exam and standard retina fundoscopy
for diabetic retinopathy screening, macular degeneration evaluation, glaucoma optic disc evaluation and many other back-of-the-eye
conditions. Most optometrist and ophthalmologist offices have multiple bottles of both phenylephrine and tropicamide and use each
bottle on multiple patients, which carries a risk of contaminating patients&rsquo; eyes and spreading infections. The bottles are
purchased directly from suppliers and are not subject to insurance reimbursement. Our combination therapy, if approved, will allow
the purchase of one product for eye dilation, and our system does not come in direct contact with the eye, thus minimizing the
risk of infection. We believe the addressable market is over $150&nbsp;million in the U.S. alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Most dilated eye exams require that two
separate topical pharmacologic agents/drops be administered sequentially (tropicamide and phenylephrine). All current mydriatic
formulations use conventional macro-dose drop delivery (30&ndash;50 &micro;L) which significantly overdoses the ocular surface
whose physiologic capacity is only 6&ndash;8 &micro;L. Studies demonstrate that standard macro-dosed pharmacologic dilation is
associated with significant ocular discomfort and mild-moderate eye pain. On the standard visual analogue scale for pain, such
discomfort can exceed the levels of pain associated with a flu vaccine subcutaneous injection. Additionally, there are systemic
safety concerns with mydriatic macro-dosing for retinopathy of prematurity retinal screening and pediatric dilated eye exams. Studies
comparing micro-dosed phenylephrine and cyclopentolate to traditional eyedrops (30&ndash;50 &micro;L drop size) in premature babies
and in full-term infants have shown equivalent pupil dilation with drop sizes ranging from 5&ndash;8 &micro;L while reducing systemic
levels by more than 50%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With the millions of patients exposed to
mydriatic pharmacologic agents every year, we are developing a micro-dose alternative whereby targeted piezo-print technology can
be deployed to reduce ocular and systemic exposure by more than 75%. This potential improvement stems from lowering the dose from
the 30&ndash;50 &micro;L in standard drops to just 8 &micro;L with MicroStat combined with targeted delivery to the ocular surface.
We expect to achieve similar mydriatic activity as drops without the high incidence of unwanted side effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img10.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pharmacologic mydriasis: dilated pupil after application</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Phase&nbsp;III Clinical Development Program </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Based on our prior Phase&nbsp;II clinical
trials and subsequent FDA feedback, we are proceeding towards the initiation of the Phase&nbsp;III mydriasis program for the potentially
first-in-class fixed-combination, micro-formulation of phenylephrine 2.5% and tropicamide 1% (MicroStat). The MicroStat program
will consist of two Phase&nbsp;III randomized controlled clinical trials to investigate pharmacologic dilation of our fixed combination
micro-formulation versus drops of individual components (phenylephrine drops alone and tropicamide drops alone) with the primary
endpoint of pupil change from baseline. We estimate 50 patients per clinical trial and are planning to commence the clinical trials
in the second half of 2018. If the primary objectives of our Phase&nbsp;III program are met, we plan to submit an NDA to the FDA
for marketing approval of MicroStat for pharmacologic mydriasis in the U.S. under the 505(b)(2) pathway. We have entered into a
master licensing partnership for all of our micro-therapeutic programs, including our MicroStat program, with Senju Pharmaceuticals
for Asia, including China, Japan and India.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>MicroTears </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">MicroTears is a differentiated micro-droplet
ocular surface tear replenishment product candidate for the $2&nbsp;billion-plus (200 million units sold annually) OTC artificial
tear market. Our piezo-technology enables accurate delivery directly to the ocular surface, which we believe enhances its effectiveness.
The lower volume of MicroTears will also lower the incidents of droplet overflow. While no FDA studies are required for registration
of a monograph formulation, we expect to conduct multiple Phase&nbsp;IV post-marketing studies to demonstrate the benefits of MicroTears.
We plan to complete formulation and manufacturing scale-up activities for expected introduction to market in mid-to-late 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Background of Dry Eye Syndrome and Market Opportunity
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Dry eye syndrome, or DES, is a common ocular
condition. It is a chronic, episodic, multifactorial disease affecting the tears and ocular surface that can result in tear film
instability, inflammation, discomfort, visual disturbance and ocular surface damage. DES can have a significant impact on quality
of life and can potentially cause long-term damage to the ocular surface. In addition, the vast majority of DES patients experience
acute exacerbations of their symptoms, which are commonly referred to as flares, at various times throughout the year. These flares
can be triggered by numerous factors, including exposure to allergens, pollution, wind and low humidity, intense visual concentration
such as watching television and working at a computer, contact lens wear, smoking and sleep deprivation, which cause ocular surface
inflammation and impact tear production and/or tear film stability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Over 20&nbsp;million people in the U.S.
suffer from the symptoms of dry eye. Twenty-five&nbsp;percent of patients visiting ophthalmology clinics report dry eye symptoms.
DES is a complex condition caused by a decreased tear production and/or increased tear evaporation. This can result in discomfort,
visual disturbance, and tear film instability with potential damage to the ocular surface.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While many patients receive prescriptions
for dry eye symptoms, the majority opt for OTC products. The artificial tears market is expected to exceed $2.0&nbsp;billion in
2018, yet all artificial tears are delivered in single or multi-dose bottles that are not highly differentiated. We believe MicroTears
will offer improved accuracy in delivering artificial tears to the eye, better ocular coating, and lower incidence of tears running
down the patient&rsquo;s face. We believe these factors will differentiate MicroTears from eye drop versions of artificial tears.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Pipeline Assets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the three late-stage development
programs, we plan on leveraging our existing platform technology to continue developing other micro-therapeutic treatments for
front-of-the-eye diseases that can be administered using our piezo-print technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recently initiated the development of
a micro-formulation of atropine for moderate to severe myopia (nearsightedness), an ocular disorder in which the optical power
of the eye is too strong for the corresponding ocular anatomy. Myopia is the most common refractive error requiring correction
seen in children. It is estimated that there are over 80 million children diagnosed with myopia worldwide and over 5&nbsp;million
in the U.S. While currently there are no FDA-approved therapies for myopia progression, there is growing evidence of the therapeutic
activity of topical atropine, an anticholinergic agent use for dilation, as a treatment to slow progression. Despite activity,
safety concerns such as pupil dilation, photosensitivity and accommodation difficulties associated with standard atropine 1% have
tempered initial clinical adoption. While macro-dose atropine 1% is currently FDA-approved for pupil dilation in the U.S., its
significant side effect profile has impeded clinical utility and adoption for myopia progression. If the primary objectives of
our Phase&nbsp;III program are met, we plan to submit an NDA to the FDA for marketing approval of MicroPine to slow the progression
of myopia under the 505(b)(2) pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our Technology </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The piezo-print device comes in two parts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The base contains the electronic components which enable generation of control signals that ensure consistent, accurate columnated
arrays of micro-droplets, as well as dose tracking via Bluetooth connectivity; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The disposable cartridge contains the drug formulation in a primary drug container, targeted dosing system and piezo-driven
ejector nozzle, and comes in one-month doses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For administration of our product candidates,
the patient receives both the base and the disposable cartridge. For refills, the patient receives only the disposable cartridge.
Patients deliver their dose by attaching the cartridge to the base, pressing an activation button which loads a single drug dose,
then, holding it between one and two inches from the eye while looking directly into an illuminated circle, pressing a second button
to emit the micro-droplet delivered medication. The micro-droplets are emitted in a quickly repeating array, that in aggregate
form a micro-jet. The delivery of the full dose occurs in less than 80 milliseconds, which beats the blink reflex of the eye and
enables the medication to consistently coat the ocular surface while not flooding the eye&rsquo;s tear capacity. The patient feels
a wet sensation on the eye, but does not experience any pain, as demonstrated in studies to date. Several acute clinical trials
have been performed to date that demonstrate its usability. As a precise and quick-delivered micro-dose, it does not drip down
the face or drain down the naso-lacrimal duct thereby minimizing delivery of extra product or preservatives to the eye. The rechargeable
base has intelligent power management and precision designed circuitry that maximizes battery life allowing for infrequent recharging,
while always providing consistent dose delivery over the life of each cartridge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="tv488528_img11.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our system is partially based on piezo-driven
printer technology, which is also used for high-precision ink jet printing. In ink jet printing, piezo technology enables ink to
be sprayed with precision to form letters and numbers on paper. Our patented system takes aspects of piezo driven printer technology,
and applies it to the delivery of therapeutics to the eye. Our technology has six issued U.S. patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sales and Marketing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In light of our stage of development, we
have not yet established a commercial organization or distribution capabilities. We have licensed commercialization rights in Asia
to Senju Pharmaceuticals, and have retained global commercial rights for our product candidates in all other regions. As partial
consideration, Senju Pharmaceuticals purchased $5&nbsp;million of our Series&nbsp;A preferred stock in April&nbsp;2015. Pursuant
to the exclusive license agreement, Senju Pharmaceuticals also agreed to pay us royalties equal to 5% of the net sales (excluding
manufacturing costs, rebates and other charges) for the licensed products sold by Senju Pharmaceutical on a semi-annual basis until
the expiration of all patents or pending patent applications covering such licensed product, at which time the royalty rate will
be reduced to 1%. The royalty payment will continue, on a country-by-country basis, until the latter of the 10th year of the first
commercial sale of a licensed product in any country or the expiration of the licensed patents. Upon expiration of the exclusive
license agreement, Senju Pharmaceuticals will own an exclusive, fully paid up, irrevocable and perpetual license. The exclusive
license agreement may be terminated by either party for any material breach by the other party that is not cured within 90&nbsp;days
of receipt of written notice by the breaching party. If so terminated by Senju Pharmaceuticals, the license will survive the termination
with no further payment obligations to us. If so terminated by us, the license will terminate and Senju Pharmaceuticals will transfer
all rights to regulatory approvals to us, with no refund or recovery of any development costs. Senju Pharmaceuticals may also terminate
the exclusive license agreement without cause upon 60&nbsp;days&rsquo; written notice on a country-by-country basis, in which event
Senju Pharmaceuticals will transfer all rights to regulatory approvals pertaining to any licensed product to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If our product candidates receive marketing
approval, we would plan to commercialize them in the United States through a combination of distributors and our own specialty
sales force. We would expect to work with distribution companies or through other marketing arrangements in the EU and other regions
outside the United States. We believe that the U.S. commercial organization will consist of approximately 100&ndash;125 sales and
marketing professionals calling on ophthalmologists and optometrists. We would expect to make hires and sign distribution agreements
for commercialization following NDA approval of any of our product candidates. Our management team and directors, which would lead
the commercialization planning of our lead product candidates, have substantial experience in the commercialization of ophthalmic
therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Manufacturing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently rely on a combination of internal
manufacturing capacity and third-party manufacturers to produce the product candidates for our clinical trials. We manage such
production with all our vendors on a purchase order basis. Relationships with vendors of critical components are governed by applicable
master service and supply agreements. We do not currently have long-term agreements with these manufacturers or any other third-party
suppliers. We intend to procure quantities on a purchase order basis for our clinical and initial commercial production. If any
of our existing third-party suppliers should become unavailable to us for any reason, we believe that there are a number of potential
replacements, although we might experience a delay in our ability to obtain alternately sourced quantities of materials or services.
We also do not have any current contractual relationships for the manufacture of commercial supplies of our product candidates
if they are approved. With respect to commercial production of our product candidates in the future, we plan to outsource production
of the majority of the product candidates if they are approved for marketing by the applicable regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Competition </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The biotechnology and pharmaceutical industries
are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we
believe that our technologies, knowledge, experience and scientific resources provide us with competitive advantages, we face potential
competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies,
academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully
develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our potential competitors include large
pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic or biosimilar drug companies. Many of our
competitors have significantly greater financial and human resources and expertise in research and development, manufacturing,
preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller
and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management
personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring products, product
candidates or other technologies that we may target to in-license or acquire in pursuit of our updated business plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For the MicroProst program, there are currently
no FDA-approved therapies for chronic angle closure glaucoma and we are not aware of any in ongoing FDA registration studies. Physicians
currently use off-label IOP lowering medications that are FDA-approved for a different disease entity, namely open-angle glaucoma.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For MicroStat, we are not aware of any micro-therapeutics
nor of any existing phenylephrine-tropicamide topical fixed combination even in standard macro-dose. There are competitive macro-dose
drop formulations of individual therapeutics such as phenylephrine and tropicamide for mydriasis by companies such as Akorn, Alcon
and others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For MicroPine, we are not aware of any FDA-approved
therapies to slow the progression of myopia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">For MicroTears, there is a $2&nbsp;billion
market of multiple competitive artificial tear products with an aggregate of 200 million units sold annually, but none that we
are aware of with targeted, ocular surface coating micro-droplet delivery. We believe the simplicity and convenience of our MicroTears
system, which can be administered without tilting the head and with minimal risk of inconveniences such as dripping down the patient&rsquo;s
cheek, will differentiate our product from other artificial tears.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Intellectual Property </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our success may depend on our ability to
obtain, maintain and enforce our proprietary rights related to our products and other technologies. We must also operate without
infringing the proprietary rights of others while preventing others from infringing our proprietary rights. We will seek to protect
our proprietary position by, among other methods, filing U.S. and foreign patent applications. We may also rely on trade secrets
and know-how for some proprietary methods, methods of manufacture, and systems and devices. We continue innovating our technologies,
and will file appropriate U.S. and foreign patent applications for our future innovations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patents </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of January&nbsp;9, 2018, we owned five
U.S. issued utility patents, one issued design patent, and nine pending U.S. patent applications, as well as twenty-five issued
and allowed foreign patents and fifty-six pending foreign patent applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Exemplary patent coverage within the portfolio
includes issued and pending patent applications disclosing and claiming the following devices and methods:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A piezoelectric device configured to generate an ejected stream of droplets is the subject of one patent family. The device
ejects droplets having an average ejected droplet diameter greater than&nbsp;20&nbsp;microns and an average initial droplet ejecting
velocity between 0.5 m/s and 10 m/s. Furthermore, the stream of droplets is generated with low entrained airflow so that at least
75% of the mass is deposited on the eye. U.S. patent(s) for these devices are expected to expire in 2031.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A method of delivering a medicament or solution to an eye with a piezo-ejector device is the subject of another patent family.
The method involves delivering an average droplet size of 20&nbsp;microns to 100 microns in diameter with an average initial droplet
ejecting velocity between 1&nbsp;m/s and 10 m/s to the eye. About 85% to 100% of the ejected mass of droplets is deposited on the
eye. U.S. patent(s) for these methods are expected to expire in 2031.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A device having a piezo-ejector that generates a directed stream of droplets through specially shaped openings in the piezo-ejector
is the subject of still another patent family. The openings provide laminar flow through the openings. Laminar flow is provided
by shaping the openings with a gradual slope change so that an external entry radius has a circular shape which reduces airflow
while providing laminar flow through the openings. U.S. patent(s) related to these devices are expected to expire in 2033.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A piezo-electric ejector device having a microcontroller which auto-tunes the ejector mechanism is the subject of a yet another
patent family. The device generates at least one cycle in a range of drive signal frequencies and obtains time-energy product feedback
from a decay signal emitted by the actuator. U.S. patent(s) related to these devices are expected to expire in 2033.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A method of monitoring the treatment of ophthalmic subjects by capturing images of the eye is the subject of another patent
family. Images of the eye are taken which are sufficient to obtain information about the diagnosis or health of the eye. The data
is stored and analyzed to monitor treatment. U.S. patent(s) related to this method are expected to expire in 2031.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A fluid ejector having a fluid loading plate in parallel arrangement with an ejector mechanism is the subject of patent family
patented in Europe. The fluid loading plate forms a capillary separation with the ejector mechanism to generate capillary fluid
flow therebetween. The fluid loading plate is also attached to the reservoir (at a fluid reservoir interface) and to the ejector
mechanism (at an ejector mechanism interface) and may have one or more fluid channels from the fluid reservoir interface to the
ejector mechanism interface. The ejector produces a stream of droplets having a droplet diameter greater than 15 microns with the
stream having low entrained airflow so that the pressure of the stream will be substantially imperceptible.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The expiry of any patent depends upon the
legal term for patents in that particular country. In the U.S., the patent term is generally 20&nbsp;years from the earliest claimed
filing date of a non-provisional patent application. In the U.S., a patent&rsquo;s term may be lengthened by patent term adjustment
which compensates a patentee for administrative delays by the U.S. Patent and Trademark Office, or the USPTO, in examining and
granting a patent. A patent term may also be shortened if a patent is terminally disclaimed over another patent or application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Drug Price Competition and Patent Term
Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five&nbsp;years beyond the expiration
date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review while the patent is in
force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A&nbsp;patent term extension cannot extend
the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval, only one patent applicable to
each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method
for manufacturing it may&nbsp;be extended. We cannot provide any assurance that any patent term extension with respect to any U.S.&nbsp;patent
will be obtained and, if obtained, the duration of such extension. Similar patent term extension/reduction provisions are available
in the European Union and other jurisdictions. In the future, if and when our product candidates receive approval by the FDA or
foreign regulatory authorities, we will apply for patent term extensions on issued patents covering our products to the extent
available under the applicable law, depending upon the length of any such clinical trials for any product and other factors. The
expiration dates referred to above are without regard to potential patent term extension or other market exclusivity that may be
available to us. However, we cannot provide any assurances that any such patent term extension of a foreign patent will be obtained
and, if obtained, the duration of such extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In Asia, we have been granted a patent in
each of China, Japan and South Korea, that describes a piezoelectric device configured to generate an ejected stream of droplets
with a particular droplet diameter and ejection velocity. We also have two additional patents granted in China, four additional
patents granted in Japan, and two patents granted in Singapore, all related to aspects of the piezoelectric device and methods
of using the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Proprietary Technology </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to patents, we may rely on trade
secrets and proprietary know-how to protect our technology. We will protect our proprietary technology and processes in the appropriate
manner to maintain their secrecy including confidentiality agreements when dealing with third parties. We will also seek to preserve
the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and
electronic security of our information technology systems. We shall also require invention assignment agreements with our employees,
consultants, and contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Government Regulation and Product Approvals </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Government authorities in the U.S., at the
federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling,
advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical
products. The processes for obtaining regulatory approvals in the U.S. and in foreign countries and jurisdictions, along with subsequent
compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time
and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Review and Approval of Drugs in the U.S. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the U.S., the FDA regulates drug products
under the Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations. The process of obtaining regulatory approvals and
the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure
of substantial time and financial resources. The failure to comply with applicable requirements under the FDCA and other applicable
laws at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor
to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal
of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, voluntary product recalls,
product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of
Justice or other governmental entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An applicant seeking approval to market
and distribute a new drug product in the U.S. must typically undertake the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&rsquo;s good
laboratory practice, or GLP, regulations;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>submission to the FDA of an investigational new drug application, or IND, which must take effect before human clinical trials
may begin;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may
be initiated;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>performance of adequate and well-controlled human clinical trials in accordance with good clinical practices, or GCP, to establish
the safety and efficacy of the proposed drug product for each indication;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>preparation and submission to the FDA of an NDA;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>review of the product by an FDA advisory committee, where appropriate or if applicable;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or
components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls
are adequate to preserve the product&rsquo;s identity, strength, quality and purity;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical
data;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>payment of user fees and securing FDA approval of the NDA; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval
studies required by the FDA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Preclinical Studies </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Preclinical studies include laboratory evaluation
of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient and the formulated drug or drug
product, as well as <I>in vitro</I> and animal studies to assess the safety and activity of the drug for initial testing in humans
and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements,
including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any
available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an
IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue
after the IND is submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The IND and IRB Processes </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">An IND is an exemption from the FDCA that
allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA
authorization to administer an investigational drug to humans. Such authorization must be secured prior to interstate shipment
and administration of any new drug that is not the subject of an approved NDA. In support of a request for an IND, applicants must
submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.
In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical
data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. The FDA requires
a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow
the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time
during this 30-day period, the FDA may raise concerns or questions about the conduct of the clinical trials as outlined in the
IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical
trials can begin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Following commencement of a clinical trial
under an IND, the FDA may also place a clinical hold or partial clinical hold on that clinical trial. A clinical hold is an order
issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical
hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part
of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&nbsp;days after imposition of a clinical
hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance
of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation
may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously
cited or otherwise satisfying the FDA that the investigation can proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A sponsor may choose, but is not required,
to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements
must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study
complies with FDA certain regulatory requirements in order to use the study as support for an IND or application for marketing
approval. Specifically, such studies must be conducted in accordance with good clinical practice, or GCP, including review and
approval by an independent ethics committee, or IEC, and informed consent from subjects. The FDA&rsquo;s regulations are intended
to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity
of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required
for IND studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition to the foregoing IND requirements,
an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial
before it commences at that institution, and the IRB must conduct a continuing review and reapprove the study at least annually.
The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study
subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial
at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&rsquo;s
requirements or if the product candidate has been associated with unexpected serious harm to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, some clinical trials are overseen
by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee.
This group provides authorization for whether or not a clinical trial may move forward at designated check points based on access
that only the group maintains to available data from the study. Suspension or termination of development during any phase of clinical
trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other
reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Information about certain clinical trials
must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on its ClinicalTrials.gov
website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Human Clinical Trials in Support of an NDA </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Clinical trials involve the administration
of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements,
which include, among other things, the requirement that all research subjects provide their informed consent in writing before
their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things,
the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness
criteria to be evaluated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Human clinical trials are typically conducted
in three sequential phases, which may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Phase&nbsp;I.</I>&nbsp;&nbsp;&nbsp;The drug is initially introduced into healthy human subjects or, in certain indications
such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism,
distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Phase&nbsp;II.</I>&nbsp;&nbsp;&nbsp;The drug is administered to a limited patient population to identify possible adverse
effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine
dosage tolerance and optimal dosage.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><I>Phase&nbsp;III.</I>&nbsp;&nbsp;&nbsp;The drug is administered to an expanded patient population, generally at geographically
dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy
and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information
for the labeling of the product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Progress reports detailing the results of
the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition,
IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings
from other studies or animal or <I>in vitro</I> testing that suggest a significant risk in humans exposed to the drug; and any
clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator
brochure. Phase&nbsp;I, Phase&nbsp;II and Phase&nbsp;III clinical trials might not be completed successfully within any specified
period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds,
including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend
or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being
conducted in accordance with the IRB&rsquo;s requirements or if the drug has been associated with unexpected serious harm to patients.
The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data
submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Concurrent with clinical trials, companies
often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics
of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things,
must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo
unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Submission of an NDA to the FDA </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Assuming successful completion of required
clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information
relating to the product&rsquo;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the
FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission
of most NDAs is subject to an application user fee, which for federal fiscal year 2018 is $2,421,495 for an application requiring
clinical data. The sponsor of an approved NDA is also subject to an annual prescription drug program fee, which for fiscal year
2018 is $304,162. Certain exceptions and waivers are available for some of these fees, such as an exception from the application
fee for drugs with orphan designation and a waiver for certain small businesses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA conducts a preliminary review of
an NDA within 60&nbsp;days of its receipt and informs the sponsor by the 74th day after the FDA&rsquo;s receipt of the submission
to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information
rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted
application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA
begins an in-depth substantive review. The FDA has agreed to certain performance goals in the review process of NDAs. Most such
applications are meant to be reviewed within ten&nbsp;months from the date of filing, and most applications for &ldquo;priority
review&rdquo; products are meant to be reviewed within six&nbsp;months of filing. For applications of drug products that are not
new molecular entities, FDA aims to conduct standard reviews within 10&nbsp;months of receipt of the NDA and priority reviews within
6&nbsp;months of receipt of the NDA. The review process may be extended by the FDA for three additional&nbsp;months to consider
new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following
the original submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before approving an NDA, the FDA typically
will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover
all facilities associated with an NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients),
finished drug product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines
that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production
of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more
clinical sites to assure compliance with GCP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, as a condition of approval,
the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure
that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the
size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration
of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include
medication guides, physician communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU
may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain
circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval
if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the
potential market and profitability of a product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA may refer an application for a novel
drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent
experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether
the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee,
but it considers such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The FDA&rsquo;s Decision on an NDA </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On the basis of the FDA&rsquo;s evaluation
of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue
an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific
prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission
and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those
deficiencies have been addressed to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.
The FDA has committed to reviewing such resubmissions in two or six&nbsp;months depending on the type of information included.
Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory
criteria for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the FDA approves a product, it may limit
the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product
labeling, require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess the drug&rsquo;s
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other
conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect
the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the
results of post-market studies or surveillance programs. After approval, many types of changes to the approved product, such as
adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA
review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Post-Approval Requirements </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Drugs manufactured or distributed pursuant
to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating
to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences
with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims,
are subject to prior FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, drug manufacturers and other
entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the
FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance
with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before
being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly,
manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Once an approval is granted, the FDA may
withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions
to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety
risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other
things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product
recalls;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fines, warning letters or holds on post-approval clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product seizure or detention, or refusal to permit the import or export of products; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions or the imposition of civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA strictly regulates marketing, labeling,
advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and
in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting
the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant
liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the distribution of prescription
pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and
drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states.
Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure
accountability in distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Section&nbsp;505(b)(2) NDAs </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NDAs for most new drug products are based
on two full clinical trials which must contain substantial evidence of the safety and efficacy of the proposed new product. These
applications are submitted under Section&nbsp;505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative
type of NDA under Section&nbsp;505(b)(2) of the FDCA. This type of application allows the applicant to rely, in part, on the FDA&rsquo;s
previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section&nbsp;505(b)(2) applies
to NDAs for a drug for which the investigations made to show whether or not the drug is safe for use and effective in use and relied
upon by the applicant for approval of the application &ldquo;were not conducted by or for the applicant and for which the applicant
has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Thus, Section&nbsp;505(b)(2) authorizes
the FDA to approve an NDA based on safety and effectiveness data that were not developed by the applicant. NDAs filed under Section&nbsp;505(b)(2)
may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses
of previously approved products. If the Section&nbsp;505(b)(2) applicant can establish that reliance on the FDA&rsquo;s previous
approval is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical studies or clinical
trials of the new product. The FDA may also require companies to perform additional studies or measurements to support the change
from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the
referenced product has been approved, as well as for any new indication sought by the Section&nbsp;505(b)(2) applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Abbreviated New Drug Applications for Generic Drugs </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In 1984, with passage of the Hatch-Waxman
Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by
the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated
new drug application, or ANDA, to the agency. In support of such applications, a generic manufacturer may rely on the preclinical
and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug,
or RLD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Specifically, in order for an ANDA to be
approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route
of administration, the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic
drug is &ldquo;bioequivalent&rdquo; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if&thinsp;
&ldquo;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption
of the listed drug...&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon approval of an ANDA, the FDA indicates
whether the generic product is &ldquo;therapeutically equivalent&rdquo; to the RLD in its publication Approved Drug Products with
Therapeutic Equivalence Evaluations, also referred to as the Orange Book. Clinicians and pharmacists consider a therapeutic equivalent
generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance
programs, the FDA&rsquo;s designation of therapeutic equivalence often results in substitution of the generic drug without the
knowledge or consent of either the prescribing clinicians or patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Hatch-Waxman Amendments, the FDA
might not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period
of five&nbsp;years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision,
a new chemical entity, or NCE, is a drug that contains no active moiety that has previously been approved by the FDA in any other
NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance.
In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five&nbsp;years
unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four&nbsp;years
following the original product approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDCA also provides for a period of three&nbsp;years
of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence
studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity
period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination
or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety,
provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of
three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the
date of approval of the original drug product. The FDA typically makes decisions about awards of data exclusivity shortly before
a product is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Hatch-Waxman Patent Certification and the 30-Month Stay
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon approval of an NDA or a supplement
thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&rsquo;s product or an
approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA
applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for
the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking
approval. To the extent that the Section&nbsp;505(b)(2) applicant is relying on studies conducted for an already approved product,
the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the
same extent that an ANDA applicant would.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Specifically, the applicant must certify
with respect to each patent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the required patent information has not been filed;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the listed patent has expired;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the listed patent is invalid, unenforceable or will not be infringed by the new product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A certification that the new product will
not infringe the already approved product&rsquo;s listed patents or that such patents are invalid or unenforceable is called a
Paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval
of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product
have expired (other than method of use patents involving indications for which the ANDA applicant is not seeking approval).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the ANDA applicant has provided a Paragraph
IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders
once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit
in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45&nbsp;days after
the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&nbsp;months
after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable
to the ANDA applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent that the Section&nbsp;505(b)(2)
applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning
any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval
of a Section&nbsp;505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until
any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for
the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until
the earlier of 30&nbsp;months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section&nbsp;505(b)(2)
applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Pediatric Studies and Exclusivity </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Pediatric Research Equity Act
of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product
for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric
subpopulation for which the product is safe and effective. With enactment of the Food and Drug Administration Safety and Innovation
Act, or FDASIA, in 2012, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain
an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any
deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&rsquo;s internal
review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the
applicant may request an amendment to the plan at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The FDA may, on its own initiative or at
the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product
for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating
to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation,
the pediatric data requirements do not apply to products with orphan designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pediatric exclusivity is another type of
non-patent marketing exclusivity in the U.S. and, if granted, provides for the attachment of an additional six&nbsp;months of marketing
protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month
exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such
data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial
is deemed to fairly respond to the FDA&rsquo;s request, the additional protection is granted. If reports of requested pediatric
studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of
exclusivity or patent protection cover the product are extended by six&nbsp;months. This is not a patent term extension, but it
effectively extends the regulatory period during which the FDA cannot approve another application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patent Term Restoration and Extension </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A patent claiming a new drug product may
be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent restoration of up to
five&nbsp;years for patent term lost during product development and the FDA regulatory review. The restoration period granted is
typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission
date of an NDA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent
past a total of 14&nbsp;years from the product&rsquo;s approval date. Only one patent applicable to an approved drug product is
eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question.
A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals.
The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation
with the FDA. We cannot provide any assurance that any patent term extension with respect to any U.S. patent will be obtained and,
if obtained, the duration of such extension, in connection with any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The 21st Century Cures Act </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December&nbsp;13, 2016, President Obama
signed the 21st Century Cures Act, or Cures Act, into law. The Cures Act is designed to modernize and personalize healthcare, spur
innovation and research, and streamline the discovery and development of new therapies through increased federal funding of particular
programs. It authorizes increased funding for the FDA to spend on innovation projects. The new law also amends the Public Health
Service Act to reauthorize and expand funding for the NIH. The Act establishes the NIH Innovation Fund to pay for the cost of development
and implementation of a strategic plan, early stage investigators and research. It also charges NIH with leading and coordinating
expanded pediatric research. Further, the Cures Act directs the Centers for Disease Control and Prevention to expand surveillance
of neurological diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With amendments to the FDCA and the Public
Health Service Act, or PHSA, Title III of the Cures Act seeks to accelerate the discovery, development, and delivery of new medicines
and medical technologies. To that end, and among other provisions, the Cures Act reauthorizes the existing priority review voucher
program for certain drugs intended to treat rare pediatric diseases until 2020; creates a new priority review voucher program for
drug applications determined to be material national security threat medical countermeasure applications; revises the FDCA to streamline
review of combination product applications; requires FDA to evaluate the potential use of&thinsp; &ldquo;real world evidence&rdquo;
to help support approval of new indications for approved drugs; provides a new &ldquo;limited population&rdquo; approval pathway
for antibiotic and antifungal drugs intended to treat serious or life-threatening infections; and authorizes FDA to designate a
drug as a &ldquo;regenerative advanced therapy,&rdquo; thereby making it eligible for certain expedited review and approval designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Review and Approval of Drug Products in the European Union
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to market any product outside of
the U.S., a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding
quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and
distribution of products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary
approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in
those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional
product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions
might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does
not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction
may negatively impact the regulatory process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Procedures Governing Approval of Drug Products in the
European Union </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the European Clinical Trials
Directive, a system for the approval of clinical trials in the European Union has been implemented through national legislation
of the member states. Under this system, an applicant must obtain approval from the competent national authority of a European
Union member state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial after
a competent ethics committee has issued a favorable opinion. Clinical trial application must be accompanied by an investigational
medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and corresponding national
laws of the member states and further detailed in applicable guidance documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To obtain marketing approval of a product
under European Union regulatory systems, an applicant must submit a marketing authorization application, or MAA, either under a
centralized or decentralized procedure. The centralized procedure provides for the grant of a single marketing authorization by
the European Commission that is valid for all European Union member states. The centralized procedure is compulsory for specific
products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products,
advanced therapy products and products with a new active substance indicated for the treatment of certain diseases. For products
with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which
a centralized process is in the interest of patients, the centralized procedure may be optional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the centralized procedure, the Committee
for Medicinal Products for Human Use, or the CHMP, established at the European Medicines Agency, or EMA, is responsible for conducting
the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such
as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the
European Union, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days, excluding clock stops, when additional information
or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation
might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public
health and in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of
the CHMP is given within 150&nbsp;days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The decentralized procedure is available
to applicants who wish to market a product in various European Union member states where such product has not received marketing
approval in any European Union member states before. The decentralized procedure provides for approval by one or more other, or
concerned, member states of an assessment of an application performed by one member state designated by the applicant, known as
the reference member state. Under this procedure, an applicant submits an application based on identical dossiers and related materials,
including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference member state and
concerned member states. The reference member state prepares a draft assessment report and drafts of the related materials within
210&nbsp;days after receipt of a valid application. Within 90&nbsp;days of receiving the reference member state&rsquo;s assessment
report and related materials, each concerned member state must decide whether to approve the assessment report and related materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a member state cannot approve the assessment
report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute
resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Within this framework, manufacturers may
seek approval of hybrid medicinal products under Article&nbsp;10(3) of Directive 2001/83/EC. Hybrid applications rely, in part,
on information and data from a reference product and new data from appropriate preclinical tests and clinical trials. Such applications
are necessary when the proposed product does not meet the strict definition of a generic medicinal product, or bioavailability
studies cannot be used to demonstrate bioequivalence, or there are changes in the active substance(s), therapeutic indications,
strength, pharmaceutical form or route of administration of the generic product compared to the reference medicinal product. In
such cases the results of tests and clinical trials must be consistent with the data content standards required in the Annex to
the Directive 2001/83/EC, as amended by Directive 2003/63/EC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Hybrid medicinal product applications have
automatic access to the centralized procedure when the reference product was authorized for marketing via that procedure. Where
the reference product was authorized via the decentralized procedure, a hybrid application may be accepted for consideration under
the centralized procedure if the applicant shows that the medicinal product constitutes a significant therapeutic, scientific or
technical innovation, or the granting of a community authorization for the medicinal product is in the interest of patients at
the community level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Clinical Trial Approval in the European Union </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Requirements for the conduct of clinical
trials in the European Union including Good Clinical Practice, or GCP, are set forth in the Clinical Trials Directive 2001/20/EC
and the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system for the approval
of clinical trials in the European Union has been implemented through national legislation of the E.U. member states. Under this
system, approval must be obtained from the competent national authority of each E.U. member state in which a study is planned to
be conducted. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier, or IMPD,
and further supporting information prescribed by Directive 2001/20/EC and Directive 2005/28/EC and other applicable guidance documents.
Furthermore, a clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical
trial application in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In April&nbsp;2014, the E.U. passed the
new Clinical Trials Regulation, (EU) No 536/2014, which will replace the current Clinical Trials Directive 2001/20/EC. To ensure
that the rules for clinical trials are identical throughout the European Union, the new E.U. clinical trials legislation was passed
as a regulation that is directly applicable in all E.U. member states. All clinical trials performed in the European Union are
required to be conducted in accordance with the Clinical Trials Directive 2001/20/EC until the new Clinical Trials Regulation (EU)
No 536/2014 becomes applicable. According to the current plans of EMA, the new Clinical Trials Regulation will become applicable
in 2019. The Clinical Trials Directive 2001/20/EC will, however, still apply three&nbsp;years from the date of entry into application
of the Clinical Trials Regulation to (i)&nbsp;clinical trials applications submitted before the entry into application and (ii)
clinical trials applications submitted within one year after the entry into application if the sponsor opts for old system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The new Clinical Trials Regulation aims
to simplify and streamline the approval of clinical trial in the European Union. The main characteristics of the regulation include:
a streamlined application procedure via a single entry point, the E.U. portal; a single set of documents to be prepared and submitted
for the application as well as simplified reporting procedures that will spare sponsors from submitting broadly identical information
separately to various bodies and different member states; a harmonized procedure for the assessment of applications for clinical
trials, which is divided in two parts (Part&nbsp;I is assessed jointly by all member states concerned, and Part&nbsp;II is assessed
separately by each member state concerned); strictly defined deadlines for the assessment of clinical trial applications; and the
involvement of the ethics committees in the assessment procedure in accordance with the national law of the member state concerned
but within the overall timelines defined by the Clinical Trials Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Periods of Authorization and Renewals </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Marketing authorization is valid for five&nbsp;years
in principle and the marketing authorization may be renewed after five&nbsp;years on the basis of a re-evaluation of the risk-benefit
balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder
must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy,
including all variations introduced since the marketing authorization was granted, at least six&nbsp;months before the marketing
authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European
Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional
five-year renewal. Any authorization which is not followed by the actual placing of the drug on the European Union market (in case
of centralized procedure) or on the market of the authorizing member state within three&nbsp;years after authorization ceases to
be valid (the so-called sunset clause).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Data and Market Exclusivity in the European Union </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the European Union, new chemical entities
qualify for eight&nbsp;years of data exclusivity upon marketing authorization and an additional two&nbsp;years of market exclusivity.
This data exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&rsquo;s
data to assess a generic (abbreviated) application for eight&nbsp;years, after which generic marketing authorization can be submitted,
and the innovator&rsquo;s data may be referenced, but not approved for two&nbsp;years. The overall ten-year period will be extended
to a maximum of eleven&nbsp;years if, during the first eight&nbsp;years of those ten&nbsp;years, the marketing authorization holder
obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be
a new chemical entity and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could
also market another version of the product if such company can complete a full MAA with a complete database of pharmaceutical test,
preclinical tests and clinical trials and obtain marketing approval of its product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Regulatory Requirements after Marketing Authorization
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As in the U.S., both marketing authorization
holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent
authorities of the individual EU Member States both before and after grant of the manufacturing and marketing authorizations. The
holder of an EU marketing authorization for a medicinal product must, for example, comply with EU pharmacovigilance legislation
and its related regulations and guidelines which entail many requirements for conducting pharmacovigilance, or the assessment and
monitoring of the safety of medicinal products. The manufacturing process for medicinal products in the European Union is also
highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing
requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out
in the applicable EU laws, including compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical
ingredients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the European Union, the advertising and
promotion of approved products are subject to EU Member States&rsquo; laws governing promotion of medicinal products, interactions
with clinicians, misleading and comparative advertising and unfair commercial practices. In addition, other legislation adopted
by individual EU Member States may apply to the advertising and promotion of medicinal products. These laws require that promotional
materials and advertising in relation to medicinal products comply with the product&rsquo;s Summary of Product Characteristics,
or SmPC, as approved by the competent authorities. Promotion of a medicinal product that does not comply with the SmPC is considered
to constitute off-label promotion, which is prohibited in the European Union.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pharmaceutical Coverage, Pricing and Reimbursement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Significant uncertainty exists as to the
coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend,
in part, on the extent to which third-party payors, including government health programs in the U.S. such as Medicare and Medicaid,
commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such
products. The process for determining whether a payor will provide coverage for a product may be separate from the process for
setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are
increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products
and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list,
or formulary, which might not include all of the approved products for a particular indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In order to secure coverage and reimbursement
for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable
regulatory approvals. Nonetheless, product candidates might not be considered medically necessary or cost effective. Additionally,
a payor&rsquo;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.
Further, one payor&rsquo;s determination to provide coverage for a drug product does not assure that other payors will also provide
coverage for the drug product. Third-party reimbursement might not be sufficient to maintain price levels high enough to realize
an appropriate return on investment in product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The containment of healthcare costs also
has become a priority of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments
have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement
and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of
more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&rsquo;s revenue generated
from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable
coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory
approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Outside the U.S., ensuring adequate coverage
and payment for our product candidates will face challenges. Pricing of prescription pharmaceuticals is subject to governmental
control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory
marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of our product
candidates or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays
in our commercialization efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the European Union, pricing and reimbursement
schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement
price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a
particular drug candidate to currently available therapies. For example, the European Union provides options for its member states
to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the
prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or it
may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market.
Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward
pressure on healthcare costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers
are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert
competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations
for drug products might not allow favorable reimbursement and pricing arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Healthcare Law and Regulation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Healthcare providers and third-party payors
play a primary role in the recommendation and prescription of drug products that are granted regulatory approval. Arrangements
with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare
laws and regulations that may constrain our business and/or financial arrangements. Such restrictions under applicable federal
and state healthcare laws and regulations, include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting,
offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral
of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole
or in part, under a federal healthcare program such as Medicare and Medicaid;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws,
which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal
government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation
to pay money to the federal government;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal
laws that prohibit, among other things, knowingly and willingly executing, or attempting to execute, a scheme to defraud any healthcare
benefit program or making false statements relating to healthcare matters;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations,
which also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission
of individually identifiable health information;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the Affordable Care Act, which
requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare
&amp; Medicaid Services, or CMS, within the U.S. Department of Health and Human Services, information related to payments and other
transfers of value to clinicians and teaching hospitals and clinician ownership and investment interests; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare
items or services that are reimbursed by non-governmental third-party payors, including private insurers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some state laws require pharmaceutical companies
to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government in addition to requiring drug manufacturers to report information related to payments to clinicians and
other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information
in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Healthcare Reform </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A primary trend in the U.S. healthcare industry
and elsewhere is cost containment. There have been several federal and state proposals during the last few&nbsp;years regarding
the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products,
government control and other changes to the healthcare system in the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March&nbsp;2010, the U.S. Congress enacted
the Affordable Care Act, or ACA, which, among other things, includes changes to the coverage and payment for products under government
healthcare programs. Among the provisions of the ACA of importance to our potential drug candidates are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products,
apportioned among these entities according to their market share in certain government healthcare programs, although this fee would
not apply to sales of certain products approved exclusively for orphan indications;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage
to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&rsquo;s
Medicaid rebate liability;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expanded manufacturers&rsquo; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for
both branded and generic drugs and revising the definition of&thinsp; &ldquo;average manufacturer price,&rdquo; or AMP, for calculating
and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate liability to prescriptions for
individuals enrolled in Medicare Advantage plans;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for
drugs that are inhaled, infused, instilled, implanted or injected;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expanded the types of entities eligible for the 340B drug discount program;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>established the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to provide a 50% point-of-sale-discount
off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for
the manufacturers&rsquo; outpatient drugs to be covered under Medicare Part&nbsp;D;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
research, along with funding for such research;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the Medicare program to
reduce expenditures by the program that could result in reduced payments for prescription drugs. However, the IPAB implementation
has been not been clearly defined. The ACA provided that under certain circumstances, IPAB recommendations will become law unless
Congress enacts legislation that will achieve the same or greater Medicare cost savings; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models
to lower Medicare and Medicaid spending, potentially including prescription drug spending. Funding has been allocated to support
the mission of the Center for Medicare and Medicaid Innovation from 2011 to 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Other legislative changes have been proposed
and adopted in the U.S. since the ACA was enacted. For example, in August&nbsp;2011, the Budget Control Act of 2011, among other
things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending
a targeted deficit reduction of at least $1.2 trillion for the&nbsp;years 2012 through 2021, was unable to reach required goals,
thereby triggering the legislation&rsquo;s automatic reduction to several government programs. This includes aggregate reductions
of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April&nbsp;2013 and will remain in effect
through 2024 unless additional Congressional action is taken. In January&nbsp;2013, President Obama signed into law the American
Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals,
imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments
to providers from three to five&nbsp;years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With the new Administration and Congress,
there may be additional legislative changes, including potentially repeal and replacement of certain provisions of the ACA. It
remains to be seen, however, whether new legislation will be enacted and, if so, precisely what any new legislation will provide
and what impact it will have on the availability of healthcare and containing or lowering the cost of healthcare. It is possible
that any repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance
coverage or in individuals having insurance coverage with less generous benefits. While the timing and scope of any potential future
legislation to repeal and replace ACA provisions is highly uncertain in many respects, it is also possible that some of the ACA
provisions that generally are not favorable for the research-based pharmaceutical industry could also be repealed along with ACA
coverage expansion provisions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Employees</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As of March 27, 2018,
we had 11 full-time and 2 part-time employees. We also engage various consultants and contractors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1in"><A NAME="a_003"></A>Item 1A.</TD><TD>Risk Factors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Investing in our common stock involves
a high degree of risk. You should carefully consider the risks described below, as well as the other information in this report,
including our financial statements and the related notes and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations,&rdquo; before deciding whether to invest in our common stock. The occurrence of any of the events or
developments described below could harm our business, financial condition, results of operations and growth prospects. In such
an event, the market price of our common stock could decline and you might lose all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISKS RELATED TO OUR FINANCIAL POSITION
AND NEED FOR ADDITIONAL CAPITAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We have incurred operating losses since our inception.
We expect to continue to incur losses for the foreseeable future and may never achieve or maintain profitability. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have incurred net losses of&thinsp;approximately
$19.3&nbsp;million since inception, have not generated any product sales revenue and have not achieved profitable operations. Our
net losses were approximately $5.1 million and $3.5&nbsp;million for the years ended December&nbsp;31, 2017 and 2016, respectively.
We expect to continue to incur substantial losses in future periods while we continue to test and prepare our product candidates
for the market. It could be several&nbsp;years, if ever, before we have a commercialized drug. The net losses we incur may fluctuate
significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if, and as,
we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>continue the ongoing and planned preclinical and clinical development of our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>initiate preclinical studies and clinical trials for any additional product candidates that we may pursue in the future;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>seek marketing approvals for our current and future product candidates that successfully complete clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establish a sales, marketing and distribution infrastructure to commercialize any product candidate for which we may obtain
marketing approval;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>develop, maintain, expand and protect our intellectual property portfolio;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>implement operational, financial and management systems; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>attract, hire and retain additional administrative, clinical, regulatory and scientific personnel.</TD></TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even if we are able to generate revenues from
the sale of our potential products, we might not become profitable and may need to obtain additional funding to continue operations.
If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue
our operations at planned levels and be forced to reduce our operations. Even if we do achieve profitability, we might not be able
to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease
the value of our company and could impair our ability to raise capital, expand our business or continue our operations. In addition,
because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount
of increased expenses, or when, or if, we will be able to achieve or maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our relatively short operating history may make it difficult
for investors to evaluate the success of our business to date and to assess our future viability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a clinical-stage company which commenced
active operations in 2014. Our operations to date have been limited to organizing and staffing our company, business planning,
raising capital and developing our product candidates. We have not yet demonstrated our ability to successfully complete a Phase&nbsp;III
program, obtain regulatory approval, develop an in-house manufacturing facility, manufacture a commercial scale product, or arrange
for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization.
Consequently, any predictions about our future success or viability might not be as accurate as they could be if we had a longer
operating history.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, as a new business, we may encounter
unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a
company with a product development focus to a company capable of supporting commercial and manufacturing activities. We might not
be successful in such a transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We will need to raise additional funding
in order to receive approval for our product candidates. Such funding might not be available on acceptable terms, or at all. Failure
to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development efforts
or other operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may require substantial additional funding
to fund completion of our research and development activities. We also may require substantial funding to fund our commercialization
efforts, operating expenses and other activities. If additional funds are not available, we may need to significantly scale back
or cease our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We will require substantial funds to discover,
develop, protect and conduct research and development for our product candidates, including preclinical testing and clinical trials
of any of our product candidates, and to manufacture and market any such product that may be approved for commercial sale. Even
if we are successful in raising additional capital, such funds may prove to be insufficient for these activities. Our financing
needs may change substantially because of research and development costs, competition, clinical trials and costs arising from additional
regulatory approvals. We might not succeed in raising needed additional funds. The timing of our need for additional funds will
depend on a number of factors, which factors are difficult to predict or may be outside of our control, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the resources, time and costs required to initiate and complete our research and development, to initiate and complete preclinical
studies and clinical trials and to obtain regulatory approvals for our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>progress in our research and development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the timing, receipt and amount of milestone, royalty and other payments from future collaborators, if any; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>costs necessary to protect our intellectual property.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If our estimates and predictions relating to
any of these factors are incorrect, we may need to modify our operating plan. Additional funds might not be available to us on
acceptable terms, or at all, when needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Raising additional capital may cause dilution to our existing
stockholders, restrict our operations or require us to relinquish rights to our technologies. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Until such time as we can generate substantial
product revenues, we may attempt to finance our cash needs through equity offerings, debt financings, government and/or other third-party
grants or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and
licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities,
our investors&rsquo; ownership interest will be diluted. Debt financing, if available, may involve agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail one or more
clinical research or development programs, which would adversely impact potential revenues, results of operations and financial
condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we raise additional capital through future
collaborations, strategic alliances or third-party licensing arrangements, we may have to relinquish valuable rights to our intellectual
property, future revenue streams, research programs or product candidates, or grant licenses on terms that might not be favorable
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we are unable to raise additional capital
when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts,
or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we are unable to use carryforward tax losses or benefit
from favorable tax legislation to reduce our taxes, our business, results of operations and financial condition may be adversely
affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have incurred significant net operating
losses since our inception in July&nbsp;2014. As of December&nbsp;31, 2017, we had federal net operating loss carry-forwards of
approximately $11.0&nbsp;million. If we are unable to use carryforward tax losses to reduce our future taxable basis for corporate
tax purposes, our business, results of operations and financial condition may be adversely affected.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Net operating loss and tax credit carry-forwards
are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities and may become subject
to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a
three-year period in excess of 50%, as defined under Sections&nbsp;382 and 383 of the Internal Revenue Code of 1986, as amended,
as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future
taxable income or tax liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The federal and state income tax returns are
generally subject to tax examinations. To the extent we have tax attribute carryforwards, the tax&nbsp;years in which the attribute
was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized
in a future period. Any unfavorable tax adjustment could have a significant impact on our results of operations and future cash
flows. Furthermore, if the U.S. government decides to eliminate, or reduce the scope or the rate of any tax benefit, either of
which it could decide to do at any time, our results of operations could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RISKS RELATED TO DEVELOPMENT AND COMMERCIALIZATION
OF OUR PRODUCT CANDIDATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We might not be able to develop marketable products utilizing
our technology and we might not be able to identify and successfully implement an alternative product development strategy. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The approach we have adopted to discover and
develop product candidates is new and may never lead to marketable products. We have concentrated our efforts on developing therapeutic
product candidates utilizing new advanced technology for drug delivery. To our knowledge, no person or company has developed any
therapeutic product utilizing the same technology and no such ophthalmic micro-therapeutic product has been approved for marketing
to date. We are leading a new field of ophthalmic micro-therapeutic research and development and the scientific discoveries that
form the basis for our efforts to develop products are relatively new. The scientific evidence to support the feasibility of developing
such products and treatments based on these discoveries is both preliminary and limited. Our focus solely on developing products
utilizing our proprietary technology as opposed to more proven technology increases the risks associated with investing in our
stock. If we are unsuccessful in developing product candidates utilizing our technology, we may be required to change the scope
and direction of our product development activities. If we are not able to identify and successfully implement an alternative product
development strategy, our business may fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Ophthalmic micro-therapeutic research and development is a
highly uncertain undertaking. Our development efforts may be delayed for any number of reasons, in which case potential marketing
approval or commercialization of our proprietary technology could be delayed or prevented. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our research and development activities to develop
ophthalmic micro-therapeutics utilizing our proprietary technology may be impeded due to scientific or technological difficulties
or our lack of complete understanding of the challenges. Our research and development activities might not give rise to a marketable
product and we might not succeed in developing a marketable product in a timely manner or in accordance with our estimated budgets.
Even if we are successful in developing such products, there is no certainty that our products, when developed, will be found to
be sufficiently effective and safe for use to receive regulatory approval for marketing, which would adversely impact our potential
revenues, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Even if we complete the necessary preclinical studies and
clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals
for the commercialization of some or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining,
required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue
would be materially impaired. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business depends on the success of our lead
research and development programs which will require significant additional clinical testing before we can seek regulatory approval
and potentially launch commercial sales. In addition, we do not have any products that have gained regulatory approval. Our business
and future success depends on our ability to obtain regulatory approval of and then successfully commercialize our lead product
candidates. We are currently preparing for Phase&nbsp;III clinical trials and our ability to develop, obtain regulatory approval
for, and successfully commercialize, products will depend on several factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>further ascertaining the FDA&rsquo;s expectations with respect to the nonclinical and clinical testing requirements across
the development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>successful completion of our current clinical trials or other clinical trials, which will depend substantially upon the satisfactory
performance of third-party contractors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>successful achievement of the objectives of planned clinical trials, including manufacturability qualification of devices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>receipt of marketing approvals from the FDA, and similar regulatory authorities outside the U.S.;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establishing commercial manufacturing and supply arrangements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establishing a manufacturing and commercial infrastructure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>acceptance of the products by patients, the medical community and third-party payors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establishing market share while competing with other therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>successfully executing our pricing and reimbursement strategy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a continued acceptable safety and adverse event profile of the products following regulatory approval; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering
the products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business strategy is to develop several
pipeline product candidates over the next approximately two to three&nbsp;years which will require additional clinical and nonclinical
development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial
manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We are not permitted
to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory
authorities, and we may never receive such regulatory approval for any of our product candidates. If we are unable to develop or
receive marketing approval in a timely manner or at all, we could experience significant delays or an inability to commercialize
the product, which would materially and adversely affect our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We may encounter substantial delays in or failure of our clinical
trials. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the clinical trials that we are required
to conduct to gain regulatory approval are delayed or unsuccessful, we might not be able to market our prospective product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may experience delays in any phase of the
development and commercial launch of product candidates, including during research and development and clinical trials. Implementing
a clinical trial is time-consuming and expensive, and the outcome of any clinical trial is uncertain. The completion of any of
these clinical trials may be delayed or halted for numerous reasons, including, but not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the FDA, institutional review boards, or IRB, the European Union regulatory authorities, or the European Medicines Agency,
and national authorities, or other regulatory authorities do not approve a clinical trial protocol or place a clinical trial on
hold;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">patients do not enroll in a clinical trial or results from patients are not received at the expected rate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patients discontinue participation in a clinical trial prior to the scheduled endpoint set forth in the clinical protocol at
a higher than expected rate, especially if such discontinuations interfere with our ability to assess the efficacy of our drug
candidate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patients experience adverse events from our treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patients get hurt during a clinical trial for a variety of reasons that might not be related to our product candidates, including
the advanced stage of their disease and other medical problems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>third-party clinical investigators do not perform the clinical trials in accordance with the anticipated schedule or consistent
with the clinical trial protocol and good clinical practices or other third-party organizations do not perform data collection
and analysis in a timely or accurate manner;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>enrollment and sample size of our clinical trials may be substantially different than estimated which may lead to longer timelines
and larger expenses;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>third-party clinical investigators engage in activities that, even if not directly associated with our clinical trials, result
in their debarment, loss of licensure, or other legal or regulatory sanction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory inspections of manufacturing facilities, which may, among other things, require us to undertake corrective action
or suspend the clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in governmental regulations or administrative actions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the interim results of the clinical trial, if any, are inconclusive or negative; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the study design, although approved and completed, is inadequate to demonstrate effectiveness and safety.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our dependence upon clinical trials in developing
product candidates may impede them from reaching advanced stages of development, and might prevent all or part of our commercial
operations. To date, the aforementioned situations regarding potential delays in research and development activities and clinical
trials have yet to occur in a manner which adversely affects our research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our product candidates are based on a novel technology, which
makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Human clinical trials are expensive, time-consuming
and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our product
candidates are based on new technologies, we expect that such human clinical trials will require extensive research and development
and have substantial manufacturing and processing costs. Accordingly, our clinical trial costs could be significantly higher than
other conventional therapeutic technologies or drug products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We may find it difficult to enroll an adequate number of patients
in our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Identifying and qualifying patients to participate
in our clinical trials is critical to our success. Patient enrollment depends on many factors, including the size and nature of
the patient population, eligibility criteria for the clinical trial, the proximity of patients to clinical sites, the design of
the clinical protocol, the&nbsp;availability of competing clinical trials, the availability of new drugs approved for the indication
the clinical trial is investigating, and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the
drug being studied in relation to other available therapies. Any inability to locate and enroll a sufficient number of patients
for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether
and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may also result
in increased development costs for our product candidates, which would cause the value of our company to decline and limit our
ability to obtain additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, any negative results we may report
in clinical trials of our product candidate may make it difficult or impossible to recruit and retain patients in other clinical
trials of that same product candidate. Delays in the enrollment for any clinical trial of our product candidates will increase
our costs, slow down our product development and approval process and delay or potentially jeopardize our ability to commence product
sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion
of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our product candidates may cause undesirable side effects
or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant
negative consequences following any potential marketing approval. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If our product candidates are associated with
undesirable side effects or have characteristics that are unexpected, we may need to abandon our development or limit development
to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe
or more acceptable from a risk-benefit perspective. Any serious adverse or undesirable side effects identified during the development
of our product candidates, could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval
by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us from commercializing our
product candidates and generating revenues from their sale. In addition, if any of our product candidates receive regulatory approval
and we or others later identify undesirable adverse effects caused by the product, we could face one or more of the following consequences:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory authorities may require the addition of labeling statements, such as a boxed warning or a contraindication, or other
safety labeling changes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory authorities may require a Risk Evaluation and Mitigation Strategy, or a REMS;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory authorities may withdraw their approval of the product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory authorities may seize the product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be required to change the way that the product is administered, or conduct additional clinical trials or we may need
to recall the product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we may be subject to litigation or product liability claims fines, injunctions or criminal penalties; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our reputation may suffer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If the market opportunities for our future product candidates
are smaller than we believe they are, our product revenues may be adversely affected and our business may suffer. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are currently focusing our research and product
development efforts on our glaucoma, pupil dilation and dry eye products. Our understanding of both the number of people who have
these needs, as well as the subset of people who have the potential to benefit from our product candidates, are based on estimates
in published literature. While we believe these estimates are reasonable, they may prove to be incorrect and new studies may reduce
the estimated incidence or prevalence of glaucoma and dry eyes and the need for pupil dilation. The number of patients in the U.S.,
the European Union and elsewhere may turn out to be lower than expected or these patients might not be otherwise amenable to our
product candidates or may become increasingly difficult to identify and access, all of which would adversely affect our business,
financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The commercial success of our product candidates will depend
on the degree of market acceptance among ophthalmologists and optometrists, patients, patient advocacy groups, third-party payors
and the medical community. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even if we receive regulatory approval to market
our product candidates, our product candidates might not gain market acceptance upon their commercial introduction, which could
prevent us from becoming profitable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may have difficulties convincing the medical
community, third-party payors and consumers to accept and use any of our product candidates that may be approved for commercialization
in the future. Other factors that we believe will affect market acceptance of our product candidates include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>safety, efficacy and ease of administration of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the success of physician education programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the availability of government and third-party payor reimbursement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the pricing of our product candidates, particularly as compared to alternative treatment methods and medications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which alternative treatment methods and medications are more readily available as compared to the availability
of any product candidates that we may develop in the future; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the prevalence and severity of any adverse effects.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We face significant competition in an environment of rapid
technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies that
are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully market
or commercialize our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The specialty pharma market is highly competitive.
If we are unable to compete effectively with existing products, new treatment methods and new technologies, we may be unable to
commercialize any therapeutic products that we may develop in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The specialty pharma market is subject to rapid
technological change and is significantly affected by existing rival products and medical procedures, new product introductions
and the market activities of other participants. Pharmaceutical and biotechnology companies, academic institutions, governmental
agencies and other public and private research organizations may pursue the research and development of technologies, drugs or
other therapeutic products for the treatment of some or of the diseases we are targeting. We may also face competition from products
which have already been approved and accepted by the medical community for the treatment of these same indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a result of any of the foregoing factors,
our competitors may develop or commercialize products with significant advantages over any therapeutic products that we may develop.
If our competitors are more successful in commercializing their products than we are, their success could adversely affect our
competitive position and harm our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Even if we are able to commercialize any of the product candidates
that we may develop, the product may become subject to unfavorable pricing regulations, third-party reimbursement practices or
healthcare reform initiatives, which could harm our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our ability to commercialize our therapeutic
products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related
treatments will be available from government healthcare programs, private health insurers, managed care plans and other organizations.
However, any therapeutic products we may develop could become subject to unfavorable pricing regulations, third-party reimbursement
practices or healthcare reform initiatives in the U.S. or other jurisdictions, which could adversely affect the profitability of
our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The regulations that govern pricing for new
medical products vary widely from country to country. As a result, we might obtain regulatory approval for a product in a particular
country, but then be subjected to pricing regulations in that country that delay the commercial launch of the product and negatively
impact the revenues able to be generated from the sale of the product in that country. In addition, our ability to commercialize
any approved products successfully will depend in part on the extent to which reimbursement for these products will be available
from government health administration authorities, private health insurers and other organizations. Even if we succeed in bringing
one or more therapeutic products to market, these products might not be considered cost-effective, and the amount reimbursed for
any products may be insufficient to allow their sale on a competitive basis. If the price we are able to charge for therapeutic
products is inadequate in light of our development and other costs, our profitability could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we fail to establish an effective distribution process
our business may be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have limited experience in the sale, marketing
and distribution of drug products. To achieve commercial success for the product candidates for which we obtain marketing approval,
we will need to establish and maintain adequate sales, marketing and distribution capabilities, either ourselves or through collaborations
or other arrangements with third parties. Failure to secure contracts with wholesalers could negatively impact the distribution
of our potential products, and failure to coordinate financial systems could negatively impact our ability to accurately report
product revenue. If we are unable to effectively establish and manage the distribution process, the commercial launch and sales
of our potential products may be delayed or severely compromised and our results of operations may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We might not be able to maintain insurance coverage at a reasonable
cost or in an amount adequate to satisfy any liability that may arise. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are exposed to the risk of claims seeking
monetary damages being filed against us for loss or harm suffered by participants of our clinical trials or for loss or harm suffered
by users of any drug that may receive approval for commercialization in the future. In either event, the FDA or the regulatory
authorities of other countries or regions may commence investigations of the safety and effectiveness of any such clinical trial
or commercialized drug, the manufacturing processes and facilities or marketing programs utilized in respect of any such clinical
trial or drug. Such investigations may result in mandatory or voluntary recalls of any commercialized drug or other significant
enforcement action such as limiting the indications for which any such drug may be used, or suspension or withdrawal of approval
for any such drug. Investigations by the FDA or any other regulatory authority in other countries or regions also could delay or
prevent the completion of any of our other clinical development programs. Our insurance policies might not fully cover the risk
of loss associated with our operations. In the event that we are required to pay damages for any such claim, we may be forced to
seek bankruptcy or to liquidate because our asset and revenue base may be insufficient to satisfy the payment of damages and any
insurance that we have obtained or may obtain for product or clinical trial liability might not provide sufficient coverage against
potential liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Product liability lawsuits against us could divert our resources
and could cause us to incur substantial liabilities and to limit commercialization of any products that we develop. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We face an inherent risk of product liability
exposure related to the use of our product candidates that we develop in human clinical trials. We face an even greater risk if
we commercially sell any products that we develop. If we cannot successfully defend ourselves against claims that our product candidates
or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may
result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>decreased demand for any product candidates or products that we develop;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injury to our reputation and significant negative media attention;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>withdrawal of clinical trial participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>significant costs to defend the related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>substantial monetary awards to clinical trial participants or patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>loss of revenue;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>reduced time and attention of our management to pursue our business strategy; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inability to commercialize any products that we develop.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our insurance policies might not fully cover
liabilities that we may incur in the event of a product liability lawsuit. We may need to increase our insurance coverage as we
expand our clinical trials. We will need to further increase our insurance coverage if we commence commercialization of any of
the product candidates for which we obtain marketing approval. Insurance coverage is increasingly expensive. We might not be able
to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>RISKS RELATED TO REGULATORY APPROVAL OF OUR PRODUCT CANDIDATES
AND OTHER LEGAL COMPLIANCE MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we are not able to obtain, or if there are delays in obtaining,
required regulatory approvals, we might not be able to commercialize our product candidates, and our ability to generate revenue
would be materially impaired. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any product candidates we may develop will be
subject to extensive and burdensome governmental regulations relating to development, clinical trials, manufacturing and commercialization.
Rigorous preclinical testing and clinical trials and extensive regulatory approval processes are required to be successfully completed
in the United States and in many foreign jurisdictions such as the European Union and Asia before a new product may be offered
and sold in any of these countries or regions. Satisfaction of these and other regulatory requirements is costly, time-consuming,
uncertain and subject to unanticipated delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the United States, the product candidates
that we intend to develop and market are regulated by the FDA under its drug development and review process. The time required
to obtain FDA and other approvals for our product candidates is unpredictable. Before such product candidates can be marketed,
our investigational new drug application, or IND, must go into effect permitting the conduct of clinical trials, then we must successfully
complete human testing under three phases of clinical trials and FDA must approve our new drug application, or NDA. Even after
successful completion of clinical testing, there is a risk that the FDA may request further information from us, disagree with
our findings or otherwise undertake a lengthy review of our submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">It is possible that FDA will not approve any
application that we may submit. It is possible that none of the product candidates that we may develop will obtain the appropriate
regulatory approvals necessary for us to commence the offer and sale of such products. Any delay or failure in obtaining required
approvals could have a material adverse effect on our ability to generate revenues from a particular prospective product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Failure to obtain marketing approval in foreign jurisdictions
would prevent our product candidates from being marketed in such jurisdictions. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Because we intend to market any therapy that
we may develop in jurisdictions in addition to the United States,&nbsp;such as the European Union, we will likely incur the same
costs or more in satisfying foreign regulatory requirements governing the conduct of clinical trials, manufacturing and marketing
and commercialization of our product candidates. Approval by the FDA by itself does not assure approval by regulatory authorities
outside the U.S. and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities
in other countries or jurisdictions or by the FDA. Each of these foreign regulatory approval processes includes all of the risks
associated with the FDA approval process, as well as risks attributable to having to satisfy local regulations within each of these
foreign jurisdictions. In addition, any failure or delay in obtaining regulatory approval in one country may have a negative effect
on the regulatory process in other countries. Our inability to obtain regulatory approval outside the United States may adversely
compromise our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The terms of approvals, ongoing regulations and post-marketing
restrictions for our products may limit how we manufacture and market our products, which could materially impair our ability to
generate revenue. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Once marketing approval has been granted, an
approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. The FDA closely regulates
the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance
with the provisions of the approved labeling and regulatory requirements. The FDA imposes stringent restrictions on manufacturers&rsquo;
communications regarding off-label use and if we do not restrict the marketing of our products only to their approved indications,
we may be subject to enforcement action for off-label marketing. We, and any potential collaborators we may have in the future,
must therefore comply with requirements concerning advertising and promotion for any of our products for which we or our collaborators
obtain marketing approval. Thus, if any of our product candidates receive marketing approval, the accompanying label may limit
the approved use of our product, which could limit sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, manufacturers of approved products
and those manufacturers&rsquo; facilities are required to comply with extensive FDA requirements, including ensuring that quality
control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMP, applicable to drug manufacturers,
which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records
and documentation and reporting requirements. We, any contract manufacturers we may engage in the future, our future collaborators
and their contract manufacturers will also be subject to other regulatory requirements, including submissions of safety and other
post-marketing information and reports, registration and listing requirements, requirements regarding the distribution of samples
to clinicians, recordkeeping, and costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy
of the product such as the requirement to implement a risk evaluation and mitigation strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We may be subject to substantial penalties if we fail to comply
with regulatory requirements or if we experience unanticipated problems with our products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Violations of the Federal Food, Drug, and Cosmetic
Act, or FDCA, relating to the promotion or manufacturing of drug products may lead to investigations by the FDA, Department of
Justice and state Attorney General alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer
protection laws. In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers
or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on such products, manufacturers or manufacturing processes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on the labeling or marketing of a product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on product distribution or use;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>requirements to conduct post-marketing studies or clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>warning letters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>withdrawal of the products from the market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>refusal to approve pending applications or supplements to approved applications that we submit;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>recall of products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>fines, restitution or disgorgement of profits or revenues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>suspension or withdrawal of marketing approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>refusal to permit the import or export of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product seizure or detention; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions or the imposition of civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We are subject to federal and state healthcare fraud and abuse
laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied,
with such laws, we could face substantial penalties. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are subject to U.S. federal and state and
also foreign healthcare fraud and abuse laws and regulations. Any finding of our failure to comply with such laws and regulations
could have a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our operations may be directly or indirectly
affected by various broad U.S. federal and state healthcare fraud and abuse laws. These include the U.S. federal anti-kickback
statute, which prohibits any person from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly
or indirectly, in return for or to induce the referring, ordering, leasing, purchasing or arranging for or recommending the ordering,
purchasing or leasing of an item or service, for which payment may be made under U.S. federal healthcare programs, such as the
Medicare and Medicaid programs. The U.S. federal anti-kickback statute is very broad in scope, and many of its provisions have
not been uniformly or definitively interpreted by existing case law or regulations. In addition, many states have adopted laws
similar to the U.S. federal anti-kickback statute, and some of these laws are broader than that statute in that their prohibitions
are not limited to items or services paid for by a U.S. federal healthcare program but, instead, apply regardless of the source
of payment. Violations of these laws could result in fines, imprisonment or exclusion from government-sponsored programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additionally, our relationships with customers
and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations,
which may expose us to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm and diminished
profits and future earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Healthcare providers, physicians and third-party
payors play a primary role in the recommendation of any product candidates for which we obtain marketing approval. Our future arrangements
with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations
that may constrain the business or financial arrangements and relationships through which we plan to market, sell and distribute
products for which we obtain marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Some state laws require pharmaceutical companies
to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government and federal and state laws may require drug manufacturers to report information related to payments and
other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern
the privacy and security of health information in some circumstances, many of which differ from each other in significant ways
and often are not preempted by the Health Insurance Portability and Accountability Act, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Efforts to ensure that our business arrangements
with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental
authorities will conclude that our business practices might not comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of
any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal
and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid,
and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect
to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative
sanctions, including exclusions from government funded healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Recently enacted and future legislation may affect our ability
to commercialize and the prices we obtain for any products that are approved in the United States or foreign jurisdictions. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In the United States and some foreign jurisdictions,
there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could
affect our ability to profitably sell or commercialize our product candidates for which we obtain marketing approval. The pharmaceutical
industry has been a particular focus of these efforts and have been significantly affected by legislative initiatives. Current
laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria
and in additional downward pressure on the price that we receive for any FDA approved product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The U.S. Medicare Prescription Drug, Improvement,
and Modernization Act of 2003, or the Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products.
The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based
on average sales prices for clinician administered drugs. In addition, this legislation provided authority for limiting the number
of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could
decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to
drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting
their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result
in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In March&nbsp;2010, President Obama signed into
law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or
collectively the ACA. Among the provisions of the ACA of importance to our business, including, without limitation, our ability
to commercialize and the prices we may obtain for any of our product candidates and that are approved for sale, are the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>a new Medicare Part&nbsp;D coverage gap discount program, in which participating manufacturers must agree to offer 50% point-of-sale
discounts off negotiated drug prices during the coverage gap period as a condition for the manufacturer&rsquo;s outpatient drugs
to be covered under Medicare Part&nbsp;D;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute,
and the addition of new government investigative powers, and enhanced penalties for noncompliance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>extension of manufacturers&rsquo; Medicaid rebate liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expansion of eligibility criteria for Medicaid programs; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, other legislative changes have
been proposed and adopted since the ACA was enacted. In August&nbsp;2011, the Budget Control Act of 2011, among other things, created
measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted
deficit reduction of at least $1.2 trillion for the&nbsp;years 2013 through 2021, was unable to reach required goals, thereby triggering
the legislation&rsquo;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare
payments to providers of up to 2% per fiscal year, which went into effect in April&nbsp;2013 and will remain in effect through
2024 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare
payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers
from three to five&nbsp;years. These new laws may result in additional reductions in Medicare and other healthcare funding and
otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the
frequency with which any such product candidate is prescribed or used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">With the new Administration and Congress, there
may be additional legislative changes, including potentially repeal and replacement of certain provisions of the ACA. It remains
to be seen, however, whether new legislation will be enacted and, if so, precisely what any new legislation could provide and what
impact it will have on the availability of healthcare and containing or lowering the cost of healthcare. For example, it is possible
that any repeal and replacement initiatives, if enacted into law, could ultimately result in fewer individuals having health insurance
coverage or in individuals having insurance coverage with less generous benefits. The timing and scope of any potential future
legislation to repeal and replace ACA provisions is highly uncertain in many respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Accordingly, such reforms, if enacted, could
have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain
marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. We
expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions
in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure
on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any
approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the
frequency with which any products we may develop are prescribed or administered. Any reduction in reimbursement from Medicare or
other government programs may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The costs of prescription pharmaceuticals has
also been the subject of considerable discussion in the United States, and members of Congress and the Administration have stated
that they will address such costs through new legislative and administrative measures. The pricing of prescription pharmaceuticals
is also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities
can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in
some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to
other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set
at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If third-party manufacturers fail to comply with manufacturing
regulations, our financial results and financial condition may be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We currently rely on a combination of internal
manufacturing capacity and third-party manufacturers to produce the product candidates for our clinical trials. If we commence
additional clinical trials for any of our product candidates, our ability to complete such clinical trials successfully and to
apply for and obtain regulatory approval for marketing will depend upon such third-party manufacturers&rsquo; consistent production
of a product candidate of a defined quality for all phases of clinical testing and for commercial production in accordance with
cGMP. Our third party manufacturers&rsquo; inability to satisfy the chemistry, manufacturing and control concerns of regulatory
bodies such as the FDA would either prevent us from completing clinical trials or prevent us from obtaining regulatory approval
for marketing, either of which would significantly compromise our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We are subject to anti-corruption laws, as well as export
control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could
be subject to civil or criminal penalties, other remedial measures and legal expenses, be precluded from developing manufacturing
and selling products outside the United States or be required to develop and implement costly compliance programs, which could
adversely affect our business, results of operations and financial condition. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our operations are subject to anti-corruption
laws, including the U.K. Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption
laws that apply in countries where we do business and may do business in the future. The Bribery Act, FCPA and these other laws
generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed or making other prohibited
payments to government officials or other persons to obtain or retain business or gain some other business advantage. Compliance
with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem.
In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are
operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals
in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led
to FCPA enforcement actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may in the future operate in jurisdictions
that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with
third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA or local anti-corruption laws.
In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations
might be subject or the manner in which existing laws might be administered or interpreted. If we expand our operations outside
of the U.S., we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in
which we plan to operate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are also subject to other laws and regulations
governing our international operations, including regulations administered by the governments of the United Kingdom and the U.S.,
and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons,
customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various
laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with
certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical
data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional
resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products
and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We might not be completely effective in ensuring
our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA or other legal requirements, including
Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA and other anti-corruption laws or Trade Control
laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses,
which could have an adverse impact on our business, financial condition, results of operations and liquidity. The Securities and
Exchange Commission also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&rsquo;s
accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or
Trade Control laws by U.K., U.S. or other authorities could also have an adverse impact on our reputation, our business, results
of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RISKS RELATED TO OUR BUSINESS OPERATIONS
AND MANAGING GROWTH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We are highly dependent on the services of our senior management
team, including our Chief Executive Officer, Dr.&nbsp;Tsontcho Ianchulev, and if we are not able to retain these members of our
management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are highly dependent on our senior management
team, including our Chief Executive Officer, Dr.&nbsp;Ianchulev. The employment agreements we have with these officers do not prevent
such persons from terminating their employment with us at any time. The loss of the services of any of these persons could impede
the achievement of our research, development and commercialization objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, we are dependent on our continued
ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not
able to retain our management and to attract, on acceptable terms, additional qualified personnel necessary for the continued development
of our business, we might not be able to sustain our operations or grow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We might not be able to attract or retain qualified
personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses.
Many of the other pharmaceutical companies that we compete against for qualified personnel and consultants have greater financial
and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse
opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates
and consultants than what we have to offer. If we are unable to continue to attract, retain and motivate high-quality personnel
and consultants to accomplish our business objectives, the rate and success at which we can discover and develop drug candidates
and our business will be limited and we may experience constraints on our development objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our future performance will also depend, in
part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop
an effective working relationship among senior management. Our failure to integrate these individuals and create effective working
relationships among.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have limited corporate infrastructure, and may experience
difficulties in managing growth. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of March 27, 2018, we had 11 full time employees
and rely (and anticipate continuing to rely) heavily on third-party contractors for the provision of professional and other services.
As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales,
marketing, financial, legal and other resources. Our management may need to divert a disproportionate amount of its attention away
from our day-to-day operations and devote a substantial amount of time to managing these growth activities. We might not be able
to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational inefficiencies,
loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of our
current and potential future drug candidates. If our management is unable to effectively manage our growth, our expenses may increase
more than expected, our ability to generate and grow revenue could be reduced and we might not be able to implement our business
strategy. Our future financial performance, our ability to commercialize drug candidates, develop a scalable infrastructure and
compete effectively will depend, in part, on our ability to effectively manage any future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our employees, third-party clinical investigators, consultants,
licensors and strategic partners may engage in misconduct or other improper activities, including non-compliance with regulatory
standards and requirements and insider trading. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are exposed to the risk of fraud or other
misconduct by our employees, third-party clinical investigators, consultants, licensors and strategic partners. Misconduct by these
parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions,
provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations
in the U.S. and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular,
sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to
prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit
a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions
with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation.
It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity
might not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or
other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted
against us and we are not successful in defending ourselves or asserting our rights, those actions could have a negative impact
on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other
sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We rely upon information technology and any failure, inadequacy,
interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our
business effectively. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business operations could suffer in the
event of system failure. Despite the implementation of security measures, our internal computer systems and those of our contract
research organizations, and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access,
natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical
trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly
increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss
of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur
liability and further development of our product candidates could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We could be impacted by unfavorable results of legal proceedings,
including a current litigation seeking to recover damages from us in connection with our purchase of assets from Corinthian Ophthalmic,
Inc. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On October&nbsp;10, 2014, Eyenovia entered into
an asset purchase agreement and plan of reorganization with Corinthian Ophthalmic, Inc., or Corinthian, pursuant to which Corinthian
sold its intellectual property portfolio and related assets to us for 1,445,627 shares of our Series&nbsp;A preferred stock and
1,333,333 shares of our common stock. A shareholder of Corinthian alleging a fraudulent transfer, is seeking to recover the purchase
price of its Corinthian shares and other damages and named our Chief Executive Officer and members of our Board of Directors as
defendants in a legal proceeding that has not yet been fully resolved in connection with our asset purchase from Corinthian. We
are indemnified by Corinthian in this litigation and Corinthian&rsquo;s applicable insurance policy provides coverage of&thinsp;$10,000,000.
As a result, we do not expect to incur a material loss as a result of this litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">However, litigation results are inherently unpredictable
and regardless of the merit of the allegations, litigations are expensive, time-consuming, disruptive to our operations and distracting
to management and may adversely affect our financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have material weaknesses in our internal control over financial
reporting. In addition, because of our status as an emerging growth company, our independent registered public accountant is not
required to provide an attestation report as to our internal control over financial reporting for the foreseeable future. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are required, pursuant to Section&nbsp;404
of the Sarbanes-Oxley Act, to furnish a report by our management on, among other things, the effectiveness of our internal control
over financial reporting for each fiscal year beginning with the one ending December 31, 2018. This assessment will need to include
disclosures of any material weaknesses identified by our management in our internal control over financial reporting. We are in
the very early stages of the costly and challenging process of compiling the system and processing documentation necessary to perform
the evaluation needed to comply with Section&nbsp;404.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A &ldquo;material weakness&rdquo; is a deficiency,
or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that
a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. As of
December 31, 2017, we determined that our disclosure controls and procedures were not effective at the reasonable assurance level&nbsp;due
to the material weaknesses described below. This Annual Report on Form 10-K does not include a report of management&rsquo;s assessment
regarding internal control over financial reporting as of December 31, 2017 for the reasons specified above, however, the following
material weaknesses in our internal control over financial reporting were identified in the normal course:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>We had insufficient segregation of duties in our finance and accounting function because of our
limited personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>We did not properly identify all related party relationships and transactions so that they could be evaluated for disclosure
in our public filings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>The terms of certain agreements entered into by us were not properly communicated to the Board of Directors in order for the
Board of Directors to take the appropriate actions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD><P>We did not adequately record research and development
expenses in our internal books and records to permit timely and accurate financial reporting.</P>



</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to address the weaknesses identified
above by (a) increasing the oversight and review procedures of the Board of Directors and our Audit Committee with regard to financial
reporting, financial processes and procedures and internal control procedures and (b) hiring additional finance and accounting
personnel, including a Chief Financial Officer (hired December 2017), who will assist in the process of remediating the weaknesses
identified above. If we are unable to remediate the material weakness, or otherwise maintain effective internal control over financial
reporting, we might not be able to report our financial results accurately, prevent fraud or file our periodic reports in a timely
manner. We cannot assure you that we have identified all of our existing significant deficiencies and material weaknesses, or that
we will not in the future have additional significant deficiencies or material weaknesses.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our independent registered public accounting
firm will not be required to formally attest to the effectiveness of our internal control over financial reporting pursuant to
Section&nbsp;404 until the later of the year following our first annual report required to be filed with the SEC, or the date we
are no longer an &ldquo;emerging growth company&rdquo; as defined in the recently enacted JOBS Act, if we take advantage (as we
expect to do) of the exemptions contained in the JOBS Act. We will remain an &ldquo;emerging growth company&rdquo; for up to five&nbsp;years,
although if the market value of our common stock that is held by non-affiliates exceeds $700&nbsp;million as of any June&nbsp;30th
before that time, we would cease to be an &ldquo;emerging growth company&rdquo; as of the following December&nbsp;31st. At such
time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with
the level at which our controls are documented, designed or operating. Our remediation efforts might not enable us to avoid a material
weakness in our internal control over financial reporting in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any of the foregoing occurrences, should they
come to pass, could negatively impact the public perception of our company, which could have a negative impact on our stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RISKS RELATED TO OUR DEPENDENCE ON THIRD
PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have limited clinical trial experience. We may rely upon
third parties in conducting our clinical trials, and those third parties might not perform satisfactorily, including failing to
meet deadlines for the completion of such clinical trials. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have limited experience in conducting and
managing the clinical trials necessary to obtain regulatory approvals for our product candidates. We may rely on third parties
for clinical development activities. Any reliance on third parties would reduce our control over these activities but would not
relieve us of our responsibilities. For example, we would remain responsible for ensuring that each of our clinical trials is conducted
in accordance with the general investigational plan and protocols for the clinical trial. Moreover, the FDA requires us to comply
with standards, commonly referred to as good clinical practices for conducting, recording and reporting the results of clinical
trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of
clinical trial participants are protected. We are also required to register ongoing clinical trials and post the results of completed
clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result
in fines, adverse publicity and civil and criminal sanctions. If we engage third parties and they do not successfully carry out
their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or
our stated protocols, we might not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates
and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. If these third
parties do not successfully carry out their contractual duties or meet expected deadlines, we may be required to replace them,
which may delay the affected clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We contract with third parties for the manufacture of our
product candidates for clinical trials and expect to continue to do so in connection with the potential commercialization of our
product candidates and for clinical trials and commercialization of any other product candidates that we develop or may develop.
This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such
quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We do not currently operate manufacturing facilities
for clinical or commercial production of our product candidates. We rely on a number of third parties for the supply of parts,
formulations, active pharmaceutical ingredients, and other materials required for our manufacturing, research and development activities.
If we were unable to reach agreements with these third parties, or if we were unable to maintain contractual relationships with
these third parties, our research and development activities would be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We rely on third parties to provide the materials
required for our research and development activities. Obtaining these materials requires various approvals as well as reaching
a purchase or commercial agreement on acceptable terms with the provider of the materials. We might not be able to reach agreements
with a sufficient number of suppliers or do so on acceptable terms. If we are unable to reach acceptable agreements with a sufficient
number of suppliers of materials, our research and development activities will be delayed and our ability to implement our business
plan will be compromised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our manufacturing process is a complicated and
expensive and it requires&nbsp;months of advance planning. We rely on a limited number of manufacturers for our supply. If we were
unable to acquire the necessary amount of deliverables to complete our clinical trials, our progress could be delayed substantially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Additional potential risks related to reliance
on third-party manufacturers include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our product
candidates or otherwise do not satisfactorily perform according to the terms of their agreements with us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>delays in obtaining regulatory approval for our product candidates, if our third-party manufacturers fail to satisfy or comply
with regulatory requirements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible breach of the manufacturing agreement by the third party;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product loss due to contamination, equipment failure or improper installation or operation of equipment or operator error;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the failure of the third-party manufacturer to comply with applicable regulatory requirements; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the possible misappropriation of our proprietary information, including our trade secrets and know-how.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have no manufacturing capacity or experience and anticipate
reliance on third-party manufacturers for the development and commercialization of our product candidates in accordance with manufacturing
regulations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In order to develop product candidates, apply
for regulatory approvals and commercialize our product candidates, we will need to develop, contract for or otherwise arrange for
the necessary manufacturing capabilities. We have no manufacturing experience or resources and must incur significant costs to
develop this expertise or rely on third parties to manufacture our product candidates. Manufacturing of the product candidates
must comply with the cGMP requirements set forth in FDA&rsquo;s regulations. The manufacturing process for our product candidates
is an element of the FDA approval process and we will need to contract with manufacturers who can satisfy the FDA requirements
on an ongoing basis before seeking to obtain FDA approval. In addition, if we receive the necessary regulatory approval for any
of our product candidates, we also expect to rely on third parties, including our collaborators, to manufacture our products in
quantities sufficient for commercial marketing. We may experience difficulty in obtaining adequate and timely manufacturing capacity
for clinical trials and commercial needs. If we are unable to obtain or maintain contract manufacturing for our product candidates,
or are unable to do so on commercially reasonable terms, we might not be able to successfully develop and commercialize our product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we, our service providers or our third-party manufacturers
fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could harm our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we, our service providers, or any third-party
manufacturers fail to comply with laws regulating the protection of the environment and health and human safety, we could be subject
to enforcement actions and our business prospects could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our research and development activities, and
the research and development activities of our service providers and third-party manufacturers, may involve the use of hazardous
materials and chemicals or the maintenance of various flammable and toxic chemicals. Failure to adequately handle and dispose of
these materials could lead to liabilities for resulting damages, which could be substantial. We also may be subject to numerous
environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-home
pathogens and the handling of bio-hazardous materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we, our service providers, or any third-party
manufacturers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement
actions, which could adversely affect our ability to develop, market and sell our product candidates successfully and could harm
our reputation and lead to reduced acceptance of our product candidates. These enforcement actions may include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on, or prohibitions against, marketing our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>restrictions on importation of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>suspension of review or refusal to approve new or pending applications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>suspension or withdrawal of product approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>product seizures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>injunctions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>civil and criminal penalties and fines.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>RISKS RELATED TO OUR INTELLECTUAL PROPERTY AND POTENTIAL LITIGATION
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our success depends on our ability to protect our intellectual
property and proprietary technology. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our success depends in large part on our ability
to obtain and maintain patent, trade secret and other intellectual property protection in the U.S. and other countries with respect
to our proprietary product candidates. If we do not adequately protect our intellectual property rights, competitors may be able
to erode, negate or preempt any competitive advantage we may have, which could harm our business and ability to achieve profitability.
To protect our proprietary position, we file patent applications in the U.S.&nbsp;and abroad related to our novel product candidates
that are important to our business. The patent application and approval process is expensive and time-consuming and we might not
be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If the scope of the patent protection we obtain
is not sufficiently broad, we might not be able to prevent others from developing and commercializing technology and products similar
or identical to ours. The degree of patent protection we require to successfully compete in the marketplace may be unavailable
or severely limited in some cases and might not adequately protect our rights or permit us to gain or keep any competitive advantage.
Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable
aspects of our research and development output, such as our employees, contractors and other third parties, any of these parties
may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek
patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries,
and patent applications in the U.S. and other jurisdictions are typically not published until 18&nbsp;months after filing, or in
some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or
pending patent applications, or that we were the first to file for patent protection of such inventions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation
in recent&nbsp;years. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights may
be uncertain. Our pending and future patent applications might not result in patents being issued which protect our technology
or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates.
In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope
can be reinterpreted after issuance. Even if our patent applications issue as patents, they might not issue in a form that will
provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide
us with any competitive advantage. In addition, changes in either the patent laws or interpretation of the patent laws in the U.S.
and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of
foreign countries might not protect our rights to the same extent or in the same manner as the laws of the U.S. For example, patent
laws in various jurisdictions, including significant commercial markets such as Europe, restrict the patentability of methods of
treatment of the human body more than U.S. law does.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Some of our future patents and patent applications
may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&rsquo; interest
in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our
competitors, and our competitors could market competing products and technology. In addition, we would need the cooperation of
any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation might not be provided
to us. Furthermore, we, or any future partners, collaborators, or licensees, may fail to identify patentable aspects of inventions
made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore,
we may miss potential opportunities to strengthen our patent position. Any of the foregoing could have a material adverse effect
on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our patents covering our proprietary technology maybe subject
to challenge, narrowing, circumvention and invalidation by third parties. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any of our patents may be challenged, narrowed,
circumvented, or invalidated by third parties. The issuance of a patent is not conclusive as to its inventorship, scope, validity,
or enforceability, and our patents may be challenged in the courts or patent offices in the U.S. and abroad. We may be subject
to a third party preissuance submission of prior art to the USPTO or become involved in opposition, derivation, revocation, reexamination,
post-grant and <I>inter partes</I> review, or interference proceedings challenging our patent rights or the patent rights of others.
An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent
rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or
result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may
have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge
proceedings, such as oppositions in a foreign patent office, that challenge priority of invention or other features of patentability.
Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held
unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products,
or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial
cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, our competitors and other third
parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing
manner. For example, a third party may develop a competitive therapy that provides benefits similar to our product candidates but
that uses a technology that falls outside the scope of our patent protection. Our competitors may also seek approval to market
generic versions of any approved products and in connection with seeking such approval may claim that our patents are invalid,
unenforceable or not infringed. In these circumstances, we may need to defend or assert our patents, or both, including by filing
lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find
our patents invalid or unenforceable, or that our competitors are competing in a non-infringing manner. Thus, even if we have valid
and enforceable patents, these patents still might not provide protection against competing products or processes sufficient to
achieve our business objectives. If the patent protection provided by the patents and patent applications we hold or pursue with
respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize
our product candidates could be negatively affected, which could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We cannot be sure that we were the first to make the technologies
claimed in our patents or patent applications or that we were the first to file for patent protection.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Assuming the other requirements for patentability
are met, currently, the first to file a patent application is generally entitled to the patent. However, prior to March&nbsp;16,
2013, in the U.S., the first to invent was entitled to the patent. Publications of discoveries in the scientific literature often
lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are not published until 18&nbsp;months
after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed
in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly,
we cannot be certain that parties from whom we may license or purchase patent rights were the first to make relevant claimed inventions,
or were the first to file for patent protection for them. If third parties have filed patent applications on inventions claimed
in our patents or applications on or before March&nbsp;15, 2013, an interference proceeding in the U.S. can be initiated by such
third parties to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.
If third parties have filed such applications after March&nbsp;15, 2013, a derivation proceeding in the U.S. can be initiated by
such third parties to determine whether our invention was derived from theirs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The patent application process is subject to numerous risks
and there can be no assurance that we will be successful in obtaining patents for which we have applied. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pending patent applications cannot be enforced
against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications.
The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of
our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These
risks and uncertainties include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or
lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In
such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be
reinterpreted after issuance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patent applications might not result in any patents being issued;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, narrowed, found
to be unenforceable or otherwise might not provide any competitive advantage;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our competitors, many of whom have substantially greater resources and many of whom have made significant investments in competing
technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use,
and sell our potential product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding
worldwide health concerns; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>countries other than the U.S. may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign
competitors a better opportunity to create, develop and market competing product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Any of the foregoing events could have a material
adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>It is difficult and costly to protect our intellectual property
and our proprietary technologies, and we might not be able to ensure their protection. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our commercial success will depend in part on
obtaining and maintaining patent protection and trade secret protection for the composition, use and structure of our products
and product candidates, the methods used to manufacture them, the related therapeutic targets and associated methods of treatment
as well as on successfully defending these patents against potential third-party challenges. Our ability to protect our products
and product candidates from unauthorized making, using, selling, offering to sell or importing by third parties is dependent on
the extent to which we have rights under valid and enforceable patents that cover these activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The ultimate determination by the USPTO or by
a court or other trier of fact in the U.S., or corresponding foreign national patent offices or courts, on whether a claim meets
all requirements of patentability cannot be assured. Although we have conducted searches for third-party publications, patents
and other information that may affect the patentability of claims in our various patent applications and patents, we cannot be
certain that all relevant information has been identified. Accordingly, we cannot predict the breadth of claims that may be allowed
or enforced in our patents or patent applications, in our licensed patents or patent applications or in third-party patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We cannot provide assurances that any of our
patent applications will be found to be patentable, including over our own prior art patents, or will issue as patents. Neither
can we make assurances as to the scope of any claims that may issue from our pending and future patent applications nor to the
outcome of any proceedings by any potential third parties that could challenge the patentability, validity or enforceability of
our patents and patent applications in the U.S. or foreign jurisdictions. Any such challenge, if successful, could limit patent
protection for our products and product candidates and/or materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The degree of future protection for our proprietary
rights is uncertain because legal means afford only limited protection and might not adequately protect our rights or permit us
to gain or keep our competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>we might not be able to generate sufficient data to support full patent applications that protect the entire breadth of developments
in one or more of our programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>it is possible that one or more of our pending patent applications will not become an issued patent or, if issued, that the
patent(s) will be insufficient to protect our technology, provide us with a basis for commercially viable products or provide us
with any competitive advantages;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if our pending applications issue as patents, they may be challenged by third parties as not infringed, invalid or unenforceable
under U.S. or foreign laws; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>if issued, the patents under which we hold rights might not be valid or enforceable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, to the extent that we are unable
to obtain and maintain patent protection for one of our products or product candidates or in the event that such patent protection
expires, it may no longer be cost-effective to extend our portfolio by pursuing additional development of a product or product
candidate for follow-on indications. Any of the foregoing could have a material adverse effect on our business, financial condition,
results of operations, and prospects</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Obtaining and maintaining patent protection of our technologies
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Periodic maintenance fees, renewal fees, annuity
fees and various other governmental fees on patents and applications are required to be paid to the USPTO and various governmental
patent agencies outside of the U.S. in several stages over the lifetime of the patents and applications. The USPTO and various
non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent application process and after a patent has issued. There are situations in which non-compliance can
result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. Under the terms of some of our licenses, we do not have the ability to maintain or prosecute patents in
the portfolio, and must therefore rely on third parties to comply with these requirements. Failure by us or our licensors to maintain
protection of our patent portfolio could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, it is possible that defects of
form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with
respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we fail to establish,
maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If any of our
present or future partners, collaborators, licensees, or licensors, are not fully cooperative or disagree with us as to the prosecution,
maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the
form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable,
and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent
competition from third parties, which may have a material adverse effect on our business, financial condition, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Patent terms may be inadequate to protect our competitive
position on our products for an adequate amount of time and if we do not obtain protection under the Hatch-Waxman Amendments and
similar non-U.S.legislation for extending the term of patents covering each of our product candidates, our business may be materially
harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Patents have a limited lifespan. In the United
States, the natural expiration of a patent is generally twenty&nbsp;years after it is filed. Various extensions may be available,
however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development,
testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after
such candidates are commercialized. As a result, our patent portfolio might not provide us with adequate and continuing patent
protection sufficient to exclude others from commercializing products similar to our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Depending upon the timing, duration and conditions
of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension
under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar
legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five&nbsp;years for a patent covering
an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process.
A patent term extension cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval,
only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing
it may be extended. However, we might not receive an extension if we fail to apply within applicable deadlines, fail to apply prior
to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could
be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request,
the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval
to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material
adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Changes to the patent law in the United States or other jurisdictions
could diminish the value of patents in general, thereby impairing our ability to protect our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our success is heavily dependent on intellectual
property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and
legal complexity and is therefore costly, time consuming and inherently uncertain. The Leahy-Smith America Invents Act, or the
America Invents Act, reformed U.S. patent law in part by changing the U.S. patent system from a &ldquo;first to invent&rdquo; system
to a &ldquo;first inventor to file&rdquo; system, expanding the definition of prior art, and developing a post-grant review system.
This legislation changed U.S. patent law in a way that may weaken our ability to obtain patent protection in the U.S. for those
applications filed after March&nbsp;16, 2013.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, the America Invents Act created new
procedures to challenge the validity of issued patents in the U.S., including post-grant review and <I>inter partes</I> review
proceedings, which some third parties have been using to cause the cancellation of selected or all claims of issued patents of
competitors. For a patent with an effective filing date of March&nbsp;16, 2013 or later, a petition for post-grant review can be
filed by a third party in a nine-month window from issuance of the patent. A petition for <I>inter partes</I> review can be filed
immediately following the issuance of a patent if the patent has an effective filing date prior to March&nbsp;16, 2013. A petition
for <I>inter partes</I> review can be filed after the nine-month period for filing a post-grant review petition has expired for
a patent with an effective filing date of March&nbsp;16, 2013 or later. Post-grant review proceedings can be brought on any ground
of invalidity, whereas <I>inter partes</I> review proceedings can only raise an invalidity challenge based on published prior art
and patents. These adversarial actions at the USPTO review patent claims without the presumption of validity afforded to U.S.&nbsp;patents
in lawsuits in U.S. federal courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore,
it is generally considered easier for a competitor or third party to have a U.S.&nbsp;patent invalidated in a USPTO post-grant
review or <I>inter partes</I> review proceeding than invalidated in a litigation in a U.S. federal court. If any of our patents
are challenged by a third party in such a USPTO proceeding, there is no guarantee that we or our licensors or collaborators will
be successful in defending the patent, which would result in a loss of the challenged patent right to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, recent court rulings in cases such
as <I>Association for Molecular Pathology v. Myriad Genetics, Inc., BRCA1- &amp; BRCA2-Based Hereditary Cancer Test Patent Litigation,
Promega Corp. v. Life Technologies Corp. and Abbvie Deutschland GmbH v. Janssen Biotech, Inc.</I> have narrowed the scope of patent
protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing
uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with
respect to the value of patents once obtained. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and
the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways
that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the
future. Any changes to patent law in the United States or other jurisdictions that impairs our ability to protect our product candidates
could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We might not be able to enforce our intellectual property
rights throughout the world. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Filing, prosecuting, enforcing and defending
patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual
property rights in some foreign countries can be less extensive than those in the United States. The requirements for patentability
may differ in certain countries, particularly in developing countries; thus, even in countries where we do pursue patent protection,
there can be no assurance that any patents will issue with claims that cover our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Moreover, our ability to protect and enforce
our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. Many companies
have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions.
The legal systems of some countries, including India, China and other developing countries, do not favor the enforcement of patents
and other intellectual property rights. This could make it difficult for us to stop the infringement of our patents or the misappropriation
of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent
owner must grant licenses to third parties. Consequently, we might not be able to prevent third parties from practicing our inventions
in certain foreign countries. Competitors may use our technologies in jurisdictions where we have not obtained patent protection
to develop and market their own products and, further, may export otherwise infringing products to territories where we have patent
protection, if our ability to enforce our patents to stop infringing activities is inadequate. These products may compete with
our products, and our patents or other intellectual property rights might not be effective or sufficient to prevent them from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Agreements through which we license patent rights
might not give us sufficient rights to permit us to pursue enforcement of our licensed patents or defense of any claims asserting
the invalidity of these patents (or control of enforcement or defense) of such patent rights in all relevant jurisdictions as requirements
may vary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Proceedings to enforce our patent rights in
foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and resources from other
aspects of our business. Moreover, such proceedings could put our patents at risk of being invalidated or interpreted narrowly
and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We might not prevail
in any lawsuits that we initiate and the damages or other remedies awarded, if any, might not be commercially meaningful. Furthermore,
while we intend to protect our intellectual property rights in major markets for our products, we cannot ensure that we will be
able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our
efforts to protect our intellectual property rights in such countries may be inadequate. Any of the foregoing could have a material
adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Others may claim an ownership interest in our intellectual
property and proprietary technologies which could expose us to litigation and have a significant adverse effect on our prospects.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">A third party may claim an ownership interest
in one or more of our or our, or our licensors&rsquo;, patents or other proprietary or intellectual property rights. A third party
could bring legal actions against us and seek monetary damages and/or enjoin clinical testing, manufacturing and marketing of the
affected product or products. While we are presently unaware of any claims or assertions by third-parties with respect to our patents
or other intellectual property, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents
or intellectual property. If we become involved in any litigation, it could consume a substantial portion of our resources, and
cause a significant diversion of effort by our technical and management personnel. If any of these actions are successful, in addition
to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected
product, in which case we may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot, however,
assure you that any such license will be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing
a product, or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation
of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that
cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse
party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon
which experts may reasonably disagree. Any of the foregoing could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we are sued for infringing, misappropriating, or otherwise
violating intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or
delay us from developing or commercializing our product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our commercial success depends, in part, on
our ability to develop, manufacture, market and sell our product candidates without infringing, misappropriating, or otherwise
violating the intellectual property and other proprietary rights of third parties. Third parties may have U.S. and non-U.S. issued
patents and pending patent applications relating to compounds, methods of manufacturing compounds and/or methods of use for the
treatment of the disease indications for which we are developing our product candidates that may cover our product candidates or
approach to complement inhibition. If any third-party patents or patent applications are found to cover our product candidates
or their methods of use or manufacture, or our approach to complement inhibition, we might not be free to manufacture or market
our product candidates as planned without obtaining a license, which might not be available on commercially reasonable terms, or
at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There is a substantial amount of intellectual
property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation
or other adversarial proceedings regarding intellectual property rights with respect to our product candidates, including interference
and post-grant proceedings before the USPTO. There may be third-party patents or patent applications with claims to materials,
formulations, methods of manufacture or methods for treatment related to the composition, use or manufacture of our product candidates.
We cannot guarantee that any of our patent searches or analyses including, but not limited to, the identification of relevant patents,
the scope of patent claims or the expiration of relevant patents are complete or thorough, nor can we be certain that we have identified
each and every patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization
of our product candidates in any jurisdiction. Because patent applications can take many&nbsp;years to issue, there may be currently
pending patent applications which may later result in issued patents that our product candidates may be accused of infringing.
In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.
Accordingly, third parties may assert infringement claims against us based on intellectual property rights that exist now or arise
in the future. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified
in advance. The pharmaceutical and biotechnology industries have produced a significant number of patents, and it might not always
be clear to industry participants, including us, which patents cover various types of products or methods of use or manufacture.
The scope of protection afforded by a patent is subject to interpretation by the courts, and the interpretation is not always uniform.
If we are sued for patent infringement, we would need to demonstrate that our product candidates, products or methods either do
not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we might not
be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of
clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these
proceedings, we may incur substantial costs and the time and attention of our management and scientific personnel could be diverted
in pursuing these proceedings, which could significantly harm our business and operating results. In addition, we might not have
sufficient resources to bring these actions to a successful conclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">If we are found to infringe, misappropriate,
or otherwise violate a third party&rsquo;s intellectual property rights, we could be forced, including by court order, to cease
developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to
obtain a license from such third party in order to use the infringing technology and continue developing, manufacturing or marketing
the infringing product candidate or product. However, we might not be able to obtain any required license on commercially reasonable
terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to
the same technologies licensed to us; alternatively or additionally it could include terms that impede or destroy our ability to
compete successfully in the commercial marketplace. In addition, we could be found liable for monetary damages, including treble
damages and attorneys&rsquo; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent
us from commercializing our product candidates or force us to cease some of our business operations, which could harm our business.
Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative
impact on our business. Any of the foregoing could have a material adverse effect on our business, financial condition, results
of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We may be subject to claims by third parties asserting that
our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual
property and proprietary technology. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Many of our current and former employees and
our licensors&rsquo; current and former employees, including our senior management, were previously employed at universities or
at other biotechnology or pharmaceutical companies, including some which may be competitors or potential competitors. Although
we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be
subject to claims that we or these employees have used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such third party. Litigation may be necessary to defend against such claims. If we fail in defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages.
Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third
party to commercialize our technology or products. Such a license might not be available on commercially reasonable terms or at
all. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, while we typically require our
employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning
such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual
property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property.
If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial
costs and be a distraction to our senior management and scientific personnel. Any of the foregoing could have a material adverse
effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We may become involved in lawsuits to protect or enforce our
patents or other intellectual property, which could be expensive, time consuming and unsuccessful. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Competitors may infringe, misappropriate, or
otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use,
we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of
our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert
counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid
or unenforceable, or both. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours
is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention
at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&rsquo;s
claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds
that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving one or more of our
patents could limit our ability to assert those patents against those parties or other competitors, and may curtail or preclude
our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark
infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against
whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be
forced to cease use of such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Even if we establish infringement, the court
may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which might
not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation.
There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities
analysts or investors perceive these results to be negative, it could adversely affect the price of our common shares. Moreover,
there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims,
which typically last for&nbsp;years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost
of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we
receive as a result of the proceedings. Any such litigation could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we fail to comply with our obligations under our existing
and any future intellectual property licenses with third parties, we could lose license rights that are important to our business.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may be reliant upon licenses to certain patent
rights and proprietary technology form third parties that are important or necessary to the development of our product candidates.
These and other licenses might not provide exclusive rights to use such intellectual property and technology in all relevant fields
of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a
result, we might not be able to prevent competitors from developing and commercializing competitive products in territories included
in all of our licenses. Our licensors may have relied on third party consultants or collaborators or funds from third parties such
that our licensors are not the sole and exclusive owners of the patents we in-license. This could have a material adverse effect
on our competitive position, business, financial conditions, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, the agreements under which we license
patent rights might not give us control over patent prosecution or maintenance, so that we might not be able to control which claims
or arguments are presented and might not be able to secure, maintain, or successfully enforce necessary or desirable patent protection
from those patent rights. We cannot be certain that patent prosecution and maintenance activities by our licensors will be conducted
in compliance with applicable laws and regulations or will result in valid and enforceable patents. Even if we are permitted to
pursue such enforcement or defense, we will require the cooperation of our licensors, and cannot guarantee that we would receive
it and on what terms. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement
of such patents or defense of such claims to protect our interests in any licensed patents. If we cannot obtain patent protection,
or enforce existing or future patents against third parties, it could have a material adverse effect on our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Further, the agreements under which we currently
license intellectual property or technology to or from third parties are complex, and certain provisions in such agreements may
be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow
what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe
to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on
our business, financial conditions, results of operations, and prospects. Moreover, if disputes over intellectual property that
we license prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable
to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business,
financial conditions, results of operations, and prospects. Disputes may arise regarding intellectual property subject to a licensing
agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the scope of rights granted under the license agreement and other interpretation-related issues;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the
licensing agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the sublicensing of patent and other rights under current and any future collaborative development relationships;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our diligence obligations under any license agreement and what activities satisfy such obligations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property
by our license counterparties and us and our partners; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the priority of invention of patented technology.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In spite of our efforts, our license counterparties
might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, which
may remove our ability to develop and commercialize the product candidates and technology covered by these license agreements.
If any in-licenses are terminated, competitors would have the freedom to seek regulatory approval of, and to market, products identical
to ours. It is possible that we may be unable to obtain any additional licenses that we require at a reasonable cost or on reasonable
terms, if at all. In that event, we may be required to expend significant time and resources to redesign our product candidates,
technology, or the methods for manufacturing them or to develop or license replacement technology, all of which might not be feasible
on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product
candidates, which could harm our business, financial condition, results of operations, and prospects significantly. Any of these
events could have a material adverse effect on our competitive position, business, financial conditions, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If we are unable to protect the confidentiality of our trade
secrets, the value of our technology could be negatively impacted and our business would be harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition to the protection afforded by patents,
we also rely on trade secret protection for certain aspects of our intellectual property. However, trade secrets are difficult
to protect. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with
parties who have access to them, such as our employees, consultants, independent contractors, advisors, contract manufacturers,
suppliers and other third parties. We also enter into confidentiality and invention or patent assignment agreements with employees
and certain consultants. Any party with whom we have executed such an agreement may breach that agreement and disclose our proprietary
information, including our trade secrets, and we might not be able to obtain adequate remedies for such breaches. Enforcing a claim
that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome
is unpredictable. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient
recourse against third parties for misappropriating the trade secret. Further, if any of our trade secrets were to be lawfully
obtained or independently developed by a competitor, we would have no right to prevent such third party, or those to whom they
communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets
were to be disclosed to or independently developed by a competitor, it could have a material adverse effect on our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If our trademarks and trade names are not adequately protected,
then we might not be able to build name recognition in our marks of interest and our business may be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our trademarks or trade names may be challenged,
infringed, circumvented or declared generic or determined to be infringing on other marks. We rely on both registration and common
law protection for our trademarks. We might not be able to protect our rights to these trademarks and trade names or may be forced
to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During
trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections,
we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions,
third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition
or cancellation proceedings may be filed against our trademarks, and our trademarks might not survive such proceedings. If we are
unable to establish name recognition based on our trademarks and trade names, we might not be able to compete effectively and our
business may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our management and members of our Board of Directors have
the ability to substantially influence all matters submitted to stockholders for approval. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of March 27, 2018, our management
and members of our Board of Directors, in the aggregate, beneficially owned shares representing approximately 48.1% of our capital
stock. As a result, they can substantially influence all matters submitted to our stockholders for approval, as well as our management
and affairs. For example, these persons would substantially influence the election of directors and approval of any merger, consolidation
or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of
our company on terms that other stockholders desire or result in management of our company that our public stockholders disagree
with.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>A significant portion of our total outstanding shares are
restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our
common stock to drop significantly, even if our business is performing well. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Sales of a substantial number of shares of our
common stock in the public market could occur at any time, subject to certain restrictions described below. These sales, or the
perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common
stock. As of March 27, 2018, we had outstanding 9,936,771 shares of common stock, all of which may be resold in the public market
immediately without restriction, other than shares owned by our affiliates, which may be sold pursuant to Rule&nbsp;144. However,
the resale of an aggregate of 6,247,724 shares are restricted until July 24, 2018 as a result of lock-up agreements executed in
conjunction with our IPO. We may register all shares of common stock that we may issue under our equity compensation plans on a
Registration Statement on Form S-8. These shares can be freely sold in the public market upon issuance, subject to volume limitations
applicable to affiliates and the lock-up agreements described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>If securities analysts do not publish research or reports
about our business or if they publish negative evaluations of our stock, the price of our stock could decline. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The trading market for our common stock will
rely, in part, on the research and reports that industry or financial analysts publish about us or our business. If securities
analysts do not commence coverage of us, the trading price of our stock could decrease. Additionally, if one or more of the analysts
covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts
cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>The price of our common stock may be volatile and fluctuate
substantially, which could result in substantial losses for purchasers of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The market price of our common stock is likely
to be highly volatile due to many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to successfully proceed to and conduct clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>results of clinical trials of our product candidates or those of our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the success of competitive products or technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>commencement or termination of collaborations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>regulatory or legal developments in the U.S. and other countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>developments or disputes concerning patent applications, issued patents or other proprietary rights;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the recruitment or departure of key personnel;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the level of expenses related to any of our product candidates or clinical development programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the results of our efforts to discover, develop, acquire or in-license additional product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our inability to obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable
prices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain
patent protection for our technologies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>significant lawsuits, including patent or stockholder litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>variations in our financial results or those of companies that are perceived to be similar to us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>changes in the structure of healthcare payment systems;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>market conditions in the pharmaceutical and biotechnology sectors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>general economic, industry and market conditions; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the other factors described in this &ldquo;Risk Factors&rdquo; section.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>An active trading market for our common stock might not develop
or be sustained and you might not be able to resell your shares at or above your purchase price. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Prior to our IPO in January 2018, there was
no public market for shares of our common stock. Although our common stock has been approved for listing on the Nasdaq Capital
Market, an active trading market for our shares might never develop or be sustained. In the absence of an active trading market
for our common stock, investors might not be able to sell their common stock at or above their purchase price or at the time that
they would like to sell.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We have broad discretion in the use of our cash, including
the net proceeds from our IPO, and might not use them effectively. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our management will have broad discretion in
the application of our cash, including the net proceeds from our IPO, and could spend our cash in ways that do not improve our
results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively
could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock
to decline and delay the development of our product candidates. Pending their use, we may invest our cash, including the net proceeds
from our IPO, in a manner that does not produce income or that loses value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Raising additional capital may cause dilution to our existing
stockholders, restrict our operations or require us to relinquish rights to our technologies. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may seek additional capital through a combination
of public and private equity offerings, debt financings, collaborations and licensing arrangements. To the extent that we raise
additional capital through the sale of equity or debt securities, your ownership interest will be diluted and the terms may include
liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of indebtedness would result
in increased fixed payment obligations and could involve restrictive covenants, such as limitations on our ability to incur additional
debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could
adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances
and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or grant licenses
on terms unfavorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We are an &ldquo;emerging growth company&rdquo; and the reduced
disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions
and relief from various reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth
companies.&rdquo; In particular, while we are an &ldquo;emerging growth company: (i)&nbsp;we will not be required to comply with
the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act; (ii) we will be exempt from any rules that
may be adopted by the Public Company Accounting Oversight Board; (iii) we will be subject to reduced disclosure obligations regarding
executive compensation in our periodic reports and proxy statements and (iv) we will not be required to hold nonbinding advisory
votes on executive compensation or stockholder approval of any golden parachute payments not previously approved. Investors may
find our common stock less attractive if we rely on the exemptions and relief granted by the JOBS Act. If some investors find our
common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may
decline or become more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have taken advantage of reduced reporting
burdens in this report. In particular, we have not included all of the executive compensation information that would be required
if we were not an emerging growth company. We cannot predict whether investors will find our common stock less attractive if we
rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a
less active trading market for our common stock and our stock price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, the JOBS Act provides that an emerging
growth company may take advantage of an extended transition period for complying with new or revised accounting standards. This
allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply
to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>We will incur increased costs as a result of operating as
a smaller reporting public company, and our management will be required to devote substantial time to new compliance initiatives.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a smaller reporting public company, and particularly
after we are no longer an emerging growth company, we will incur significant legal, accounting and other expenses that we did not
incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed
various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls
and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these
compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make
some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult
and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us
to attract and retain qualified members of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">For as long as we remain an emerging growth
company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies
that are not emerging growth companies as described in the preceding risk factor. We might remain an emerging growth company until
December 31, 2023, although if the market value of our common stock that is held by non-affiliates exceeds $700&nbsp;million as
of any June&nbsp;30 before that time or if we have annual gross revenues of&thinsp; $1.07&nbsp;billion or more in any fiscal year,
we would cease to be an emerging growth company as of December&nbsp;31 of the applicable year. We also would cease to be an emerging
growth company if we issue more than $1&nbsp;billion of nonconvertible debt over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to Section&nbsp;404, we will be required
to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal
control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging
growth company, we will not be required to include an attestation report on internal control over financial reporting issued by
our independent registered public accounting firm. To achieve compliance with Section&nbsp;404 within the prescribed period, we
will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging.
In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed
work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes
as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement
process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent
registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial
reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the financial markets due to
a loss of confidence in the reliability of our financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Provisions in our amended and restated corporate charter documents
and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent
attempts by our stockholders to replace or remove our current management. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Provisions in our corporate charter, as amended,
and our bylaws, as amended, may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders
may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions
also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing
the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of
our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these
provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>allow the authorized number of our directors to be changed only by resolution adopted by a majority of our board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limit the manner in which stockholders can remove directors from the board, as may be permitted by law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations
to our board of directors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>limit who may call stockholder meetings; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a
stockholder rights plan, or so-called &ldquo;poison pill,&rdquo; that would work to dilute the stock ownership of a potential hostile
acquirer, effectively preventing acquisitions that have not been approved by our board of directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, at our 2018 Annual Meeting of Stockholders
we intend to seek stockholder approval for the elimination of the ability of our stockholders to act by majority written consent,
forcing all stockholder action to take place at duly called stockholder meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Moreover, because we are incorporated in Delaware,
we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a person who owns
in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three&nbsp;years after the date
of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination
is approved in a prescribed manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Because we do not anticipate paying any cash dividends on
our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have never declared or paid cash dividends
on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of
our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital
appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><A NAME="a_004"></A>Item 1B.</TD><TD>Unresolved Staff Comments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Smaller reporting companies
such as us are not required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><A NAME="a_005"></A>Item 2.</TD><TD>Properties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our principal executive offices are
located in approximately 1,000 square feet of office space in New York City, New York. We lease this office pursuant to a
sublease agreement. In addition, we lease approximately 1,000 square feet of office space in Reno, Nevada where we perform
certain of our research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We believe that our existing facilities are
adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially
reasonable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><A NAME="a_006"></A>Item 3.</TD><TD>Legal Proceedings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Chief Executive Officer, Dr.&nbsp;Ianchulev,
and two members of our Board of Directors, Drs.&nbsp;Eshelman and Mario, are named as defendants in a legal proceeding filed in
the United States District Court for the District of New Jersey on September 2, 2014 that has not yet been fully resolved in connection
with our asset purchase from Corinthian Opthalmic, Inc. A shareholder of Corinthian, alleging a fraudulent transfer, is seeking
to recover the purchase price of its Corinthian shares and other damages in the aggregate amount of approximately $1.1 million.
The parties are not close to agreement on a settlement, and although further discussions may occur, the parties are prepared to
proceed to trial. The court conducted a pretrial conference on January 22, 2018 and entered a final pretrial order on January
23, 2018. The order provided, among other things, for a final pretrial conference to be conducted on August 15, 2018 to address
objections to expert witnesses&rsquo; opinions and testimony, with objections to be submitted by July 18, 2018 and responses by
August 1, 2018. Trial briefs, requests for jury instructions, and proposed voir dire questions are due on August 30, 2018. The
trial is scheduled for September 10, 2018. We are indemnified by Corinthian in this litigation and Corinthian&rsquo;s applicable
insurance policy provides coverage of $10,000,000. As a result, we do not expect to incur a material loss as a result of this
litigation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><B><A NAME="a_007"></A>Item 4.</B></TD><TD STYLE="text-align: left"><B>Mine Safety Disclosures.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Set forth below is information regarding our
current executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Name </B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Age </B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 56%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Position </B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tsontcho Ianchulev, M.D., M.P.H. </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">44 </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer, Chief Medical Officer and Director </FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">John Gandolfo</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">57</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer and Secretary</FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Jennifer &ldquo;Ginger&rdquo; Clasby </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">64 </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Vice President, Clinical Operations </FONT></TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Luke Clauson </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">39 </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Vice President, Research &amp; Development </FONT></TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Dr.&nbsp;Tsontcho Ianchulev</B> has been
serving as our Chief Executive Officer and Chief Medical Officer and a member of our Board of Directors since March 2014. From
2009 to 2016, he was the chief medical officer and the head of technology and business development for Transcend Medical, Inc.
(acquired by Novartis International AG/Alcon, Inc. (NYSE: NVS)). Prior to that, while at Genentech, Inc. (Nasdaq: DNA, before going
private in 2009), Dr.&nbsp;Ianchulev headed the ophthalmology research group and directed the development and the FDA approval
of Lucentis. Dr.&nbsp;Ianchulev received his B.S. from the University of Rochester. He received both his M.D. and an M.P.H. from
Harvard University and completed his specialty training at the Doheny Eye Institute. Currently, Dr. Ianchulev serves as a professor
in the New York Eye and Ear Infirmary of Mount Sinai.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>John Gandolfo</B> has been serving as our
Chief Financial Officer and Secretary since December 2017. Mr. Gandolfo has approximately 30 years of experience as a chief financial
officer of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and
medical device areas. Mr. Gandolfo has had direct responsibility over capital raising, including five public offerings, financial
management, mergers and acquisition transactions and SEC reporting throughout his professional career. Prior to joining us, Mr.&nbsp;Gandolfo
was Chief Financial Officer of Xtant Medical from July 2010 through September 2017. Prior to joining Xtant, he served as the Chief
Financial Officer for Progenitor Cell Therapy LLC, a manufacturer of stem cell therapies, from January 2009 to June 2010. Prior
to joining Progenitor, Mr. Gandolfo served as the Chief Financial Officer for Power Medical Interventions, Inc., a publicly held
developer and manufacturer of computerized surgical stapling and cutter systems, from January 2007 to January 2009. Prior to joining
Power Medical Interventions, Mr. Gandolfo was the Chief Financial Officer of Bioject Medical Technologies, Inc., a publicly held
supplier of needle-free drug delivery systems to the pharmaceutical and biotechnology industries, from September 2001 to May 2006,
and served on the Bioject&rsquo;s board of directors from September 2006 through May 2007. Prior to joining Bioject, Mr.&nbsp;Gandolfo
was the Chief Financial Officer of Capital Access Network, Inc., a privately held specialty finance company, from 2000 through
September 2001, and Xceed, Inc., a publicly held Internet consulting firm, from 1999 to 2000. From 1994 to 1999, Mr.&nbsp;Gandolfo
was Chief Financial Officer and Chief Operating Officer of Impath, Inc., a publicly held, cancer-focused healthcare information
company. From 1987 through 1994, he was Chief Financial Officer of Medical Resources, Inc., a publicly held manager of diagnostic
imaging centers throughout the United States. A graduate of Rutgers University, Mr. Gandolfo is a certified public accountant (inactive
status) who began his professional career at Price Waterhouse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Jennifer &ldquo;Ginger&rdquo; Clasby</B>
has worked in the field of regulated medical products during most of her career. She has been serving as our Vice President, Clinical
Operations since September&nbsp;2017. From 2009 to September&nbsp;2017, she served as Vice President, Clinical &amp; Regulatory
Affairs/Quality Assurance at Transcend Medical, an early-stage, venture-backed company developing novel products for management
of glaucoma, which was acquired by Alcon in May 2016. In that position, she was responsible for overseeing clinical operations
and regulatory processes for the company&rsquo;s clinical trials in the US, Europe and Latin America, as well as worldwide regulatory
affairs, quality assurance and compliance activities. Previously, Ms.&nbsp;Clasby worked with ophthalmic device companies American
Medical Optics and Optical Radiation Corporation in various roles in the areas of Clinical Affairs, Manufacturing Operations and
Marketing/Sales. She was also a pivotal executive with Promedica International, a contract research organization, from 1994 to
2009. She serves on the University of California-Irvine Extension Life Science Advisory Committee. She holds an MS degree in Industrial
Engineering from Arizona State University and BS degrees in Mathematics &amp; Physics from Guilford College.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>Luke Clauson</B> has been serving as our
Vice President, Research &amp; Development since August&nbsp;2017. He founded a medical device-focused engineering development company,
Innovative Drive Corporation, that has helped businesses of all sizes conceptualize and bring dozens of products to market, including
several in ophthalmology in 2014 and has been serving as its President since then. From 2009 to March 2016, Mr.&nbsp;Clauson was
Vice President, Research &amp; Development and Operations at Transcend Medical, which developed a micro-stent for glaucoma and
was acquired by Alcon. He started his engineering career at Cardica, where he eventually directed product development for the core
anastomotic business. Mr.&nbsp;Clauson has extensive experience in designing, validating, achieving regulatory approval and scaling
for commercialization with multiple products. He holds a bachelor of science in mechanical engineering degree from the University
of California, Davis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><A NAME="a_008"></A>PART II</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in"><A NAME="a_009"></A>Item 5.</TD><TD>Market for  Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Market for Common Equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our common stock trades on the Nasdaq Capital
Market under the symbol &ldquo;EYEN.&rdquo; From our IPO in January 2018 through March 27, 2018 the high and low sales prices for
our common stock as reported by Nasdaq were $10.74 and $7.32, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Based upon information furnished by our transfer
agent, at March 27, 2018, we had approximately 67 holders of record of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have never declared dividends on our equity
securities, and currently do not plan to declare dividends on shares of our common stock in the foreseeable future. We expect to
retain our future earnings, if any, for use in the operation and expansion of our business. Subject to the foregoing, the payment
of cash dividends in the future, if any, will be at the discretion of our Board of Directors and will depend upon such factors
as earnings levels, capital requirements, our overall financial condition and any other factors deemed relevant by our Board of
Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Securities Authorized for Issuance under Equity Compensation
Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">See Item 12 of this report for disclosure regarding
securities authorized for issuance under equity compensation plans required by Item 201(d) of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The following list sets forth information as
to all securities we have sold since January 1, 2017 up to the date of this report after giving effect to the 1-for-3.75 reverse
stock split of our outstanding common stock and preferred stock effected on January 8, 2018, which were not registered under the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2017, we issued and sold 741,145
shares of Series B preferred stock to eight investors for $6.98 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2017, we issued options to purchase
897,747 shares of our common stock with an exercise price of&thinsp;$1.95 per share to our employees, directors and/or consultants
under our 2014 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In September 2017, we issued and sold 177,838
shares of Series B preferred stock to two investors for $6.98 per share.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Each of the foregoing issuances was made in
a transaction not involving a public offering pursuant to an exemption from the registration requirements of the Securities Act
in reliance upon Section 4(a)(2) of the Securities Act, or Regulation D promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Use of Proceeds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On January 24, 2018, the SEC declared effective
our Registration Statement on Form S-1 (File No. 333-222162), as amended, filed in connection with the initial public offering
of our common stock. Pursuant to the Registration Statement, we registered the offer and sale of up to $35,000,000 of our common
stock. On January 29, 2018, we issued and sold 2,730,000 shares of our common stock at a price to the public of $10.00 per share.
Ladenburg Thalmann &amp; Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., and Roth Capital Partners acted
as joint book-running managers for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As a result of the offering, we received net
proceeds of approximately $24.5 million in the aggregate, which consists of gross proceeds of $27.3 million, offset by underwriting
discounts and commissions of approximately $1.9 million and other offering expenses of approximately $0.9 million. No payments
for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons
owning 10% or more of any class of our equity securities or (iii) any of our affiliates. The offering has terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">There has been no material change in the expected
use of the net proceeds from our initial public offering as described in our final prospectus, dated January 24, 2018, filed with
the SEC pursuant to Rule 424(b) relating to our Registration Statement on Form S-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Purchases of Equity Securities by the Issuer and Affiliated Purchasers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: 13.5pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in"><A NAME="a_010"></A>Item 6.</TD><TD>Selected Financial Data</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Smaller reporting companies such as us are not
required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.75in"><A NAME="a_011"></A>Item 7.</TD><TD>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>The following discussion and analysis is
based on, and should be read in conjunction with our financial statements for the years ended December 31, 2017 and 2016, which
are included elsewhere in this Annual Report. This Management&rsquo;s Discussion and Analysis of Financial Condition and Results
of Operations contains statements that are forward-looking. These statements are based on current expectations and assumptions
that are subject to risk, uncertainties and other factors. These statements are often identified by the use of words such as &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimate,&rdquo; or &ldquo;continue,&rdquo; and similar expressions or variations. Actual results could differ materially
because of the factors discussed in &ldquo;Risk Factors&rdquo; elsewhere in this Annual Report, and other factors that we may not
know.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are a clinical stage biopharmaceutical company
developing a pipeline of ophthalmology products utilizing our patented piezo-print technology to deliver micro-doses (6&ndash;8
&micro;L) of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye. This micro-dosing technology has the
potential to replace traditional macro-dosing applications (e.g. conventional eye droppers) that routinely overdose or under-dose
when used in the topical administration of ophthalmic therapeutics. We believe our micro-therapeutic product candidates may be
able to achieve similar pharmacologic effects as traditional macro-dosing applications while reducing the adverse effects associated
with these techniques. We have received written FDA feedback indicating that we can proceed to Phase&nbsp;III clinical trials for
two of our lead&nbsp;programs: MicroProst, a novel micro-therapeutic latanoprost formulation for CACG, an indication with no FDA-approved
drug treatments; and MicroStat, a fixed combination of micro-therapeutic phenylephrine-tropicamide formulation for mydriasis, also
known as pupil dilation for use in eye exams. MicroTears, our OTC product candidate for dry eye, will not require Phase&nbsp;III
clinical trials, and we plan to proceed with registration activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have completed two Phase&nbsp;II clinical
trials, treating more than 110 subjects, with results published in peer-reviewed literature. Applying multiple front-of-the-eye
(the area in front of the lens) formulations in subjects for mydriasis, our piezo-print technology delivered microliter precision
at the volume of the eye&rsquo;s natural tear film capacity of 6&ndash;8 &micro;L, which reduced ocular and systemic drug and preservative
exposure when compared to eye drops, resulting in comparable efficacy with fewer side effects. We believe that these clinical trials
support our advancement into late stage clinical trials utilizing the 505(b)(2) pathway. We intend to use this pathway for future
clinical trials in new indications with significant unmet needs. We plan to commence clinical trials for MicroProst and MicroStat
in the second half of 2018, pending IND submission and FDA feedback.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We have not completed development of any product
candidate and we have therefore not generated any revenues from product sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Historically, we have financed our
operations principally through private placements of preferred stock as well as our initial public offering that closed in January 2018. Although it is difficult to predict our liquidity
requirements, based upon our current operating plan, we believe we will have sufficient cash to meet our projected operating
requirements for at least the next fifteen&nbsp;months. Thereafter, the Company will need to raise further capital, through
the sale of additional equity or debt securities, to support its future operations. If the Company is unable to secure
additional capital, it may be required to curtail its research and development initiatives and take additional measures to
reduce costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our net losses were $5.1&nbsp;million and
$3.5&nbsp;million for the&nbsp;years ended December&nbsp;31, 2017 and 2016, respectively. As of December&nbsp;31, 2017, we had
an accumulated deficit of&thinsp;$19.3&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We amended our Certificate of Incorporation
on January&nbsp;8, 2018 in order to effect a 1-for-3.75 reverse stock split of all outstanding shares of our common stock and preferred
stock. Throughout this Annual Report, each reference to a number of our issued and outstanding common stock or preferred stock
gives effect to the reverse split, unless otherwise indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Financial Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Revenue</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have not generated any revenue from product
sales since our inception and do not expect to generate any revenue from the sale of products in the near future. Our ability to
generate revenues will depend heavily on the successful development, regulatory approval and commercialization of our micro-therapeutic
product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses are incurred
in connection with the research and development of our micro-therapeutics and consist primarily of contract service expenses. Given
where we are in our life cycle, we do not separately track research and development expenses by project. Our research and development
expenses consist of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>direct clinical and non-clinical expenses, which include expenses incurred under agreements with contract research organizations,
contract manufacturing organizations, and costs associated with preclinical activities, development activities and regulatory activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>personnel-related expenses, which include expenses related to consulting agreements with individuals that have since entered
into employment agreements with us as well as salaries and other compensation of employees that is attributable to research and
development activities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, marketing,
insurance and other supplies used in research and development activities; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>travel and entertainment expenses, which include travel and entertainment costs for consultants and employees that conduct
and support clinical trials and preclinical studies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expense research and development costs
as incurred. We record costs for some development activities, such as clinical trials, based on an evaluation of the progress to
completion of specific tasks using data such as subject enrollment, clinical site activations or other information our vendors
provide to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We expect that our research and development
expenses will increase with the continuation of the aforementioned initiatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General and Administrative Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expenses consist
primarily of payroll and related expenses, legal and other professional services, as well as non-cash stock-based compensation
expense. We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to
support our continued research and development and the potential commercialization of our product candidates. We also anticipate
increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange
listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with being a public
company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Year Ended December&nbsp;31, 2017 Compared with Year Ended
December&nbsp;31, 2016</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Research and Development Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses for the
year ended December&nbsp;31, 2017 totaled over $3.8&nbsp;million, an increase of $0.8&nbsp;million, or 29%, as compared to the
less than $3.0&nbsp;million recorded for the year ended December&nbsp;31, 2016. Research and development expenses consisted of
the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Direct clinical and non-clinical expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">2,783,344</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">2,555,998</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Personnel-related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Facilities and other expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">233,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72,119</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Travel and entertainment expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">19,328</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,816,732</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,966,165</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The increase in direct clinical and non-clinical
and personnel-related expenses is primarily due to an increase in contracted services and headcount as we expanded our research
and development activities for our micro therapeutic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>General and Administrative Expenses</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">General and administrative expense for
the year ended December&nbsp;31, 2017 totaled $1.3&nbsp;million, an increase of $0.7&nbsp;million, or 131%, as compared to the
under $0.6&nbsp;million recorded for the year ended December&nbsp;31, 2016. The increase was primarily attributable to an increase
in professional fees of $0.2 million, non-cash stock-based compensation costs of $0.1 million, and expenses related to travel
and entertainment of $0.1 million as compared to 2016, as our business grew and began to prepare for our IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since inception, we have experienced negative
cash flows from operations. Through December 31, 2017, we have financed our operations primarily through sales of preferred stock.
At December&nbsp;31, 2017, our accumulated deficit since inception was $19.3&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At December&nbsp;31, 2017, we had total
current assets of $5.3&nbsp;million and current liabilities of $0.6&nbsp;million, resulting in working capital of $4.7&nbsp;million.
At December&nbsp;31, 2017, we had total assets of $5.6&nbsp;million and total liabilities of $0.6&nbsp;million, resulting in stockholders&rsquo;
equity of&thinsp;$5.1&nbsp;million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At December&nbsp;31, 2017 and 2016, we had
no debt outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At December&nbsp;31, 2017, we had a cash
and cash equivalents balance of $5.2&nbsp;million. In January 2018, we raised aggregate net proceeds of $24.5 million in connection
with our initial public offering. We expect our current cash on hand to be sufficient to meet our operating and capital requirements
for at least the next fifteen&nbsp;months from the date of this filing. Thereafter, we will likely need to raise further capital,
through the sale of additional equity or debt securities, to support our future operations. Our operating needs include the planned
costs to operate our business, including amounts required to fund research and development activities including clinical studies,
working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on
many factors, including our ability to successfully commercialize our products and services, competing technological and market
developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance
or complement our product and service offerings. If we are unable to secure additional capital, we may be required to curtail our
research and development initiatives and take additional measures to reduce costs in order to conserve our cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the years ended December&nbsp;31,
2017 and 2016 our sources and uses of cash were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in operating activities for
the year ended December&nbsp;31, 2017 was $4.7&nbsp;million, which includes cash used to fund a net loss of $5.1&nbsp;million,
partially offset by $0.4 of non-cash stock compensation and depreciation and amortization costs. Net cash used in operating activities
for the year ended December&nbsp;31, 2016 was $3.2&nbsp;million, which includes cash used to fund a net loss of $3.5&nbsp;million,
partially offset by $0.3&nbsp;million of cash provided by changes in operating assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Net cash used in investing activities was
less than $0.1&nbsp;million for the years ended December 31, 2017 and 2016 and was attributable to purchases of property and equipment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Cash provided by financing activities
for the year ended December&nbsp;31, 2017 totaled $6.6&nbsp;million, which was primarily attributable to $6.4 million of
proceeds from the sale of Series&nbsp;B convertible preferred stock and $0.4 million of proceeds from the sale of a warrant,
reduced by offering costs of $0.2 million. Cash provided by financing activities for the year ended December&nbsp;31, 2016
totaled $4.1&nbsp;million, which related to the sale of Series&nbsp;A-2 convertible preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">There are no off-balance sheet arrangements
between us and any other entity that have, or are reasonably likely to have, a current or future effect on financial conditions,
changes in financial conditions, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that is material to stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Use of Estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) requires management to
make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed
in the related notes to the financial statements. We base our estimates and judgments on historical experience and on various other
assumptions that we believe are reasonable under the circumstances. The amounts of assets and liabilities reported in our balance
sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which
are used for, but not limited to, fair value calculations for equity securities, establishing valuation allowances for deferred
taxes, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain
of our estimates could be affected by external conditions, including those unique to us and general economic conditions. It is
reasonably possible that these external factors could have an effect on our estimates and could cause actual results to differ
from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See our critical accounting policy on stock-based
compensation for additional disclosure of the use of estimates in estimating the fair value of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Convertible Instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We evaluate our convertible instruments
to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately
accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting Standards
Codification (&ldquo;ASC&rdquo;). The accounting treatment of derivative financial instruments requires that we record embedded
conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and
at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income
or expense for each reporting period at each balance sheet date. We reassess the classification of our derivative instruments at
each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as
of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments
are recorded as a discount to the host instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the instrument is determined to be a
derivative liability, we then evaluate for the existence of a beneficial conversion feature by comparing the market price of our
common stock as of the commitment date to the effective conversion price of the instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We apply the accounting standards for distinguishing
liabilities from equity when determining the classification and measurement of our preferred stock. Preferred shares subject to
mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred
shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to
redemption upon the occurrence of uncertain events not solely within our control) are classified as temporary equity. At all other
times, preferred shares are classified as stockholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Income Taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We recognize deferred tax assets and liabilities
for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns.
Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities
and their respective financial reporting amounts (&ldquo;temporary differences&rdquo;) at enacted tax rates in effect for the&nbsp;years
in which the temporary differences are expected to reverse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We utilize a recognition threshold and measurement
process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Management has evaluated and concluded that
there were no material uncertain tax positions requiring recognition in our financial statements as of December&nbsp;31, 2017 and
2016, respectively. We do not expect any significant changes in its unrecognized tax benefits within twelve&nbsp;months of the
reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our policy is to classify assessments, if
any, for tax related interest as interest expense and penalties as general and administrative expenses in the statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock-Based Compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We measure the cost of services received
in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award
is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and
interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period
during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors
are treated on the same basis as awards granted to employees. Upon the exercise of an option, we issue new shares of common stock
out of our authorized shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During the year ended December 31, 2016,
the fair value of our common stock was based on an analysis completed by management that considered the cash sales prices of the
convertible preferred stock as well as the relative characteristics, rights and privileges of the convertible preferred stock as
compared to the common stock. During the year ended December 31, 2017, we obtained a third-party 409A valuation of our common stock,
which was also considered in management&rsquo;s estimation of the value of the equity instruments issued during that period. This
third-party valuation was done in accordance with the guidance outlined in the American Institute of Certified Public Accountants&rsquo;
Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. The estimates
used by management are considered highly complex and subjective. Subsequent to the IPO, the shares began trading on January 24,
2018, which is the date the use of such estimates is no longer necessary to determine the fair value of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The independent analysis utilized the Backsolve
method since this method is generally considered the most reliable and is recommended by the American Institute of Certified Public
Accountants&rsquo; Accounting and Valuation Guide,&nbsp;<I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>.
In addition, the method utilizes the economics from a direct transaction in our securities in determining the fair market value.
This method utilizes the Black Scholes option pricing model which allocated a probability weighted equity value to our Series A-
2 preferred stock. The Series A-2 preferred stock was utilized since it included new investors, was considered at arms&rsquo; length
and closed in the fourth quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The March 2017 independent appraisal utilized
the option pricing method, or OPM, as the most reliable method with the following steps being applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Establishment of total enterprise or equity value;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Analysis of equity rights for each class of security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Selection of appropriate model for valuation purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Determination of key valuation inputs; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Computation of the fair value of the subject security.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the OPM, it was determined our common
stock had an allocated per share value of&thinsp;$0.86 per share (which, after giving effect to the 1-for-3.75 reverse stock split
effected on January&nbsp;8, 2018, is equal to options at an exercise price of&thinsp; $3.23 per share). As a private company, the
analysis provided for a discount for lack of marketability of 40% resulting in a fair market value of our common stock of&thinsp;$0.52
per share ($1.95 per share post reverse stock split) as of March 2017 based upon the independent appraisal. This price represents
the same exercise price of the stock options we granted in July 2017 as management determined no material events or conditions
occurred at the Company that would have a material effect on this per share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Research and Development</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Research and development expenses are charged
to operations as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt; color: red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In February 2016, the FASB issued Accounting
Standards Update (&ldquo;ASU&rdquo;) No. 2016-02, &ldquo;Leases (Topic 842),&rdquo; (&ldquo;ASU 2016-02&rdquo;). ASU 2016-02 requires
an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also
require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the
amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December
15, 2018, with early adoption permitted. We are currently evaluating ASU 2016-02 and its impact on our financial position, results
of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In August 2016, the FASB issued ASU 2016-15,
&ldquo;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments,&rdquo; (&ldquo;ASU 2016-15&rdquo;).
The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement
of cash flows. The new standard is effective for fiscal years beginning after December 15, 2017. We will require adoption on a
retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively
as of the earliest date practicable. We are currently evaluating ASU 2016-15 and its impact on our financial position, results
of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In May 2017, the FASB issued ASU No. 2017-09,
&ldquo;Compensation&mdash;Stock Compensation (Topic 718): Scope of Modification Accounting,&rdquo; (&ldquo;ASU 2017-09&rdquo;).
ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective
basis in the annual and interim periods for our fiscal year ending December 15, 2017 for share-based payment awards modified on
or after the adoption date. We are currently evaluating ASU 2017-09 and its impact on our financial position, results of operations,
and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In July 2017, the FASB issued ASU No. 2017-11,
&ldquo;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with
Down Round Features,&rdquo; (&ldquo;ASU 2017-11&rdquo;). Equity-linked instruments, such as warrants and convertible instruments
may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings.
Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion
option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market).
However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether
liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share
(&quot;EPS&quot;) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered
by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this
ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15,
2018. Early adoption is permitted, including adoption in any interim period. We are currently evaluating ASU 2017-11 and its impact
on our financial position, results of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recently Adopted Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2016, the FASB issued ASU No. 2016-09,
&ldquo;Compensation &ndash; Stock Compensation (Topic 718),&rdquo; (&ldquo;ASU 2016-09&rdquo;). ASU 2016-09 requires an entity
to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification
of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal
years beginning after December 15, 2016, with early adoption permitted. The adoption of this standard did not have a material impact
on our financial position, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="a_012"></A>Item 7A.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Quantitative and Qualitative Disclosures About Market Risk.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Smaller reporting companies
such as us are not required to provide the information required by this item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="a_013"></A>Item 8.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Financial Statements and Supplementary Data.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">See the financial statements included at
the end of this report beginning on page F-1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="a_014"></A>Item 9.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="a_015"></A>Item 9A.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Controls and Procedures&nbsp;&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Evaluation of Disclosure Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of the end of the period covered by this
Annual Report on Form 10-K, we carried out an evaluation, under the supervision and with the participation of our management, including
our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure
controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) (the &ldquo;Exchange Act&rdquo;). Based
on the foregoing evaluation, our principal executive officer and principal financial officer concluded that, as of December 31,
2017, our disclosure controls and procedures were not effective at the reasonable assurance level&nbsp;due to the material weaknesses
described below.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Management's Report on Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Annual Report on Form 10-K does not
include a report of management&rsquo;s assessment regarding internal control over financial reporting as of December 31, 2017 or
an attestation report of our registered public accounting firm due to a transition period established by the rules of the SEC for
newly public companies. However, the following material weaknesses in our internal control over financial reporting were identified
in the normal course:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>We had insufficient segregation of duties in our finance and accounting function because of our
limited personnel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>We did not properly identify all related party relationships and transactions so that they could be evaluated for disclosure
in our public filings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>The terms of certain agreements entered into by us were not properly communicated to the Board of Directors in order for the
Board of Directors to take the appropriate actions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD>We did not adequately record research and development expenses in our internal books and records to permit timely and accurate
financial reporting.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A material weakness is a deficiency, or
a combination of deficiencies, within the meaning of Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) Auditing Standard
AS 2201, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We intend to address the weaknesses identified
above by (a) increasing the oversight and review procedures of the Board of Directors and our Audit Committee with regard to financial
reporting, financial processes and procedures and internal control procedures and (b) hiring additional finance and accounting
personnel, including a Chief Financial Officer (hired December 2017), who will assist in the process of remediating the weaknesses
identified above.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Changes in Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our internal control over financial reporting
did not change during the fourth quarter covered by this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="a_016"></A>Item 9B.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Other Information.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">None.</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_017"></A>PART III</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><A NAME="a_018"></A>Item&nbsp;10.</TD><TD>Directors, Executive Officers, and Corporate Governance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Information required by this Item concerning
our directors is incorporated by reference from the sections captioned &ldquo;Election of Directors&rdquo; and &ldquo;Corporate
Governance Matters&rdquo; contained in our proxy statement related to the 2018 Annual Meeting of Stockholders currently scheduled
to be held on June 11, 2018, which we intend to file with the Securities and Exchange Commission within 120 days of the end of
our fiscal year pursuant to General Instruction G(3) of Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this Item concerning
our Audit Committee is incorporated by reference from the section captioned &ldquo;Corporate Governance Matters&mdash;Board Committees&mdash;Audit
Committee&rdquo; contained in our proxy statement related to the 2018 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have adopted a code of business conduct
and ethics relating to the conduct of our business by all of our employees, executive officers, and directors. The policy is posted
on our website,&nbsp;<U>www.eyenoviabio.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this Item concerning
our executive officers is set forth at the end of Part I of this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this Item concerning
compliance with Section&nbsp;16(a) of the United States Securities Exchange Act of 1934, as amended, is incorporated by reference
from the section of the proxy statement captioned &ldquo;Section 16(a) Beneficial Ownership Reporting Compliance&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><A NAME="a_019"></A>Item&nbsp;11.</TD><TD>Executive Compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.75in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information required by this Item is
incorporated by reference to the information under the sections captioned &ldquo;Executive Compensation,&rdquo; and &ldquo;Director
Compensation&rdquo; in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.75in"><A NAME="a_020"></A>Item&nbsp;12.</TD><TD>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The following table provides
information as of December 31, 2017 about our common stock that may be issued upon the exercise of options, warrants and rights
under all of our existing equity compensation plans (including individual arrangements):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Equity Compensation
Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Plan Category</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of securities<BR> to be issued upon <BR> exercise of outstanding<BR> options, warrants and<BR> rights<BR> (a)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-average<BR> exercise price of<BR> outstanding options,<BR> warrants and rights<BR> (b)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of<BR> securities remaining<BR> available for future issuance<BR> under equity compensation<BR> plans (excluding securities<BR> reflected in column (a)<BR> (c)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Equity compensation plans approved by security holders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">2014 Equity Incentive Plan, as amended</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,684,416</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.68</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">48,917</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Equity compensation plans not approved by security holders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.1in; padding-left: 16.2pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,684,416</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.68</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">48,917</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt">The other information required by this
Item is incorporated by reference to the information under the section captioned &ldquo;Security Ownership of Certain Beneficial
Owners and Management&rdquo; contained in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="a_021"></A>Item&nbsp;13.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Certain Relationships and Related Transactions, and Director Independence.&nbsp;&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt">The information required by this Item is
incorporated by reference to the information under the section captioned &ldquo;Certain Relationships and Related Party Transactions&rdquo;
and &ldquo;Corporate Governance Matters&rdquo; in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="a_022"></A>Item&nbsp;14.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Principal Accounting Fees and Services.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 28.1pt">The information required by this Item is
incorporated by reference to the information under the section captioned &ldquo;Audit Committee Report&rdquo; in the proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="a_023"></A>PART IV</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="a_024"></A>Item 15.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Exhibits, Financial Statement Schedules.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD>List of documents filed as part of this report:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD>Financial Statements:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: left; text-indent: 0in">The financial statements
of the Company and the related reports of the Company&rsquo;s independent registered public accounting firm thereon have been filed
under Item 8 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">2.</TD><TD>Financial Statement Schedules:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">3.</TD><TD>Exhibit Index</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">The following is a list
of exhibits filed as part of this Form 10-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Incorporated by Reference (Unless Otherwise Indicated)</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; text-align: left; border-bottom: Black 1pt solid"><B>Exhibit Number</B></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 38%; text-align: center; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>&nbsp;</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>Exhibit Description</B></P></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center; border-bottom: Black 1pt solid"><B>Form</B></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center; border-bottom: Black 1pt solid"><B>File No.</B></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center; border-bottom: Black 1pt solid"><B>Exhibit</B></TD>
    <TD STYLE="width: 1%; text-align: center; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: center; border-bottom: Black 1pt solid"><B>Filing Date</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">Third Amended and Restated Certificate of Incorporation</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418004366/tv484256_ex3-1.htm" STYLE="-sec-extract: exhibit">January 29, 2018</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">3.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">Amended and Restated Bylaws</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">8-K</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">001-38365</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">3.1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418014097/tv488018_ex3-1.htm" STYLE="-sec-extract: exhibit">March 12, 2018</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">Exclusive License Agreement, dated March 18, 2015, between Eyenovia, Inc. and Senju Pharmaceutical Co., Ltd.&#9;&#8203;</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-1.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit">10.2*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit">Engagement Letter and Offer of Employment, dated July 6, 2017, between Eyenovia, Inc. and Dr. Tsontcho Ianchulev</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit">10.2</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-2.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit">10.3*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit">Engagement Letter and Offer of Employment, dated July 6, 2017, between Eyenovia, Inc. and Luke Clauson</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit">10.3</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-3.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit">10.4*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit">Engagement Letter and Offer of Employment, dated July 6, 2017, between Eyenovia, Inc. and Jennifer G. Clasby</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit">10.4</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-4.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit">10.5*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit">Engagement Letter for Professional Services, dated July 6, 2017, between Eyenovia, Inc. and Dr. Curt LaBelle</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit">10.5</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-5.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit">10.6</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit">Amended and Restated Investors&rsquo; Rights Agreement, dated September 27, 2017, between Eyenovia, Inc. and investors party thereto</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit">10.6</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-6.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit">10.7</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit">Amended and Restated Right of First Refusal and Co-Sale Agreement, dated September 27 2017, between Eyenovia, Inc. and investors party thereto</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit">10.7</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-7.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit">10.8</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit">Amended and Restated Voting Agreement, dated September 27, 2017, between Eyenovia, Inc. and investors party thereto</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit">10.8</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-8.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit">10.9*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit">Correction Letter, dated November 8, 2017, between Eyenovia, Inc. and Dr. Tsontcho Ianchulev</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit">10.9</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-9.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">10.10</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">Master Consulting Services Agreement, dated November 4, 2014, between Eyenovia, Inc. and Private Medical Equity, Inc.</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">10.10</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-10.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-11.htm" STYLE="-sec-extract: exhibit">10.11</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 38%"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-11.htm" STYLE="-sec-extract: exhibit">Master Consulting Services Agreement, dated November 4, 2014, between Eyenovia, Inc. and Point Guard Partners, LLC</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 8%"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-11.htm" STYLE="-sec-extract: exhibit">S-1</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 12%"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-11.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 8%"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-11.htm" STYLE="-sec-extract: exhibit">10.11</A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 19%"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000157104917008733/t1703004_ex10-11.htm" STYLE="-sec-extract: exhibit">December 19, 2017</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit">10.12*</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit">Engagement Letter for Professional Services, dated December 18, 2017, between Eyenovia, Inc. and John Gandolfo</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit">S-1/A</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit">333-222162</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit">10.12</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/1682639/000114420418001370/tv481714_ex10-12.htm" STYLE="-sec-extract: exhibit">January 9, 2018</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv488528_ex31-1.htm" STYLE="-sec-extract: exhibit">31.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv488528_ex31-1.htm" STYLE="-sec-extract: exhibit">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex31-1.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex31-1.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex31-1.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex31-1.htm" STYLE="-sec-extract: exhibit">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv488528_ex31-2.htm" STYLE="-sec-extract: exhibit">31.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv488528_ex31-2.htm" STYLE="-sec-extract: exhibit">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex31-2.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex31-2.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex31-2.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex31-2.htm" STYLE="-sec-extract: exhibit">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv488528_ex32-1.htm" STYLE="-sec-extract: exhibit">32.1</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv488528_ex32-1.htm" STYLE="-sec-extract: exhibit">Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex32-1.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex32-1.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex32-1.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex32-1.htm" STYLE="-sec-extract: exhibit">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tv488528_ex32-2.htm" STYLE="-sec-extract: exhibit">32.2</A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv488528_ex32-2.htm" STYLE="-sec-extract: exhibit">Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex32-2.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex32-2.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex32-2.htm" STYLE="-sec-extract: exhibit">--</A></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left"><A HREF="tv488528_ex32-2.htm" STYLE="-sec-extract: exhibit">Filed herewith</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>101</TD>
    <TD>&nbsp;</TD>
    <TD>Interactive data files pursuant to Rule 405 of Regulation S-T: (i) Balance Sheets as of December 31, 2017 and 2016; (ii) Statements of Operations for the Years Ended December 31, 2017 and 2016; (iii) Statements of Changes in Stockholders&rsquo; Equity for the Years Ended December 31 2017 and 2016; (iv) Statements of Cash Flows for the Years Ended December 31, 2017 and 2016; and (v) Notes to Financial Statements</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">--</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">--</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">--</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: left">Filed herewith</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Management contract or other compensatory plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; font-weight: bold; text-indent: 0in"><A NAME="item16"></A>Item 16.</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">Form 10-K Summary.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>EYENOVIA, INC.</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>April 2, 2018</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Tsontcho Ianchulev</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Tsontcho Ianchulev</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Executive Officer)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>April 2, 2018</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ John Gandolfo</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>John Gandolfo</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant
and in the capacities and on the dates indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; border-bottom: Black 1pt solid; text-align: center"><B>Signature</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 51%; border-bottom: Black 1pt solid; text-align: center"><B>Title</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid; text-align: center"><B>Date</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Tsontcho Ianchulev</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer and Director</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Tsontcho Ianchulev</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Executive Officer)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ John Gandolfo</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>John Gandolfo</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Financial and Accounting Officer)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Fredric N. Eshelman</TD>
    <TD>&nbsp;</TD>
    <TD>Chairman of the Board and Director</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Fredric N. Eshelman</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Curt H. LaBelle</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Curt H. LaBelle</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Kenneth B. Lee, Jr.</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Kenneth B. Lee, Jr.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Ernest Mario</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Ernest Mario</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Charles E. Mather IV</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Charles E. Mather IV</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Anthony Y. Sun</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Anthony Y. Sun</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Shuhei Yoshida</TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>April 2, 2018</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Shuhei Yoshida</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 20.9pt 0pt 23.9pt">&nbsp;</P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INDEX TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="width: 90%; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 10%; border-bottom: Black 1pt solid; text-align: center"><B>Page<BR>
 Number</B></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><B><U>Years Ended December 31, 2017 and 2016</U></B></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 20pt"><A HREF="#fin_001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="text-align: center"><A HREF="#fin_001">F-2</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 20pt"><A HREF="#fin_002">Balance Sheets as of December 31, 2017 and 2016</A></TD>
    <TD STYLE="text-align: center"><A HREF="#fin_002">F-3</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 20pt"><A HREF="#fin_003">Statements of Operations for the Years Ended December 31, 2017 and 2016</A></TD>
    <TD STYLE="text-align: center"><A HREF="#fin_003">F-4</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 20pt"><A HREF="#fin_004">Statements of Changes in Stockholders&rsquo; Equity for the Years Ended December 31, 2017 and 2016</A></TD>
    <TD STYLE="text-align: center"><A HREF="#fin_004">F-5</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 20pt"><A HREF="#fin_005">Statements of Cash Flows for the Years Ended December 31, 2017 and 2016</A></TD>
    <TD STYLE="text-align: center"><A HREF="#fin_005">F-6</A></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: 20pt"><A HREF="#fin_006">Notes to Financial Statements</A></TD>
    <TD STYLE="text-align: center"><A HREF="#fin_006">F-7</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U><A NAME="fin_001"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Shareholders and Board of Directors
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eyenovia, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying balance
sheets of Eyenovia, Inc. (the &ldquo;Company&rdquo;) as of December 31, 2017 and 2016, the related statements of operations, changes
in stockholders&rsquo; equity and cash flows for each of the two years in the period ended December 31, 2017, and the related notes
(collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2017 and 2016, and the results of its operations
and its cash flows for each of the two years in the period ended December 31, 2017, in conformity with accounting principles generally
accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&quot;PCAOB&quot;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 50%; text-align: left">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></TD><TD STYLE="width: 50%"></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcum LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&rsquo;s auditor since 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 2, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_002"></A>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding: 0; text-indent: 0">Assets</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Current Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; font-size: 10pt; padding: 0 0 0 0.25in; text-indent: 0">Cash</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,249,511</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">3,387,288</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.25in; text-indent: 0">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37,149</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,335</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.5in; text-indent: 0">Total Current Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,286,660</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,389,623</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27,960</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">43,192</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Deferred offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">328,700</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.5in; text-indent: 0">Total Assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,643,320</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,432,815</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding: 0; text-indent: 0">Liabilities and Stockholders' Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Current Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.25in; text-indent: 0">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">246,384</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">302,031</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.25in; text-indent: 0">Accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">306,263</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">121,703</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.5in; text-indent: 0">Total Current Liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">552,647</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">423,734</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Commitments and contingencies (Note 7)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0; text-indent: 0">Stockholders' Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding: 0 0 0 0.25in; text-indent: 0">Preferred stock, $0.0001 par value, 36,000,000 shares authorized <BR></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.375in; text-indent: 0">as of December 31, 2017 (see Note 9);</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.5in; text-indent: 0">Series A Convertible Preferred Stock, 20,000,000 shares designated</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.5in; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;as of December 31, 2017 (see Note 9),</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">2,932,431 and 3,232,294 shares issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">as of December 31, 2017 and 2016, respectively,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">liquidation preference of $10,996,014 and $12,121,102</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">as of December 31, 2017 and 2016, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">293</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">323</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.5in; text-indent: 0">Series A-2 Convertible Preferred Stock, 5,714,286 shares designated</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.5in; text-indent: 0">&nbsp;&nbsp;&nbsp;&nbsp;as of December 31, 2017 (see Note 9),</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">788,827 shares issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">as of December 31, 2017 and 2016,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">liquidation preference of $4,141,338</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">as of December 31, 2017 and 2016</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.5in; text-indent: 0">Series B Convertible Preferred Stock, 10,000,000 shares designated</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">as of December 31, 2017 (see Note 9),</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">918,983 and 0 shares issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">as of December 31, 2017 and 2016, respectively,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">liquidation preference of $6,409,657 and $0</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">as of December 31, 2017 and 2016, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">92</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding: 0 0 0 0.25in; text-indent: 0">Common stock, $0.0001 par value, 60,000,000 shares authorized</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.375in; text-indent: 0">as of December 31, 2017 (see Note 9),</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.375in; text-indent: 0">2,566,530 and 2,266,667 shares issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.375in; text-indent: 0">as of December 31, 2017 and 2016, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">227</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.25in; text-indent: 0">Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,351,138</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">17,139,651</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.25in; text-indent: 0">Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(19,261,186</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(14,131,199</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">Total Stockholders' Equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,090,673</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,009,081</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding: 0 0 0 0.625in; text-indent: 0">Total Liabilities and Stockholders' Equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,643,320</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,432,815</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of these financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_003"></A>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Year Ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3,816,732</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2,966,165</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,315,635</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">568,775</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Total Operating Expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,132,367</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,534,940</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Loss From Operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,132,367</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,534,940</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Other Income:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,380</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,497</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Net Loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(5,129,987</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,533,443</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Net Loss Per Share</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">- Basic and Diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2.19</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1.56</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Weighted Average Number of Common Shares Outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.375in">- Basic and Diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,344,712</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,266,667</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral
part of these financial statements.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_004"></A>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Changes in Stockholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Years Ended December 31, 2017
and 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="22" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Convertible Preferred Stock</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Additional</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Series A</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Series A-2</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Series B</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Paid-In</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center">Stockholders'</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Equity</TD><TD STYLE="padding-bottom: 1pt; font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; width: 12%">Balance - January 1, 2016</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">3,232,294</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">323</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">2,266,667</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">227</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">12,995,702</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">(10,597,756</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 5%; font: 8pt Times New Roman, Times, Serif; text-align: right">2,398,496</TD><TD STYLE="width: 1%; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 12px">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in">Issuance of Series A-2 convertible preferred stock</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
788,827</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
79</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
4,141,259</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR>
4,141,338</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR>
&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 12px">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Stock-based compensation</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">2,690</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">2,690</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;.&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(3,533,443</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(3,533,443</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif">Balance - December 31, 2016</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">3,232,294</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">323</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">788,827</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">79</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">2,266,667</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">227</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">17,139,651</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">(14,131,199</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">3,009,081</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 12px">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">Issuance of warrant</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">431,574</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">431,574</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Issuance of Series B<BR> convertible preferred stock,<BR>
net of issuance costs [1]</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
918,983</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
92</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
6,367,601</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
6,367,693</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 12px">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Conversion of Series A<BR> convertible preferred stock<BR>
into common stock</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
(299,863</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
)</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
(30</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
)</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
299,863</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
30</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;<BR> &nbsp;<BR>
-</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;<BR> &nbsp;<BR>
&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 12px">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Stock-based compensation</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">412,312</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">412,312</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(5,129,987</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right">(5,129,987</TD><TD STYLE="padding-bottom: 1pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance - December 31, 2017</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,932,431</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">293</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">788,827</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">79</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">918,983</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">92</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">2,566,530</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">257</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">24,351,138</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">(19,261,186</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right">5,090,673</TD><TD STYLE="padding-bottom: 2.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[1] Includes gross proceeds of $6,409,651,
less issuance costs of $41,958.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="fin_005"></A>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">For the Year Ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Operating Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(5,129,987</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(3,533,443</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Depreciation and amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">25,466</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">12,802</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">412,312</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,690</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(34,814</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">310,498</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(55,647</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">55,509</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Accrued expenses and other current liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">51,560</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(51,598</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net Cash Used In Operating Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(4,731,110</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,203,542</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Investing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Purchases of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,234</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(43,119</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net Cash Used In Investing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(10,234</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(43,119</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Cash Flows From Financing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Payment of initial public offering costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(195,700</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from sale of Series A-2 Convertible Preferred Stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,141,338</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Proceeds from sale of Series B Convertible Preferred Stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,409,651</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Payment of&nbsp;&nbsp;Series B Convertible Preferred Stock issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(41,958</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Proceeds from sale of warrant</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">431,574</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Net Cash Provided By Financing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,603,567</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,141,338</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 20pt">Net Increase in Cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,862,223</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">894,677</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Cash - Beginning of Period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,387,288</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,492,611</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Cash - End of Period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,249,511</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,387,288</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Supplemental Disclosure of Non-Cash Financing Activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Accrual of intitial public offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">133,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Conversion of convertible preferred stock into common stock</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">30</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="fin_006"></A>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 1 &ndash; Business
Organization and Nature of Operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eyenovia, Inc. (&ldquo;Eyenovia&rdquo; or the &ldquo;Company&rdquo;)
was organized as a corporation under the laws of the State of Florida on March&nbsp;12, 2014 under the name, PGP Holdings V, Inc.
On May&nbsp;5, 2014, PGP Holdings V, Inc. changed its name to Eyenovia, Inc. On October&nbsp;6, 2014, Eyenovia, Inc. reincorporated
in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eyenovia is a clinical stage biopharmaceutical company developing
a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-doses (6&ndash;8 &micro;L)
of active pharmaceutical ingredients (or &ldquo;micro-therapeutics&rdquo;) topically to the eye. This disruptive micro-dosing technology
has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers), that routinely overdoses or
under-doses the topical administration of ophthalmic therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective January 8, 2018, pursuant to authority granted by
the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&rsquo;s issued and outstanding
common stock and preferred stock (the &ldquo;Reverse Split&rdquo;). The number of authorized shares remains unchanged. All share
and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise
indicated.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 2 &ndash; Summary
of Significant Accounting Policies</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Liquidity and Financial Condition </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company incurred net losses of $5,129,987 and $3,533,443
for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, the Company&rsquo;s working capital and accumulated
deficit were $4,734,013 and $19,261,186, respectively. The Company has not yet generated revenues or achieved profitability and
it is expected that its research and development and general and administrative expenses will continue to increase and, as a result,
the Company will eventually need to generate significant product revenues to achieve profitability. Subsequent to December 31,
2017, the Company raised aggregate net proceeds of approximately $24.5 million in connection with its initial public offering (&ldquo;IPO&rdquo;).
See Note 10 &ndash; Subsequent Events for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company believes its current cash on hand is
sufficient to meet its operating and capital requirements for at least the next fifteen months from the date these financial
statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or
debt securities, to support its future operations. The Company&rsquo;s operating needs include the planned costs to operate
its business, including amounts required to fund working capital and capital expenditures. The Company&rsquo;s future capital
requirements and the adequacy of its available funds will depend on many factors, including the Company&rsquo;s ability to
successfully commercialize its products and services, competing technological and market developments, and the need to enter
into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and
service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and
development initiatives and take additional measures to reduce costs in order to conserve its cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Use of Estimates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;) requires management to make estimates,
judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related
notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other
assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&rsquo;s
balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions,
which are used for, but not limited to, fair value calculations for equity securities, establishment of valuation allowances for
deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred
costs. Certain of the Company&rsquo;s estimates could be affected by external conditions, including those unique to the Company
and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&rsquo;s
estimates and could cause actual results to differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Summary of Significant Accounting Policies&thinsp;&mdash;&thinsp;Stock-Based
Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Cash</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company considers all highly liquid investments with an
original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2017 and 2016,
the Company had no cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
- Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Cash</U> &ndash; Continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has cash deposits in several financial institutions
which, at times, may be in excess of Federal Deposit Insurance Corporation (&ldquo;FDIC&rdquo;) insurance limits. The Company has
not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. On December
31, 2017 and 2016, the Company had cash balances in excess of FDIC insurance limits of $4,999,511 and $3,137,288, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Property and Equipment, Net</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Property and equipment are stated at cost, net of accumulated
depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge
the cost of depreciable assets to operations over their estimated useful lives, which range from 2 to 5 years. Leasehold improvements
are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are
charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when
such betterment extends the useful life of the assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Deferred Offering Costs</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Deferred offering costs, which primarily
consist of direct, incremental professional fees incurred in connection with the Company&rsquo;s IPO as well as other private equity
offerings are capitalized as non-current assets on the balance sheet. As of December 31, 2017 and 2016, there were deferred offering
costs in the amount of $328,700 and $0, respectively. Upon the closing of the IPO, the deferred offering costs will be offset against
the proceeds of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Impairment of Long-lived Assets</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company reviews for the impairment of long-lived assets
whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment
would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition
are less than its carrying amount. The Company did not record any impairment losses during the years ended December 31, 2017 and
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company applies the accounting standards for distinguishing
liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to
mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred
shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to
redemption upon the occurrence of uncertain events not solely within the Company&rsquo;s control) are classified as temporary equity.
At all other times, preferred shares are classified as stockholders&rsquo; equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Convertible Instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company evaluates its convertible instruments to determine
if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted
for in accordance with Topic 815 of the Financial Accounting Standards Board (&quot;FASB&quot;) Accounting Standards Codification
(&ldquo;ASC&rdquo;). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion
options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value
as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for
each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each
balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the
date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded
as a discount to the host instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If the instrument is determined to be a derivative liability,
the Company then evaluates for the existence of a beneficial conversion feature by comparing the market price of the Company&rsquo;s
common stock as of the commitment date to the effective conversion price of the instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
&ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Fair Value of Financial Instruments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company measures the fair value of financial assets and
liabilities based on the guidance of ASC 820 &ldquo;Fair Value Measurements and Disclosures&rdquo; (&ldquo;ASC 820&rdquo;), which
defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ASC 820 defines fair value as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value
hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring
fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 1 &mdash; quoted prices in active markets for identical
assets or liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 2 &mdash; quoted prices for similar assets and liabilities
in active markets or inputs that are observable; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Level 3 &mdash; inputs that are unobservable (for example, cash
flow modeling inputs based on assumptions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The carrying amounts of the Company&rsquo;s financial instruments,
such as cash, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature
of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Income Taxes</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recognizes deferred tax assets and liabilities for
the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred
tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their
respective financial reporting amounts (&ldquo;temporary differences&rdquo;) at enacted tax rates in effect for the years in which
the temporary differences are expected to reverse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company utilizes a recognition threshold and measurement
process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Management has evaluated and concluded that there were no material
uncertain tax positions requiring recognition in the Company&rsquo;s financial statements as of December 31, 2017 and 2016. The
Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s policy is to classify assessments, if any,
for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Research and Development</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development expenses are charged to operations
as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in
advance of services being provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock-Based Compensation</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company measures the cost of services received in exchange
for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured
on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial
reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services
are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the
same basis as awards granted to employees. Upon the exercise of an option, the Company issues new shares of common stock out of
its authorized shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
- Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock-Based Compensation</U> &ndash; Continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2016, the fair value of the
Company&rsquo;s common stock was based on an analysis completed by management that considered the cash sales prices of the convertible
preferred stock as well as the relative characteristics, rights and privileges of the convertible preferred stock as compared to
the common stock. During the year ended December 31, 2017, the Company obtained a third-party 409A valuation of its common stock,
which was also considered in management&rsquo;s estimation of the value of the equity instruments issued during that period. This
third-party valuation was done in accordance with the guidance outlined in the American Institute of Certified Public Accountants&rsquo;
Accounting and Valuation Guide, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>. The estimates
used by management are considered highly complex and subjective. Subsequent to the IPO, the shares began trading on January 24,
2018, which is the date the use of such estimates is no longer necessary to determine the fair value of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The independent analysis utilized the Backsolve method since
this method is generally considered the most reliable and is recommended by the American Institute of Certified Public Accountants&rsquo;
Accounting and Valuation Guide,&nbsp;<I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>. In addition,
the method utilizes the economics from a direct transaction in our securities in determining the fair market value. This method
utilizes the Black Scholes option pricing model which allocated a probability weighted equity value to the Company&rsquo;s Series
A- 2 preferred stock. The Series A-2 preferred stock was utilized since it included new investors, was considered at arms&rsquo;
length and closed in the fourth quarter of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The March 2017 independent appraisal utilized the option pricing
method, or OPM, as the most reliable method with the following steps being applied:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Establishment of total enterprise or equity value;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Analysis of equity rights for each class of security;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Selection of appropriate model for valuation purposes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Determination of key valuation inputs; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Computation of the fair value of the subject security.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the OPM, it was determined the Company&rsquo;s common
stock had an allocated per share value of $3.23 per share. As a private company, the analysis provided for a discount for lack
of marketability of 40% resulting in a fair market value of the Company&rsquo;s common stock of&thinsp;$1.95 per share as of March
2017 based upon the independent appraisal. This price represents the same exercise price of the stock options the Company granted
in July 2017 as management determined no material events or conditions occurred at the Company that would have a material effect
on this per share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Net Loss Per Common Share</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic net loss per common share is computed by dividing net
loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential
dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
- Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Net Loss Per Common Share</U> &ndash; Continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following securities are excluded from the calculation of
weighted average dilutive common shares because their inclusion would have been anti-dilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%">Options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,684,416</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">786,667</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0pt 0">61,875</P>


</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Series A Convertible Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,932,431</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,232,294</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Series A-2 Convertible Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788,827</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788,827</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Series B Convertible Preferred Stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">918,983</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total potentially dilutive shares</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,386,532</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,807,787</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Subsequent Events</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has evaluated subsequent events through the date
which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized
subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Recently Issued Accounting Pronouncements </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2016, the FASB issued Accounting Standards Update
(&ldquo;ASU&rdquo;) No. 2016-02, &ldquo;Leases (Topic 842)&rdquo; (&ldquo;ASU 2016-02&rdquo;). ASU 2016-02 requires an entity to
recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new
qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing,
and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019,
with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results
of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In August 2016, the FASB issued ASU 2016-15, &ldquo;Statement
of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments,&rdquo; (&ldquo;ASU 2016-15&rdquo;). The new
standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement
of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. We will require adoption on a
retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively
as of the earliest date practicable. The Company is currently evaluating ASU 2016-15 and its impact on its financial position,
results of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In May 2017, the FASB issued ASU No. 2017-09, &ldquo;Compensation&mdash;Stock
Compensation (Topic 718): Scope of Modification Accounting&rdquo; (&ldquo;ASU 2017-09&rdquo;). ASU 2017-09 provides clarity on
the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and
interim periods for our fiscal year ending December 15, 2018 for share-based payment awards modified on or after the adoption date.
The Company is currently evaluating ASU 2017-09 and its impact on its financial position, results of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 2 &ndash; Summary of Significant Accounting Policies
- Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Recently Issued Accounting Pronouncements</U> &ndash; Continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In July 2017, the FASB issued ASU No. 2017-11,
&ldquo;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments
with Down Round Features&rdquo; (&ldquo;ASU 2017-11&rdquo;). Equity-linked instruments, such as warrants and convertible
instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of
future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked
instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the
income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion
option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified
instruments are not marked-to-market. For earnings per share (&quot;EPS&quot;) reporting, the ASU requires companies to
recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of
income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal
years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted,
including adoption in any interim period. The Company is currently evaluating ASU 2017-11 and its impact on its financial
position, results of operations, and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Recently Adopted Accounting Pronouncements</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2016, the FASB issued ASU No. 2016-09, &ldquo;Compensation
&ndash; Stock Compensation (Topic 718)&rdquo; (&ldquo;ASU 2016-09&rdquo;). ASU 2016-09 requires an entity to simplify several aspects
of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either
equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after
December 15, 2017, with early adoption permitted. The adoption of this standard did not have a material impact on the Company&rsquo;s
financial position, results of operations and cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 3 &ndash; Prepaid
Expenses and Other Current Assets</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2017 and 2016, prepaid expenses and other
current assets consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Prepaid research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">28,932</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid patent expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,833</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Prepaid insurance expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">383</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,335</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">37,149</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,335</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Note 4 &ndash; Property and Equipment,
Net</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2017 and 2016, property and equipment consisted
of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%">Equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">34,979</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">24,745</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">40,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,979</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,745</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(47,019</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(21,553</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,960</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">43,192</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation and amortization expense was $25,466 and $12,802
for the years ended December 31, 2017 and 2016, respectively, which is included within research and development expenses in the
statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 5 &ndash; Accrued
Expenses and Other Current Liabilities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2017 and 2016, accrued expenses and other
current liabilities consisted of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Accrued research and development expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">120,455</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">61,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued legal expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,597</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued rent expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,590</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued professional services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">41,831</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accrued offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">133,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,977</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">306,263</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">121,703</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 6 &ndash; Income
Taxes</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The income tax (provision) benefit consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">For The Years Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Federal:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; padding-left: 0.125in">Deferred</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">235,473</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">1,287,931</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State and local:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in">Current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.125in">Deferred</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">80,301</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">151,521</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">315,774</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,439,452</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(315,774</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,439,452</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Income tax (provision) benefit</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">A reconciliation of the statutory federal income tax rate to
the Company&rsquo;s effective tax rate is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">For The Years Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Tax benefit at federal statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">34.0</TD><TD NOWRAP STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">34.0</TD><TD NOWRAP STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State income taxes, net of federal benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.0</TD><TD NOWRAP STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.0</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Incremental research and development credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.3</TD><TD NOWRAP STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.7</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prior period adjustments and other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8.1</TD><TD NOWRAP STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Effect of tax rate changes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30.0</TD><TD NOWRAP STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6.2</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(40.7</TD><TD NOWRAP STYLE="padding-bottom: 1pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0.0</TD><TD NOWRAP STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6 &ndash; Income Taxes &ndash; Continued </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The tax effects of temporary differences that give rise to deferred
tax assets and liabilities are presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred Tax Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 66%; text-align: left">Net operating loss carryforwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">2,588,641</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">2,742,397</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347,977</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333,066</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research &amp; development tax credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">526,134</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">201,840</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Intangible assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">364,508</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">234,183</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,827,260</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,511,486</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,827,260</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,511,486</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Deferred tax assets, net of valuation allowance</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Changes in valuation allowance</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(315,774</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1,439,452</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company assesses the likelihood that deferred tax assets
will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company&rsquo;s
history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets
will not be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At December 31, 2017 and 2016, the Company estimates that it
has approximately $11,000,000 and $7,200,000, respectively, of federal net operating losses that may be available to offset future
taxable income. The net operating loss carry forwards, if not utilized, will expire from 2034 to 2037 for federal purposes. At
December 31, 2017, the Company estimates that it has approximately $2,000,000 of New York State net operating losses that may be
available to offset future taxable income. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company&rsquo;s
net operating loss carry forwards could become subject to annual limitations if there are greater than 50% ownership changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company files income tax returns in the U.S. federal jurisdiction,
the State of New York and the state of Florida (where the Company filed its final return in 2015), which remain subject to examination
by the various taxing authorities beginning with the tax year ended December 31, 2014.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Tax Cuts and Jobs Act (the &quot;Act&quot;) was enacted
in December 2017. Among other things, the primary provision of Tax Reform impacting the Company is the reduction to the U.S. corporate
income tax rate from 35% to 21%. The change in tax law required the Company to remeasure existing net deferred tax assets using
the lower rate in the period of enactment resulting in an income tax expense of approximately $1.5 million which is fully offset
by the corresponding tax benefit of $1.5 million from the reduction in the valuation allowance in the year ended December 31, 2017.
There were no specific impacts of Tax Reform that could not be reasonably estimated which the Company accounted for under the prior
tax law. However, further analysis of the estimates and further guidance on the application of the law could result in additional
revisions during the allowable one-year measurement period, as outlined in Staff Accounting Bulletin No. 118.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 7 &ndash; Commitments
and Contingencies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Operating Leases</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 15, 2016, the Company entered into a lease agreement
to lease 953 square feet of space located in Reno, NV with respect to its research and development activities. The monthly base
rent is $3,895 per month over the term of the lease. The lease expires on September 14, 2018 and is subject to an extension at
the option of the Company at a fixed rental rate for an additional 2-year period. The Company&rsquo;s rent expense amounted to
$45,678 and $18,590 for the years ended December 31, 2017 and 2016, respectively. See Note 8 &ndash; Related Party Transactions.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 7 &ndash; Commitments and Contingencies - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Operating Leases</U> - Continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Future minimum payments under this operating lease agreement
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center">For the Year Ending</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 50%; text-align: center; padding-bottom: 1pt">2018</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 47%; border-bottom: Black 1pt solid; text-align: right">33,108</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">33,108</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Litigations, Claims and Assessments</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the normal course of business, the Company may be involved
in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated
with loss contingencies as incurred and accrues for all probable and estimable settlements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company, its Chief Executive Officer and members of its
Board of Directors are named as defendants in a legal proceeding filed in the United States District Court for the District of
New Jersey on September 2, 2014 that has not yet been fully resolved in connection with the Company&rsquo;s Asset Purchase Agreement
with Corinthian Ophthalmic, Inc. (&ldquo;Corinthian&rdquo;). A shareholder of Corinthian, alleging a fraudulent transfer, is seeking
to recover the purchase price of its Corinthian shares and other damages in aggregate amount of approximately $1.1 million. The
parties are not close to agreement on a settlement, and although further discussions may occur, the parties are prepared to proceed
to trial. The court conducted a pretrial conference on January 22, 2018 and entered a final pretrial order on January 23, 2018.
The order provided, among other things, for a final pretrial conference to be conducted on August 15, 2018 to address objections
to expert witnesses&rsquo; opinions and testimony, with objections to be submitted by July 18, 2018 and responses by August 1,
2018. Trial briefs, requests for jury instructions, and proposed voir dire questions are due on August 30, 2018. The trial is
scheduled for September 10, 2018. The Company is indemnified by Corinthian and Corinthian&rsquo;s applicable insurance policy
provides coverage of&thinsp;$10 million, such that the Company does not expect to incur a material loss as a result of this litigation
and, as a result, did not record a loss contingency as of December 31, 2017 or 2016, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 8 &ndash; Related
Party Transactions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s Chief Executive Officer as well as a
member of its Board of Directors are both partners in Private Medical Equity, Inc. (&ldquo;PME&rdquo;). The Company and PME
are parties to a consulting agreement dated November 4, 2014 that provides for the payment of $33,200 per month to PME in
consulting fees for general management and strategy services. Any time spent by PME in excess of the specified amount is
billed separately. During the years ended December 31, 2017 and 2016, the Company incurred $329,400 and $398,400,
respectively, related to the agreement, of which, $176,344 and $318,720, respectively, was included within research and
development expenses and $152,656 and $79,680, respectively, was included within general and administrative expenses on the
condensed statements of operations. On August 1, 2017, the agreement was terminated and the Company&rsquo;s Chief Executive
Officer was employed full time by the Company. The Board member now bills the Company through a separate consulting agreement
dated July 6, 2017 that is discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company that beneficially owns greater than 5% of the Company&rsquo;s
common stock has a consulting agreement with the Company for research and development services. During the years ended December
31, 2017 and 2016, the Company recognized $0 and $366,209, respectively, related to the agreement, which was included within research
and development expenses on the statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since July 2016, the Company pays $3,000 per month to a company
controlled by a member of its Board of Directors for office space in New York, New York for its Chief Executive Officer. During
the years ended December 31, 2017 and 2016, the Company recorded rent expense of $36,000 and $18,000, respectively, related to
the office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A company in which a member of the Company&rsquo;s Board of
Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment
of $9,567 per month, and $250 per hour for any additional work, for advisory services performed by such director. During the year
ended December 31, 2017, the Company incurred $85,835 related to the agreement which was included within general and administrative
expenses on the statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 8 &ndash; Related Party Transactions &ndash; Continued
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 6, 2017, the Company entered into an engagement letter
with its Vice President of Research and Development (&ldquo;VP of R&amp;D&rdquo;). Pursuant to the terms of the engagement letter,
starting on August 1, 2017, the VP of R&amp;D was to provide service to the Company as a non-employee on a part-time basis in exchange
for $9,167 per month and $175 per hour for any additional work. On July 7, 2017, the VP of R&amp;D was granted options to purchase
100,264 shares of common stock at an exercise price of $1.95 per share that vest in equal monthly installments over 36 months starting
from the date of grant. The options had a grant date fair value of $173,900. On August 16, 2017, the VP of R&amp;D changed from
a non-employee to an employee of the Company but remained employed on a part-time basis at the same compensation rate. Subsequent
to December 31, 2017, the VP of R&amp;D&rsquo;s salary was increased to $165,000 per year in connection with the increase from
two (2) to three (3) days of work per week. The following are related party transactions involving the VP of R&amp;D:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The VP of R&amp;D owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease 953 square
feet of space located in Reno, NV with respect to its research and development activities. The monthly base rent is $3,895 per
month over the term of the lease and the security deposit is $3,895. The lease expires on September 14, 2018 and is subject to
an extension at the option of the Company at a fixed rental rate for an additional 2-year period. The Company made $40,000 of leasehold
improvements related to this lease which are included on the balance sheet. The Company&rsquo;s rent expense amounted to $45,678
and $18,590 for the years ended December 31, 2017 and 2016, respectively.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>The VP of R&amp;D is the sole owner and President of a company that performs contract engineering services for the Company.
During the years ended December 31, 2017 and 2016, the Company recognized research and development expense of $1,155,500 and $1,427,958,
respectively, related to services provided by such vendor. As of December 31, 2017, the Company had a liability of $94,998 to the
vendor and $9,906 related to expenses incurred by the VP of R&amp;D.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2015, the Company entered into a license agreement with
Senju Pharmaceutical Co., Lt. (&ldquo;Senju&rdquo;) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing
license for its micro-dose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market,
sell, and otherwise distribute the micro-dose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia
five percent (5%) royalties for the term of the license agreement. The agreement shall continue in full force and effect, on a
country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose
product candidate in Asia; or (ii) the expiration of the licensed patents. As of the date of filing, there had been no commercial
sales of a micro-dose product candidate in Asia such that no royalties had been earned. Senju is owned by the family of a member of
the Company&rsquo;s Board of Directors and both beneficially own greater than 5% of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 9 &ndash; Stockholders&rsquo;
Equity</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>Reverse Stock Split</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective January&nbsp;8, 2018, pursuant to authority granted
by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&rsquo;s issued and outstanding
common stock and preferred stock (the &ldquo;Reverse Split&rdquo;). The number of authorized shares remains unchanged. All share
and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise
indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Authorized Capital</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2017, the Company was authorized to issue
60,000,000 shares of common stock, par value of&thinsp;$0.0001 per share, and 36,000,000 shares of preferred stock, par value of&thinsp;$0.0001
per share. The holders of the Company&rsquo;s common stock are entitled to one vote per share. As of December 31, 2017, the preferred
stock was designated as follows: 20,000,000 shares designated as Series&nbsp;A Convertible Preferred Stock; 5,714,286 shares designated
as Series&nbsp;A-2 Convertible Preferred Stock; and 10,000,000 shares designated as Series&nbsp;B Convertible Preferred Stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Stockholders&rsquo; Equity - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Authorized Capital</U> &ndash; Continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 29, 2018, in connection with its IPO and the conversion
of all then existing preferred stock into common stock, the Company filed its Third Amended and Restated Certificate of Incorporation
(the &ldquo;Third Amendment&rdquo;) with the Secretary of State of the State of Delaware, effective the same day. Pursuant to
the Third Amendment, the Company is authorized to issue 90,000,000 shares of common stock and 6,000,000 shares of preferred stock.
The holders of the Company&rsquo;s common stock are entitled to one vote per share. No shares of preferred stock were designated.
Pursuant to the Third Amendment, the Board of Directors is empowered, without stockholder approval, to issue preferred stock with
dividend, liquidation, redemption, voting or other rights.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>2014 Equity Incentive Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s 2014 Equity Incentive Plan (&ldquo;2014
Plan&rdquo;) provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock,
stock appreciation rights, restricted stock and restricted stock&nbsp;units to employees, directors and consultants of the Company
and its affiliates. The 2014 Plan became effective on December&nbsp;14, 2014 and shall terminate on the tenth (10th) anniversary
of the effective date. The 2014 Plan requires the exercise price of stock options to be greater than or equal to the fair value
of the Company&rsquo;s common stock on the date of grant. As of December&nbsp;31, 2017, there were 48,917 shares available for
future issuance under the 2014 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 5, 2018, the Company&rsquo;s Board of Directors and
shareholders approved an amendment to the Company&rsquo;s 2014 Plan to increase the number of shares of common stock authorized
under the 2014 Plan from 1,733,333 shares to 1,866,667 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Series A and Series A-2 Convertible Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October&nbsp;6, 2016, the Company sold an aggregate of 788,827
shares of Series&nbsp;A-2 Convertible Preferred Stock to investors at a price of&thinsp;$5.25 per share for aggregate proceeds
of&thinsp;$4,141,338.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On July 6, 2017, the Company&rsquo;s Board of Directors adopted,
and the Company&rsquo;s stockholders approved, the Second Amendment to the Company&rsquo;s Certificate of Incorporation (the &ldquo;Second
Amendment&rdquo;). Pursuant to the Second Amendment, in the event that any holder of shares of Series A Convertible Preferred Stock
or Series A-2 Convertible Preferred Stock (collectively, the &ldquo;Series A/A-2 Preferred Stock&rdquo;) does not participate in
a subsequent financing (as defined in the Second Amendment) by purchasing in the aggregate, in such subsequent financing, at least
75% of such holder&rsquo;s pro rata amount, then each share of Series A/A-2 Preferred Stock held by such holder shall automatically
be converted into common stock concurrently with the consummation of such subsequent financing. Such conversion is referred to
as a &ldquo;Special Mandatory Conversion.&rdquo;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 27, 2017, in connection with the sale of Series
B Convertible Preferred Stock, holders of an aggregate of 299,863 shares of Series A Convertible Preferred Stock did not participate
in such financing by purchasing at least 75% of such holder&rsquo;s pro rata amount. As a result, the Special Mandatory Conversion
of the Series A/A-2 Preferred Stock was triggered and, accordingly, such shares of Series A Convertible Preferred stock were automatically
converted into an aggregate of 299,863 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The preferred stock did not contain a redemption provision and
an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been
classified within stockholders&rsquo; equity on the balance sheet. While the embedded conversion option (&ldquo;ECO&rdquo;) was
subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required
to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the preferred stock did
not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company&rsquo;s
common stock as of the commitment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series&nbsp;A and Series&nbsp;A-2 Convertible
Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis.
In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion
price shall be reduced on a weighted average basis. Each share of preferred stock shall automatically be converted into
shares of common stock at the then effective conversion price: (i)&nbsp;immediately prior to the closing of a firm commitment
underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters&rsquo; discounts and
expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than
$20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then
outstanding shares of preferred stock. See Note 10 &ndash; Subsequent Events for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Stockholders&rsquo; Equity &ndash; Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Series B Convertible Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended December 31, 2017, the Company sold an
aggregate of 918,983 shares of its Series B Convertible Preferred Stock to investors at a price of&thinsp;$6.98 per share for aggregate
gross proceeds of&thinsp;$6,409,651. The Company incurred $41,958 of legal costs in connection with the sale, such that the aggregate
net proceeds from the sale were $6,367,693.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 9, 2017, the Board adopted resolutions ratifying
each of the issuances of Series B Convertible Preferred Stock, which were then approved by the Company&rsquo;s shareholders. On
November 13, 2017, the Company filed a certificate of validation with the Delaware Secretary of State in respect of such ratifications,
such that, as of that date, the Series B Convertible Preferred Stock was duly authorized, validly issued, fully paid and nonassessable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series B Convertible Preferred Stock is convertible, at
the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the
event of any issuances by the Company for less than the in-force conversion price, the Series B Convertible Preferred Stock conversion
price shall be reduced on a weighted average basis. Each share of Series B Convertible Preferred Stock shall automatically be converted
into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten
initial public offering provided that (A) the aggregate offering price, net of underwriters' discounts and expenses, is at least
$2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date
specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Series B Convertible Preferred did not contain a redemption
provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore,
has been classified within stockholders&rsquo; equity on the balance sheet. While the embedded conversion option (&ldquo;ECO&rdquo;)
was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not
required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible
Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the
Company&rsquo;s common stock as of the commitment date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 10 &ndash; Subsequent Events for additional details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 27, 2017, the Company issued a warrant to purchase
61,875 shares of common stock at an exercise price of $6.98 per share to an investor for cash consideration of $431,574, which
was included within additional paid-in capital on the balance sheet as of December 31, 2017. The warrant is exercisable any time
through September 27, 2027. The warrant was sold to an investor for the amount of the investment in excess of what was permitted
to be purchased of Series B Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the warrant activity during the year ended December
31, 2017 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Life</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Outstanding January 1, 2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%">Granted</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">61,875</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">6.98</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding December 31, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">61,875</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.98</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable December 31, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">61,875</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6.98</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9.7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Stockholders&rsquo; Equity - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock Warrants</U> - Continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table presents information related to warrants
as of December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Remaining Life</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 23%; text-align: right; padding-bottom: 1pt">6.98</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 22%; text-align: right; border-bottom: Black 1pt solid">61,875</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 22%; text-align: right; padding-bottom: 1pt">9.7</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="width: 22%; text-align: right; border-bottom: Black 1pt solid">61,875</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">61,875</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">9.7</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">61,875</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock Options</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In applying the Black-Scholes option pricing model to stock
options granted, the Company used the following approximate assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the Year Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="width: 70%; text-align: left">Expected term (years)</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 12%; text-align: right">5.32 - 10.00</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD><TD NOWRAP STYLE="width: 12%; text-align: right">10.00</TD><TD NOWRAP STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Risk free interest rate</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">1.95 - 2.39</TD><TD NOWRAP STYLE="text-align: left">%</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">1.53% - 1.83</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="text-align: left">Expected volatility</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">130</TD><TD NOWRAP STYLE="text-align: left">%</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">131</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="text-align: left">Expected dividends</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">0.00</TD><TD NOWRAP STYLE="text-align: left">%</TD><TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="text-align: right">0.00</TD><TD NOWRAP STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has computed the fair value
of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence.
The expected term used for options issued to non-employees is usually the contractual life and the expected term used for options
issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company
utilizes the &ldquo;simplified&rdquo; method to develop an estimate of the expected term of &ldquo;plain vanilla&rdquo; employee
option grants. The Company does not currently have a trading history to support its historical volatility calculations. Accordingly,
the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities
over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined
from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument
being valued.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The weighted average estimated grant date fair value of the
stock options granted for the year ended December 31, 2017 and 2016 was approximately $1.77 and $1.16 per share, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company recorded stock-based compensation expense related
to stock options of $412,312 and $2,690 during the year ended December 31, 2017 and 2016, respectively. As of December 31, 2017,
there was $1,327,224 of unrecognized stock-based compensation expense, of which, $377,816 related to non-employee grants, which
will be recognized over a weighted average period of 2.4 years. Subsequent to December 31, 2017, the Company closed on its IPO
at an offering price of $10.00 per share and as of March 27, 2018, the Company&rsquo;s shares closed at $9.20 per share. The Company&rsquo;s
stock-based compensation expense related to non-employee grants that is recognized subsequent to December 31, 2017 will be materially
impacted as a result of the increase in stock price subsequent to December 31, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 9 &ndash; Stockholders&rsquo; Equity - Continued</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Stock Options</U> &ndash; Continued</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of the option activity during the year ended December
31, 2017 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Life</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Intrinsic</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Value</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Outstanding January 1, 2017</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">786,669</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1.37</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">897,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding December 31, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,684,416</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.68</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8.5</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,361,825</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable December 31, 2017</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">920,383</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.39</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7.6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">883,675</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following table presents information related to stock options
as of December 31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Average</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercisable</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Remaining Life</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Price</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">In Years</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 23%; text-align: right">1.24</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">760,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">7.2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">760,001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">897,747</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">152,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">5.25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">26,668</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: right">8.8</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,917</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,684,416</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">7.6</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">920,383</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">Note 10 &ndash; Subsequent
Events</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Initial Public Offering</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 29, 2018, the Company consummated its IPO of 2,730,000
shares of its common stock at an offering price of $10.00 per share, generating $27.3 million and $24.5 million in gross and net
proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $2.8 million, a portion
of which is included within deferred offering costs on the balance sheet as of December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Conversion of Preferred Stock</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immediately prior to the closing of the IPO on January 29, 2018,
all outstanding shares of preferred stock were automatically converted into an aggregate of 4,640,241 shares of the Company&rsquo;s
common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EYENOVIA, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2017
AND 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 10 &ndash; Subsequent Events &ndash; Continued </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>2018 Omnibus Stock Incentive Plan</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On March 6, 2018, the Company&rsquo;s Board of Directors approved
the 2018 Omnibus Stock Incentive Plan (&ldquo;2018 Plan&rdquo;). The 2018 Plan provides for the issuance of incentive stock options,
nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock&nbsp;units
to employees, directors and consultants of the Company and its affiliates. The 2018 Plan will be approved and adopted by the Company
upon receipt of stockholder approval and shall terminate on the tenth (10th) anniversary of the effective date. The 2018 Plan requires
the exercise price of stock options to be greater than or equal to the fair value of the Company&rsquo;s common stock on the date
of grant. There are 750,000 shares of common stock authorized under the 2018 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tv488528_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 31.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">I, Tsontcho Ianchulev,
certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">I have reviewed this annual report on Form 10-K of Eyenovia, Inc. for the year ended December 31, 2017;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2, 2018</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tv488528_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">Exhibit 31.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER<BR>
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">I, John Gandolfo, certify
that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">I have reviewed this annual report on Form 10-K of Eyenovia, Inc. for the year ended December 31, 2017;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2, 2018</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ John Gandolfo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John Gandolfo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tv488528_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 32.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In connection with the annual report of Eyenovia,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Tsontcho Ianchulev, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tsontcho Ianchulev</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>tv488528_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 32.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER<BR>
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In connection with the annual report of Eyenovia,
Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ended December 31, 2017, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, John Gandolfo, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">April 2, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ John Gandolfo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%">&nbsp;</TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif">John Gandolfo</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>tv488528_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ =@ C P$1  (1 0,1 ?_$ +<   (!!0$!
M      @*"0 ! @,&! 4! 0$  04!              @'!@$" P0% !   0(#
M! 0*!0@(!P       0(#$00% !(&""$Q$P=!46$R<K(SMG<X@2(4%PFQ0E(C
M0Q46&'&AP=%B@J)3HS0E-E8H&1$  0$%! @""0,"!P       0( $0,$!2$Q
M$@=!46%QL<%R$S0&@:$B,D(S%!4U\-%2HK+2\B.CPX4(_]H # ,!  (1 Q$
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>D\F4N32)1-()EUA2W6ARKO2'-.5:(M:FJWS?-__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tv488528_img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ I@)D P$1  (1 0,1 ?_$ +\  0  !@,!
M       ! @,&!P@$!0D* 0$  04! 0$              @$#! 4&" <)$
M!00! P($ P8#!@0""P$! @,$!0 1!@<((3$2$PE!42(483(5<8%"(Q87D:&Q
MX5)R,R08\,'18D,9\8*2TF/#-$2$)28*$0 " 0,# @0#! D# P,%     0(1
M P0A!08Q$D%1$P=A<2*!D3(4\*&QP=%2(Q4(0A87X3-3\6(8<H)#)#3_V@ ,
M P$  A$#$0 _ /OXH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@) Z&&_0!M;\1ZW_P!: GH!
M0"@% * IF_.7]W^M 4UE+ )2]3?'\*EV2>I2J*9%C$(/D =!Z7Z=_P 1&J.+
M74K2IR"'\@ 1Z (7_P ;?XU1Z=0<83B03&$Q3  ]@[]^EKC5>V54DG5D7."Z
MRBOFTC'&7[6PC!DW3G*LCB(1NV3!91:0D$&I"$$/*YRG-ZGY?D%ZV6+L6XYT
MD[5N;ATT53E]WYML&R)K)R+'<E5UDM#1K.?=0XE8,X52=[2Q^251,8ADH98T
MB83E 2^!1(B)A4 0&X? *['!]M=TS6I*,E%Z:Z?J;J?(=[_R0X/LMV4;ER-R
M22?T]S7ZD:\R_O?<86BJOZ8WRR:*7_XC*''TS"'\)3*E)>X!W[5UF#[$[UGR
M<X-]GCJM/UGSW-_R]X@I.6+9DW_]W[T6>?WWM#E&Q->[!5+U #_I[0 'Y&L9
M4O?Y5L?_ (][LG^+3]/B:S_YD[!'3\G/3XO^!<L/[X?&M^)32&/YK$E$Q04.
MM&@<I?*X^1O0\NA;?C6-=_Q_WBU]7>D_C_ZFRQ?\P.*7/_Z;$XU^?[D9_P .
M]VOAIEZJ34-AI0SI7Q Q)INJR\?(!N4!52 ! +=1#M>N8W+VJY)BQE^%QH^G
M7[#N=E_R5]O<Y).Y&$FZ5;=%^HW1P;>^J=E-".\$SS&IYNH4AO%G*-@$WJ#]
M)0 3 )C?.P#:N*RM@W/:&K>59NT?BXO]Q]7V?GW&^18\KVWYEB5/!2I^VAEQ
MJX]4+A]/4!Z&]4H@/:QBA8;AWK07;=SU:.,D_BFCL<+*MY5KNM3A*/FI+^)V
M0&* 'N<!$2CTZA\?QI"$E*GB9C3KV_ZB9)2W3X=/@/0*NN$EU*]DEU1R ,4?
MC_J'^M6^^%>VJJ1::(C491;=4"41 .]6VJ:,$;@ 7^ U+MDP<<>X_MJ^7ET%
M 3$_,'[:%)=#D50LDH&$3"'RO_K0$U * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0$IOX?
M^(* FH!0"@% * E, 6$1[@ _Y=:4KIYBE=#K$EE#** HB< *H)0.(6+X]+"(
M?LJ,[,;,'>[ZT,975ZKMTE5=733[SIY/(8N**<TA+,F;9,#'4.Z6(@5,I1O<
M5#=+% +C61CXN=E-.Q;E-/R52WD;KM>WQ=W<;]NQ!?SM1U\.IYD<G/=;T'Q[
M?OL98R#W8N7-E13- X81"25:%\$S I(.SV:LT2^76YA&U?2MC]KMRW-0R;\)
M1MOJG6IYVYS_ )(<8XQ<N8F/.&3>C5?1K3XUKYZ'ACR-]VKDEMWTVVOE6>J8
M$QU1,Z0=@[DW#8?(J:9Q#P*1<H6O;H!KUZ(XK[/;*E&%Y*5UT_%X'C7G/^3'
M)N0/TMIB\:TG*C3:[JTZ^5*?K/-O(=N[)S]T]#.MEY!.NA\5U0=R[T$5?$+D
M_DBJ)/ >U@ >E?6K/MQM.WP[,9P@O'1/6AY_W'?>1;K=_,YV7>N7&NG>_.M"
MSD%R+&,7PB&Z?145#-/6-Z1; HMYG3N8PE"]78<8Q+5SU)N$DO'I^HTKEFSE
MW=\_DVW^LEEI^"C"MP++I."/W:*2(-V/0"D&QQ$0 .QK_LJW=R(;1EI824H2
M9!865?FY)TD_"IP7>18^**AFTR4%#/1;F 69N@6*/IA;YWKH%OR[5W6XUIY$
MY[9.VOZD]?F3D5!T+A"-EV2QVX$,\24:J)F;H" "900->X7MUK!>^Q]1V\BW
M'NHZ#\LEXR.<]9 D1F!GC!14ZA17]-J6Y8\Y!,=4XB7RN!P"P_"]8"G8S8MQ
MMP[Z:-^9:C97=5)P:?A,Y,%L'*\/.U-C.6RT&ZN9=,\5*/XX2 FH)0%N5 _I
M&$2=P$.E8^;L>!G6XK)A;FUU7:M?M_6;?;MQWC;NYX^5=LKP:F]/L-^-%>YI
MR/U$[;(N,O;YY&%,FI^DY8LX.^.4# 82(R0*^/F(% /J#I7S'D'MML^8I3MV
M80FWX:'V#A?O;RWC4XV[M^6396M')]//[#W'XV^\7J':+V/Q;94>YU[D[L$T
M$A=+(N(A5V)RD A9!$IDB"H @(>8@%J^"\K]I,K:H1SL-J49S[6JZK1OR^![
M,X#_ )1[)N\HXFY=N//L2[I>,JI4JW]I[ 8OGF+Y2U2<PLLRD$U4TU"'9/$'
MI#%.%P'U$+D#O:UZ^59VQY>*GZL9I*M7K^C/3>U<GVK>;4+N#D6[KFJ_3).E
M>E?(NDYBJCT,IXAU["4HA?M<!ZWK1_E_1N5<DT_B=#'NE5OP.=XE, &\Q +
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M/QU\3.Z"A3)E$IKEO8H"(=!L'0/VA7.4TZUT/H#MJ+IY%<;?/]E8U2:FZZ]
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M*%^_RKU#P#B>QX/;E[IC.5Z*6K;Z_'S/S5]TO?KF&Z[G<P]K[X;1.L8?3_\
MDKX/R\D>,F&8GN35F:&G,%UYFF(YWD[IQ^GR61,@:(2D^N/K?IC-P\2,5$2(
MB8Q$A'R,(6"OMEOENP3M^A;QXN"TU5>FG4^'S6\[JU+>+<FZIUDM?.IN9IW6
M/*7D_B&X)E?(83&LTQ[)\:CY8N4R!86660C7I5WCI18/2%%NV](3%  *![5S
MF\<@VBVI/&L2HD_V?+0[W8.!XFXW)9EW*C;E+JI2TIXZ%X;-_4-.\A<U3>[/
MQ3*M>YAI]W%.LC@GB+A4F9%C@;GBW16Q_%=(CPE@.:X@'>L"QO=W.L54*6$N
MC6IEY?$-JVN<O2R8RD_'N_8:=*[^R@NJ-&ZTCVMY_5N5+9/-R+DRI8-=J#I=
M5O'QQ1$Q_OC$$!-<?C5B/Y5-OTY:FSV["VR#BGE=DXZI]_BCO7/(;=F:[:GM
MU(S,/A^5/\>)CWV,<P34)'Q+=,R+5VBNL8]E_ ?(PEZB)A"I>MEI4M*D/BJF
MQCM_'K.0\J[?MRNSEJZK5FN3S6>P\SE'#Z8VXZ*BM(*9 <Y!'[!>3^H/7>MQ
MN7[I83B("'6PU9N7]SMVW.,FG\M/N,];3Q&]BO&G*UZ;=>JK5EKMN,LB[S4^
M2I9GE),ODQ*EZK5V9.'DT_$J)!]"]OH3 .X=!K7;E>WAXJO6[DHRIK3I^GQ,
MG*AQ1;+/9\Z6/Z+=;-**7J=%5^*IX%^DX,8?A,A,O8_/\V4R?,FO_P#K&I7R
M(H$%T!C"1$%2JF$/J$ M;O5O:/[Y#&N3MW9OO3K5U,B?]MW';,?:,F[86XXW
M:[*@E%5\>Y?ZOM,7GX!X-A>/3.)0>U<A9P.7NR.\EAWADS/E7"IQ\P:JE"Q0
M\3= Z"(]ZP,/8]XR,:]CN[/T+DNYZZU^9L=[W[:K^\XN=E3QY9N+",(NB2T2
MK5>.I=+WV^<&;:^3UU';<R9UBS]5)T6 67;'<(+G"P&<$32 " )C7[]:S([#
MO3P8X/?<>.G7J^OS\BX]SV6YO7^XN_&6Z-:2HM/DJG5/?;M=RT# :P+L%RMC
M4+_U3!BI+(@HT$IQ6]<4"@8P)E&XC<>E+N%OMNW;LJY-PMOZ:ZT^9G\8R]FR
M.<1S+5VQ^;R82[Y4571>'D<W(.#</,2^,L,DW$\>LL2*DP8FCW@I-VQA\#IM
MR70\3G*JD%S=1Z=:JGR*O_>N5^9S6T9NSX>9N^T*=KU,JZU-2H]956E>BUZ'
M:K<9("1S=/(Y[(,Z"9BE48]@Y8Y(FLT>M6Y 2;+_ &ADP('B0 '\H=:LNYN]
MJ;]2Y/NEU3>GW&/QO#XW';<C8<YXWKQNN4DE%?354^/6A>^-<6D&61R,K!;8
MSQ%TZ?%>*Q17C11N54HE$%%BJ"F4? "6Z6&L*Y;WFY-RA)N/R-G+;N*3N1A"
M6/!QZ-43T-S\5B]G?W#QO:#?>,MFV6Z^9)LHZ.RULS%@T9I) V^T>&:G(8[0
MB(B7YB/<:86W[M&_*\V^Y+]Y?S=DXQE.%^=^T[T7I1I+H7/B+O8,;)[_ )+*
M7;>08[GC)'TR01"-<<BY]8A#(**N3*'4*Q\41!2XWO:U8VY[AFVY4R_JC5Z4
M,&WQ?8[L[LOS$%ZB725.E?XF5-8X8XFU.)F/R&:0C1/"UW3W-I%\^*, @JLX
M4\$$"]2J*$1L'U%'K3;N8V,)]MBS*O1UUU(_[$V6_3\QDP]%.GXJ,RGR XP;
M7U/J+.MD8[LO$LE9GVJKE6,M<?DE/U)TB]4(9D02%(()'*N8H@!  "B'RKH\
M+FFU7,CLS,5N;U;:TU\#/WWVRN+9U/8]PMV8RJJ=R^_YGFWLG5'+[918<=A:
MUE]@/Y:-"5'&D9]>9DHYFY,0S&5$+@FT54*H!0+T[UVV'O\ QV[)P]&$8275
MK]Y\5O>SG*[:E?EGJ\HNJHZO[6;>Z!]QS=/"9EB^I<PQ-SBL+#-TVYL/S5JJ
MSDDV JG.=5JNJ E52*)Q$OCW#XUI.6</XOR;#]:U&#O):-.GW^9W?MQS?FGM
MYGPVR_=F\)3K2E75>3\%Y(^LCCKNR#WYK+#]BP*I$F.11I'I$$O(4P4$ *8
M$X=P. UY)Y%LJV/+E8KW03T_3X'Z)\-Y=9Y5MBRTJ7Z*O@ON-@ 34*/YP  '
MKU"WX_MZ5R7;<ZOH=:E=;U:^XKE$A0\A,41"_4+V_ *N1_$B3BTJOH<P@_0
M_@(_ZU?($] * 4 H!0"@% * 4!*8; /6U@N(@(!8/G<W0.U >9O,;W#,(X\-
MOZ1UVU-M3<LJLNPCL9@5B.&, N E3!_D[A,Q@;MD%3A<I1N8 &L+)NW(-]KH
M#R Q32.Y^6><'V7R(GE\GE_NU'33&43*HXSCS0% /_T;!<I$W)D2E+XF$INW
M0:Q\>Y.XZS;;8/:W2G&""QR.B#_;M442-T#))BG?UR$-<JZI?R?4(6\>P6K8
M*W;:K0M.3J;?2F%8KD&-RV)S$(RDX"7:F92L:Y2*=J]1\1+XK%'KU#H40$+6
MZ556X1_"J%T^8_FI[%F=LL[<[GX<[1F<<*B*\XXUG+S+I1PR7 3JFC\23**K
M==-=0;@BKU$/V!5LE5U/.R'Y]^X?Q&GD]=[,U%F60R[5\E'QCU7$IB+ ")G\
M -(2C9-PS<"8 _@* #5;;:FFB4M4>['&S<O*;FO&,V^5XX?#HHK=#]3!-=PF
M@0H%*< 6*HR0,*@VM^>]9/=+S+5$CV1UEIK%M<QS1%FU(XE$DB YD3@(J'5M
M902F,(FL80JC;?4J9@\"B-Q*6][WL%ZH"(  =J C0"@% * 4 H!0"@% * 4
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MN8A0+ZBQRE QSC\ZO%"[+ '8+4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M9]2^V_J@D'F8IA+<#7#O\?\ "PU V=Q)2TZ'(*-P*/S 1_S#_2A GH!0"@%
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M2[1F4@'<))JV$0*>XFL0+G\2A83& O6P4J@8 V'M,C)W^CL4Q?3C\GA#1C$
M<GE!4+X^HHH03"Q.0?X!O8 JCZ%E5J4,!T:]FUTLKVHLM(R"@>JRQLQS&C8T
MIA\B&73 3 J[3*-@&]@Z]*MJM47Z(VM;M4&S9%JBB1)N@0J2*)"@0J29 \2D
M*!;6  "KQ0Y   !8.U 1H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4! P>06[=: X:ICDMX_,0&X?B !_K5JYK2/F.NGB8MVGF^/
M8)B,Y,3SCT6L='N';FPE!1)L1(YG2I 'ZCB1(!$  .HA:M]QO9LG(SHJSK&M
M?M1SG)]WV_:]JNRS91491<=6JZKYGP[<I>.N79!F,[RKQ;=6*RW'K+<^6+*/
M'"JCK+8PBKCQ69%:K$LD=) 1 "]NE>C]NWO<]I=JTTUCQ\EU\S\]>:^VW'^0
M[H\RW*L+DT_Q5IKKXFIF9XKK*<V G":BG<A=XFJ*IF\](N"IKOR(E 7P@4+
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M;,J&2\R>L9:L]Z\+Y5QU[+9VO"DOS%E45&OUZ^1Z7LUO52M<WE:X@)@,);B
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M5JF3ZKDU%556Z_2_(S#KGC#G\?#R:F0:;RUVL,:9-L*V//#&(Y5 ?3-U)XB
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M!LW^(6'J*=^M7;<96H]L)NAE8L;.+:]&$/I8) LD_$Z;&/(J6]CE9-@-U'J
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M'3X5(E%45#91,GA8H 4A"$*0I"=" !>WB7IX@4.@4)%2@% * 4 H!0"@% *
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MBLH[=(HL2IB<SD#I'(5(W4C@3>7TD, VMWJ2^C5CO3-;FTGDVZI!U&8D#QA
M <R+[(5$U$6ZR8&&YFJX@4R@F*/0H=.M'_4Z>!1_5T-H<$UIC>"1R3:+:IJ/
M@( .Y94MW;Q;_P"(<YC>5BF$1"P5.*[50DE14,B@%@ !J14C0"@)3& @7-T#
MY]/_ #&@*'K>=A(4?$;_ )K$$/$?JO<0$+_#_&@(E5$W8+ (=+^70; (^0_[
MMAZ"% 4TW1CD$PI^ @(AXB8#B)0&P* )!,!BF^'Q^= 516\>IO$;_ HVL/R'
MR'K0$ <$$1 0$HA?Z1MY6+^8; -PM_G0$Y50$IC6$"@/0>GU!:_E_P"T/VVH
M"0'!! @A<?/Y" ^/2_U"%R@'[Z J I?^$?\ $.M^UNO41H"D9<2CU"Q+C]8B
M)2@  -[F#Y"% 127!7L';QN-PM]0C;Q, B4_0/AV[4!-ZQ;@ @(&\_ 0"PV$
M36"X@-@OWH"3UP\RE^D##<0**@7,4!L(@ =.E 5 .;R,!@+X@%[]0&WPN AW
MH"7U#":Q0"P!]0#<1*81[= ZC;X!0%>@*8GMY6*)A#L "'U#:XAWL4?VVO0%
M(%E/("F);XF'X%+WMW'R-;O;M0$YU/$H]A-TN "(6 QA HW"_>U 2 N(CXAX
M>5[ 43"!C=;>07M< ZT ]<0\KV^FX_E-80#L'E?Q 1'YT!,16Z8&,'B8>Q+^
M1O@'7QO>PCU$* B"P>'F;IU /CTN/01 ;"% 0!4/(>GTV[W&XC\@+\?W4!3^
MZ#RMX#<? "E$0 P^0_FL(@4  ._QH"N0_GY?(!L @!@ >][>0!>WX4!4H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%$50]3T[V$ \A\BF !#XV-T+VH"/
MJ?2 ^(@)KVN%PZ#W$2C;J'XT  YA$O3H-P,'B;R#\;=RA</C0$OKWOXE$P%$
M $WD4I;]A_,-^@T!,)^UOI#_ -P"'E^ 4!("XG*8Q  HDZ'*>]R&[@4WA>UP
M$!OVH 9<"W+X'$W7Z;]1[6MU$PB-_A0$GKFZ6+]0@(^%S'-8O<O2Y?+\* J*
M*B4H" #<3%  N%Q*8.AA#N!;]_V4!$JMQ* V$#7$!#MT[WOUZ7H"8AC"-C@4
M!ZB E&X"6]BC^\!H"I0"@% * 4 H!0"@% * ^1[_ /Z:\NYA<4\(PCF3Q.V;
MF6 K8\Y;XQG)L;!5Q&$9/3@F@^DV1@4;B<P6 51+T O>CZ ]+O8EY]Y?[B?
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M*^,.883JZ.>;S@HHT6[TYO'/&KAM&P^>)()_IQ=:YA*M3MXU\;Q%HZ.F581
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M-8_IS(-=XVAGL;%9WB>5\E5%RD.[QCCK^M,\:RC+B)H 8S-4TO(I 4P$ J8
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MQAIGV#F?&75+ 9.U8%<ID!=P4ACB '&@/0J@% * 4 H!0"@% * 4 H!0"@%
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MZ8 %P.'D':LJS<?9X ]36Z2:1 33222*D4J9"I)E3*4A0L4I2D "E*4.P
M%2;;!7 +7'YU0$AU"D,4IK_5>P_ +6[C<+7O0$!6* "( (V$ $.UA'YB/0*
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MOP>EL9Q\^]T>/N9:;:H(Y;'GQQS*Y'^K(-)@9\K4B*$4DG)E.<ID_4^@2]Z
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MU"(WM8.]A* @'X_5_A0#U2CT+U'MVH"0[@B9#',(?0%S#_"  ;Q'MY#](]P
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MT^4K?C+@>_\ 4^8\8\8T5'X_D>>X+$/0DH;)W\Y*S9VV50\BFP:.VCST!(F
M*GL("-K4!GO%]9;^R[8?'3)MJ:5UYB^*8=AVS<9RW$,9RN+EL?Q+'<KCAQW'
M\6;QKMB']1HMX(O@Z%(H(B4_B4H % :8I^S9*N(3G9QY?;05/Q0Y$:GQS$^/
MF/.E%7V2:#D6F1Y!EK[&V"JGU+X1"9)(HN(U$!NW2,=(A0*4M@.XVOQ9YO<J
MN)NL.!&X\+P? -;1Y];8YR!WU'[#93Z>T=<ZOD8M^ZB\-P9LR2R''Y#.S0;<
MJAWRI@0()P&XB% ; >XIP/S3D9A_'.2XY9,UUQMOCCGD 7$YE986Z#C4,Q%)
MXCLO!W#L"@LJSF<,#TP3_*94 \@^% 3<\^(6S]KXMP<P70^)P;['>-7(_3.U
M)U.3R5EC!6^%:G*BD,7%).&ZYG4@]03 $PL!0$OU7O0%'/\ @TZY;;1Y*Y1R
MEPZ4C,9R7"D-2Z@8XQLE(H.M=?9/E90)EE'H FQ?S4\[.L?U@,44?3 >I* R
ME[7NJN1_'CB/@NA>33&$-E.H%Y?"L.G8#)29/_4>LHZ3<%P1W)N/117)-M($
MR2+H#W\E"7+TH#T5]8@V, E$E[>7D6PB/8 ZV'KT^=Z CZQ1L)>H"-A$1 H!
MUMU$>_6@(>N7X ;J4#=2C:UQ 0Z7$#  7'\* CZO7X6$/(/Q+?O_ )T! 5B@
M%[=.O41 H7 +B%Q'X!0$OW!1.4H (B8/(MKB(D^)K %@Z_"][4!4!4@_$?S"
M7M\0"XW^(6_UH"F+E,I1,8?'Q 1-Y=/'K8 'I<!-\/G0$0<$, "40[7&_P O
MP'L- 5/,/'RL;_AL-[_*UN] 0.D0]Q,6XC;XC\+VMU[]: T,S[AWH7,.1LUM
MO*=7X5/YGE&$IPKB=F<?83#\[5J8R"B2BSY-442&;B !X6$+7K#R.J!G'C?Q
MZUIQPP)UA6K<6B,4@I+(97)'<?#-09M%).44\G+@$0,(%,;Q#L-OE5^S^ &P
M90$!"X=BV[][?/KU&KH)Z Z/)!D2P4PK$K(H2B,4_5CE7*17#9-ZFW.HW.NW
M,) 53*J4+@(VH#R,]M;W-9?EMIS?DQOO"HS56Y>-.6Y(TSS#XY\J9I):_*D_
MDM?9[$?=^DJ*&90C+R*4+IE<' A1&]J NKVO.>N><VN/FX^0FV\1A-6PV#[J
MV7@L'C+%1=R[989@!&KEE/3LBN)/.4F6+PJBB $+Z!OI&]^H'>^W=[@[CF3C
M7(,^>X<35>=: VKD&/3>)NE0.[<:S?- R76^>*('_GD;9)AKE)<P>( "Q#EZ
M6H#$^A^57,;G#K+8O)[C8UU?A^HH/)-AXQH'7V=Q+Z5GM_$P5\_A"Y)EN3M5
MTO[?Q.12S(Y&B;9!V<R5C*>% 8LS_P!P#F/B?(G8.BTX'CQC<MK#ACBG*J<C
M=B3DG"-5YUZH+/)]<Q\E'IN'(M8UX@H#9R!#++V( D"XB &5LD]T9_)\<N#&
M7X%K 6?(;W!9;'<:U-KC+5W@1&(NWD:M-9CEV4OH]$[QQC&)P[51TB4A"K.K
MI%$"@8WB!?<5R[VYH3FSJ3A9RC=XKF[;DKA>5Y/HW=N(P!L,:/\ ,<,(W<91
MJG(\4^\DD6[Q-@X!PP?(N#"Y2*(*E(;I0%U>X]RDW9Q9QSCP_P!,1F$2TUN?
MD3K;0JL;G#:1/',?[B2HQJ,XBZC@.Y!:+* G,GXB4X!W"@,2._<9V/QHY4->
M,7.7#\%Q6#SW4V>[:TEO;6LI*/<3RMGJQ@,KL/"\IAIEFT=P>4Q,9XN43) H
MV5(;Q\O*@,9L^>G+[)N%+WW-,/PK7R^BVL+)[)A.-CZ/=ML^R30<3(N 6S4V
MQU%BHQV8OL8;C+(1P,C,Q"R9E0O>@.NDO=2E=P<F];:6T-F^IM98]L3B7CW)
M?3\GN9%9(O):6RK[CT]98;("JV:L5,6%($Y%= [AT18W\M(X"% ;!3_*OD>T
MYG\4N*LA%8'A[S>_&K/]QYD\%@[EUL-RW ACV*N*1H.5$B340Z?OS'!PJ9)P
MD1/\@B(A0%B<4?<PR??\9R8TYL+%8;4/+/1A=GR>*0KOUWV+;<UQAN13D# [
M.PXRQ$WCR'5D(11O(M?$7#10/(Q0*8@B!S5N>&W<XS7BWQ9U>WPY;DYO33KG
M?.Q,TDF*JVN=):L8N5(Y::5@2."/\CGGTF)6\8T56027L<RABV * WBTC,\D
M6.PLSU]NMUK;+\7@X2$DL/VKAJJ<',97*.1,,\SRK79GSLV+.XL?#T ;JK(+
M)!Y&, C0&N>\N1_,34N]-3,&&KM'SFC]D;8C=8IXVIG<LCR%>P<J)DW>QX6
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MB(%^7E<;_P"% / 1ZF[B'B/B(E 2]AZ!\: @*?B40(!1^0&N ?&_8.HW&@(
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M( -S?,* &1&Y1*(_2-^@AYC^\0M\: JE 0_A*4+!T#N W&]Q#H(6H">@% *
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MP^5 4B)FM]0>(@8?X_(1"_0P#8+"- 1!$I0$I; 4;B(6#J8;=1H"0Z1^Z?I
M/B)>I1OV^D+@8 \0&WP[4!,5(?3 #V%3H81"]@/W$27ZA^% 3"E<H@($N8MA
M^FY?C^SO?K0%/T3>/C_+M?MXF\?'Y6\K]OQH"B\<I,6;QZH(%(S16<JB(_F*
M@D8XW^06"CZ ^7EUKS<G-[?.VMVLYR29XG'RTK@6,1#<RP-/MHI46SL ^NQ!
M!1(3!?O\*UEZO>OF@;R>VE%9WH?-\]T=F+QZ[BI5R>?Q[[U0R@ED N5PB01
M?23,B6]QZ"/XUG6?P ]KDQ 2C8+?48/\!$*N@GH!0"@% * 4 H!0"@% * 4
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M!<%1+<W_ #ONDTG/F ]_(H#0%_D^/^]?Z_V_Z4!/0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
K% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tv488528_img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img3.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ K )Q P$1  (1 0,1 ?_$ ,8   $"!P$!
M       #!@$"! 4'" D*"P$!  ,! 0$! 0$           $" P0%!@<("1
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MU2$ ^J)1)223CG/#@/D@';2R6-,\#*9'<! 71MH- R),R,Y<2!P@%8 @" (
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M.XP'7+I);6]%&I*9GFH[L^\#$P'4/X(?\,?ZH^N ].<<Z1 1B;?- C&Z! $
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M2,9^OM@*NG9U.)292,\/1B.SC .IBG2$)5.2I#&0[H"L EZ>WM@(P! $ 0!
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MYSE+/" JTI4E:=/J/S]LL(!P4_,+8&H8=H^;N@*L3D)Y\?3 $ 0! $ 0! $
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M9P!, YTAK3[F<^ ]'; 55(@:=21(:CAEB-/I@+PPX$X?/WR^F J>:.[_ %A
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MV+I45+"%MBY4CJ9!."N0J1/I!,!['_RZJQ \OU,^V$M\ZZW*4O#_ +Q/'A.
MW_:NB@G,D_-AA+#$0 W<U:CCQ^3YI" O;-T(2)E4ACX?>SR'#* =%LO@3*54
MMJ?%8P'IGV" >=#>7@H+;KZ=9,I3TSGV2D(!Q4^Y+BA:BARC7@ 0L(&$^&$!
M>&=V*&E-114;A)$U!*)8_:S$ ZZ._P!"" Y04KG[H2</48"_IW#MHHTU-N6T
MZ.+=,MQ&GAX@E8F3 (*K]JU1T!PIU?9+7PQPQ_B%*)8=^,!%BT[?J5DH6?\
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MTUF'\K?J-^A\\WWSE_)O9XOLLRQ%T68L=D6VS%L12)K$ZTKT>?2MV1NOI+U
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MTF7$^Z,H"I54)3B]R3CC, G'^K "7:)9F&T ]HTID>X3$H!;^[\/$/WQA[3
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M\6GW1/.(V7=THFV>YH&J\[GV3N^V;?W;9*BW5:;I14S+[[+C"*DH>;22RI8
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MM1/ ))Q, V]L[RI]R5;K= IU3;9,U.#2E4L9IDI4Q+* ?RP2$GL)G\WSP"<
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M5"W=2D5#1"<=)Q''A >X;RH-$;-0_*7-I&04]DD@Y\<8#;,Y ?T!\I'U0"<
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MM*BE=0QI5I\)\6(&4QC >ZCRN,<G8U--,BJE92)X34$)) ] @-FE'QD#W0V
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AK\(Y:>7\7_'GH$M?]3/O@,K+EXO1X_D^6 0^[_35 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tv488528_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img4.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ W )7 P$1  (1 0,1 ?_$ .8   $"!P$!
M       &!P(#! 4("0H!"P$  04! 0$!              ,$!08' @$("1
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M!>#Y,U.?%.CDW<#NA9#W)>8RV\+?NCLB)&F/Y1>D^27;%&,KII^(I25J#9-
M..K-E8(: #-X!4[.7S@/<X,+NTIV,P[B6:\=M.QE^L&17]$Q.$O,9O>&LMOQ
MF7');2W";3!5%^)GHI=<<7[VP<N>FT#&BZCE<!0.KP7=XQT,$HS.% >?)8SY
M)W*[IQW(EU7FN1MF_P QI+,/[S7@+1%86"D$>?X52K4U=S12-HUK<3V*OVT4
MDPS%S\M.T\4X.3Y-EU[RC#\ZQ[/KPF\2H\94BUN95>][3\-(BE+C2;D$#?T
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MF7<[S:]R%VMJ*[M4B&P$DI1>'J<D@ $'CI\8/R72#B D)KILL;H2?,X436Y
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MRJA0$ J#FW8*'@!QU$:EJEG&VC)&D]RXT':NXKN0.O;:5D7:\+7QW$[[9OW
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MH\60A'22$@;MIVDF@\!J@AF9ZV\/,<(!P5AQR7<+=#N<I)EW"TRU.*<9"7'
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M,&R,JDJA%V0^AMYV&VI:HJ&"H%!)/$4UYZ<=F"0>QC2:@8),/Y;8IDV[Y&U
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MMQR)'>H2!M2I5>%*@@5.LO>[JW6;O6^V<70M&@8"B;CS5I.02GA$?>C25!B
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M6AQ '/@#I>!D4U<*45CCNL[3BD=!M:(-.A)62TCIN]0E2>I4_5 XCY]*OMF
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M(T(1H0C0A&A"-"%+5S/\/#7B['!>:%ZC0A&A"EG^L:^=7\FA!X%?,;_SD?\
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MOY5Z ?'7F0KPTY+WCKT-(-2A>>][!_#Z=*X(P1[WL'\/IT8(P7O$\]&')>$
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M2TTQ"R:P6ZJ9<AFM "D\ ?D/+GJX-<SBU?-^Z].O8FDS- X\PMLGI6R8JO\
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MKW'^K&H1_P#6%NX&OH;2G_FS?I5 C\W[U3;_ 'Y>/#C_ /@$UI__ "VN/_\
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MZZ#^KXKPQ!J]UZ8^GAVKJ,X8]J->+M&A"A+E#3CP^0:%Y0*!:]P'/Z:?R:$
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M4MS;IW%)FU*XN9:G'.ZM4ULK(K0_95RKM=[DZY(OC-LM,=APLQ6VP\ AUMD
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MHKJ: #;IA?:O>:?8LN_3O<]YP9P)[3PY*9T[;L>IWDD5C.VYLHR?S6#,PY?
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M^_@K3*P-=1IS A3.J*TV.4\%;2$_2?#4DQK'"I< 4T,KPZF0KQ3U.2"KYO\
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M.E-/K75<S*9.'>I:Q:R_A,KB&$.ICCRXK&G);8<=??CH3(;4A&U,AESI\%J
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M&NF]*04!73"J@$T'#GKU/+:_+&X'[0KJU8;"S<F7(3/EUEMM*NHK8EQU*0'
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M'=1*/(>YW;_OAZ/V_4)D/;G%DY=@'<R-9,9R=B!"A2[-?[4^P\FYPE,M!7E
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MQNQ"66RM"2V^Y]F0/$'<.(YGAJ'=,X&@Y)@#=QGB*^"DNP!-G)3);0M#*!M
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MOKR[Z32WIGA@I34Q8V]H)<>KSQ7&1^:EZHC&@WQH7$L/SW9310VH"@'40C:
M12H.OK#;.E6MGHL<A!]1Q.)I7P*^3MZZK<ZKN&6R>0;(4 % #PQQ"XULZR"5
M>K]=Y\J27^I*<4@J^L0M:C4D\2::8ZS<R2@M<?*K)M/1+'3PV6W:6O&/$E7'
ML"&_O7W 7X_@?WQ//_X8Y*>7+5+]+ '9@#]:T.YO9[A['2D$L>TC"F(-1]J^
MY]J+/%-T:$*1)*TQWBU0N!!**\MWA7Y-=,=&UX=+7I XTXT2L(896B3X*XJT
M19;C@4B2Y');^LAI0ZB?;45]FN+F72'._+ZN;P76H,L&M)!=0=ZU3_FJ^IG)
MO3]Z?[QD&"2YEOE29[<:=D;#Y2+,@!OJ;0GB*M?*.)UK'MOI.F7E^U^H!_IQ
M0MR\:]^"^>?<]NIR:9)'I#H\SJGS.I^*Y"\=]167^H[N#!L]HGWK*KUD=P3&
M-VN<Q]^#)=6VL;Y$97NAE#M%$E7(:^O=4L-(L]$AFT5K_4APS9Z4RTY8<:KX
M/TS:6[=8W+<0ZO)";7(2 V2AK4<ZG"G<ME]^_+)[R,V;%[U=>^F,VZ+DEN99
MO<U+335AQUX,A3L4.F84NNI)(YI)(UG5Q[AZC;-=#!DRQN+2"PUJ,.U6\>QM
MB]_J=0S4-#Y9A^A8)XMV+M]ZS+-NVF6]VTP7>V[,B5C$V W2W90_#ZKD5N1+
M$C:E+KR/EH#IUHVY]6N9A+)T^.'E_6D-0V)[?Z9&8;DW6:G)X/X+)'T*R/3;
M9)/?"U>HF7=IKMVL:[7;YUI=W1XS4=]2TQ6$E*AUPL=1+@/,@4TYW=I.Y=VW
M$-_IO1R1LR.S.R<ZX#GQ2V@WWMGH^WKG9T9O.O=SB0 MKPI^URX<*)[OQH]&
MV)]FLQ[%]L>TF8YA8<LE2IUSOE^N_P +N";@8S\9J8S+7!?4D1D.53[0*:H\
M_M]NT/J>C_S%IFL[U]M]M[,=HMV;H/EB;2C,W CGRX+!;M7D\;!.R/<;L#8F
MUY!C.<7-^1)D79SK7>RA3CQBB+<% J6Y!;<+:2$BH.G=K[?;M%#2&A_\1)V6
ML^WMKL&\U FYZ$EMG^'EX?2D6P]FK';%GLM%R"19\!3?'[E(L"92G$J>5TNF
MXMX; ZZHHXG;72EELJ]TN^DFN .N\XT?4?1@C:'N5LO=>@OTRW,YMM+A'&/*
M<IK3'',<.Y6A>*C'6K99X+!D6V0E?F+<[(6[ <DJ20N:Y0H2E9:IQ(/+4ZS9
M5U-+ZV@P-?C[.ZBRO3/>O:VJ;GGVY:&;);OHZL-,/\5<?J2TLUEMD>W+DR+8
MV^B#U4/1X,I+*78Y2HE*STU_U8/#YM--8VG=7\+GM +HP7#S4X!2^X?>+:FG
M:E'I=B9A<LE96L6&-*8U[U:K+A&*WTBXO8BZN,IY\H5=IJ9"%-!1Z!:"HZ-Y
M(YC47M+;=YK\+GW-,PKP=3@I+W#]TWZ)I#=:@RB0R-;_  JX$$\*]R643M_8
M;RTS:X./V^$VE<;XF[%:2A"V$J7YEFH'$H32GMKICN#0KW2[KHPTI0?M)Y[=
M^Z+MS;9=KET&F=LKV5$=!1@%,"3V]JBF8!9I\UNU/.PX\(3&X++* W1$!00E
M+:E"E%NN*4*>%=6FQV;,S0SK;A^>W^]ACW454V5[Z2ZSO>.UO\IM&]5N$-#@
M#3F>:?JX8]B6"V*%;+9C\%00VAE(DMM+:!6!5Y+BD"I-:ZR_0=I7][N%LI K
MU''XJ=O<IKW%]VK[:I.I1Y!9G$?E9CB:<*A(*V6;&[E<'TI@6UUR-60XTB*V
MI@N)-357U0H5/"FKIO+;=R1#"ZF+3^UWA2^Q/=5V[M)=JD67-&0#^5EQ/=56
MO(HV"K4N8]BMD>0TXTH-R RS1Q.[S*FV^F:UX?/I:SV9=V&EQO:!21E?CJJW
MKG]2$?SUNTYB/4&7I-_(YG#XLWVT5VQN=B"; R[<L.M,AE$U:;>R[":2T@/!
M*&^FYM(6K=\VH6';=ZZYY4K^\K!KN^K_ &39,UV]R="0X49GX8\*A3H^'XQD
ME0]CMJ"F'7&7XC+#1V(?4HMIJ$GA1P5]FO=9VI>OM":"N/[7=X*4VI[XG<EM
MZJURY *FL.7[*JV7OMIVM^*-VYS%V8B[1$:3<7H;S8*EO;%M!# :&X)0./'G
MJ4T#VX9>;3CGGKU2]_"2G GN5.WC[WOMM5<VWR^I\H-8<.'BE/>\$[96BUL/
M6["69J+C$997<7"A:VMJ2"5-]&J7./#CIA9>UUKZ@5S_ /,_4K7ION-<V^B?
M/-0RT%:TCK@.&%4CK/8<7CON.6O ;-%G2VS"7&9=9K-CJ!27W"&?LGB%'AQX
MZE=1]KK4L'Q?\S]2K.TO?V;W"U4Z/%E+&AW_  <GP]]2K1(QQFUWM(MK\F"I
MB,Y.<MR-B@Q*25(3M44CS"0D#A0:<:-[46FMVKYILQ,;\@_-IA3P3+7_ '?N
M-MZD;*'*!_Y5>=.T*^/EJWV6/)OD9M]#KO6>D/PT-N+9DU6L!DCWO[4I->/$
M<=56T]OX+G71I+LW2,SF?Q.0KSIW*W77NC)9:&=79EZHA:_^'VTY5[TL,8L]
MFO+KPD62&7T0XCX7'CM=/IH0KCO":5(/'4[NGVZAVG9BZLLPE->,F;AW4"@M
ML^[[-T73K?4Z&T;3-EBH<>RI*N;%^QJ'>9]H?QZWRH5O<:BFD9D*2[7W-J]I
MXA1Y^&H>/9UU<:+\Y('5,)D^+F.ZG<K1N[WGVCZ2UVNTS]&,Y*='D>&-?P5]
MRJT]NK="MZWK)(B/7-3T-AJV/=-UYN2P3-5(VHHX%QG%)K347MK0;W6[F6&X
MH1&P.^*G.BMVXO<G9N@^VD%K;=<.,;FFL5?BJ>[M5Q[>V+&NW\";GF WM-LM
MS5MFL7BVNM5DS(25& N$\[O2#M6L )V\0*Z8;EV_K%SJUOH-AD_+GC=YG4XT
M/%5?VNWSM,;>-VSK=4A^;\OD">"N/IRS&Q]L,HS#)<.Q<&[938KC;;P%-]?_
M *(N+9ZKD-@)'4=":':-73W2V)ND6\->C\;?^(O-F>[^S-1W7-I5N9^H+>0X
MPTX4'&J<[T>]Q/3KV43F.(2<)DYBCN<U(M>7WFZS0Q-,64](\U%C1UL.EIMP
M25)/O4H-<:CL7=HV]&]IBH,N'4P->U<>W_NGLG9ON3Z*YZ_4=!*?X6;XAAC4
M+)Q=Y]!K?;CNUVUQW'+M9+QE5K=BQK<VR)08N<9/FK6VU+"6]B#,"/?">!U#
MZ7:;LT,L@DZ72,A<X!U:@MH/J/)2;M9]MC-,=4-V)YI7/;E;AE<XGZ.*U@X%
MZ9NT]W:O]_[B=S;ACZ\.C*%DQ6.]UI]UN:G4NLQU2>HA72X^\=IY4U9':UK,
M;AD$9QQPX*/FM?:N_JUIO:GZ/P3C=I_RZXW>R!)DX[ZD,9L^19;/NSTO W+4
MF7>\;B)EH=A3WFQ<V5],, E2MHIIO+N_6(7.8[I^1M3Y?UJ(E]O/;"^Q'K:D
M_O ?@F^]5W8S./26ERZP>Y-K[P6A<2WQ6[O9H/3;CR5%QM?G%M2Y*8;H*14$
MDBFK1H>\=/U.S8;@/]0!1WDPS<Z=RHFO^V-KI4[YM+<[TIQ9FEQIRJ*!+C\M
M_P!;>8S?4)AF"V&ZWM4:Z/AJ]VER2](C-Q64;E+Z:MJ6FRL$!7&NH#>8T6_T
M]XI)FQIA3'ZE,;$U+7-(U1D43H\@/,D_BNRVTW2%>X2Y;<AGK;6BYY=U"D-J
M.T;'2/JKH>(U\F:YJHT^86<8.)IBVO$]J_1C8VKWE]8-?<EF2@X<>'BE!%+8
M);#K9420$A=5&AY@>(U%7%M)'Y@K?=.BN6T''B%4JH5H30A25*!J*#A3B/:#
M71#(0X-YJ-9));G+A0A?,H_SC!"OS*^TE.0]+.*@_1F>64_5J9:PE@<.*2E8
M)/S.W^WXKDO(]FN0:'%=Q>5N4I2X^[TI.Y?]60 GQ]X<.7@*ZLNFS@4IP41J
MC3(S+R656"I9F1D-2$ARJ*T4. !'#]6M TQXFB?3DLJW)&;66%W;7[*)N\QB
M&V7AU]EH)9*_=4%<0JO#A[*Z0N<'GQ4_H<8G8/!6F%>)6\$N* KX\.7_  ZY
MMYQ&_'@K-/I$;F XU\4L[?>E[FU![WZ_TN/ \/HT]Z["\N*INHZ*T3N#1AX]
MR=:UY8&$1C(5O0EQ!4"K:*5Y@\B1IS'(RE.:HFIZ/)CA]J=2=FUI?M]K:M45
M#DAE]#L@*4$U2-I.W@2H\#IVUX!JJ/<:')G). \53W#N-'90J8\RTRN*RM)A
MO)Z2%DA024*-=YXZ9OFRDU3*PT65\^0CB>U(2[99?)F/HNCCJ7DK;D/0HD)7
M6,:-UJ*ZH3_5U<(YZ;OO<JT6PVXUS<IK]:3ED[VS\=BLH<A.B4%!R0AY"FBE
MK]D+KQ!6#P]M--SJ.-#P/<G]QLD7C'6H'F=A\7;]"N,_O[-O,9YIMGIE22*)
M<(Y@^.E&7C:$GB4UM/;&2RD!<,!_?_4L;\LO,B^2R_+=<"VRHA!)4 2*CC7Y
M=16H71RG*M3V]I4.FEH>#]=4VOQF9'=4DT(#E4DGDD$T-?;JH&Z=UB3P!6HR
MQ6>K67HQ7RBO9]JR-[1]V;EC-WB2D25]-LM@IJ>'O"O"H%-6K3-4#0&NX>"^
M>MY[?+)'&'B#VKI6]&'JE:V6)IR8),AEQC>%.>[^Q2AJ:G4K=P,OF>(\%7ML
M:A/IT_FH #V575GZ/>[?WW3<))DPXJ84$.[%R$C>D- [A6E5D^&L3W[H3X=1
MCZ8\IAKQ[ROKKV_UJ'4-%<Z4U<):<*<@MC.-9JU>[?';ZH6IE\TH*^[4I'+C
MQKK+)[!\;B#]ZO+V6\K"X53DM*/F2#1*E,A0J:"A \=+V[>F '<0J[=QD$Y5
M6(LD:<REY] 4YT]Z:<B/G/RZB9W.-R\CAF5<==/$CFCD4GY%@MS<F'(=;VMN
M.O-.N);ZBF_LZ(*4\*\3IQ#.1CS"F[*_/T_J5CN.#V1-RC2%L(?HEQ:I!:^U
MZ:@HT#?.NT^W4@R](/>IV&_;2A[.Q(=6&081DJ89++<AZ0IA09JL)=4HH*D\
MTFATX^8/_L$KUXZ).S.ULUTVI*[L]Y6,DO*C(:)2XX]2J5'=X;?9H^8._L$=
M:-5MI[8?"UN.K:=6)!=ZB0"E+;3B:*VN<:$I\/'7CM1>T5_!=Q7$;7@XI:V_
M"HK,9J+':Z$8+*D*Z8<<WFIJ4\/$Z:RWU022N9[QE,$X]MQ5,9/2"6B7&DU>
M*??W$"IVFM/TZCI;ESO!5^XU$MK3CX)01K8(S BK"'@UN)44A--U.'C77MLW
MU >YW!M%7=0UI[',C!'F)'#]:HW^E'0MU<<)82."E< =O'@?'4-=3RRR=!E*
M5HK)I9RP]9W&E5IG_,4]35MQ.QW:U0[B6C&BO=4)<^R1M0:A2PJ@(UNGMIMH
M]5DLPP)[?U+.M^;FZ<9CB/F'=^M?/K]?GJ*E]R,QG1(\MQR&Q)"*;B4D@*"E
M @FH)UN&J/;9O-NSX  LETNW=J0%Z[XW./=P6JB]22TZX5+!4^4J3M.[AQKN
M/AK/]0NL[J=ZTK2XC"S'@$Y'I_+@R3N"3S/8KOH0:^/X7Y-_+J*#Z@UXJ7)J
M>]?=/U$'BE4:$*BN*TM0)CJU%*&X[KBE#F$H05$CZ!I>U;GN&-XU<%'ZM-Z?
M39YZTR1D_4%S1^K_ /-FRBQ9MDF"]M# QMC&);\"?=ISR$/2'&E%"BFJT>S7
MT?M+8FW;V.-]\^871'F RT![O*O@7W0]T=R01O@TX1$&H%2\'_>"U+=R?5UW
M.]0V/9-A]VF9'W/MZ8B+K<L7LMMD7")N7(2WU%K98>!;2GB>/AK9K;0-JZ%#
MU6R2C+_='X!?/%KJ/NINEQBL88'-<:8RN'WO3#8JU?<%O-MDXKVUN5KD6^*Q
M<'%(MCT)%K8>C!#J5/+:0/,HZWU:U^34CI6]=O/N)+6.0N+6$T+#RP[*)PWV
MD][!-ZUUI"&O.!%RW'_;JKI)]17>2+8LKQ*[2KZYAB93UTM$>[SG$FXW%TN%
M3$9:E()0A2N0U3[G6]$N-0+,*N/[GZE>C[<>YUI89[^%K:#&DX-/]I,3:^X6
M26NQ7.8_9V[G>[[O0U,;6I3UM"J@%Y85NHG=XZO)U'0['3^K7S@?N?J5$MMC
M:S?:B(;\R-)-,)*_>2J2#W R"!8Y\1W'8[KBXAZLEO<'9,U:U'JU"B2D(('T
M:K5CNZXO8I'Z2V-]NV2A)!&/A4*;O_9ST&\;+4,]QT60&OYC2*FO*F*CQS,L
MW@1@Q;6/-W"Z,%E<8#<BWH<X!2^-4T!IQ/CIO/N#70[&*'[?TKS=_M*_=E[
MVW?<%L<9::2!O.O/BG;Q["<PM5H,M,QANYR7#+D(4?J)5[Y'%7"E=.[/<.O!
MM3%#_;Z59]1]NHSM7^5F/GZC[814SBN  X\/I59$E79*ILF5?XS[GF%4CH9W
M^74*#82*UH1IENK=L=G;VQGR"X=FS -/'#FI?VS]NM)V'H5_97LDXN+V(,Q(
M?P!X$##CS5#)^,R+BU<;S>TOVR,-[,6,T6W"HBA2LT-4E.I_2]W6\FWA<U;_
M  7'X3RJJOLGV@T32MSWVLS.G'J@*',TU(/93!0LQ\FR:4J)99[6.60NI7)?
MEG89+*5 O(3N*:EQL$?3J(VMN^VU"2XC):?\N[]D\_%.=;]J-&9NQVONDN,C
MBS+5S:$M '"G<GMEL_$L<:M4&X-P4VZC5O?04I5(1]6I(/'@-1.E[OMM #HP
M6BM>+2?N5FW3MRQUW1F:;5^$@=R' $<QWI2XO:X>#6 3I6^_7*:XZN1(;D#[
M)+@%&@T"35O25]N&#5Y>N<M*<FD?>I;8^V;'0-OG2@74,KWXT/Q4Y@4Y*Q.8
MPFZ7>-?D7R2Q;Q);??M"V5)"W4K"F?MBD ;%@'GQU(2[[@BTEVE#)0T_9-?K
M53M_;FRT>=VI1]3/U">+>9KR%57YA=)N509D14WR9M[B&V5UVE00$A)KJ.V9
MKMM\T+O+@3^RKQN[:^F[VVW\M;FZN1HPHTU%*XN";IMF[66S.6ZW25)N<UQ3
MBY154J;<).X'V$'47O\ WK;P:M%$2W@?V3VA1.Q=#L-@:=/IDQ=^8X$9J..
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M\-M[%%R0X)(G[Z@=/<*>RIUG.\-XS,U:&_TX1ND?<1@U!' CAB"G.WO;_0M
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MMD_YCEH!]H]O_OL_Y3$T^%]JIF5VV/ O66R6+0W-1<)TI2$CK-A8<7&#2EA
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tv488528_img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img5.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!-P&V P$1  (1 0,1 ?_$ .H  0 " 04! 0$
M       ("0<! @4&"@,$"P$!  $% 0$               ,! @0%!@<($
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MT9H)T"!VJ)G*(=^B+FI;D5RTB$:VJKPE6=>TLU%PB!&.?*4Y-'*RJ"S@CV8
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MC%*9190%"D I@[M?.GN#[6<0FYA'[C"Q]?D%DS6^CWU+<<=(=3OT6RM[VY;
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MM6[[;O=DW<MIF9<;<\5;*P@L/< CJ.N"2L?$[0\>93(*8#=VL]DC)!J8:A6
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M$VBJ-7S$5HI>$*FH4Y.@XKEV'<-M;K_R!]OK7W)VVTXG=7$MON!<"!$XC"@
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ML'W!UV=MN5A=LUVTT3QX.%?HH2R1I\PH%^KK#;?\S</?UF:NI!5N>6(6X!W
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MDV!)/L$HF[L_V5]I.-^T^Q/L^,F1T=Y_=>7&OF?B: 84\U1X*S<;QU].9'@
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M8I"F <1SW"[ \%G1Q/-HZA%*_P E-3RBI&NN8OF%'(QHK9"AN4\VUR3>660
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MO#E23>H-ETF:RJ:XB?K*4 [=?-G_ )![;SGE^RQ<7]N9WQ[['-ZDCXS2C<-
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M.HY7H5QNMMG9NJ(VBP*/*):*@6&8P(.YR)9L$%#/3BY.)%C')\$.G??7SO\
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MQC:[R]MW'NYN*U>GE/6E.-EJNUQHJ*K2/8OSL7LQ=ZQ5I )YN+H/'221423
MQ0$P'W*&2X4MV'J2L-I)N'=@%/O55,FB)HB@=EZ+FYKFCB.)K=D7I\](<6^1
M#6)M#>,83*\$]4O.%@2DDHN3*:/?G0'N36 4S>[HB^>..)6;,?9.MF3%>7]N
MLJV09VJS5^K[[$N,X^/L*=2B48-E'-G4<S3>PJ3B+1\,ZB!O$ P]0=NB*>8
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ME$G!# 8!;F4V((&'L$!U0.#LD+2,UFKV^J/RRG]BO_BNKE1/;ZH_+*?V*_\
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M;33HB&>+H.TSIBDFL93J(;L^".K0X.R5KCIH'8$K/\M?ZD>*E"!-(B)HU\
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M )='+6'Y0X@.RB,:9!H9<)-JIB2=?7-. 5BK#;*]4XE*?3JLG!2\JC*-H1T
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M R8-A*'A]NQG:!&PQG _A@M=$#ZS]>)'^U7::QU.FB)HBA?<?Y?&"/YM>?\
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MYJEI]-KJ5::$D.[T^JA_P5\ZGEAECSB[*PS3B:+;4&QU2QX:NM0IN/K4]M.
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M[2(E7[^L0KTU>N3.-E3'CE3''QVSA4H%,7JV@A(_52?_ )&T^%/Q5]RU[K7
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M5(]S"T%HH7 ?+K5>\\:]J=UM]CAYG<&VDL;IPCC(D!TO?Y&EW@":FJ^7DO\
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MTG,2%'+!R+0D<PBU,<1<K6).'+%Q212 1P50@FV,'8._IT$45M&V&!K6PM
M:/#!>3RETSWRN)]:1Q<YU:DN)K7' ?+!3*PZ;-X0[M#-</C.(DFJC1K"DQI,
MV6:9.(])J1-9>24LL7%KMW7CD^ 1(%"] ]H[ZJUC6DD=3]/!6C5A4X ?7Q69
M-7*J:(M!#?W1U:]NH4!(^"H!C7-?(42F 0'M W> @ @("&P@("&P@.J/8V5I
M9+1T9&1 58_[=*=#AX?11XOO'R"F'DA:L=2SW$N3')0.6Z4]LR12D7"6YD"6
M^OJ)>I[4R$VP'!PGX_3V$5(/;KDKSAUE(776TN?9[@3B^,CS'N001]*+LMLY
MQ?V[6[;OP;N.STP9-5SHQVBD^]GA0T7@6\S;*5HD^47**I\G\J8WA97A[DF*
MR"6FP.,X>L(9RB+-7(ULNR1LL>C#WAX:6&6.@1%1=X""QDU.M0A>K7FG-.3>
MX&USVG"K"&2ZN+S 746$D9Z$D@M %0348XT7L_"^&^V6Z6EQS:[G;;LM@*03
MN&DC^G#S'L#6N2ACP>RGPNC^44KR%NK&>@.+&&3Q]LQ!PHI4!9[5<,^6FT'/
M1I1_,Q,JNM6F"#X5Q<R*#M<4WC!%)(I?A&WZS@?#]VV?:8]SYC+^MY4XAKYG
M-:'$5^VK0*M ZKCO<'W!VV^OG;'P>U?9\58TEL;7.+0:9XGOBO8IY7BJN)K]
MF;'T'Y4N;>.>/>3.=++=V-X=TO%D/1H#&4S6HX\!#77U3:'4MZJ0.BZ*DR11
M602,[V*4NY@#TN.&*$GTFAH/9>.S7-Q<&LSW.^))_%70(</>*;=PB]1XWX00
M?(*)*I/4<8U!-VDH@J"R)DG(1(+D\)8.LFQMBF[0V'4BA4B3-D#M_13I)G;B
MGX(HG(4R1DNGH%(R8@)#)B3X(E$-A#LVVT1< %,J)3%.6KUPIR&*8IRP44!P
M,40$H@8&FY1*(;@(=VF*H15=@%$NX" B78-NP [O>#L^" ?0U6IRZ*@CB!U%
MHUC(XX+%>1\&8HRV@"&0Z/ 64Z0%%G(NF*;>>C%"&$Q%XBR,?19^*<$,.Y3M
MW*9@$-]]1&*,2>O& RYI36,Z=NRVNW;SNNTO]3;YY(W' XU:6_TEKJM(^2C=
M:.,&3(1L#?&>7E;3!-! T=C[/S5Q=V$>!! R:-=R7%JQF2Z^H4 V356=2/AC
MMN!@#;6FW/88=RB<)B'N.1( +:=00 5T%IRN%LPEN8FP/)\[H1377,NC<2P_
M(8JO?GGSHY=<">+F0\GH8OB6MAIB\ >-D,G*2F1,6/&+V::1;QLTO]!]"G&:
MQR.@,V3G6#-01 0%8YN_G;&+>>-F0/U7&TL82=6+QX-(H#\PNBDV78^7,9+L
MUQ!%?N>!0^4&O4MZ'_E-/ +QH\K>5?F&\IKPUE>?-RPMEOC7BV]O[:\PBWF8
M"OA-5NU,$'L0KCTL''1%NMK<(5ZD>%37<+&=.$N@P&4WV\^WSW-VOEVSNX_Q
M22\@Y'+7T90W)X)&@U % 10G&F!7?<?]K=PX;O;>0\J;9S\=A ,L=206TP=2
MN9&*]*/D;<,/+CRKB;(TNSJ52LE]M=GAK\KB-J^RM%*X6QW'G(QQQ$S*4@[A
MFGMF[?,UY1_X"C@6KQ<I"F#PMQ],X#LF_;/QBW9RN=UUO4M7.D=IK7_T@##X
M+R;W%WS8-[Y,^^XC$+;C1%&QMRKXUJKYLB^6_P 2\H5&(H=DH<P2I0A[$HSB
M(Z[V](IC6M%LWG/27KN8>R2Y7:+0A0**W2F&_0 ".^NSQ/W$GXKA<!]H 7?N
M-/"[ ?$A&6;81KTO7FLQ&0\.Z;2-DEYY(D? D43C&[?UJX<'1!NFH)=^H1,&
MV^JHI6:(M! ![]$_!;/"+[NX]@AOV=F_O=FF3@X=$ :'![0 X*/F4^,N)LIN
M_7\M".(&]()"E&Y%I3U2JWJ/W 0*!IN+!$9AD7^^:2*;QH<-P,D(#K%N[2&_
MC,%WY[9V;:"E>]<Z_.BWFV\BW3:Y ^*4^B/RG$?#P^5**+Z-:Y;\8G8KU5C&
M<F\4$5\1_!-3L:?E.*:F-UN7D?$?XO4IQVF B/A,18%6'ZUN!A$1X.XVG=N+
MS&ZXT6W%E6KX'UU,'4LTGKG0U7H0W3A/-K<6^\'_ $[?*49* #$\C+U"<?GA
M\52)YM?GJYZX83L6VX]Y.XQSEKN+FM'KO&;).&,P#FRHQ+SJCYQ_DJQLK;'5
M>$6]:(J&9-A:D6=-P 4NL/ACT&W\GV^[LG7+]4#F-)<R3!PIF,A_N7,_]@[U
M_K+=I;H=&74]=IU1.!R<TCI3OUJO)/0\^\[N7G*S(_):U9FJ6"\EN5[;<W^<
M,J3%[B,/1;%L\(R4Q-&0SV#M,2YJQT.EJ$&[;FC_  " HX#<O7K5.W[8YMTM
M@=SA9=2N%(ZX@$5'C6B])W&RNMHXH>,2[")[@R%KMQ /I1L!H'$]#0 GHK'O
M*;XG9E=\[./=T<<F,86]#(MGL5YR!&2</ /O9Y:J@NTD+-"M[8R>5LUI961=
M)C"E8H(F,+@IVY2 F4Q>/V+G%]S/D5WQ=EG<V<-L3624$:VBH-,*8C)3\JXI
ML7#^*V/)[6Z@E=*PM],$9D4_+CB2O7Y+>53>Y3DW4N5@<DX ,@TUB_;-63_!
M,;*PECE!,[3KMRNK)S=P&P7BG1\@X;1S[]*!!)80!/X"71Z)M_$=DL+UNYB,
M2[HT:1,\ R!G] -,!^]>/W?+]ZN+!VT0R&#97XN@87>FY_\ 6:DG5\Z*XJ#:
M2+*)C6TP^1DY9NR;)24BV9%C6S]\FB4CEVA'D57*Q2<*@)BI <P$ =MQVWUT
M^'R7+-&FO4E<MHJIHB:(OBHB17Z[W@#Z@[A^?JUS6O:8Y '1$8@Y*US6O :_
M%@-:98]ZC%1!Y)8YO\'BW*UHXZ^DMLD+5&<?,J0T- IP][E$F:JZD:DWLD7,
MU^-GI9$ID$G"K15NHHH +I*%$=N-NN-R6,[MSX_(^&84+V"FAP'AW[KJK7>X
M;R-FU[TT2ZB&QR9/CI@T5Z@>.(7\N[F>[ME)STCG3',I 4-K>+Y"S<9A_&D9
M3YRUTV:@X@R,RYNU)JF/(*H%D"SY':1D#,P1*L=0O@B<%#:T>S\X=R?>KK:-
MOLIF7ULTZY-.ECW #[3USQ[8KV&?ANP[#MMINW-KPS[?=%NEK7!SVMK3(UQP
M4QN-5O:6WCG)9$S@RM\'&R4P\B"2S;&%1C)O*6!C=;25F(QX:K24HE(8XRB4
M$$B1Z+9:4;2+@1,?T(.G6<YN^='C;QPV5D7)Z8-;YFUZZLS6N="I-L9[66W-
M9+2]BF/#(X0YDDE!(YU,L@VGRJO<!Y*]*K5/XKJ*,\B5N\6VW6,+E9(B 95%
M%YC2,FV::M1Q[/OJM7X$TM-14,4%7:SHJR@.UE2%,!"@&NYXCMVY;9QNQAW<
MUW+35YZN<15U?G5>+<QO]MW/E-])LXT;?J&@#( 94^2N/UU2YM<;,_N/*_O:
M^_8JNB*HT/['<?X'1_#@FB+.N3?+7P_E;(%JR--YAY@5V7MTD:4D(BA\JLMT
MRH,EQ110\&"JT'.MHF%9@5 !!%!,J8&$1VW$=6,8UGVJYSRZE>BD;QYXYU/C
M74I"FT^W9;N<?)S:LZM)YCRA:LK6-!RL@BW,U8SUN?/Y!G%E(@ E;$."13"(
M@&XCJ61[I  [(*,- >7C[BL_*J DF90P@4I ZC&,.Q2E#M,(CW  !WCJWQ.5
M$>2&U'<?BH6.O,+XCHU'+E[8YB@[)5L(Y%B<07M_4&DI:U RG.HQRL/0*PU@
M&4@XN-HD#RJ"2;:,*Y-XYA3'X1#;&LD$<3G9R5_<*JX@MF?&?R@?O6<,%9\Q
MAR.H:61\43ZTY6C2\U7'Q)&(EJY/P%FKKTT?/5FS5N?9QTW7Y^(=AT+M72"2
MI.HH[;& =7.:6YHL+7$!'GO@D=AV_%KS]V[#MVWS"^WU=6HIH;@'>.VB+3</
M?#ZH:(FX>^'U0T1-P]\/JAHBQ5E7#E+S+#L8.YJVI-A'/C2#<:G>+;1G@N#(
MG;F*XD*A,PKUVW%)0?TI50Z>_;T[]NJ$5:YO1^?R1M&::?E-0H>TWRI^$5!>
M-GU6QO:HY=G&.X5GTYDS *;.*?2YY]XP:I>W )HMG,TJ=T<A0 IEC";O'?53
MJ?42$N:36AQ ([#HC_,UK1Y=(I5N!/\ S'JLVV?A!Q*NTNG8;E@?']KL"2K5
MP2=L,:I*RX.V;((YN^]8/'*KD) C$OA"N!@5,01 3#N.Y6AC1CU6>Z+0Z9C.
MLQ]-H->C*K5HKQ@CH.)3%!@S!PL9=<$$C'.)?$6.)A[>\=%<NW[A[X?5#1$W
M#WP^J&B)N'OA]4-$3</?#ZH:(FX>^'U0T1;! O:/?N.^V^^X[;;?EZM<W4X.
MJ01V5*#JO.#SJ\C3)_-+DDSY$O.0N)8.8KDY-N*BC;^/\9D!\VK,@P581=8F
MEWLQ&MY=K7RK&5:&<$7\%4"F)T](:K0"1DS/+/&:M</N^JF$\HB? 3J@D%"T
MXMP\%.SR^O+>#A;4Z_7+3*8"R._A:4WJ2]NJ?'*!QM>)Q5I*'?MY*Q6E.QSR
MLR5-$P$\+T=#<Y0-U;AL-Q))U.))\58Z21PIJ<!X?Q5J90(0 *7I*4  H  [
M  %#8  .X   U16K=N'OA]4-$3</?#ZH:(FX>^'U0T1-P]\/JAHB;A[X?5#1
M%MV(([[AO],-4IC6I3 Y@*)/-WC,WY><<[MQ_>'@QA+\>.:61G9'5H:PLK!M
MG17+R-?*TZ5AIT"N#ID,3PW!"@<@"/<&FEI<2\!P<W20<01XA70O=;RMF@.B
M1CM0IACXKS58)_U9?D-QZS7"9GQWSMHS9Y5YLTK6:Y<\%2F48"-:Q(.DL?Q#
MR/N5_.UFVN.$'ARQ2BQ"J)F'K-U& -M-%QW8X'PR06L,<MO*Z1CFM .IQJZI
M&8)Z+?W7*N07HN&W5U*^*YC#'M));I H-(R:?%>L#$]2M-3H55B,BV.#NN1&
M$*S:7*[U^J,:1'6J:1#=U+-:TP5<HP[9P?82MP65*3_"'6W#*%IJXZ00*FN!
M7/ -::M  [#+Z+)NX>^'U0U>B;A[X?5#1$W#WP^J&B)N'OA]4-$3</?#ZH:(
MMH@41W$?S0T2JT$A#=F_;[X"&_U>_5H:UKB]H ><SU-%0M:[[@"%Y#_/1P[B
M5?/K/*=$JUPF,TY17QOQ[RVQ6QPYL%:;QRYG+O'F8Z=+@#1R:\XX%<R8LFCE
M,)5$Q4A$AD0,/G///;IG-# ZWNWVMRQ^IXC<6ZH\G!X&8(ZE>K^VON/+P0W8
MO[87>VR6[O3:\:M,E,-!)P%<Q_-0PX8\$.9&=,K/T<Z\:K!DOC-:I.P3-]H%
MO5#"E4R/-4-%.K5EW)6=N2P#'L<C-4DYJ>BP$%E'R2:)#] +=6GV3V6XML6[
M0[P^4R7%NXF-Q<7 @FHU X&@R^*V/(???E?(>.R;#%"R#;KJ)K9(VM#1D*TZ
M@]UZ?L.^4/Y>^-)NM9-K?$ND8[R0P6K=A*2(M-LF$:O880B"[1&*=*3*;!R2
M-=)!^F%;ID7,4#F)N.O6VP0,+W-8WU)""YU!J-/'.G@O(9+NXGMHK2=Q?;Q?
M:UQ) \?BK0PZ0]T.T=Q[0[1]_4JQEKN'OA]4-$3</?#ZH:(FX>^'U0T1-P]\
M/JAHB;A[X?5#1%U>Y0<E9:U,0<+:9:E2DDS4;,;5 (1;J8A%S[=+Y@A-,9**
M4<H[?!!=!5/WRCITH%4&F- ?BO#UYLWEW5WBKFISE7YU\F9)2Y&VZ*G*H68F
M8)G"QW)>&>/'R52N5+HU=CHMC2K;'R#B3!8&Z!$51>&/U'$@Z\3]Q=BYG+?0
MQ<'>RVMKII;<D-\]#@2QU06. H015>X>VW(>&0V,DG/&2W4MF0ZV:7G2",0'
M-Q#Q6N!I@K0O(QPU@H']JS>Z,%1S-D"JO*LSXZQL;/-Z=0L95>>_3I*88R,,
M2 F+5/VPR\@D[15*9*/<(IE*/4H.NC]M^(;AQ#8RS>)I+F]?,X:GNU.H#A7Q
M/4KF/<OG6T\UWMHV:WCM[2*,.(8W2-1SRPT]AT7I:9Q47'@(,&3-B4P@8Y6;
M=!J50P   90J!$P.8H!V;]VO1RP.>V0UJT4&.&*\UZ.']6??ZKD=P]\/JAJY
M%QLP(#$2H (?N:^]T/\ S571%4< _P#^.P_P/"'_ ,<D#\_1%<)HB:(ODND1
M=)1%0I3IJD%,Y#AN4Y#!L<I@[A*8HB A[VJ$5%#DJ$5P*I4R9PBS'7Y#.MRP
M?CW&BBL7S,XZ<G<,XM3E8VEUVZP6)\?0-7M]:<N&D8,739J2>@^59+J(G3%R
MFFHIV'$P3-?5S/4Q;&"&^%10_L4<35S_ ,[J5/>BF3P9Q)E?']0S5<,UUV#H
MV0^0G('(.<)7'U:L25K84!A9FD%!PE;5M+5LQ:SDVE$UU)P]<H(D1%RN8";@
M7J%(X.  R HJ-).:Q,A@:KT#S L4.XNTY6EE++QTS^Z>$MF5;K:6[(Y;_B%7
MP85M,2KI&%;=3PVZ;<$R"4I VV*&HE<K#0I$<7NDK,'_ $FF/C&B+7V)C_E.
MS??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)
MC_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-
M$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-
M,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.
MS??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)
MC_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-
M$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-
M,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.S??-,?&-$3V)C_E.
MS??-,?&-$3V)C_E.S??-,?&-$6'K7Q!XWWV9<V2\XCIURL+PZ"CR=M$.SG)=
MTHV2*@V47D)%%=RJ=NB4"$$3;D*  &VJL<8WF1F#W,+">[3T_;%4(U --=(-
M<SFN\U+"6.Z!#)URB0IZ;7D5W#E&#J[YU!Q*3AV?Q'2Z<?'&0:D5<*?".8"[
MF-VB.K6@-8(P!H:  / ([S'4XFI\5VCV)C_E.S??-,?&-554]B8_Y3LWWS3'
MQC1$]B8_Y3LWWS3'QC1$]B8_Y3LWWS3'QC1$]B8_Y3LWWS3'QC1$]B8_Y3LW
MWS3'QC1$]B8_Y3LWWS3'QC1$]B8_Y3LWWS3'QC1%'BX<$>)60;(\N-[P92+C
M;)%ZG)/K)8V)I69=2** -47RKYT<ZPNTFQ03*H @8"!MOJYKBW%N:HYH=@<E
MF"HX4Q_0*]'U*CQ;NIU>)!4L97X*8DF$4P*NJ=98K5JDN!$BJJJ&,(!WB(ZL
M #7!X^X.+OF<S3)5;Y0X-H-0H?$+L_L3'_*=F^^:8^,:J<<43V)C_E.S??-,
M?&-$7'2]*CRQ,H/K*RCM&ONP;++F ?\ %5>P2BXV$/IZ(JM0;A_4VBVZC[?,
MR*?5UF\3;VX(&_B;]?7M[N^^^B*XW1$T1-$6G27??I#?W]@W^KHB  !W  ?2
M#1**&%Q_E\8(^AQKS_\ AYA?1%-#1$T1-$31$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1<;,_N/*_O:^_8JNB*HT/['<?X'1_#@FB*X31$T1-$31
M$T10ON/\OC!'\VO/_P"'F%]$4T-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31%QLS^X\K^]K[]BJZ(JC0_L=Q_@='\.":(KA-$31$T1-$3
M1%"^X_R^,$?S:\__ (>87T130T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$7&S/[CRO[VOOV*KHBJ- 0_J=A'<-OF='M_Z<DT17":(FB)
MJA( J<D7Q5710(9190J9"%$YSG,!"$(4-S'.<P@4I0#O$1 -'.#!5V554 N%
M1DB+A%P0JB"A54SE Y%$QZTSD-V@8BA=R'*(#V" B ZN(+30J-LC7_:<E#6X
M_P OC!'\VO/_ .'F%]45ZFAHBTZ@WVW[?H=OYVB+71%H(@'>.B+4!W[OR>[H
MB:(GY/JZ(FB+3< ';?M'W-$6NB)HB:(F^B+3</?T1:Z(M-PVWW[/?T1-P#\S
M\WN_.T1:_1]S1%H @/: [A]#1%KHB:(F^B)HB:(FB+3</?[^[\K1%KHB:(FX
M=VB)HB:(FB)HB:(FX?\ @]WZFB)OO[_U!#\_1$T1-$31$T1:;A[_ '=_Y>B+
M71%H @/:&B+71$T1-]_S_JZ(FB+C)K;U/*A[\:^#_P"R*C^5V:(JC0 /ZG80
M]SYG1_#DFB*X71$T1:#W#]+5'4ICDBK$\U11DG@3'BMQ4LJ.#R\D,)&Y'*5H
MTZF8N$QL9RV4; :LB$V%."2]"];^#L4&(G\3]+ZM0>=]RTN_Z< U^-,,%1SG
M,@<&?Y"1]*XK9Y6*D6MA_-A\<'FE./H\G\O%XQFFS3QFGS.@:#]!]E#V;JG!
MHGM;ZT]5"KU$]&_W+]*Z-9;G!S1_4J-$8^Q<S9\:\\Y3D/4\UQL=Q/!A2J#D
M;'L9#/;+EI-Y(Q]WL50FFLJ]<(5E1!L[9(U$A%$2 <ASK&$#  !JQ7+ZTO,_
M/2YY"RSCYOCWBFQ=8EE*I&2,DXNV6A:S!K77$K$W5CR%IX'(5FDJ"2G4)MS^
M]HBY1&)\S-/'[NM*O^):]R68RR#>^#-94(LV>/'CM>.>A$!5?13^K&RR:(%$
M0!0$@,;M$=$7,3"'F0ODJV6-;\1HI2+FHM].J!8LLN!L,2T073D(=0JE4Z61
M9)50A_%(/4F*>P;@.B+>HEYCYK<UF2->(Y*TC .8U:K!9,M"1Q+JO45T)OU@
M-5\8AF[1,R/A;=(@??O#1%OA@\Q]C)65W)L>(THQE91!W!1IK-EEN6N,$HUF
MT6CB+IU,3O@</D%7(G/L8HJ](=@!HBQ7CC*WF%<A<*,[W3:MQ5Q\]MK>PLHA
MQ(VK*TE(P#N&L,I7C/%&IJBDW<F.K%&5(4P!\$X /=HBR3-M?,ED%:@>+3XD
M0R<).-G]D2)8\LN@M40E&OVCB$4,K5.I@1R^<HN?%( G** $[C&T1?J!/S'0
MMI)H&?$@*Z%</%FJP67+7A&G#29'1; #\:KXVY6!1;^!MT_"ZM]]$7SBT?,?
M:/;8O(MN),HTF90'==9FL>66PUB/"(9,AC"+)U7J?E-)-U77B'V, KB0 V*&
MB+%E^RCYB/'7 DW?KQ7N*V2G^/X1FYF7;"SY5B9*S.',PTC?%1:DJ2C5HKM(
ME-T@ EV3'W1#1%E68_K')5U6'D4QXD0K./E"R,XQ"RY9<^T$6>->(>IE%5*H
M!F0%>N$E_%( FW1Z>XPZ(M2I>8X6VFFO0^) UL:^2-+5/:7+($)-ED%'1[!Z
MR&J&7%11B8&P([=  7J[]$6V%1\R!@>S&DVW$>7)+33E]!)C8\M-?9R*59-4
M$(<ATJH(OB-G2*BP*GV.85ND>PH:(N%&*\S/YO2UD'W$H+H$:BU-?O7>5!6.
M^(N5162&'&I@T ZJ)>CH >DN^^B+K&1,[\\\<W_"&/7F.N*TJ\S7:;#4XZ4:
M77+*;2"=5RI25L7?29#5$ZAV[MO&"D0"B!@4.&XZ(L@)H^8^6XNIT6_$A2LJ
MUUG&-ZF-CRP"36<0D73EU80D0JHN%%';%9-OX(_ ("0&#M$=$7RAV_F1LD;4
MG)(<2)0\Q.2K^OJFLF6435J)>,VR$?$D M4$KXL8Y2.L"A]C*>()1V  T1<2
ME$^9N3'\-6E)/B4K<&+> 2E+R,SE4JTLM'2#)S,KFB2U7T5MZ\:-U4# 41\(
M%A,7M -$7/2J?F//9RL/X]GQ&BXF)<2BL_#%LF67)+(@[CE6T<V.Y/5"*L?5
MCTQ7'43<5!+TC\$=$72V.:N>;O-L]A+YO>*99. QG7<E+3X73+?JIPSL%DG*
MTG#I)FJ/B$?M5H,ZQS"82B10H;;[Z(NU0[7S)&3.RHRB?$B8=2DO-OX%V:Q9
M8;&KL=($#U7#@1.JB5\G#*!N54_PU ^NT1?A7C?,P4I$= (N>)"%L;-X%-_<
M@G<K'5D5H]VS6F%QC!J@-D/739!5(0 ?TH%A$O: ;$7+RR?F0O9RK2$:VXC1
M43#NI)6?A2V3+3@ME;NHY5JQ;'=*50%& 1[PY7 &( B<2](]FB+Z,P\Q]&S3
M4JZ9<1G4$_CX9I%U[VERTF6&>,3R)I.2!Z%4\9T,N5TB IF  2!N'3VF-HBQ
MGBS-//O.%5R$]@:-Q7J;JJY$R5B@B\A<<KNE1F*-*+P(V-J0E2(FHQ<NR@NB
MF;<1*&PCV[Z(NYGCO,O-4ZU#$=<24K'$K5E6=LX3F5C'L:<2X:J3Z"C :IX+
M+VE114(8Q!_2/%$2]P:(N<D"^8RZL-?DVK#B0RAHQO-)S,"%FRRL6>5?H-"1
M:QGAJF"C/U,LBH< * @KXH@/<&B+XL$O,<;62?E';#B0]A)%I"(PM?&S9923
M@G# CXLLZ(\+5/&=FF3N$3"4X;)>  %^N'1%T^>MWF*XFQID.\6J%XGW3V0C
M+S>_!:6?+$>[4@XIJ_GF=;:$+4SI'6:,&WHR2IMQ.(%,8!'?<B_>SL/F+Y(H
M=(L]:B>)M0-8FE*N9O$M&6'[@(9^@PG7U<<IJ5%,A%'S%P+518O:F(B8ON:(
MNR/R>8ZYLD!*-&?$AC!QK2:1F*_[2Y96+.N'Z;4L6X.]-5 69^J%$5#;$ ?%
M\78>X-$6V.)YCC6?L4B]8<1G\/)%B0@H3VERT@2OF9-%4I$Q71*J*KOULY,5
M0>K_ ',2[%[!T1<2T8^9@C4IV&<K<2'-CD3V8T1: G\KD/"A+.GBL$!8_P!E
M/ =A7&[A-(O6(>," "?M,.B+IN2\S<_L+P&-1GZ1Q5M;VWWRBXL4?,;AEAJ<
M)FS]3(]B>(#43D29$<-S**)E'<H&V =$62'"7F.*VR*FD6G$A"OM(2482-9"
MR99.G)2SQU'K1\R,@:J N@:+;M5T@2 !*H#D1'M*&B+=&$\QUG.V21>L^(\C
M$2RD0:$A#V7+2!:X1E'^CR1$W9*F95]ZT>?IXB< \,1Z0[-$7 DC/,R"CS%>
M5=<25+6]+8?5=S+.Y6(>(/)OGSB$.$7[*B@X&OM'"2)=QV6!$#&[1'1%RLPW
M\R)ZVK:4:WXCQ:\7,0[Z=<^T>67 V*,8IG+)PYDSU39BG+*& PJ$$3)=( &B
M+J\KF7GG%9CIN'%,?<4UI*X4>WWA";3NF6O5S!K4)2OQCB.<I#4/%,[?'L!#
MIB ](%3-O] B[;"D\R!C,V=_*-.)$K&2[YBO PXV3+#8*TT;QZ#9VS([3JIC
MOP?/$SN!,< $@GZ0[-$7$I1OF8%HKZO*.>)"EM<-)A)I=!G<K@HS<O';M:+<
MA%A5?1E!BFZR:0 ([*>$!C=HCHB_9+M/,F>HU9.,3XCQ"L1-Q3ZPKEL.6'(V
M>)9H*IR,.<JM5VCR2JRA5!4)N=/H  [QT1?K43\Q\;>VFTVO$<E;2K[J,7JH
M63+'AN9E9^@Y;SPR U3QTS-VB9V_@@'2;KZA[0#1%TO'^:>>>0;AF*H,\>\5
M(]SAV[1M*D7;NZ9;,A..).GU^WDD(TI:@04FJ;>P%0$#B8WBI&'N$ T1<@XA
MO,Z5QR^JR,OQ+0NKAL\3;9!++Y2%9HY7DCNFS@(8:J+,_HK P-MM]C=(&'M$
M=$78YE+S'WSBK*1C7B1$H1$PB]L""=CRPY]HXLD:^:J0YCK57J8D,^<(N/%)
MN?='I[A'1%O.7S'AM:<P#'B,%=+ *QBE9]ILM="DN>03<ISH/O93Q@.FS*9O
MX.W0(&ZN\ T1<:@3S'(XEZ<3+3B1,1TLX</8&/\ :/+#;V;B2PB#56)(LE50
M._\ $>H*N/%. & 5A+W &Q%&$ M?]2R)?0HSVR#!NPL?^$?4H3OMF4? ZO1_
M6HQ0N>SJ\+Q_"[>GJ[-$5S^B)HB:H1441?)1%-4ATU$TU$U"F(H0Y"G(<A@V
M,0Y# )3%,'> ]@ZM:VAJAQ% M$4$FY"IHIII)$*!")I$*FF0I?K2E(0 *4H!
MW  :O5H:0:K'>8<JU/"&,;OEJ].7#.HT&O/[)/.&C<7;ST-@F @W9-"F*9R^
M>KG(BB3< ,J<H"(!N(6O<&-+CD%(QI>\,&941<,\^L:7[(D!B_(>),T\8,J9
M%*X=8\K.>Z,QK),JH1['TTXT^Y5N4LE.G9=M&D%48X\@2132*.R.P#M?&/4
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MHBT$-PVU0BHH50BHHM@IE$! =^WL'N[0]X>S80'WA[-6AC:UI6B 46XI"E
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M%Q/&G)[QHNI,P&6GL.JX7;QJ*#N0:+$05(W4+OM%#)(#9OTU,<,@D!'W.<2
M3W<T8U.(65,Z*0M;D/2;2@ICU77*QQ8EIKE= YSS%R(X;5G.T[YDF'<JY/P!
M2<MQ<DWI+JE<?[Y2:)BF"++DC+%:,]V^,E_7)V[F.8.'C1N99!(2(]6LNSDA
MMXM!;KD,4K22*T+W @BM3Y,J].ZAD=(Z-K2 *2"A'4=:^%5E?%?&."B6/#E%
MAR%XP29\>^9OR/S NI7\F5]T6\RML>905<XMI:C<X#/YCK*<X0LO$%_QIIZ&
ML!P_2]0VYD8&1BI+;<M)SKBXZCWSS*D>6^H\X:=>'T"['YF/&AEF'D1-6QUR
M XZXM*X\N3DOB56M9;R3$U"S(-K?8()VKDYU$OU"JDQ76 ;BE+RP_I+-0Y2G
M'X6L>W9HOG2,()Z@9_1135,#.^HK%/+7BA"7^:R:Y8<E>*=*)+< >(N+UT+7
ME6 @%XYO1^0<-;(O(<TB*H%9XRN#=L$97Y0_Z2]D%"()#VZN87#<))75,9?E
MVP'13-TT\5U4O$^[&R^]-$<G.'T5 L>?G+C+N-+ 7)\7.W1Q=LH8%L->L>,Y
MFC/4O5+F_P")IA=%_)Q";A98L2155RFF!=AE;-=?IAI:='Z6X&1IB\T\*#J1
M@.JG=(/6:7-&BF-0H3O^ &:UHB0)FGECPV@9UYP4S/BU>?N',&;MP6J.GIVB
M/U,V0M?LD57:EBO#L>ZC$4'#.$9@RCA<I%.NH!B%U+;F1LD3C4T>T@=R",!W
M/:BA9))^H;5KJ^@\.P-<6G/P\>BO>YQX11R5Q1XK4A;+V'* G1\^\0;0E;\@
M71C7*;<5*%/0KE.N4Z;<G*WFK'=10\.#:I[F?J'(4G?K,MYY8^0?JHV.=/ZC
MB6 $NQK@6YU%>RQH0&[9+$*%ABH2,@,,2<@/%0TL7%R"=8L) AR.XH,WB?G)
M6CD":=E,DU\\*$@Z?65TIA5XL9= 76<6L8Z.1U7!.5WX*2I!$I0$0TCXF.$;
M(G4<Q[BXC\Q.K TS(KC7*G@LJ9SPZ1CP2-#*$CQ&5?@H-47@;D9_B',PU/EC
MPLQIQQG>.69:FFE0.4<IE'CU=K/-6N/?5S(,,RN!'C+CC2*_,-2)R[:&FG[4
M7+D$Q#X!0&>!S!9^G1O^44.'W8Y'^K]Z2.<)@6 GRJ7LYQ8L=DS5:+S?N0?$
M*H7B=Y+\4+S9\?QF9F3QW79RD\4;72%Z4F$FVC912Q6XKWUO"-5VZ2[V%24<
M@7I((ZN;J$T;\?*\X=S3\5<R1P/VXT[*%V0^ '("9P3[)PO,3A_/X15X,4G&
MXV!#E')XEH.,%(QK.$ELJW!_CZ,-\^N-K'XYCQYIJ59QC04U  AR ;>74\W+
MW,!]5TC2:?< *UKUQ1[I3)5P<(_3<.M*X4_WJ4WXIMN,XOL*XY&<-S8^LV9_
M+4OECLI<ULT+!5LB8BK5*AS8\5CRMQBO'RC!QI7M0ZUT'<J+A/H1,0Q3ZQM+
M=$_H%VLW#CAE0M94&G:F(/?'HHX7R,E:9!4^A1U?NIJ=3QIV.2_!C_BI=QH?
M#;"UDY'<%$N)N".2>1L@8$Y 4_++)QDOD;;U'F2'D-C2*B5 0J+&W1\G87J-
ME/%R\HX=IQJFR"9@4 MVLO(DD #LJ =L*T\<U:W^U@-3@<17'/$#X#(*5_%C
MCC#4V9\I=Q&YYXXVQ7!6&.3->*C1,BP<LYS&E;D(U"0G,-),3B:\UZL2" GF
M7"&Y&9S@*GPAU*"]PU"H:5K[UC)-#P[3(V45&1(\>X5[A/K"_P"U+^<&K#FM
A@:5-,ENU1431$T1-$31$T1-$31$T1-$31$T1-$31%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tv488528_img6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img6.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!A@'X P$1  (1 0,1 ?_$ 0    (" @,! 0$
M       (!PD&"@($!0$#"P$!  $% 0$               ,! @0&!P4($
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MVEIQIQ54?@:P8^'(7EF/_P!_,]^TM$!!%1B%]_ TA/RA.6G^/F>_:6F>2(_
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M/]QX^SS"X5Y*NN5*9C.9R/9%*IER+>(3IQ6>MUVY&3=N#E0X)* &KF'!8Z8
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M#()-#M0[#59)GWN#;7'4!9E^?Y:T''*M.U-@V2*=,!'8Q=MP/N B<!#<!'H
M>&LCU6R8LK088KS]1>T.D(+B,\,5B]\J];M=)M]1M!"$K%JK<W7[,;WH(_N@
MIB-=1TMWO@,G[GLP<*!YO<'EAUW#;?4%P1Z6?%5RR53M3],'@'D2M&HS;*&0
M.04/5<<N,75)A/\ )9[DHF(:?(#')G0HK&-?J-ZJZ.6":) X,B<YD6Q4Q$2"
M8HUH=#?Y5<I'3](GB^$7:F9+3GM.7O<NWG;=94\LR!9FQ&2J'T#582+4([X
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MG\H;</9HB7[+@@'-[AR B #]!N2G0?'^Y^E>S1$[FB(T1&B(T1&B*%^1I?\
M-_SH??J.'LE!M_\ 0Z8T1=3C:J5/CK@DQM@*7#F-Q$?_ *(Q ".X[%  [=^H
MATT1>:^Y9\8HMXXCI+D'AB/?LU7"#MB]R54FSQNNT5\EV@JU5E"KD6;*_-.4
M2[E'H.B*<XF7C)V.92\,_:2D5)-$'T=)1[A-VP?LG) 4;NF;I QT'#==,>XI
MRF$!#KX:(O2T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B
M(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&__ $-$1HBP/*?^#'(_]X=O_>_(
MZ(H/X4G!/B!QJ,(@ !ABA[B/L*-?9[CTW$=@UAW,PB=5V#:9\/FKVY%,8I.Q
M9#=H24=]DHOVH'$=Q 0 GF=V^X;;#L.O%DWO:VOI+<VP;Q!EC!^6I2",N&I5
MSV7U=N"E3?6UA-9-LS<*-:9.F6N20Q9DAY"P]CB),L,_CW,RUK2L:8Z$B<J6
MY5# 83EVZ&#7FS=;](6E\S;3=Q,O7LU ![22"2*X'F"AC>W@K$V-D@Y%BSD6
MTHP%L^:-WK85722"HMW2)'" JMU3%614%)0!$A@ Q1'80 =;!'NM@T"EU"_5
MB*O8#3N)JE#EBE>Y6<LX[C$PQBHWQ=?,S63+EW7H%,I^-W-7;2SR7:UF:M[M
MPL]MLY 0S9FC#P*XE,9P G4V* ==]>I;7$4[:QO:['@0>'84<'>D<.(4:8]]
M2OCC=Z4SRA,3XXWQF[QA1\GIV6^2$2Q?)#=++8*BUJ"]9C7<G.J6%K/5MP@'
MNZ3A!V<O]3G4 !$,F5A817DH<-((Y*9TN;?%)Q-XJKS7.M <3.<V9'V(F2<J
M<_T_;F%WW? %_)%LJX;?#W'G('.FLCY"GF$+VZB5%D&&^67''D+/7"K83S%2
M\E3]#6\FUQ=8E =NHHHNW# 'I2G21]_B3R#15 KUL*S0RQ#$!3N#;1%CQN;/
M%0^5[%@M'.V/CY>J:,\M9,?!-!]((4*O'$F+$D]0.D5%-Y#Q*A72[<#BN5N(
M*]@I_.U$_P"P"J5IB5&\-ZB_%BQ'F+%#95IKW#T!1#7N4S6E9V!:.V10MR-,
M7CCE4[94Y4Y9RF7WTB)F1S'!,J@FZ:HV5K7>FZFHJN>62\R0]0S@S9+;QS@$
M,JTNZ2^=+-;66#IF-BEY]B%OI281<\DE)&8&5J\ZDI)^Y$\P$5S&7$H[$-N.
M5Z18TNX%4JI(RUSLXA8%O9,99FY#8VQM?3Q[.2-5[;/_  V31CI)%TO&/G)3
MI'0;I2Q6BA6@J'+[TJ44T@,?YNL6.OK_  52O-6YS\>U$<>VB*R#5)7$E_H&
M1LC-LP$MD$SI\;7L:*Q36PG=HR#IO,N%D7<J5%4J3<3M%2]BI2G,4HW6\1D?
M,> (_%1/DT. X+L1_/;AT_)CD[+D-CHY<M(S#G'22LLNU7L[2O+*-[$]:-G+
M5)PU9P"R9@>JN2H)M@V%0Q=PWC+-)T#BI7S#"N:\YCS_ .&$]0;CE6(Y(XQ=
M4+'TS&UZXV0DVH#:%FYM048"..R403DWBLZH(^X&;H*D?E 3("H4!U'-;>@W
M4?S'-70/$LH@;B2,JJ%Z/ZE'#?*V%*!D++]\QW0JEF6UWBOT2NY E6$ZRN+&
M@7MY4VUK22]P.V)7)"2C47*+MXDDV;'63*=0% UF1@F!C@,*)+1DSH>+?Q3,
M/.9W%N%E\H0,AF_'[22PQ'MY+**2DJ!&U,:KJ,D6Z4B\(@,>I(&6DVR8-$%5
M77F.$R>7W'*46>2L4DXTR+B3.\%7\LXOL-7R'73EDV=>N,05)X=H<%BLYR-2
M<KHIR$2[!RU!)XU4*BL4R0%4(&P:4(S13!HB-$1HB-$1HBAGD;^+YG3[S^2O
MWFS.B+I<:RE/QWP2!OM1PYC;?KM_\DHH=M^@]=M$2O90Q?C53G5QD35Q]1E$
MWV(^1KIZF>I0!B/7(.,<CY[L@QXE=+_U0<>XX&'<QA#;N'<BL*9LV<>W;LV3
M9LS:M4$VS9JU12;-F[=(H$20;MT2D2102*4 *0H 4H>&B+M;^SVZ(C1$:(C1
M$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(N)Q$I1$ [A#;H'MZ]?TM$2
M@Y(YU<8\26U>DY"R(]K=E1FVM;(P7HN0'B+V=>H&<-(J+?1M7>,)1ZX03,<I
M$%3B(%'8!VT12>QS ?(6)WF2,$0Z>2'2R+@M:AIY64QTWFGS-T5NY:NG=DA"
M/HDA [A*=1H(&$O31$LF'^4?)_)^2KS1'_%FJ5J+Q;?XJBY"L),[Q4LI''DJ
MW$V<9.&B4*BW5EDF["92 4Q42.8^X:(K"B#\T-^@^T!\0$1\!ZCUT1<M]$1H
MB-$1HB-$1HB-$1HBQVT$GUH&70JCZ,C;&XCG:4%(S+%>3AV4L*1O<G$FQ:N6
M;AVR25V%1(BJ9CEW # /71%7%CB[<\K-R R=B*:R7QK"(Q UQ3-3,G'8BOB#
M^RQV0(^2DWC./*OD5PA$NF2,89,BIP7 3* (DZ"&B*SE$PF[M]]@'H(]-]_D
M#PZ;:(L)RG_@QR/_ 'AV_P#>_(Z(H.X5)$6X@<;"'*!BFPM0RF 0 0$IJ^T
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M(O&L;>8=P,LUKTHV@YYPQ<(P\P\COB[2-D5$S%:/7$8*[8'Z+=80,9+S$^\
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MR87P'F3+=,ICW(MJQMCFWW2OT..\SWRVS,!$.I!G"H^215<1=+(!W F4R@E
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MK]&)WV[C_P %.OS]$2:>F%M^ )Q9 ! =L71X?GA)2FX?G:(O)Y5_C7>G&/\
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M_%>"T4+_ .4YM2HCVE_ 9K CMT'_  X3_3?;Y=;:\736$-\E5K6@S2^D[S-
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M+01&(/\ ;#*,Z?E_Q6=X1.'U+8B !$W_ "7T$!$=PZ_12)^7??4RJEOR(/\
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MU;97>ICW.\Q)4.[[9/;W['6_]"?QM_E=B,DUF(4W.=\S6SD3(!_Q'I"DYBG
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M@ !Y]O[6[-TRT2]",^GNS_5ERUNXG"E5Z_47N?U!UD]L/6+_ %[&/"&+BUO
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M!P_(U7,R;N5C-FZ[L$C"V17<%35,@BJMVE,<"&$I1$0 1#;1%3K$7KF://\
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M'3-N<9G-D5C.N\2,D4&%>K0TC:!K#B#956/EF$@0E-NL):16<&=@;WP[81,
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MVJM@]2:EQ,?QFK!6SB7+OR/XL( 7X]+&1(F&=J04"))^]@1,I2FV "@
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MQAX?Q_)Y_@N@J0LX^Y'92Q\[M$[,2%ELZE*HTR@E5ZP$Q*K*N$XN-*Y.82$
MHK''O4$Q@ =6Q0-@C# !48+/W#J'?=V<7[G?BY:XUT Y'*G>$U_J()[<>X38
MI4Q4Y!<;0,*8 '<4<U4\# 8! 0'<!']'5Z\MCJ"L8+ >''XI]G)O+04. >
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M6=@ Q/=12/N)+CQ2.<ZG,D_>I9]3(!4XTUDR:9@ >27%8P$[![@_Y>J&'4H
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M?1CIDW=*.$I!BU<IJ+(B7S$2'*8X% 0U!+>>F]L?\0K]JS76&XQP-O)&TMW
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MO-6>C9@P52I4U2N51=M&KEW!R\M&?$:M86,DSD(^7B%5]G".Z956SDH'(;Q
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MI9B]N0-?+\L?BL+KKHVUV;=I+?98[EE@QN'K-H\G'$#^&G'G57U<W+7$#<>
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M?MW>G<>C+:WU$R636P$UJ28P&XG/@MFNZ-F$PRFH\=SQJ%/FO:NU;D+96)6
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MX>2N!)%3@2L],7N 0'?\[]+15735C8Y=0%5V#-=4 [056;(JJ 7??M ZA#&
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M,2D-]16*BE./78PT2$[3"7J!NTP[]?;J&5[R#&[R.X\5<*\%JI\DO3"SX_\
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M$UV-L4E*N50!$3/'2X%1(4@; 4 UL?3FT[;LVT0VNU1-AM2P/#6M#<7C4<
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M"^L*FT)$2BH.6JJMCFPE2($CWR(B4%0.8XJ[ (:Y?U7_ /"]7[9O[1_L9O\
M8.Y.DF.IE>9:!X:^45 S64"3#CS6#8 YC9:S19YAC-\<H?'E.JN0+?CFV6UQ
MG>FV)S%S=.\E)^LRK\?%-WDM'KNERE34(H3<.NW373@UC2X,-6AU/EA3[%C)
M["W&J[=;%#[A\K]O\FX?R_R#JY%R^F-5_=%#_L]O^N:(CZ8U7]T4/^SV_P"N
M:(CZ8U7]T4/^SV_ZYHBC+*%GK1Z9:3)3\895S%F:H@F]0,8#.#@W >WOZE 5
M@';V[:YW[K3_ $WMUO4H-#]#)3L(8X@UY@X@\#BJQ.="9KC\HA^7FQ'+@JM>
M/G'W+EN4IG(1MS)BJU86[S-P5R+-ARBOV3>%R7>DW$F=Z+N526D79FU8:%26
M.(=I0'I\[I[G2]OZ%I$*820QO(YDQMQ/;AFO Z=:6V4CJ^>=SCVD@8GF>W-/
MMR(P1AKE5@=]@//UL<6JJ3B$ I;7-7M"U!?621@'"3Y-98]?=B=I'NY!N551
MH!CI"  4=P ->_- )H9(P,"2#VBF1[%ZM[96NXVCK.\_]N\4=R([:X450GH_
M\;N/_%Z[W*T5R2LJ5KS/"6]."E;#D"0DX21J5"R7/5UU6%85<R,:M,516/;K
M).S$,Y,@[/L(%$VO'LA9[.[TKAU'$U:W(4.&66=5J.Q;1M'3&ZC:-H<'6LH]
M4@9!Q.G # 8-"M,Y866NK6+B'V3L.H9/E91Q$"O43!M]%;H AN!A\.[7OF!L
M['O<T%DD=*$8$<CS'85O8D$<I;S*G2L6BO5*TR=:/.1I(.>47G:U_5B(H-')
MU &;B"G P@F!%E <)$'KVJ&VZ!KE6Q32]+;[)M$K0S:KAQE! H&N/ATC@!05
MP67(T3LUCA@H%XPV>N$S1SB.>=BB$'D)7C%$7J( /_(_0@';Y_C\P1UU@ZR
MX@>FX M/,<_FO/#"TD'FG6^F-4_=%#_L]O\ KFJ*J/IC5?W10_[/;_KFB(^F
M-5_=%#_L]O\ KFB+';A;:NK4;40E@B#&&MSH  /VW]:G8^/F;> :(H%X &*;
MA?QM,00,0V+8 2F*("4P"5;J40\0'V#[=$3@:(C1$:(C1$:(C1$:(H"Y2Q6/
MY[C;G:$RQ.N*QC&6Q-?H_(%D:G,5W U%U69%&=EVO810QW$<P.=4A *;S#%
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M[RAQO+8BSK2V60,<3KV.D).K2#J1:,7CJ'=)OXU5<\6[8N3^ZO$BJ%)W]@F
M-P'8-93XVSQOA?0M<.*S9X8YX'6K\(Y!0\*UY\U2?Z=?&# _#8]<Y&TK';.
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M8$' \4[C#M JA2[=#;CV[;;[CN'37;2" -6+J8GXE>TVI;J.+B78\31Q'V
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MUB"YN+ TJ61:Y)5.R*5:<=UJP'@Y=$S:2;QL['&*_C#O&IC)&42,50"', "
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MV7Q;>:_?:%9MKI3+#69-G)Q2\?, 1W*1A%6:RH-GL2]>%%5LIVJH>: &*'4
MT'HQMUT[U'?=+;B]YCO9'7%HXDU,1Q(;V5U8##-;PYHEA;+$3Z;@".XBOR33
ME,';OOOMX]=QZCKK,;_49JI3/#N-%BTI@5^"IQ[3B&^P;%V'P^<&WAX;==6.
M)JJI&\G*GM/,? M6. K,ZA7[5D%TF'VB*Z#$T/'G4#<=@.ZD_FCMON77$[^*
M3>/>2SGC)$>VQ%CN]S=6/^I>-NH9+?V-L\ QAQDIF-8) =3^( 8'-/$D0$_+
M,'VO;L&WCML/Z6^NY$:21VD_,U7M/!#B#G5=L!W#?16K\%4BB43=0$O<;QV
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M0-:&M] &@&'BQ_&J\O98!%9.-!IEFD?V4<ZH^Q-<U*)6Z(#MN! \/T=;DO7
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MI>I3N0[<WB9QK[D_7KJZ%8G$T!.0XFC;!"D;2D6X[B 'F(G*< W#?1$H]?\
M3<PK4)V<L\5;,UKREFDD):VDELP7><BK:\:1Y(A ]HAY65=,9U(L6D5 R:Y3
M$.F4 $!UC3,U[?/"?,XFG^"201W5E)93&C)"?MYJ#8+DE3^$T[?\&\@<FW6
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MV=Q1AUE)5JSMX&):U"XY*A8R9+\$;1AFKE^LG*&'SSB)@$A>G3;6#>[7;[M
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MYRL6*>85?KI:TK186?R/6)B-8HV&,;3,S"(TE="%>00FW<MW3@#'4:. ^=W
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M2MF=2\8W;*+/RQS5%(LLV=D%%H#0?,*0IQ'6K;%U#;;?3;96M;;L&EN&  R
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M=('31,D.Q ,F [B ZQOHK3U?7])GK'\U,?FO,M=EV>#<9-S=:P?4/ &K2-6
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M@     !L&VP>&J(ONB(T1&B(T1&B(T1&B+YL ^(!JA (H<D1L&^^P;_+MUT
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MZ!Y.7!>5<4P+3[9T  ^C<[T#_P!ZG8?)]G3C7B5:UK6X-%$M/ +\3#C=]ZZ
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MYW(,C*1-/8*8O@CJS,A"Q+B<D6Z(IW(Q$Q;131181.(!VE';1%EP<PYS</\
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MB+'Z1SX:9&J%<O=+XK<O)VJ6R*:S<!,-L70)$9&,>$[V[I--:Z$5(54O4 ,
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MIBHW-10WW=<A=@ >IM$63)\QIE9(BJ?$+F$9-4A%$S!C*N?.(H0IBF !N^X
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MZ(F4%3' -!AB$3"@4I0V -@V /S@#;1$&,!0W$!'[!0$1'[  'MT1*0WS7Q
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M41#9=Q+9.1&.HVQTI"LQU[A7%SAV4RZCW=E@TH0DD4SQQ[U%MQ<)ID550,F
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M9-HF*:38LAY&LL?4:556(R-@L<NJ9"/C&8K(MB*KG*51015=.$TB%*4QS*'
MH!N.K2\1^%V:C:214\UXF-&>+*^:T1N.'$&#B?LDCD"VQT7*HO9(+';P0?2$
MQ+QYG2SV-7E2D3/V*$3V OVH:N:X.%0KE^=WB\690=?5;<75<L$DP>UJ\FI:
MLVV2G6ZM?F4)FM6$\0W>I2I6+69C2*)K"GY)SI"41';5R*27DDTBF3R1E'3=
MBQ9M5WCUV[721;-6C5,RKAVZ65.FF@W22()C&$0*4H=1Z:(EMP#D_BWG">R-
MEWCG?J+DN:F'L!5,DV6D3Y9E3WJI,G;>OQDJV!4?<@:LW*@MS@0A%TS"<ICE
MZZ(O9SKF+C[4EZ)AC.%VK<"\Y-2<WBBAU2>>*-5LA2;N"=.)FN,#)"42'5A^
M_<QCI@(G*4IN\Q0&RI]2G"B*=(.+CJ[ 1<'$MO<HF!BV,1&,B>88&<=&,T6;
M)HGWB94Y6[9$I $1$P[=>NI7"A1*W'9JX?Y'Y M8B!R_B>S<BL81EGIZ%:C;
MW#N+E!L9U:.6M$.E IOQ,^7.XAFX.2)IJJH&2 INP=]6HIVR#E7'^*JL%MR)
M:(ZHUT\O UY&5EA4(DM.VB7:0-?AVZ*2:SES(R\N]301233,<QS>&P"($70Q
M9%8QI<"O2L8JP2,'!R\PJZB(.7;RXQ4Q-2;N;F$Y J3QXX8.W$D]65,DKVB7
MN$   #;1%A=MN?'VYW=>K6VUU->VX#L=-O3]A*S245]!;#864HC2GK]TX7:L
M"2,NP,Y%JW44$YR#W=FPAN13?+66!@H9[89J7CHB!CF9W[^;DGC9E$L6*9.]
M1\[D7*B;-NS3(/<94YP3 O7?;1%B%)JE%AWEINE);QP#E*99W*Q3T4^+),[/
M))PS"'9RJ+I%=PR41&(C4$RF1'L,4@"'RZ(HDY)Y@XJUIE!8>Y*Y*Q]4T,SK
MHP,!4+K9$8)>XJIR;'R&S0OGH+E0"7!NGYQCI)><8B??W& HD3*IG10;$23W
M1331*4FXE\LB:0 0 \S?84R$* "8/  W$?;HB7#!F1^-O(B7L^?<&6FM9%E(
MIU.8(LUTKS]9S[D[Q]9GQYBG/4E.PB"D38'"I@/Y907 X'(<Z9BF$B9X@B)"
MB/CMHB^@ !OL&V_CHB^Z(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(O.E9%C%1[
MR2DGK..CF+99V_?R#A)JQ9,VZ9E7+IXZ6.DBV;(I$$QU#F*4A0$1$ #1%KK/
MN$DAFN@9!H/$[)W"SDUQYGKU<IVDW*[HO1S?Q=R)9;$\LDO+4?+^(EUI.SO:
MS/R9GD<E(&9/P$J:*SA1   7<JR^$888)S^5S7BIFNGT#AGD[FE7<<<D\<O,
M=6FDV)O?*K%9 89BJ,0FE5KA,U2?47@+ \?/CB\"(?$,9P=4#$ #@0P%:WRB
MN=$MW'7!%3X<9&RYR&:.\8UO$/%#"MBQCEN>QS].%<G\D<E-8F M,Q;\O0,J
MR1@"6-M*+*J1IF*LHNLXE!3]X!,H)%K+1K:CDJ1DN.//\4LF)L(-^9>5<MY"
MR=C^'K'*16/=Y3R;Z</(>Q+R.&KY:;94F-;PMGN!N#=DK:OHE&8\,#9RR;MY
M%I$S8+I@FU<;*&I 3].ZO$E5F\,S6M\I5PV-L=4GC#P.K^%>6>4Z*PJ3"AS&
M/[S:++8OA=*91]W/+()TV FKDY.^=PM?CY08V+,[.=THV:IF.&X" 6L\@[E>
MZFHTRJL1XT>G[A; /U36KB!FS+%%Q;"14,$ICRKY"1ON$,P09(L&Z$L_KE@^
M.Q\#*R1#D<FD(!>/%0_B40,.KE:OQSM@[B9R'S[E:FV7,M)?YHR)QCF,$V'!
MTC/4V5F8^%6DUK-6;ZR@'95K=7K#6YA\1P0S4Z95"^6<Y!,4@A9!X9"]N#JH
MO+XC8?Y!8UXT9GF^?69V\%D*[QCZMV.>K%V!E1\1XNI%5#'U7F:?-3!2,H.=
MG(9J:<DGJB8G+).Q W=Y8;RO-7D]J+%<+\2J!3)C%&<_31S?CZ)HZ4%5<:YH
MJR;]'(>)N0%*I9AC2VF1>UM\5:&SS D!<I9Y(1]].H=)ZFH4"B2U%+?.NHXV
MR?,X1K"/(_%N#N25-N3ZZ8#B<E)U6TP=TE)"'>UJ9KUCQA8'[)>TUZ:CWBB'
MFM#(O&J@>8W4 X" D41<<<,V#AG><Z<H>3,UQ8XWX^MU3JT)8ZW@V3M%=P[-
MW2/F'*J^79N,NA&$97+?/)/$XY)I'(&.NEMYIUE  =$2596X;\8<CH9/Y%8-
MS'B'E90,Q668K]&Q#ENVR-GQ1CKD5GZQ14?:,EL+ICYK+WF-LR[&.00CV4@@
M)XTJ?:V=-$Q'MMC)+R#E5'>*E<PLPYL7DM"Q7A3@;DZ-R-E#'F)<4XKN?,KD
M]17[]M8N/S2#EXV-Q#E4L2^:RC>\1:.08(9*9C7H.B)P#,[AR10H&WD=34:9
M*IQ.*F+BEZ?L_C'/.!<SU"WXNL]+J5"MTS?.2]2E)=;+W,BR953=2"Q\CQ#)
M=S2D*7%.WA'S)PF[>J@JFF1N5!(!)H^@8",Z+%:V7UB0?#53SF/B_P "^8O*
M)2SSF1XV1Y.X?QT[H!FV*<P#5<HXW9/+ WG&M@WJ$LUL<9.Q3](4DO>/-;@D
MJ=-5$P&$-8D$<?J&72/4)SXK*(/'-3M9<:57&_$C(N*N1?(VSV2@2E1MU0L^
M;\OV"KUFU1]6MK=Q#MDY:TLF,)$N)&':/BHH/%$0<.5  R@&,([S2..LTP"*
MO>R\,+]:;MQEM_"C,M5/@C(N+<=X5Y5Y?I<[#0EIM^+\+2S2TT.YTI6CHH0+
MZX6--HXKKQP@5(R+%\8Q1 "@&KFFHJJ)J^2''[@[R%SBG3,]Y$K[_-4[AUWC
MK'^-7V2(J)MU)B74VA:#9$QG ^\(S\'D+XG#M54Y='=?RV1"E^Y]P&M827D<
M*HF.XZU7,F'<7R-:Y(YAK.5C4E_((5O+"T4%0G)+&<<U3^%2.5O,7""&Y,&B
M)PD)!IY#1P!?.$A#";4KJ:L,D5.#C@Q+Y=Q]:<?\4<I\+^1W'26O5MG,=9%M
MK-V&?.+EWGK$[LLG+4;+^)G"SBYR-5G9-9S'ED19/MP21<.%D0U:B<GEPQXI
MY^@:'Q#R#S7KV+N3V-9FE6_'\]'WNK1U\B,P5R!,Q@;1,TR;7/!65Z^.[5=C
M$/ $YCK@=/L.!#@1+9@'"%1X59"SGR)8K8TK>(^*6#I?%^35,6)7A;)G([)*
M#*"MKRYYA@I9H6!+;"RRQQBQCU91=PXE3%.[!,H) 1+%B;!#7F)D_,]^R#C^
M"@.51F\AE#*_IK<D+(Z?X6L]^N]6A*SC#D) W)NP<7%U3VN,FY6AFJ*$BRBY
M@KA)(C5<H'$BN1I&/\?<9>"%<P9RTRU2F52:8YD\87>XVZPA#T\C:X!)M"U6
M#E[HZ,]>1L%'201T:+M15THV9D.IU VQ%B/&7@!AGCNIBVU<2,SY7IN+(R$B
MRRV.(+("=^PAER()%>0UFEJ_8PG6%=EWX'(Z%_7EX\BIA$13$#:B<2'*J\_.
MV!.*G(S.V:JC.9CI,EF[(_&5YA6PX6>3U0EY:%8-I-W9JCD%C +BK:ZY8:W-
M21%P.V.F0Y?+.<HF*0VD;B7T)P5SJ!H-,5T^*6(<]X]XO9HEN?F:4('(F1&,
MA#76P5F\A'TC$>.:I5$\=UN2I,[-[,H"8EX9F:;D'AB]WQ-^._5,-2W1T-;H
MPJL>,DN(/->!A?B;1J).XESIZ:V8L=P&-EX6HX]S/3D')+]B;.]%IA?A3>W"
M_KST',#G6 9E7*6<3,)9$3F2?D.4"F+<X4/P4[A0J2>=-4QWD^S8'KC?DCBK
M"')RFVF5N&!Z_D]"J7"!O3B8AG5;G:[9<73T@R>V6#FH\3H%<,5&[]FL45&R
M@G Q1B!/J$<%:HJXZXDF.%ELSKR9Y,S_ !:XW8^N\!4(69I^$)6SUS#$A<X^
M5?KN\MR<=<R,8^OW:T)ODH\K*,1,*R"("J9938P2NH#ADB2;)_"WC3>T,D<@
M,%YAQ#RNH>;K9*UO'>+,SV^1M>)L6\A,\V=B:Z9-B+OCMI,7-G9WJ;% K%I(
M(E5C_+!-!VU3,&P/<!0'!5J:4X++N<-\)1<9X5X,9*:Y-R/CK#..<173F#RX
MI3UVVL''U[%2;",PSE%S!.V,DROL2%YB#24Y'/2NDD8%N+AR0WSAUCOB,TP)
MRH%0 #)33Q$]/RP8JSSA#,]4LV*K#1*GCNXR-VY)TZ7FE\N\T;-E5!1^YDLE
MQ#%5S2$JI%2CLL@P72=/E 4(0B'NZ.Y-9.F.&,BGB^Y6U.NG!3KEKB_P-YB\
MG9*XRN18^3Y1XJQV3&JH8ES">I93QA&_2,\ZUERFI\LWG8V9:R2IT=W95FQD
MC"F=(>H:B:\/&H9*1X .')3O;,7U"@\1\AXEY*<C;-8L?RE0MM.MV<\KV"LU
M2V,*K;6Z\6Q"4M,>T@X567B6SPB*+PZ)572@ 90#&$V]RM2 6KAED*QY,XW7
MCA?F"JM\#9(QGC#%G*W+-&FHF&MELQ]A&8;7#']PI)J8DC7I"TW1)J>NR#A$
MA#(1CD_;TZ:D#XVQG4!JJB9SDC@3A#R!SFZJ.;<H5]SGBQ8@''F/<=NLEPL9
M<,>QJD\C<29$Q;7%%TYJ!R$$Q%M'82J7<L=)BF4 \KN <,:I9-3,D3+8 A,S
MXFQ1*U_DYE^GY/6ISB22BLMIPXTF1E\;1K0HQTQE%-=V:#;V]JS24"2>,S(-
M' D%8"IF,8 RG M-"BIB4X+2^8<7SV.>)^6>&?(;CPZNEFDL893LK)ZWS_Q9
MN,O87MED):CY=Q2HY6O,K6)J2569!(F8.S?<TG"RZ0" V:75U?E5:BFG\R=7
MEVUXJ\A8:F\0;GS5K^+N3V-I>H6B@SL9>JLPR##Y:@H$8V&L,S3IQ5: L;U^
M2057^%N0%7N7!5$"*D(H6NIKO*K0TMSJEHP%AJH\'[MGKDDR5QI5L0\5\&R.
M(,@HXO\ IRYO_)/*K!"O6->\9B@IID2'1NBLXJ9..,P5E7#A>8,4[L4R@0"J
MEKQ=QY#F!D/,E\R+0J[$<JR(R>2,O>FUR.L3I_AN4R->ZU#5K'/(:M7B/:.+
M>XIZ>-4"-$T$4)%I%RY'"2/NC@!.8BN'JV/<<\<.!];P-RYRY3&M12QL\Q/>
M+K<[(VA:PJC:4)-D6MPLO;G)G#IC!Q[\&4>9V=1RH@U(<_7?:PDZP."NH-->
M-5C/&K@+B'CZOBNS\3<VY8I6*(:"C$)?&$)?$<@X2RU$I0Q&;*:-!6'XVVJ\
MP[V*Z.^@'#$BQA'N3$HZG<YC<" HVFM5^&<,(<3^1F>\M4ZP9BI<IF6Y\8)_
M!EKPHO/U"9EX:O/I-2P5R^(0"X.+37)^LS+TC@BC0R7>/E'.!C%2'1I:X5 "
MN*Q+BAAC/6..,6;7W/[-K6N7*Z0*E(FK%6;V$=3<3XAHM6^KFJ6"M3\Z(,H.
MT6J)3/.2KPY>\9)Z!1[A3+JCP."+JX2XH4RBV#&&<O3:S1CZ'Q2\@Z9C[,M!
M161ON(<VU&EHA#M;VUDJV]*[@<[P[)(R/QDAE"27]+?)G[2G+8BMR3_I9/'[
M4/'H/YX>P=$7/1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%\$0#Q^S^EHBJ@]3
MK/4.RIL?PZAJPZOV3N5U3OT-%UFN9*QY0K;$U:N1[=U*6*);Y D&4=:))9XJ
MD@SAQ%,LL8%$!. ";:US))12(T*=B6GT?^(UYQ8-DY 9,F_@LX[B;QCU]3@Q
M!-8)LDM,OKN-NLUZRW59*5?5]:P-120CH@87NA6D6A_4RQR'':61\<; UP\8
M KW\52,EYH[%>A8^.4!G2\<BG?$C+_#'DUCC,-O>V/.7'C/<0WOK*G9,>Q;>
M#?6VC9'H*[FZUAPY;QJ2P,7*2R*2Z(G:.$.X0",&HKS5Q ::#(*1+%EK-W#>
M,XL<':HSQ%F;)\CAN1EG=[Y'Y&D\95/(CRG236-^KNB3"T+8U;!> 3=)^0C(
MJ'62CD4EC^:;NVJ?$*.Q"M  R4EX@L=>YGYGKMNR3QFA,<Y8XC2LG W@MLL)
MULN8FR=,,&,G6X^F6FG>7 9"Q#>ZL^.\!11QY"HD*"C0%"CH/"W2/*54@..H
M^8*O[U5\BR?+J?N7''"E5L-GDN*TW&2]^O\ C]UCW+SF%E<@4Z086.M3''/X
MTTR%/Q+*I2ZB*\W#=TE!O%1.@B8Y#!JRT.N<L=BT*LF KQHK ^/L'#^G5PAR
M'EC+-FJRT8W0G,Y3,'6&CO'F/JRF[KL,TKV-<>P]YD%7]?9IM8=JV(1^H1=1
M^JH<Z93&$NLBX?''D!@H862N.)J"J<L'<3<J\D^9[C(<_!R6(:+E*1;YZ@9R
M2J\3E)]!L'%ZK.2K/'8=Y3XIL!Z?+RUN>0;&.72L2*4A%1!#M&J:A $1K;,:
MR)TSQ6N(4DP+)6L'Q[597ZJF:/IZV3X*8XJDMD#+UYJ#',R[>GVS%XVNDQ]
MM\/)5AX7$^09B+2S*>5G693KUKS&_O\ 'I*")MA#6"QY=(:'PU5[J D+L^DI
MQHEN/6(K%FS)%EAX5>ZTR(AI&MM,>6;"\97VE&E[;-V2]9)J-Y?K/&63K19)
M]ZXE'!128(MB))-C'0*50<J6@8*9T4;*DFN5557DRL7SU&^3]6Y"8OI@53$>
M;E5<?0MUME6@>1V-B2%5B+;0*U?#V'$T\C=,(6Z,B95Z^904ZG\$6D3H.E5@
M4  U#;ZP_5*:QE2/%'$!7F<N<98.:<<\.85RER9A<&VFCS.-'>#\IW^8JSN1
M<Y.Q<BR:5Z3DZW<EO@]Z:OE3=C]FN42'(YZ*)JB0X7W#PZ1K8L*G@KXA5KB1
M6BBW"O%_-F(LT6GEUDEGQQ15K^$[I'65IQ-J=KJSODQ(()-)VOV6_P!4E'*U
M71L4"C$J%C3M1=N#+OE">>*6Q=72-#!AY^*@82XT/-1O1?4DRI/8RB<T90X[
MX9G, 9="-JOUCX:RRVR.MBZ?N+L:U5J1R;HLQ Q5AC&A)Z6;QDRLP!Z6/464
M [<$PW&QA+F@G-2/%'$)H+5=<1^F+PU-;5,=4FB%)+1:C?$%/O2<'1G>6\DR
M[)HO5J/8KRZ;LZ_63SSXQRF!)%LS9D45\@A ,&I*DBAR5S0/BJAN#7!W*-GY
M:R=VNC>8Q3"TC(%>S1$(6?'C=UD)S!?22WVMK0J%R0QY./,69:H-AMUJ7=R\
MJHF,V[:(MD%D2%3 0L8STW%Y\IQ4=P2'-IQS3,>JOE^3S]-V'A5A*KV"WY1P
M\PI6=K19J'(8OO<Y0Y-^%C8P#%7CO;IR,G,N((1_G.GK=D<KN-.=JNB0ZWED
M-- QEU(X@5#3BI?5BB);( :Y5_!,KZ>^(8SA+Q-O&7LE6VO1<)9:K!9.F(&)
MKMAQI2L=U.B8\90C*-:UC(3X9^%MDTTBSNID[X43KRBXAV !2[V2.C>=,0 I
MR46/%4Z,,%Y2Y_<JV>88ZO/L2XGY4Q"]UKMEGZG!YRA:N+Z"K;:1LN/\\XBL
M"9*7D9Q2ZXFU:0=I100@UW3@6QU5#"&K;:(L<]\N/>BN/]2K-49'4> X/5NM
MOLD90Y+T"W1K""B,F8[IEQAJC3F<8HYM#9ED&28,KK*OI$R2+>&,9,)D2KHB
MIL)MHF!\LFII.@JKJ:*C-05Z/W$F_P"+$;%GW)%@+'3DE VK'#RG_5#8<&3K
M^8/?WMQME^RW59N2>PKBUD>*),(T8</A#**0 K991,P=N3(W0VG&BC821CFO
MMGXTP.;[GR,;\3\Q<+^3.-LO7*5M.:./N>H=O>0Q[E.68-XV4MM&R3CUPXND
M$=P:.37(P=HJ)H+IB9JX2 =@LA:=/J/J6D_BKU)5CS!F_B"VXO\ !NFQV(,U
MY/7PHI+25ZY'Y,E<85W*;NGR+2&4HN/9=S#6A6PWI,%2*)I2"AUD6"22B@J&
M$PEM+@Z8Z<&?X!%*6&+)6.9N:JYD"^\:H3&N5^),A.5.]?2R<6/F7%&5)-C$
MRL/7:G8:AVUV_P"'[C49<SXJZKH6ZY@3W:D4*(!)*PQC6?*K6DEY!R5=WJGY
M#EN7]IN''W!E4G;.MQ/L#<<BY!HJN/LS_"9#)-,<Q]KK=BXZ)3C'),G ,JO(
MF;JV*'!21A7RJGD(F4*;:".3U'X>532M :",Z*P/#R$!Z:'!S(>5,KV:N2Q2
MO93,+ZNUD%\?T&(D+2UB&-7Q7C2+OLH9W68E%-JU;$(]5*K[R=990A3"<H73
M@"I 4+#48]JJ7P5PZR]R#YH3.0;+%R>&J?;;-'Y]CW<]4(_(4E%1R]_@LA6>
M+P=RHQ=/J42XEN\W&,F3D9HB4I&PZ)FJ"!TQ$PVV(T%\TWB81@#PX*0N!:&<
M58-ZJV:%,BHJ<%<75:3O>8+'48S.+XE.M&+75IHC"CW&,>59<N'\A3443,OQ
M69: HO7B*(BZCB'-W;]NHO2FN)*M)],&JM;ICS U+U_2EXX2W'#"-DS3D>U0
MT(A=:77$Y*NM*#;,.QU6C<=+VN0L-OOU1ODBM(1^2K5-S;UW,+_U.R31(D1#
MN1*0^LRYGBIX0*@4^2L(?)+45T4&"JQR%4;_ .HUR@JN?,>TX:AA_.IG-,KU
MRM58KW(R@-9*!KEGH-=R$C<\46!.UX1NT5 2;UVQ@)U(L22372=*+^8&VK;)
MHD+IGXM_$*9U&_ID>-7@<P\<8/' >%L,9'Y-06";C1;!C:5P/DZ_R]3D).0R
M7C%HWC:](RM7MROPN^,9,ROER314 (K[S\Q5-7RS:.<'N);E51AI:*'-1;A?
MC%F?">6[YR^R:PXZ^\0&#;=&V*$XCU.U5EQR8EF8,[#"VZ]U*8<+UII:XAK"
MJ(QAF7O3@RS]4AG!D>TNJ*JCVA^H]E&=QQ 9;RQQWPY,\?,VA$U)GDO#&5&V
M2D\=6*[*?1ZLT?DO1Y2 BK%%H'FI-&*EEF)'Q8Y950JB'9XV@N$F:N(\-1FF
M>GKABOTS^%CJVR./*/CIO$KL7)L0TJ]!#T,^4\ASC9D:I42RWERT;P-;=6"0
M$Y-DT$&;8%%2H$*40"^5X?)Z9Q=0*%C27%YRJJ@^ _"3+,URX<W*^,I+%]>H
M-Z@<U0*4Y0&K^\2]90E;O-0V/:9R.Q].O,590H<Q:+X[?3#\Y2S<@F1LFL@4
MI /J\PB&,"F.:E<\/-1E1,IZK>6)GD5-V'AS@ZM6*U9(P>2D9MM-MQW)8NR!
M8:1-2;>Q1T+&N^.-HFXVP98CVT0NNY?)QZA'L4L9JX1(=4I2CB,<XO()JB:3
M@=B>+X/\1+_E_)EMK4="3E>C<LRT%!5Z=QK1<=56D8[C8*,K\76K^_&;AY^0
M8P?O$J9\9%1Q+N#?,#<-\F0L/@H*JBIVB, Y6YU\MFV8DJDXQ)B[DTP5N\!9
MYRJ06<X:L*2<54QF[)C/D)B.?]VJN0W52JJ3)I#VE)!&#5=NBM3+',)1CC88
M<LZU5E3KI7!6]^IGG*+2I\1P>K55?Y'RIR4Q_;A8P,)D7'=3M<#5*,6(64L+
M:,R'(L8Z\2LA+*()-H(_E%FB X1$Y2@<0H23+2N%/WJ5P *B/T@N*%_Q3$3V
M=\DSK9A.3D!8*&_J*>()_!<X^E2W^4N-LR!E>F34D\BSW)>2<E9,1BQ&(:1*
M!"-55$]A">:1K8O2;YBH-#C,)*^&E%Y%FXSP6<K3R-:<4<Q\+^3.+LP7N7L^
M7<#9WAF]W-C/*TRP39R=JH.2\>.5;C"J*.62;PC%VDH#5=,1:N4BFUC6K"UA
MUU)+OW+)E>'D4X"BE>T9CS;Q/4XR\&Z3$8AS3DQ+!:<U(7;D?DV0QC$98>U%
MZT@E:=CR07A+(:RWI,.U84WZACMV1$E%/,,8QRSN%"HU)^$[15^8>::_DZ\\
M;8C&N5N*CR<I5V&VS:@YFQ1EF1;L'S.L0$[4A^CE\P];Z?+"^0<J.CHKG%,1
M:E4 PA"YWINUN_ITI\555R^J=DJ7YBVNV8,PG4IRQGXG6@K7(&0:0%!S6@T?
MY#IA6=OK-AX_-)QMD]:#9UR0,T5L<*5:2B'9U 11,(GVC:V4RB0D^G^":@!I
M_,K%\--(+TUN#F1<HY<M%?E63%6RYNE8JM-U<>T6$=6II%$@L78\B+I("[K,
M,V*V:M6R+Y4%O>%5#J$*81+J:]<QS Y@H1@K&L+":\54!QVXD99Y <R)"_6.
M'D\.4>\3\=R A)N4J$9D*991"F1(K)MDK^(.56)YQ6BV,]QGF[!JZ"=22E6,
M,B+-%)5/<P30&..WJ1XCBA:YV()HK"_52S$MDLQN"N,:G,7K+\Q4(;/DB:EV
MK%CNST1K2KFQ<5)4,+Y#F8T<SIR,LR%=W7TSH"X8I"<!,82%&&,NE?J!_3&:
ME8W0#))BU2!Z0W%RT80Q&^R+;9YD,KDZN4Z(;TN$Q_;<5,(5I2E9\']CN%(N
M3QU+-,K7"Q3;UU,JE!-L4 210 Z29#CE7!C) C &&/:H&5)<XGPDX*X/6.I$
M:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(E"YL<J:QQ&P>_P DSDE$LYZ<LE8Q
MIC=E-.&;6/F,E7Z61@:LS>K/GT8V3C&KI8SIZ<[A$J;-NH;O =AU8:^NUOY2
MJE4JY^P1R#R'R^7M>3<%UW(-;SA&8VQFM*6RCQ6=N,EDKU8\]Q'3E+OE,5C,
MW<5;6HZDWSA-<_Q&+,N9,QW!A^<&8W2PDQX8J,EP*LTYIYJQ]Q&X[T3#$;#,
MK)-YF%MQOQ?0[%F6)Q\[?HS==D(]^^4R1?W+Q=!"O113]KQ8%E3N#H$,.YP'
M6*]H>27XXJ\88A5V>D;PFRE1,K2.6<MN9FJ2F)7MK@&57F,-ML;W6V?3.L5V
MKUY.T7.K6&6QMDFBTBEUENA$*P*:;95V=1TL!%CF#50*"@R12WRH]03CQ<,V
MY"XPYXXGL\U80Q;+R+#)5\DY"JSLM1)^&5JC/Z2IXY6(:TPM?"8N;)DPF$G3
M5V\7!4S5,Y$3&"V*KG$'FB82PW3$'#O*.&>&'$2L8OIF4LUL;MFB8K]KG'+0
MLW3Z?&I1XKRMGF)AS9G%LMLV^:1D2X5"0%LF@H)D!22V"\YE$A7"KBO<V'(&
M0B^16#QK$;C:Q7//7TRRY3D([+M.L4]8'EF?.\<\N<,OH>K9MQ\O.KJ^]QEB
M:,Y!NR  53.4!#5 WZ?]4<51I+C1V(62\@LSY@]0SC3'9.PE3Y#)&"&.>Y&Y
MU)]B ^/+IDNO1^'9U:+J[W).!;TYD*YF2HV><CG,BK$I/8J1!B9N)4?,V-J)
MT9E&K\IR^*F#_3)TTJ,%+&,;W7>$N%,1F)6\.8JY'\YLJPU.I\17X6VXPQ.[
MD@;N)1U?K)AB\V1A]6KF,KC992:C8U1,3/EDR)&5,8.[(EE9Z A;0:0!\5$&
M/E#Y3B031+U+<9<U9&YQ7!MG'CXSEZIGZ_Q=BEW^1ZLTR9CMC%4N$0BHRP\>
M^3^+C5[)^";.WKL>15""G6IV*KL3 1T)C;FI%%&U@-!JIBH@74&H^),YGO,-
MNY?4/F-Q;XO,$,DTG#J<+QQO\54\D5JM9M>6$C)A(W>7H4_;7%AA)MG6(<R,
M2X9S;1L25?>\$!T)>[:CL33@I!S"R?TO\'N(-O:\TY#Q36L;9$C4OJW3G&.*
MYKC=>;##0[=L$B.;L2Q,P\Q)-6*-4;I TL4+YK9VCWG(*>XE"G#3P52:FIS5
M;W+JU6GU#\\5K(.#J2B_QGB'*+[ <K>&S6J<FL<79E4<BQ\VD?*&*J7-164<
M1UY:[QR3DDFQ4=M9=@W*F\ J&PENMX@V7U9!4<%>YSF,HTTJ%<#;;[#^EGPD
MQK#RBC[+<M6G\)CN)<2L[&4>(L-SN,G+3CMY+V6PK.XBCTV-6,Z,EYQU_=6:
M2+=,%%!( KR37,"WRDJ.V:#&XGS#BE\X\.N G)6'N7+C)7$^K8,ROAR"J^9\
MQMIQ%NA&119:K+9#J=WEG-=<1U1O+KZ/,ROT'3]B#UNIV"<H'[1U65@C%&Y*
MC7%P!.:5SD;<,^<V\3<:>4U0QPK><4PLA<,ITEQCFNX_SO$0L-<TY*NPM9Y"
M<9;!('?WL$J*X [E[7)9.38+N#]K,#E$!Q[?6'ZI#6,JA>X&@."<FM9*K7"J
MD<3>.N/H3$&,L[\MK>_LT?0D9&U1>((-C#PZ=BR!+P==OD^ULE(BY".!LR:1
M;<HF:2[[M*V4 IRCDS/;)X&4 5WGH78T2;X2XGY-M7,:QUWD/QZ]SB+MD^V9
M\F9W)M41GYJJ3)E&BJDQQTYH887KTH>.,Y:M"_1BV,F2Q60'3344*3M&. OM
MFEL9IJS[>]4>QDA#GBI&2F/D=E;)7J'<?\\P/'&!+E/#%8S4VQT=OBNXX_0S
M65UA6;*M8;DWK5\5F*1DNF3ERC4VZ%?E!BG#]HT6-YH@H01HUH::M%"KEU\1
MY"J_"+BW9^4=ZHF-L4YMSE>:YABG,H.A6;C]&7B[V*<0A*S)Y(P/9+$2F4RU
MQ\P9R\F7$4X]T<Q[<QT7(D$H:O+W.S-:HH@SKQ\S]D?F2ZLV3\$UN^53/9<;
M8]D9:VTR-SIQLL==I[988RQT#(M&^$YOXKVH0>O':1UOB$4JZ.03.=_GZEM6
MM < *4R5[SX!W*S'FYG:A\2< 8^PI'0"%LE\XND^-V,Z)-YDB,>S+QG,UF49
M/I!;)%X=NUFQH6&1,0CY;SU#O5D"&,!C]VL2=[B&FIJ3C]RMB +1^W%5W>DO
MP?R?1<HO,MY-7F:@ZQ-*62$B:I8\.ML;Y+LP62EP5.K;6W7*L6"7QKD7'M(I
MT&D2*7@"$;NGZJKM?L6,)1RYCHC#&8-IDA&*EKDEZ@/'')N<;KQ?SEQ/1R[@
MW&=AE86^9)EWU8G9BB6>#EZG7#V F.3)EN%=A7-BN+-G'RB3IL\>'*LHW243
M2,.HK.-KPYQS"CF):UM.*8=]><4\4\ST7@]PYJ>,*KE2_5*W<@K=6+-/+M?C
M]8AT2UR)8/K3*S#NSC>KQ8#(MXYVJE)$9LH]8QT?+*72-QEU-E)+6Y=BK/X-
M)9@2D)X3\6K77\[OF'(G"GT4C,12URSC]/<LTAO"YAJ<U,V&2M#]S2.6.&WL
M54\Z8W<S#E7WJ.L;1E)(,RE!9$Y0V"V/T8H,J/J?O4LAJ:<*!>GR*RMF?U!>
M/E#SAA&HNLB8/KF=+)D>C.L3-<=Y%N<+$T-5[6:NKESCS>7KB'S%6I]<'\D>
M/:OXJ30:JMS%1%7;5["R5FHXU4)PP&2GR@Y"JO!OCIA?X;7</XDS[S8RS5JI
M5:O#L+I1,/!8Y057\A<GV*<AV-@ZQFC%U%JJO,1C)5$J3]4B:?F")>ZC@ /3
M'D'!5:!YN*6I?BUF'(?."Y1^=>/S*1JF?<DH72:?Y$JK3(]+9QU1A48J+LW'
M;E9BHU=R7A:Q-JU')*-ZW86@-#KF.1-T81[C(WNB!$9H"JN <:NQ*9#D!F2W
M\SL><Q^-G&**)DN@8A=Q''&]0M3R%6:SFU]88Q%E*7J=HTK;3ST%88N$8&;Q
M"L?--FQ)9V5R4'?;W:@T-=(0X5:KP-#068%2#Z8F$%82-N6;\BXSK..LD%,M
MC]Q,Q6*)[C9;9V @TVIY!3,N'V$V^Q4]M,:JU2!&>AO.:/$ ,H10H&$@9A='
M!%H8 &T6.T2R3:R37]RK&Y5S]R]13/5.R?@VBI.,9XXR4YP*XNJ3*I<F,:W)
MM2\@!(,'&5,;TF>BLJ8;A NS5-ZF_:F=LY=BW3(\ J6PZP8JF36/Z/+[UF24
M$>@_U>?W*YBP7.%]+?A!CV)F'$CEM]2#UC&T.[E9V,I+&R7&WRCMS[],V:>6
M=15(IS-XZ74%18RP-&21$B%54[2CD/<UTW@P908+%C#PS]0U=5*OQVG/3_Y'
M0V0.6N1N)=7P1EK"M=J^<<MMY4K=.#9M9>!D[Y2KZNY@7$;4+H^>PL89\W=O
MH\'R2AR=Y0,(#HY@:X$9T5P<2[3^50!R:M_(3FCAGC5R@I>-7E[Q-'R=GS#3
M5<:P6.\Z-ZY$VABZ@8*K\@N--J>JER<1I3W!U73NORR$E'KN# FV!0@[Q4K/
MK.>"E=1OA& 37TS)5>X8TOB=QWH5?P_C3/W+NSO[F:AH2%OA\/P$1 1*4[<Y
M>$JN0)UO8<?,IIF9I'M(IN41:33X2E;J@F??)E<7.Q-<%&  ,$H6!N*&3K+R
M^L-=Y#\?RQ45:LHW+D/+3F3ZJG,6BJV)V[;NW4KQ\YJ8><0#Z4A?>VK1,*Q:
MF+-9)CW$(8Y2"74 :T&H&*JI>Y$Y@R3ZCW'W-$=QUKPY/P=7,Z,Z6@3%5KH1
M<V(.<%V--Q+7,U1O+B4IN4:+9;Q#ID2K\@,,Z?,&R@^88#D$:T%=7YD7ZXFR
M!5.$'%J;Y,WBFXQQ9G+D+D"LX8ID?!42U8 KUVO=BL'P*LS.1,!6JS(5*DVF
M/D/>GLXM%+$;K,&QC)+F*8@#(3J;4YJE!6O%0YFOC_GO(G,V7G\IX(@+O5,_
M+XXI#J2N-,8YMX[SU>I31PE$6/'.5Z">'S1Q:M?DO7KI$KHCZ+.[4((N=Q[M
M0,QJXYU5Q)*LWYN9QHO%C!>/L#1<*WMMCSMW<>,94*=S'#8XEG\>_JLFRDY(
M^1+TX>*IJPT.AV(N%Q647>JHIF.!E-]4-#+4XFBKCH^*KR])KA)E2D9.5R[E
M%[*55UB>0M=:8U:?PPAB_(EG7LU2K-4@4K=:ZU89?&^0*-2J57F[>+7KZ9&S
MUV95XOVKG, YKS'''2@!6.PG61P4F<CO4 XUY4S==^,6=N*B&7,'8QL4A 77
M)<K(5JP35$MT1/5&J)388\1(G<JI$2-DN;5G&RR#M%V\.BLHBD*:0FU' 1,2
M>2ON28V LP)3%3U[Q9Q(R[BOA)Q"J6,:SD[)E<OV=+!3K+8EHPL[6(%F6(:F
M?6N7EG5B"ZW2QK-F<:Z53DQ;-VJIS("DGTA;$V6*1TAJ&OH!\ KFUTM/8D2X
M-\6[%6LU/F/(;##FFQV%'MRS>G>LLTQ&"S'4)B=GY*T22]4Y6X<D(VG<@L;K
M3+AR=TRL#1K)-VH)^:B8I?FUB>7PFK=-'4'=@A:"[5Q7K\B,GYF]1'C?0<VX
M1J+O(V#(S.#[*%%4Q03'%XOE>C,:N'D%65LK8+O<@^KF9J[9GR3V2-$MGL5)
MHLUD-DQ7  &-H#@6NQ%5<23FIAQGDBJ\(\$82*SKF'\/\A><^8*Y4ZK68B$N
M6-L4KRX%7D)JZRV'[U8X\^+W,?4VCA66CF"B90D%4B) L)B 8_ !H\M%5I.7
M!+X'&'+V1N<%Q89XX^-9"JY]R(C=YB1R/56F1:K$Q]7A&\;'3_&_EIB<U<R#
MB.;9UV,040KMB:%:G6,<J3HQC )KXB6-(;@"5+.06",>0C$=JV48E@VBX]G'
MM 6\ABT;,43.5E7+@4&B)&Z'G.5S'7<+>4F'><YA.<VXB(B(CJ[-0# 4&07H
MZ(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(O@CM^B ?HCL'Z8Z(D7NL+PFY?Y>;
MTNY3^-<QY)XW2=ICI+"\[/QLRG6)NUP2$=(O+9BR15%.3?$@W6S%XNU5!N1<
MYD3@)Q'49C?J#ZXC)7:QE054*VV@\:O2JQEFWE)#6S)5"P]"U /?,%&R _EL
M0M+4\E&[6"-C>H6UTZ0IUAG)5VDR!LT<MHX05$YD2@4Q]3RS!K,:5YJT@5J%
M7ORPPWS5RQ>L.\DHBGXZY)4X<1M,?L_@-9HN8: ]A\CR+";M+;)N")1VV.";
M60*V1-9:7957;=NT%06IR[@,4!UFIQJBL!Y$Y.J_I\\$R5S&;&JU:^R UW#N
M+ZI%W7W&I5W-N71,TADBV'(3]^>K4Z&G'JCU(TB<2MF2!0 @@ %&UY(<0#A5
M4CQ./-(CP_X?UN]YNDL]<FJGD.7MV):O'2F5$^6F+:W*W)U8X=F69KUOQ[R,
MQ,\B*#G'&L,\9+O&3>382+A@'EBGY(@!0O8 ,1FJMQ>0<JE60,N-_IZ<W?IY
MG%G%XKY+H9:8U1C)WIG9D+@XKC>E,G3""94.9C'P3F,G#!=RJNHFP69+&>&%
M0_W0-6EDA-=1Q574U$+L3&.^,7'+#8<2LW<D+L2C\AI"UTRA(YUS*]"VNXQ]
M'-1D,94K),J=E+G:,(O<K5%T\5?"BJ<I5%.H!>ZKVALF( HK6@QG4<EWG'IN
M<6V=IHV2<,PD]QQO53-7!:VGCM9G&.T+C"01&C=O7[Y Q0J4^]PTE'M"HJG?
M,EW)B&$Q52F'NU4.+6Z!Y0*?!"&N<7TQ)7*3QWP%YR9+L-GEUL2\C;KC>N67
M"5AITM.,;<G0$5IQ%[9F+JA.G JU:UJ2D>F121*V1> DF4I%0)MJ/0RM:8E7
MM>YK=+31I7GQ5)X[^FK0K;/O,HYG88BN4W#UZGXLG[5><QDK%AD$'2"%7PA7
MA;6'(1%Y<G<I\/;K.4D"M_,(5(A.D@=I:6./B)P_<K:!1#CO@?Z=W(#"F.+U
MQ]8R=2.JTFY#'_(G#]ILF.<\H2SJ<D9"P*V&YME&%DG)UO95G(2#"P(N@27(
M=-9$O8(:I1PP=YD75S'G"X95R%F?@+QPRC69K+>(>.D6RR(UR/:HV$GKK,Y.
MCS142VC[C$ \L==OD366;B1<O4(1ZQ(X?H@J4OVHVL-7&N54X*&_3,XM7[&5
MM=6'D=A6L8VG\#PD9CK&V196M5RD91GF+QD:-.SLM^Q9.-,9YUJ!8X")MY1[
M%Q\F#X=E&Q3[F'(G=1O@R5C&RODQ)+4OW.#*-AY?YYS5B!BSS18N*>#S1N%;
M^TPI$8DS<S^NUXO'V"5L.:.,-C:/+W<L5Q47)-X])ZR%-9L[2<+(@42%6+%:
M0F<.<_Q%N78K9I1 ]L;<*YIM9R!X!\2>.-3X9<CW]<K[;+$77;7E9#&E-R7$
M0%@;%L</'L[?E)XT7M\S0Z#+R35G%*!/RA68(D.T[O)*<H4+C*\Q'%XP4S@&
M#U!_3X)K6W!+C+1LFQ&>\-GG^.TY N$[+<66$;DO1L7Y"@FS,SA5')6.&BBE
M&EHM9B0%1>$9MW78'<"WB.A;I&@\%8-+AJ&140U)#TT?40RMDRQ*0T'G.]L<
M;P%2G8W)M8LS!O'XQ;S\F]A+GBUA<XV+%O7YVQD5,%C@3@1VL@3[ON0N\<?A
MD.G.JNX+*9]GQD].S#5DI%_S#G5WBW+<E-0E(I,U9+_F:XU:+6K+KZ0P.*/A
M3&?R.UK,#"D5?JK'5<DC$P[P53 "AJLCW%Y)55XE5]/C@GDFA8@R-QO3DL2J
MM:;5GN+,Y\:[K*8YNMDJ#%LV5C%K+)Q"A6614)%,VSP)UD]4554/YFR@CM5@
M</$[$(2"*#-=3+.9_3 SAF& H'('*^*[==L!!:81C 9BDC1F,Y"?L+9G2[7Y
M"UN;,<<Y!NT1N#18&BSIU$K.#!V)&/OJ\D$U;DK0"T4=FOUMU/XR^E5B;-'*
M*L6_(]0PNRJC,C3!ZN2GL[B!"S3,L@TK1\7UVW/GC:GRMADWZ+<$VSQ&-!N/
M>*9"$$P!(UK2S#6XX(0\\3I2$<JL(\V<HY)Q-R%CJGC3DU1W^)HS&2"T96J'
MES&4A!WZ28SEG^LW"$P[9/XU)*5\E(]GI-F<NT&S8#BS4 -AC$3FM#)L7A5;
M5HHGZY-Y,K_ 7A C2L1I5FJ9'G%H'">&:TWOJ;.JUO-^5 <(PZ86K([V1+6:
MC!RKM5ZB$B)BMV::9 2'H750]SY"'&H3M2'<1^*M,D<PV+DUROB+D6:PK48V
M<RZ_Y?8TK);@TLT&R3EH.\U#D9C-]$8[S?C.#68N7+(TJPD'4=NGY9T1 "ZF
MKZ3B(\ 4< X#5C1-]7:]Z2?-JYY!F"R6+LI9:S58(M:087>;E:GG-C(42MMF
M$";&T38UJWD^CQT;#*D>-#Q";=%?SS.2B?S#&&-I+22W G-'>.FK&BDC)[GB
M%Q*P IQ;Y*<B,F2- S$A:H"/6R;=[A=,@,Z'+*MF,NP>7>"8.;%!X[K"3U)J
MI+R:A$6J2X%<.MS#O;I:1II@JDDXE<:3PPX-9*EZIFWB=96&-92GRT/'KY X
MA9,;5^O6QK5O=4U:;DB(J;Q[1K<U<M&Q4G7OS,SX"'$2J$$>[5X:8F5&#%0Z
M2--/$L9O>3_2GY19J6;9<OV',AWND5^:P_&5W+COX?2W[:T6%!"=''32[H1]
M8M]B/88E./6E8-5TY;*)@@*A!Z:M;(V0:ADC2(VZ'^929&4GB]Z:&/[W>[+F
M[(F../=DE:Y7TH/)>1[3<\;8B?3SI>)CDZ.[F@EYJE1,R[?$(<%'9F+82$[/
M*  U=0*04<*@!1[7^ 7IX96H-9# KF-@K)3XLC^J\@>..5E(O,\<%E?/9Y&>
MG,C4^44?6U2<DEUG!@G2OD70]P"F)2B&K: &O%6NKY>"\/-F9[GFB[YVX)<;
M,HU>8R?B'C["U_)<;?[5&5ZQVZ>R:Q!HQ3BKE#%?6>O76'I[5=\Y?)0;R,!U
M((@L0NW;HX!WFQ5K?#Y<%$/IF\7KYCBSREHY%X:J>-;7@Z)C<78WR%(U2 Q_
ME"QQ3EDG'&:VNX8RGD,79RJI8X$4V4LO&,)(SS^FMB*;B-^EK80&B@Q5I<YT
MI+L3@ENYHY6N?,+D'F_&$8IF:8XFX2^&8,NK;"D-B7.L:3-@NVTU9+%G?C#/
M-GEYN6*DHZ49,6KMD*2K9=NY52 A@*H&/$UP/J?EJI'BA'<G;;XQ]/WC9A7&
M?!3D-;\/XRE^0;&/LLA",W5@Q9 YTEJA(PJ[M+W^TSDL[^'?<6C92">RRH%9
M_P!2E)Y/S=2F37+AY:!6T&?%,14N#?%V,R17^17'=W+X<>,IAQ*V-KQXO"M?
MQ%E9)CY[20B[SCZ&6>T&> CA,Q55FK1!Z59(2BKON RO:T"H'B522<U&,9&^
MEQSUNMMR*>>P?R+MT]'1V#9:*M-E9R4[55JA.3COZ+5FG33AC/TNSEG <JK.
M&*+=XX.@!_,$$@V@8XN&)J:JA6925?XN^GSAF=HF7N1.0J=@_-%K7QY4U<UY
M3L5AC\>NKA!/(Y&ATC(4N"\]58ET@18[(7SY3W980!-8H@4-2!7M (6+1GI]
M<$[E&TRP<<#(8EM>.&%:A(++_%/(Y*K:E&,4S9.HZ)O$G4W;N#O3>9C.PZY)
MML^6737%0# )^_5Q #*JQSFA_ICS%=C,V1_3?S/>&;CDC<L;RRO'R^VC"\2V
MS;+L8[&<QD6T5:();&T-%658E7O-BA(9ZFU7?$24&)7<'3 Z9S:A8YQ;0Y55
MSF.8:.[UUY^E<;?2XQ!G3DY6KMDFI84C:,F_:X7=9)=V3$,38'CQ(E>4Q7!6
MM\Y1JTE9Y.0;M$V[=\G%BD<!!,A W"\%@&@#Q55JKVY.X6YJ98R)B+D*QJ>+
M>2](F,25[%X/H^N4C+^,9&"N\C'3UE')N%)!ZT?P(M)L40-9Z-9'*Z#9MWF:
M*%#8+0PM-7>95J:4X*P#E)DB#X&\(&=%PVG6JWD:><P&"\-UTE\1CZM6\Q9)
M*M\,*-OR3)2!*[685RLY=M1DCF!)NDD4$Q#8-1S2^(1NQ)"M#6@UIB4C7#SB
M9397,5LY-<DZ]D%:<PU6&<QDT_,#%=93R,C9Z\R&<B+U5.0N,Y&(QSG7'$.:
M/<.6*TE'R#N/W2\I5 P 761$PP1<G$HX!XH[$)QDJ9Z6G+B[.Y>X%QQ<\S\H
M*Q2K]%U;)EA"%SDSK,%".$J0\HL0[DV=VQNF6)$\@W0C#-5E@5]Y$H]W=K&C
M8[47C*N/>KJBFGBI&MM5XT8 Q4CPLS+F;+5FI.;H#)RS=UE#(LQ8+!5,45N+
M;RER)/Y16.UE*UCRO1ZJ;)%_).3*',Z!N*QS'VU.^LM-&  X*T-+?,:U7BXY
MXB<$<J2-0Y$\/;2QQT]K4I&-'-^XDY!1K%-NR%:!!N[IV2*U7EW5'M#)1JD"
M3DK]D+],@]Q52"/<-K6%@QS*JO*N=O\ 3%Y2WBIW?-%@Q-;IR<1R#Q[QG6,V
MRL:QB;8V87-".MTAC:HVARFC(&D[/$D9MYYHF51V* )(JCL :J0#FB;CC5Q.
MH_%LMOC<76W*:U M#N.>PF,KQD&>O=0QN+0BQ7+3'7TH7D)ZO1,EYI3*,S/%
MFZ0D*"12%#;0 #)5+B[--;JJHC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1%^#
M@VR1]A !V$=^[MV[?G;[[@ "&WM$ T15.PG'_P!/WFY;\XV5YB=[7^0<)?T(
MW*[]^:=Q=R(QS;ZO&)U^N62%FX:08V:#AIN!9).8UZR<*1<HAL<>\W>4+P]X
MP!P5FAAX+/<DVC@3:,BXOX89^RA7+#E/#YZ7DNGXVS;:UDW]\<-H^0B:K9I@
M]D*R@,JKE.54YD%!<C[ZF"@I>84!")S6N\PJK^S@LBKW#WC_ ,2K)=^1N$:W
MD:AM(ZGVR<M.#\266=6Q9D)X2.4DDG<?AD%'U>2N)U$.QB>*29&564#N*<.@
M5>!&WP8*D=2:%4T*U"UW.AKD]2;!?)C ^0LUY!F\CQ/)S"16.7,61[')"C=I
M0L8YEH</"SB$:RHU4,RB%F5KK[UDBN184WJ8G,8+6M!:"<R%<0&N.GFKK\/8
MLK7!+B$\K#..LV6(C']?G+)/QN/JQ).9FW@],9:4+3<=KS4J2+(:.,)_@\>N
M5L42'\A(G<! ORR5!@:\2HHP)PLX"7*#PWR%XK0AJ*UBTF,O5[[A*W3U$<6V
M.0>N'3RK9.C8MVBSN"*#U=9L_8S;15XV4(9(1(8NK];P*5P5:DFO%23RB/Q*
MR+EW!F >5..6EB7L;V:MF%IK(%:*]Q#/7Y**DZY)4,L\[%:'"].:W*++MHMX
M4AW:(B=OWJI@ 6*A.H4.2EO!/&'%W%""N;'#R-^;5*:<!.L<;R=WL-RKU4<,
M62@#$XUA[1(/U:LQDE2]6*#@&PK"':4@=-%0  4&23+&'&7T]N9D7;<R8^Q]
M*T?*B^5[%8+[:H!_8\.\D<79@.=LWLD):7L2ZCK) NSA&D/[BZ]XC7*1_,2(
M=,^XE5,!RZF<"T5IQQE,_GR%&5JH9JJ4I5,N0KF13@\:WR)CGL76Y?*]ICQ*
M,/5;E[\K%NW+Q/W!99T!%CI@<#!0@.(+L2,D2F0W'2*X59[SUS3RIED9'C%$
M.9^W<>L,TV%E'LG4<F\AYB#2RF9I#1JAF]WG;Q9&C-K7D6Y1$OQ%<-BBH)QN
M))-3FB];&^!?3=YC4:[SB.*'L'<7.=KBO>93(R5AQ/RBQUGJ>\A_(LALZDA'
MY!K<R=F9LI%M6SM1F=B4GNY#I!J.+SGO3@L$Y80O)>MV?C?QQPOB#+7*_!.#
MHH<K\E'%]O,,UN&8:\U7?0^-L;Q=VN$>VA;[;HB>1^-O68K,UU$V#8!<$.?K
M,\ZB:J=OAQ;FL6X@<4...5^0S?DSC><Y#UB8Q38'Z%TP5R3H]D@,HX^NTLU7
MD6#*,R7*!%7.4J)5E55ACG$G9(!RF( EY6P:FBE]*,L8 ,%B2P"23U'XFJ<?
M)E=XNY/Y1Y3PSD)C:*SFW+G%]_BH/I +V.H&;,22B\H]>)4T5E#P-PM6-)62
M6%=$@IR+ CD3]ADC <,2.@G<\8&JF>/TA&<6T7B\1>+-ZXL<<<Q#R)M4CR3R
MS=V$NID%]4&#\R]KQ]2JF:CX[H-,KKUX4R#Y"@1J9%4DSD,[E'*Q^[<P"$]P
M:^/\Q4-F*AS3D'4'8E>FN&U!Y@XJXBV;AIF23I.):' 2/'_-+:RJS*V4ICC6
MM-1$];L%23MR9O8*GD.K6BL-F I/P*JS;*KIAXE,;'C\H=^92)Z>14OQSI.<
M.(;W,4?<:G)0-@M<)A/)S+WYGBV!L<_6V]4<8PR/8TSFC&09#AU@1C6TF!4'
MCEL!2JE5V*>X@.-3FBC/A=P/M?&#,>9[];,CI76F>?,4GBM1X]-U',</83L=
MJD\EV"L2+ RGN#^QO+O-*)$<IE["1;-LD3M^<&I'G](-' *@ !J,RH-3XZ<9
M^5.-\ITGCK7*%3,Q4C*&7("Z0'*/&4AD2PX.=9HESO,K.*_C2;FF18<E]*D2
M2@)!-16./Y@*)F,43$U#'Y KB2XU.:[^4\Q>FYBI'!_$SDY:I65A.*"]&BX^
MZY'K=D<X3)D^K8^41KU8R#;@9KT:;OSJJNSR*$&Z!?L,<IRE Y2@%2UI(<<P
MJASADIVQKQXXJ8*B+#S%XE_38M"D,<V>\)XEP/=9F=PEED7$6K*1\G6<4M5I
M&OA:WKEIY3,\21ENJJ(*$,/A(Y[GNU.-7*A))J<U4NG1K3=Z*A&>I/A'DG@;
M+.:[Y,7IER:PT2-S%AOOR4NW2HN.<P4J(@IR,CF%&K1F<,+&U0#EJ@=!3L?$
M$W<%@ !J,U8TDO+>U7 L^-V+>,W 6[84NE>N&9<;,<>VTN2("@0LTI8K;$SZ
M:H6<U%II)R5=0/EL5S+H1D8Y*FU\HWNQ2AVDU<22:E2. #J!0TUX=88Y'6?C
MYR$X_P!BQ(3#B<[C'+%GR$TIBMFY!Y,L>((QG!8_CDLNOY0KZI1L?%QZ;";9
M*-1>*>6JDH!#'4 :NIHJ,U:IBY!1G$^]\GZ1C//-7F6^1,BX1ON.*!+V=.6C
ML/9;IULDF;^[X=<2+9PG"SML:+P3:0^$.O*=G;',=N*@>8 0-;(YNH$TJKG"
MC:KWN(O$N1XR+YVND_)T&1L^8YN#E'52PICEOB_&=>K]#K9ZQ5HJOTX)%][S
M9'L(D0LC(+J@=XN!"CL0I=7R.>(M#B2!^*BC \WYJI*F?$_C1S%X].:AQ>CZ
M/2)>N2^1,09%)R%QJ^R%F# U;O%J>6S(V/JS5['+LU\;VQ>?6(_AGQ_-;II"
MDJ@91/;4=N (A3*I^],))3JQR3L\K7_'B@X$JF!N2;"??X-RK&Q^!)B_2$8:
M6J]/<'@DHRJ3^2+*8IR5 TG*LT"M)A8HMDI7RN\Z8& 1D#CZA'!3'P>%N 2M
M<7^$6"/2SQSFWECD2VS%SO;B+L5RS3DV@5V7BJ_/X^B1;!6U$\,4]=U6G<G5
MZTQ254?M6AG3A95VY$VRQ@U*Y\8-*#)1N#G&M2N>,L/^D3S7B)!KB:5QEE2Z
M7:<LV>CW&H7N8A^1]>F[9)-32UL0MS&0B,J4]-H[60;H-55$FS=(J:14O+V#
M5I(=BW) "!0YKP^7,)R1KLWQIXSX4PWE;E7AS#C!',/)"0OEWA6%LRS5H-\X
MB,?8XC+_ &]@U@[E>D;& 3#MIYK1PHVCV^ZQ%% ,94TIP2@K7BL)X:<3>.V2
M.1P<E,<S'(FH3N))=ZC<,#\DJ-.U_*&.[C,MUG;!K'93=?#K78Z5]T6.6-=2
M=EA7">WE'3 "@ $AN@>5-1+Z$J>>>^/\0\P[.TX=RLV.'^2,-$!DSCEE'(&/
M(ZT4BTIOF3J#R#!U DV92$OPM:ZX40G88QDW:/F(.B%$$@.6T-:TU Q4CZ X
M<DRW&[C#B3T\N,[O'.#JK?)>HT: <6<]-BY>9N$[/33"'(K,!3(:8DUT8Y[9
MWK51T6.:'1;'>N#=I0$W6XN)S5BKDQ?Z;G$+EWR(A.=M/N!9K#;]U)Y!H^,Z
MU#N\:7S%7)F1>,6F1)N5N-?<1%UA'+4T28CJKONU-G+.'JHE,5P(#: !DB?'
MG<\P'=:M6^+W($LU6(3D$*L-CG+TE!-W]"IN8JZNSD\?M96S/05CZ]='LJD1
MQ$IO03;R?DJMO,[U (:T$^I3A15!(&"\'T__ $Z<>\$:3,!#RRT]ES(RRU@S
M=;84[^K4&\WAW*.I!Q9(/%:+Y6HT<$$'!&J*;%%+M:I%3$1  U=*\@AK<&T5
MNEI=ZA'CYI,JQP^XZ9[N7*"Y\6I!+%V;Y0]MQ)EO!W)6C*7NI8DE;U8PD\AY
M+K6(9M\B\@IO+D>W([9RC)X:&E2^6L8AMC$"D;F-;0@5JKWN<\U<:E2I;LE>
MG?CZHT_BQR3N8SE.X,2V%8$]GR8+F0I5MRRQH;Y]!UN1BHX)+Z=V2KUD/C$E
M%K,EFD6DL@JKV@0NU"^-TM !K5JFBB<>.*N HF>YG\3T+PA2G6.;->28FX_W
M"8E\+9G3>Q"C^*>PF)VRDC7%+(Z72 K):)(R$%51\PH]0"5VNM'YHJFCT&SW
M.@M:_P"I3A/DA@7+N8;S-79MR<P\VC<SX0?O\H.F84_'^7Z/#0LW%LF]*KQ6
M,$#.T0*Z#<S8XHOTQ/WA$8V%X>1XQQ17%,,"XIXJ<#K?B.[5&S9PQA T.?3R
M74:57)R5E;S!SNZ5J)5Z$$])OXM@6/<*."Q,:Y*FV32,#9,-BDU5[WO<&5QH
MB4;#GIVX?MM4PA9>-V:8>U<<5\RP?)A_>[1#ER#GZ;E*NK"!C_'M/S*NX92U
M/J%6CX,D.\:/D',JDS!1F<2;J ,K8W11ECZU)K^W[U32*ZN*EWG#A?B3R"Y%
M8-QMG0^0L:Y<D8XCS$N3HM=>$Q]EB,AK1'V>R<<+%).C.JM;4IEQ"MI!S77Z
M)%W38GFM3B8A@U#"YS=5.?X*XDG/)3UQEXQS6  Y%WV]3%4N5KSI8$K/-T[$
M- 3Q[08^(JU<5@(*!K=1&3>B]L\Q$)%))2*RQ%9%T).A2%+J0DG-45:V-. /
M''/^*LI+<.[FVI=0S!:86C9BH.=Z4\OV0.-$/29&4D)S%6(:]8G3*?PI:4[1
M)N)!)-XLZ:-W"H.FI1#RS:HBV#(&.2B(:*B4%5UD(N,81J"SM4R[M9%@U2:)
M*NESCW+N%2(@8YA !,81$?'1%Z^B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+@
M90A=MQ\?#[/7;1%4!ZF',&#K>,+#A'"EZQ;9\M65_+UK)->7F0N$WC*A1]/L
M-LLTY.8]IMGA;LHY=(0B<8@*:S<S1R^354$"AJ&9Q:VK30HD%]+;CZ?.2M1Y
M6T>-@<%Y3Q'>JE0[5E+&.>LK9OQCR,Q(>KMK-<\;F@<AR\@6*)%2-@1:F.JY
MD BY-NN#=3Y@@,LGA8",Z#[DXJUYXTX4<HL\YHPWEG#%=F,Y5>N1M7L%>R]4
M6?Q&_8D8/%)FO7C'#MVHNUL%*;S,FX*F_CU$WC%X!TU01'M[C<6BN=$7S,;G
M-?##$F"J/PFP"WSK7&^2&E&G:!;LD6-A-5VCR[.8E$I>)OL^-@,R0B9-$C<G
MQ(#M445$TNX@  A2.LAH\UQ57@,'AP4TX!Y0QN9HFX(6_%>5\!7/':+=7(E/
MS/62P+6&(Y165+(0]U:+OJ3<ZZ"350XOF#U0B90W5*EN :O( -!DK6DEH)SH
MJ-/5-YL,<EV2N5;$MQX[W[!6/9.E2LW8I;)-TAJW;[_9!N!W=</F/#%WAW6+
MW-5@:N?R0<)NE9!_(-TRI"4>N/&YQ>034554S_%&JXAX+4B-Y(*W."XP47DE
M@\,A27#K)6;E[.A)\AG@'LY+53[GD:39O@F9V!61CI!)!NB19=4BJP>87<9T
M58.(XL.>?+R4P_RCQ+0\B/\ ,ZJ%YGY+&F:,\X9ON!92#QU7\D0]EE,4GM\W
M6IZ(J[^=91,98&H11W\H@J9,!*&PT:"PZI,6HG!YS<G++C+BI3.*=3Y"86Y#
MWVJ4^T)\DLF3DQ)2ZQ&>/G42E!P5JC\:WB#MU'D[.^DF[9[/+.P(R18.%U %
M41)JXD$U&15(\7$''%9/P'Q7BZF0=&]09Q8JCQ!CW=DN>.<\NW/(NZY7PSR:
MHU93?56B6"%G\IRS9.-;DM20O89TL"[[W-,4BJ'35W"NME*$"JJYCM9H32J2
M?.N=7O+/F7!061<;8@SABO,4XXQ-1L7QF9<L8EO$OBY[E27QJPL%<M%'MLKC
MK,K-S'Q;RQRJ8Q:*#*-41+YW>8!",L>XU:3I*N#V@:2!4*Z.R80Q;Q!X8VO$
MO(-7(F>>,]>R?%N*E'1B%CM%MPAAM&Q1$E3 DY\)56ZS,'AB6CBNU95!59XT
M9 40(*:0AJH! H<U:<2NZ3A;4L@\OH#GG2,HIWC#TE2(7)T7AR",U?U:_P">
MZM3W5-QUF5I:$%U$G:C?'CY1DFD<IQ%Z8BXCW$$   &HS1+K5O4>SG@5&GY-
MYQM:U'8HS[0<F63&%5K>.9ZBY%QQES'$L4I>.\NULDNY-?;!=H!<GPA\1-H9
MX^1.!""B<@A6O%7/.EF&!HK$>1_,/'.!<,R%MFIRF5W,\OB]]<L:84OMRK5=
MNUKLA(47<95DHIU)HNY!TE+*$:KE;>8)E ,FF(G$H#9*XM%0:%(27T!XK6XX
MO8F6YJYTRQB_)E;IZ65J8]R9E>H<G,29GSQ1;/Q^R]6'45%PMFLN K'<9^(K
MXRMDG%_AI4735.3BV:IUF_EFU);LTL$K\0[%6W#];W1LP<$W'J4<Q9*Q4:B8
M4Q=E;CMEZMTV H<GGO)<W;["SJTUD ;O 4)"#EK?AR\0LMAAH#E=Y-OGZZBY
M"I$*DDF<0,&K7"2:<@?TJX!(RV"'E(<U,?""C8<XW5_'7."0NM;X>U'D+2+&
M&6L*7;D!-9!IN8+^B[00QYD*L6_*4NT.VF @HM54%$40=NF;Q,'0B!.[5\C1
M&V@S"BC$DCZ@^!5TL+4ZYV\RFV/N2V&<7Y-KW(U>I,WE'K&:LTX>R/CS'CYO
M<IB)L/T9A[=,T3+-?I5?I[1PZG4&C !E'Z2;=41* C=;-#XW.=B0I)P8RUHS
MXI]N4V>)OC-Q+CN&]%Y!XWSQEB/^LVNY"L5EF7MVMN-\+5.O6J[0<)<:S6;E
M%9#E)\8..8UDLL=X@NDJ;WI<Q3=H#CL;+(_37PU5[Z!QHL*],KC,EF(:+S"H
M4?#X%RKC?)C/'%TR!C;/>5,]8OY-X:AH)-Q::E'M,BRSDT9#(SDHFFT564?&
MCWC5;R%=M]YY&")M!G11M)+B#S5BYX?CWF3*')?%F/(J.PWRU:VR*R$I,Y/Q
M^RN O)R)KJ-0K/(;'E*LKY6H7.(5KJJL8=\T[#D4**;LI#E 1B826@G-2.%"
MHPO5?Y-\(\38!XQ\*JU&7UZRK.8;U8L@Y&ITQ/15KM-;6&^N,;MHNF/82(H4
M[F">G'I(QVL<L;%)I DDDH( &K'.(- J*>.(/-"YYML&;,?YWQ94<+WS"<12
M++;2U3+$/E>@(0EYBG\@FTE;BUCX5K 6VM*12Z<M&NB;MP JI5#IF VI&DD
ME1M_J$#FJC_5%YK-LEVZ K^*+7QUO_'W&DO2G\Q/3.3KW7X2Y7^RM+I(/(AM
MF7"UVBG&.7-5AZD5!%!PB^5D)&01*5$2[;U4KO,FLXTUO$G *BCGXMP@N.%(
MY#8-1R4'##(>;UK0=_R+=)N[4[G*;<<BRS1\61LD6Y;1KY%N@DDHZ.514H*!
MUJ22*')8[M;) XG],E5=X6J"G.CE=8,2<C,;4.VVK(L@[R@]M.,,U9ZQ+?\
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M42K(-M^P"FVU69PDD<6^2N"HVM!7-/:! [2 (!\T V^0!VVZ:B  %!DJKEL
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MZ%?HF7LD^-O/:3OWQ9DCE$ (D)3%"9CV,CT@8K+EHV0AGEH/M 6T;3Z=5Z%
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M]TK::ZU,=0#ZU _NE6A*U,+%>EBDI!6/552)LF4"  7:W4IP"$UP*M5( @4
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9(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tv488528_img7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img7.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ V@$L P$1  (1 0,1 ?_$ -D  0 !! ,! 0$
M       ) 0<("@(#!@4$"P$!  $% 0$!              $" P0&!P4("1
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MWM$I>[8 U\Z+9%(CCWCA@+$[!*+QMAC&%(8(E*5)"MTF C.PI0V*4%$&0+;
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M,0"*')7E3VB;[B&_00ZB(^OT[[[ZJK1NGHB>T0>WH/V?3<QAV_='4(H(/-*
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M-WN-N*]3D .HWI&.&"XBV6L2;-4J<C+&3]Y98#=H@&B*803E#?[([#U$P 4
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ME$&AK1++.(U)&0[_ &59#VP$3H@'>0/77/.UF^64]C<V3/N;,#EXX9K[G_\
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MMJ0B\@Z[?X^2EWG:+F5DW9Q$ZJZQCJ',(B(ZY)N^^;SR&]-YN\I>*>AI_@^
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M=Q4ZU,2N9,@HB"2%$Q%&N+C, L?N*1-VLP \>Q$IPV,958NVM^N^5V%NQL<
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MW0?7ZMM72"!4Y*@/:X5"^4X=M6:)W3UPDV0;)F4675."221" )CG,<X@4 *
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M6KJ,%  #E@K\$3 H;=H!N._H&O3!)&(HM+ IXFOB:KD)2B&PE 0^K4J578
M V#8/0-N@:(L%>;_ !QS/R1I5>J>'\[RN!WS&<6>STK',@?A/P[ABNT/$.2%
M43$B'N*@H.P[B)0#6N\AV*;>K0P0W#H'X_;7JNS]DNXG%.V_()-XY7M#-XB8
M 86N(&EXQZUR/X+!WA)XM<_<1<D5Z<#EF]L.,V$O+R\WC./@181<^_E"']QT
MY4<.EQ*L+D_N&$H?:-K4^)\+WSCET6OOO<L01A3[AX4Z57?/U ?JOXAWNV:6
M%_%HK7?A:Q0PW <TEH:?4:YX#$#K13AIE$%  3=PAWB [_XHB&P;;]=@Z:Z<
MOAQ?JT1-$728Q2"(GZ ;;MZ=W7KOZ=?40T&+M(S*?C0GZ9J"WS:Y]P^7B_>\
M+JW^!2R>L^JC\M)4=(EFU&0R3=V5<&6X*^W["8G_   &N9=R=RL?[0; R-%U
M[K30X8 YUR7WA^A+M_R[<>Z%MRNVV^X=L+K.4":GIKX4S!KT(4@_"'/.(\NX
M3HL3C>^0-PDJ72JK&6II#.TW2T(]&+2(1L^3(('04,9$P!N'42CK:N+W]I>[
M7#%:O#W,C%:9##*N2^?/U \+Y/Q+N7NUQO\ 93VT%WN4SHBX?>TO)!'@"%F9
M[Q-M]Q^KM-OZ[>FVMC7$Z8TJ/KA]58WDIGJD\7<'Y/S_ )$.^"FXKJ,M;IIO
M&)^])/THUHHLG&QR(B!#OY%8I44>X0*!S@(B !JA[PS-0HB^)GG$A^0F7,8X
MCR3Q=RK@&2S!>[3CRH2EHE8&69,;-!5X+;%0UB2C%#K-9&Q5LY7"?9W$3WV,
M(:O-C+@2.BH<\-(!S)4])>A0#80VZ;#JA5KEHB:(H'?-+_M:\0__ !)<5B/U
M?(NMP_?T13Q:(FB)HB:(FB)HB:(FB+B8?0 'KOZ;]?WM$4)?+GG5F3,V79#@
M'XV3QL]GY0A&V=N1KQ#[VQ;Q+J[LH%=2,DX2 [6QY+=) 9-A%HF.9!4Q3J@
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M?F'.^4\YO_SW)KA]VZI#03I;&W2[!K1AADHE,+D+_;9<BQ =Q-@ZN_'T[7)
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M=A,'NLUCBF;KMN77<H=1@8YXTO<*D>%>B_)'<(+:VW&X@LGF2T;._0ZOW"M
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M^FTD-'B\]!YJ,J8Y<<C^5[]S4^%>.U:S1E5%&LKR-RA'NXJND;>Y[:Z]%@C
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M$1W$=;996]M9QZ+5C6@8'KC\35?/6^\BW[DEZ^_W^X?/</QHYVIK?(-^UOR
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MYDYT13Q:(N!AV$  =A-OU^C8-_35IY]5%(5@>1')#$G%[&DYE7,]PCZE5H1
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M &1TGX__ &-HBK^H'PA_9+X\C]>)J4/_ )'T14_4#X0?#B5QY#\ 8EI0!^,
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M+5P9=%/T7(/\ _P#J@YJ%0?0=!FB^7,_T;(?T=_U)S_3']$_YL?Z1_\ $_\
MPG_1U2[^HWXHNV*_HUA_1_\ U)O_ $3_ $9^07^C_P#Q3_(_!JEW]0?X\47T
MD_4_UA_!JM%R+^4;ZQ^OUT1>8@?^MSG] ?TI_P#0O_7?R$__ -0?_67_ +G1
9%ZK1$T1-$31$T1-$31$T1-$31$T1-$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tv488528_img8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img8.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!2 )L P$1  (1 0,1 ?_$ /   0 ! P4! 0
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M>MZUU"SV!?2,I,<^=RF3V%QJ9E5)<)S8RLJ];!)@L*F]Q1J3WJX4:B>W4Q^
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M# 8# L1[H?S<?.7]E>[_ -'[Y@5BX>_^DCBU^SG2/Z,XQ@7&8# 8# 8# 8#
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MS K%P]_])'%K]G.D?T9QC N,P& P& P& P& P& P& P& P& P& P& P& P&
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MTXUQ@2V-/^*FS_)Z+^]B\#L,!@,!@,!@:;]GV=?=U@?%0[O?SI7< _:JMO\
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MD^D666,K01A"$(M:T16Z9M),EOZ)7\\K7'^HV]_R72937UEE.I]6[(,F P&
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M6\"XC 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8'BI_%DDXATPA:PP!2>91&0Q,\TU&2O)*32)I6M"DXY"HUM.N**+5]1%&_O8
M]?>B\-X&/#$^T3R7IV9<3$IW>@E")[XVQA[KOC5$))QJXR)E[;"'AO8V22QN
M,H'4L3E(%"R+,:9L&MV!6M2HPZ" 8=^T,DI(682F(*.-V><646 X_80A$<:
M 0C-$$'W@!&"UYMZUTUKKTUX8'Z<!@,!@0WT_P#/G\T_V">)7Z3;AP)D,!@,
M!@,"(/OP?-:\DO[JIW].-<8$MC3_ (J;/\GHO[V+P.PP& P& P&!IOV?9U]W
M6!\5#N]_.E=P#]JJV_RB/RVWRH5(YLL1,!@,!@,!@9+?T2OYY6N/]1M[_DND
MRFOK+*=3ZMV09,!@,!@,!@;#"P'%C*-"$98P[", PZ$$0=^W0@BUL(M?4WK>
ML#0LH!0?(#7E#KV:UK6M:UK6@ZUK6M:UH.M:UK6O@P.3 8# 8# 8# 8# 8#
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MX'88# 8# 8# TW[/LZ^[K ^*AW>_G2NX!^U5;?Y1'Y;;Y4*D<V6(F P& P&
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MAWK>!D(X# 8# 8$0??@^:UY)?W53OZ<:XP);&G_%39_D]%_>Q>!V& P& P&
MP--^S[.ONZP/BH=WOYTKN ?M56W^41^6V^5"I'-EB)@,!@,!@,#);^B5_/*U
MQ_J-O?\ )=)E-?664ZGU;L@R8# A1[]G*_D+PZX+I+5XQSQ-6]GNW("F*Y+E
M:J+L4P BCTT>5J%["4R21,I:CSQE%!V$0PZ$'>O#>NO7.3X?W=.^N)<EN6)P
MC,7(IF>S/2U-XYJ,CE)S,QC$1[+%+,[NW>#T+8 \\DXO+L6NOZL]*;Z["(0-
M[\6T736]ASUK>_*]D+F8JHS>>KR]NFF-G8HHN[4SUL=J8V<-&K7CI?FL^<FW
MX6JWX*>YY8Q<?^]V[PO\_%/_ $9J4_@S(_TK[A_[OF/^FM?&9_\ (]OYJKU9
M:?[W;O"_S\4_]&:D_P"#,?TK;B_[OF/^FM?&8_\ )%KYN?5E6SC;W/.[%9_(
M2D:YE_.Q2=%)W:$.B<D(:>.E)MCF<S/3RE0N &]R&R+ MZP:<T7D.](W1>_O
MO*+ITS@N(ORV[AW3PQFM\4[SS,W[&UA'T>U'5Y>MJF=&+=W9Q]:S=55%5$TS
MCSS,Z^2)>+L[NN=W",V;9488^=7NS+&+#G,;9R5?'&EERHMK8)2[-#<6I5C9
MB!*5 $:,&AF; #9@^HO*'KTS?W5^6+<6\-T97/3O7,TW+UFFJ8G+6M&.GEJY
MM,<\:6M>\XUJB[5;FW.-,X:YAXC_ 'NW>%_GXI_Z,U)_P9F_'Y5=QS.$;VS,
MS_#6OC*X\X]J=$6JIGLR?[W;O"_S\4_]&:D_X,S']*VXHU[VS/\ TUKXS/\
MY'M_-5>K+>7W=^\)L6O-SR)Z;^'7&:D]ZUUWH/7>ODSQUKKU^/(1^5[A^UGL
MQ8KWO?FW:M;43A5AJQ[&*5GSC6KF:ILS:PB9UZ<.WHEE\]D+DS=G+OMT4_>7
M(:7IIU:TAD%G-$AE"1@:(P4YE12P9!&VLWY%8R$[8C,TW-A?FT6'6M[\=^.>
M2=Y;LR^Y]Y9C=V5OUYBQ:O51%=6.,X3JTZ<(U/TVQF*<U:IO4QA$PEJS26F
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!X*RGZ,Q&#S":
M3)$!PB\*BK_,7Q.- G=!;:XLU+'U>-.WJ # >J+2(1[*UX=1]-=?' A!X&]Y
M6(<Q>1L!IQIX,6#Q^:['C<Q?H5;,[EM-"2/J2/0&'V2A;&M@ASHXR(QRDD'G
MK6X%E> "TQP_,+8B30@"?D/3RZWKV=-=/#>O@Z>&M^S6!NP& P&!#?3_ ,^?
MS3_8)XE?I-N' F0P& P& P(@^_!\UKR2_NJG?TXUQ@2V-/\ BIL_R>B_O8O
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M3*5'N)NM&AP,Q$&N@?K[WO[?_MW[=_5P/SK@GB2G>Z^A[SZ8_=]*=FA3B/V
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MJ;%?\PW==S?TJ8G"JY%W;V)JF(QIC&8FW-4S,TQW,MGZ77L15%=$4<D3&/\
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M6#&)*Q.R)XC#TD0-!!0-(S2R-E!$ 98@C&$04V<^V[Q8=XHS18^)31,)L.L
MQXEK;:MA-EB6"GM=4C6VJT6?/D4A)E%A,ECJ6Y,)T3.:@XH[2<L(0EA '6@O
M@CS$TQEC9X\Q-:)E9&%L1,K*T-Y!:5"U-#8F*1-K:B3%:T6G2(D2<LHL ? (
M0:U\&!$34&][[YW-+6]]?+P(XE:#U\?+K\YUQ"WH/Q:V+>]]-?#@3'X# 8#
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M>0^I6?%T]$)W\X-MF P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M?PS=/HV?S2-$_P">]Z_IBF.?+GB7R@SG\17\*7I/(?4K/BZ>B$[^<&VS 8#
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M.SQ1QAF+O@[.<O3Z<F8\U'F.RMCZ7F^%^',OEL,<;N0RU/\ [;SFJ\X>[_\
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MW)<-;CL9BG(WJZ:J,EE\8FBU55&$>#PC&:=>MFS]E\D(>U?P,.#O8="XTUX
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M<=&C4Z*21F/S!G61V4L[=(&!Q"6!>S.R8"IO6A)-"<3I02,(M"T4:#0]=/\
MG:UE^4S69R5_PEN-'/H:/$>XMW\6;NG=?$>.8L3&$S1W./I:'0)> 5/KZY<;
M:)XZU5J&()*SQ4+@..,8U3H_/ UH4Y#:W!"8M." :,6CA"T (!C#H(A;WTUV
M[+9[C;.6IOY3>$18B<(C"<8CFTQIPU>R_ LWPI^7G=?%-/ M_<>2KXGG)7,S
MA5DK55/@;5,S5<KOS;V-J8B9PFJ:IG''3,8^EDO;<J>+Z+)%1%'OZ\N4(H.\
MLD;0,KHZ1:9N*'3F@BTB+/3IDZ)R5)]#T T)QR?9A!A>S C +6K*]X<>Y6W%
M_+[QMUW9JV)C">YGEB<:8PGL8N#X5W3^6_B6YF?YCP]DJ-W_ ,LN9VBNO*4T
M4WLI8KKHJO68MTXW(IN454[.SX6<(F*=F8F?-3/@13<#LAPJI\X\U69-FYT;
M6,UM:HVS.03W9X*1G(D25:64$@\TT3@47X;V6$0M]!;UKKFK?WMQA9S-&3G>
M5/A[L8X;,X>KLX.P\-<&^8#B+@RYYRZ.']WT[BJR?A[===B:)^BTUW+<5U6Y
MC;IF*K=<11,;<X8[.F'/-^!]"0!*UNBRIJ$=RECBY-.Q1A"TN![0_,>TXEC<
MYIC4B1:0(C9P=E*2@FI%&P[],T?CEF]<[QGN>B*L_O.W%N?<Q-4=C13T8QZ+
M1X%X3\R/%N\;]&Z^&<I1&6IHN35>L1:HV:]-%5-RKN-J<,9MS,7:-&W13C#V
M(0!+"$L =   ("P #K00A 6'0  "'7AH( ZZ:U\&LZF].1$1&$:H=-)__"\F
M_P VI%_W&Y9LY+[1R_C(Z7&;_P#)/?'W;F?U%QF)]F#YJC@1^S77O_=XL]DY
M;ZM1WL/Y>L_]=K]+HA)SES5,#3?L^SK[NL#XJ'=[^=*[@'[55M_E$?EMOE0J
M1S98B8# 8# 8# R6_HE?SRM<?ZC;W_)=)E-?664ZGU;L@R8# QS?I0/S;<9_
M:]XU?E0XYVSS=^7FZ?O"WTPXK?GV-?[R6&X/\,7[L?W=9]/?;7?'5=%+SE3U
M9[Z6W,,F P& P&!R$_AA_= _M@93<_;/$S\&4[WR/?PS=/HV?S2-$_Y[WK^F
M*8Y\N>)?*#.?Q%?PI>D\A]2L^+IZ(3OYP;;,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@<)QP2= V,98/.8 H'JC"#U##-^4L
MH&Q;UK9A@O#6O'>_@UO Y "V(.M[UT\=_4]F]ZUOIOQ\?JX$.-/_ #Y_-/\
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M$8Y/5-VP$F(OLICM@VDN?H^U2 UZ VKGAF2.2<U0G),&846> 0]:ZZP)5_\
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MM70?Q]O76O\ X'X[UT\<#?\ JW\>OXA:5_DMA'\!8#]6_CU_$+2O\EL(_@+
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M'Z_9_P#@7MQLT\T&,GZMG'?^(*D_Y+(/_ 6-FGF@QD_5LX[_ ,05)_R60?\
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MVD *2M*R+)S-EHMEAZ$AWX:P*8ZX)\/M($;7^KI5&FYNW;ON*(,52!3I-7X
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MV_X:^ND=D<"*A@VYZ9HS'I@XHMOM@1:-G[(CDJ6M["XZ-3NXRQZ/.+T6 6S
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M=":- 'UMEJ0!\1!V(&A!3MI[XO!J6G2M!#WVSCW!JJ?D%<D(>I-4\TB%>6W
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M$D7(F"1.%3.4-D^J>"-[-8\F7Q*#EF6A8#'!QO$FD3>4H5-#4Q!>=*33_+L
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MKX)'I<1'M)0*M' $6I/ '6A;WTP+M.TYW7+:[ADM94TH>N!)+.Y4Z59#K J
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MY?@CVPY7PNYY<U.0;9/H\\\=[_BE=L%%5<3IR*D]*(F67S:P9?"! -;BF?\
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6@,!@,!@,!@,!@,!@,!@,!@,!@,#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tv488528_img9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img9.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ K '_ P$1  (1 0,1 ?_$ -P  0 !! ,! 0
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M5"M&6E=0;2'#[H@$JM;)'L)FN[@&0VNWMP!@# & , 8 P!@# & , 8 P!@#
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MW-SZ.(W^UZ?_  IRS9M4.M:O-G*^UCZ;I\Z:P<Z4>:1@# &":'#6ZC/W@O\
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M@$M43],5;_M2W_QA9AL;ZEO'KK>1O'9Y]67?<-VNOW]_?SDYZR.< 8 P!@#
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M#A0YW[66][Z+7YI[S-!AO\Z;_P 0S^/O.WT?P8>JMX\47_IU;G9;[.F52T&
M, DRF/I:KG]KV;\K!F'QSJZ>X;;J/]77/OF\/7^O[^<CAP>^]\]>C>]:UUWZ
M,G!TV:'6N]OKK6^G3?3T]==>S7IW@#1@1=.G>[>G3?=%TWUUU[-].F\ ^F ,
M 8 P!@'07[V4W^)_8]\@]CUD:C.7/TTNOZ$C_P"0!SIFJ'5*]9GF;M9^IO\
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M]?JJESDO^I?N9HL"BO\ _<CQ^BW+\B49)0X4.=^UEO>^BU^:>\S08;_.F_\
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MH!Y_PY5D]+I-'G$66(] O',2^ZS0AKT:^UG;8\%;AXIO/2:GKRWV<Y$H# &
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M!;MQ<O.%V6_OW&.*C@M7V97-@634,KD:VR^:#U8$O996@LGD&W2AO:VN-O#
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M:,FVM/1S_P N7P[1J0Y<"UNZ7;IV]&5@UO[&_4 ;SJ6J$=+!8.24'I/9S_\
MP\T=K%:ZO69J4I*2I[6X8S=?L9M/)Q]->(YARES_ #)<4=?L8Y./IKQ#E+G^
M9+BCK]C')Q]->(<I<_S)<4Y[-ZWUR7DYNK&G32J*5MN6RRQ9/&4J]>Z1HM*I
M*UM;'=-H[+K6^/\ 3&A>C1C=O>M_@[UU0/FNOHUTZ9QK$8S5^K.HDI:;7C/6
M%"FZFJMPY*7FZ,<K7<9X.]K^%]W+$I4Z=/-;YP[WV?NZP5>3CMKQ#O?9^[K
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MOB.6.)(P'%$@%U Q)Y!7IR).0\BQQV^-PR/M/&;S0=-U?LQTD1M[[852>83
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M9L7')QJT)#L0G !2 H80G@ '0]"T'70"R!T=3!CW#9,94M9F22N&\+374A'
MXJ)[@#47H>BVR%.FVGUV+-Y7B"[A*$9!8>]OIK77?4"M@K2OBBF\@N$Q$LAI
M!(RVHDN,L993:"8F&&R\" L" ):,$L-.&)ST7H.G#8Q>/XG7> 18/BG1J8BM
M6B,P&-0&'5A9@+A9X!7L<CL+A3K8J)L7H6*22%BC[2A3N2N.K%_M%)_L=UQ3
M)CQ]_:<O00,BM:Z:UKKUZ:UKKV=O37I[.FL YP!@# & , 8 P"+'ZH8H_6M
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MBJ5%(X=,15'60I;7;:!FK^3C@,3%(8,SE ,+*:8>\^R/:$:;"BS1A 0B,)*
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MVYRD,@D+8TH?5&I806<L"6#1"8?3H# *>_0GCL:@'(WVN*R>53#')K*RD:F
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M2]SIKN], S:P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MW #0-=W6][UUWOMWU]/N:^Q@'? & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MH:O:90VLG*;><4BD5GQX]VY#1V-M0$+4;(P,233H9,2T[ O;B%QIXS%0$^\
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B $W>]8_DO6< V-%]>[V^GJ+K]OKOK^[UP#O@# & , __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tv488528_img10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img10.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ S '* P$1  (1 0,1 ?_$ *<    & P$! 0
M      0%!@<("0(#"@$ "P$! 0$! 0                $# @00  $# @0#
M!@(&!@4(!P0+  $" P01!0 A$@8Q$P=!46$B% AQ,H&1H2,5"4)28C,D%O"Q
MP=$*X?&"HD-3)3=R8S0U%QA(TE1'IY*RPJ-$9%5E)C8X$0$!  ,  @(#
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M)CJ(T)4."5!'TX OW1O)6S-S;<FA;,C;FY)O(]0X0XB&H!!YBU*X)=U4'B,
M\)W*ZF7$F!04Q<&%K:0VY41V4%  4D9'G:J@GA3 +:WRO72DLN++;)84\AU2
MO(LI3JY>>55$4I@!ZI:DCE-A0'^J#]& U(E+D!N$I"0OUJ**K3R%*B3EPK3
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MA.9=ARWGHP4"II:E%7DR 23D,CG@)Q=-?<-)Y,9N;)Y1)2@MK<3JJ<J\> .
MG3L[K'&<;CI?DMI#B4D.%22,Z<:9\<!(RT;VCS4(6V^D:@*)*@34CCD3W8!<
M0[PM:D*YNI)IV^.> 5C,Q#J4D<>)X=M*&GA3 "G5*54 K%4J\PI4>4]OQ& M
MX_*+?YG43JLT[53@V196R=50J/\ C#AY9'ZW-J:^. KC]UBY$[W:^X!+*UQ)
ML3>TP@+6%QW4B)#H T/-4CC@&J-XG.1X[,F%%4ZPX2M]I!;"AJRI4U!& 6,'
M=%SM;#TYI38:0RD%@I4I:J$G2E1J!3 +'8F_US99DW"+)5&+@#C:0 =)-"2:
M4H"< ^[=R9_%&V(O.0RXT'2]I44("AJ"2D9U37C@%?9;ZW+8E.-2><Y%DIBF
M. 4NKJ0DN"M0$CN.> .K@\&FIDAA>I]AM&M!!JE(!.L]W'[, AYF[8\-N+=1
M5;3*M$U2%@>6E-(&="%TP /?^Z;S*VBBY;:;$VXP!^*LPZI+RF6!S*5[RD&F
M /;)U7C77;]NO=CN+,B4FV0[K<(06D)<;0XEN8TE)/[^*I1*D?-@),B]1MU6
M%<8S&U"YQ4R+<II"LTJ0%AUNAJE XZ>. 05FW?;]RQYG2K<:T-W=EIU>WWYK
M@;,OD@\A^(I92I-'DD$<33  ]C]>1 D1K=N![F/[=OS.UK^V#H<*GU+1$F,M
MN54(C*6B%JIF2,\!-&W[JCOW"7MI=SCI?7HN5IDA80V]#;0));;J=2U*;%*
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MH%?,X"=-.[ 1*MGN=V1!W[MFXP-[V9,)[8$J]2XWK4E2[PI]8#&DI'W^@\,
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M$Q"V%,(9<:?8A*\W,?64I"JK [< R35UN;DI3"''I$,+U>H.I0J34U)K4 X
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M$JQS*--O, :5AA)R+Q<\*TK@(2[LZ\-;%W#+D6JV.25LE;4Z$%DI2X#F4(X
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MW!FKE]@K@#BQ0-QV$GTH6R4D*.AY;9)2:@$ BORX"3_3K=!OL!ZVWESES7'
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M>RP]UIZPQT*<*&>G5D=JLU47?QAVHKEY1@(+^\>6%>\7W"Q5OI#+O4&05)U
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M+7U(E)64I0$!0AP5K ^\'E\V 9.1?8+<EM<'U:DQT\T.O%"-2E@**,ED^4X
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MM?54K2"<CIP"\=WO9[Q8[C&=:<<<5!F:EE*"Q4QW""3JKQ\, =_=_L_\G_\
M[O\ ]G <PON_V/U/F>['W&;EV,Y9-QV)KJ,VG<5LAO7=S\,K9+6$PKK:+2X/
M7PY !JTE"I*\ZU%,!!;J+THLEP:;D[W3;^FZY#KJG(.REVNXI92D_/<-A;A]
M2WM)MT9IYD9E1[<!!_J5MCIWM:8N1;-RONP&F9&J\W:U;+AW1_[H_=0G++$9
MN*VEG( '2*X"+5KV[;-R7Z)/MMFAHAQ5K>!:AL,S)JDKKS[A=7$)ERFUC/E*
M6?A@)7;)Z>73>]\CPVFGIMJ2TEHQ5)4$Q54%>4!0&E,B,!>%[6?;+'L,:"M-
MNU!Q,8^=@DDE""<R#4@G 7*;"Z1QH#$-28B4H(2%)+023DFM!3A@$W[L+8-F
M]&]W/6R,8LY^U2&TOJ1RDL@LJ6'UK- VE"TBARSP'.3[#?R]ND>]-K^XOW(^
MZ*!;[EU,<%^W%T8@W28RN) L=E?E.-W7T;[G\1<I5Q8<*FPDJ4QI-*$8!,=
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MNWP/' ,U[AMY-O\ IK7Z@166F$E^.2!S5Z/,L#+,D8"H+W3[WNO2/H_OK?\
M;)H2F1"F0TD/:%!)9*BGQIKP'%A>[[(W7N?<&Z)RW5R[S=),DE3A6DI4XXHD
M=^9P'I8UH"CV9@_;W8 5%:X#Q_I3 +"W,%3)3\/HS/:/C@'%V_;U!3:VFB\Z
MLAH(4?N@E0J5*2!0T. DCM;IMN;<;*&+1;)]T=;27 W;X+SR6U 5S4T"<JX
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M E_RH_[/_P#GG1P'R]W#CXX"HGW=2UQNLO546^<X)+EY4KF(!UA1@0DG,95
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M$>$&TH6E@@!U6H(0#3(*(P#?=;;(^O<KJ&8RV)ZEJ"FVV5!*6S7DKR_24JF
MZ<_\/]M3=FSF^J%MW3.F2%S=JV2Y6N/+*UIC,/3N866-?R))))& I(_,0M3,
M#WW^Y2]2;C"CMGJ5/K'D*2XLDP8/!':<!![<F[VV+8ZFVD.%;6;JM+48^4^5
M"".S[<!%3<6^;I)4FVV:*P]>I#RFUK<1S6DH/[L!0'E"E\< L+'8-UL,0)6[
M)Z;I-4MM<;;0D!=I@5(TR3%% %IX_$8":UIM5LO=E8N5YA*FW&WQ(EILI<;"
MVGYPT)4$  )% "*@9# 6P]&]MP=H].95]<A^6V6A$MXI1Y$RE1@MQ .>;;E0
M,!4MU'W0Y.G[NW(H.)7(OC[C"UGSH0MRE$JXA)I]0P$EO;#?/6<M?,+":M*"
MD&BE+U)J%=]0<!<ALN[/1X4=:1SE%M%"LUKD,C\<!)K:E\>=*4NCD@- T3D
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MI 0%+JV:U-=7]HP#V626W*MK'+*20D TXBE.S &RD% !)2:@'(U.?AQK@,<
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M4/-!+FDBIX>& 8ZSW=JRN.6=W>VS;]=([A4J%:;FUZE]H*.DQ*K7K)2/E'#
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MM5OV["81;(/,6R@)<D3%CFC*A))!(. 6[U[#94E<MH%Q5>4A=2E&6HY=QXX
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M-9R(%4]I[< Q]\W@Y8933Q47U/J'-!54)!(KF30\< $O&]K?<;>\E9:2-(H
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M@JKXX"B[\WCV\[BVAU=G=2+?%=D;6ZHR1=I4YL*TP-SMM)8DPM0^5LQD(.=
M<!1["VMKN*'X<E,E$-QQE*!0_<(.E'9G08 NNVTTNRIZFV^4"@.N%2BD)()-
M13,:L D&H*G.6\+:PXW'<Y2I  *E@9$$UJ<\ 3W7;T=J%)5/C(=?D%2HR%)!
M"0:E.G+*@P"$MD,6B^L7%32$QF4HU)   *  13AV8"1VQK[=M[W86JRP@+8W
MI&X'0HI5(A"@:9;-10HSX=AP$ZMG]/XZH;33=Q*$-)!B,1UD%F-DDM/ $:EA
M1S[< LMRQI%IM4:S6N68TCG)<*P-2UFH-:4JHGNP&>UF;O*?88E-7&Y.^4$-
MSU6^N=.Q2*9X"2VRMAR;8[_-VX[T_;6FG"W"C-2E/75*$JHTRD:E%Y*4@"M#
M7C@''W5U@W7%@,V6S/>IOMV>;MVV;?()$R2RHA,F8XG)06EM0^K +6?U8A=,
M[3:+%ZB0988;GSVHJBN7<%A)5<8;BJJ5RPZ0#W8#Z+?]W]2I-NWY<+Y(V]LM
M;;D>P['MZR)3O)!#TJ4 =82H))57LP VP;]F;WO,B$Y,W%#M]L6;1%B6$N*9
MFN_(E,]20LT430G+ 28M;NX-A2+%LR#)CL7>\1F)$B+(7S%PH#F:BHJ*B%I2
MJI[<!(6WW^P[%G6]F3<HNX9%[:<92O6%",[RB%M5KV.BN ]Z4[;;79MX;@B\
MMV^WR_&);UDE2F$%PU""2:!(X8!8[=V],;NN[;G<I 7.;A-6]BIS;=5Y)!':
M"45P#LIM+L?9,J"F1'=B*C-@H<5J>X"HU$DUP S;5KBVZVQV51=%M4TD+4<T
MJ?-3J-3F:X!6VBSH8DNO/3"0X0IE --* *I';3PP!E);<:#KT=PZD$!*B:C,
M@'^O %XN\QHA+CJ3WC*I^GCPP!1^)M7&;(M[CABE"26EH)!6KLKPK7 :HZ9R
MT&/*6HO(4OE(-2'1J)03WU'' #E+YL)^).2(ZF])T)- H=Y%?# #;6B/>V&X
M*$ZF6"-7 Y(HH'A3,C +OT$3]4?]E]+V?+W<.. ,%J 21D:_#^E< 7.-(<5J
MH!V4 !X8#68S-//GF*9<#7P[\ 4B%$7=9 T!*EQP-5!6B<TBM*D))R'9@"6X
MVRUE\/2$%89.HT%0".VG:< "?V_9I2A*#*BBE1YE4J>VG?@$K<]J;>=4I+T!
MMU=$N(+BCKU9G+M[, W]ZVIM"3);G/6EI3L0!LH4HE)*:'5I.14"./' 9S]O
M;-O4-E+MG:3R*40E6@+ R"?)2M< V=RZ6; +ZI#VV 45J0APA/>?*,C@,5;+
MZ=)CE@;1: TZ4J HN@% =5*YC (*1TBZ=*F.2'=K9K;(22LGB2:BO<3@ <?H
M]TUCI<#FU4T6HJKJS -<^'C@"&?T0Z7-21/&U0Z"0HI6X5#CP-00!@&[NG0K
MI%<)KLA>SF&E$DT2\I/_ -6F0P"75[<.C+TAQ9V>S52R2HOJJ2?APP&,WVV]
M'$A*?Y*;="DUJ7W#I'=\, D+A[7NB?*<6YL-E85Y2D/+U>:HK6E<L CH?M6Z
M'09*GD=.FW"LGYGEKH%'/CPP!O\ ^6[H.TXYKZ>M)R-1SU#LSR& 0ES]J'0*
M?+<DIZ:QW2XO4"93@[ .' 4I@!\#VN]!X/+ITSAH"2*ZGU$D^& $7?VM]!IT
MF,Y_X=Q FN83*<&9& +F/:IT BO2U+Z=1.SC)63GV5/;@!]N]KG0:',$IGIZ
MWI4?*%OK*0>RE<A]& <MCVW]%5:'OY%CI) HGGK- /* ">R@P"QC>WWHP8P9
M.R(:$E39TNN.J2K234>4BF9[<!*;HC:.E'3.YMNV[IWMV(]K0(]W0CG2HJZ%
M.MH/)6*T/92E:X"QJVS8UQAL3X3B7&76]>1!X@'37L(P#:=8^G73GJGL/<.T
MNIUNAW+:<Z*[^("<4),(E"AZF"\H:V7T#.J2,!SC;Z_+>Z%P]R2'>FG6F^6^
MS-OO"+ E;7%S7&U%6M@3!<8P>90HT15-0!@&5>_+>VOS[CKZXW)UZ1J*@O91
MHE!)II_XQ@ T#\MK9OH4<SK1.6&7P5MM[(*U+I7RA'XTG4<^\8#5>?RU=MO*
M=6CK7<X[ :JE*NG*24\*9'<%1@&HG_E?[)5;I3)Z\W;4XLJ4?_#K,:E5(K_,
M0-*X!]>DOY<6RMNQV6(_6^;(:+7,63L0,.J<534DZ;TLE-1E4X"3-@]CUGAD
MKB=5YI:!TZCLI68U#_\ >#_GP"JN7LIVU*N,-V3U5E\YA"5H"ME* 4I(\M3^
M+\#@%IM#V:[=M<AZ1_XFK4MPDIKLLDBN?;=Z@CLP"V;]H^W _(=:ZBSI$YM*
MGX[BK$I++;JO-I#*IRTH"2>&=!@$=%]GMN:OR;TSU/>D[G4%*1)=VJ9)ALDD
M!ADFYM);(()R%37 -7N'V7R[CN1ZXR^M5VYJ9*0_%_E L(#2EU<T.JNCN1H,
MJ"N F/MGVM[>M^UT0[7O^2[(5:GVUS7[)0Q2N.I"Y#:/64"FZZLJ5I@ W0/V
MM6G:T:ZO+ZAR[I<'KE(?8E&Q !:PJJ5 >L())P#\;0Z(6&'?;M?-Q;J<O-_G
M.NB&';0OF16%9)2:S24@=V ,;CT3B2=S[;F2=R(#$)V8TTR+-2K:V''"<IF9
M37CQP#Y;2V)%M$*W(MER#K'-=6LB 8P*@XKS%SU#@U?14]^ 4EOVE$2J]JDR
MB5R7-8*37MS5XX#4UM1/H9$9=TD!!>"VCI^8!0(&>5!V8!9L6I3\6/'=7K8:
M0E*%%-"L)X$@95P'TJU,*4P&9+L93:5 Z!76210G/]&E,  ?M%P<HU^)N<E1
M!4%I &FO>, ">VVRE]"F+@HOBA4%'R]M<N'9@-R;"6YBI\5])== !!2#W=AX
M<, ;0K-(CO+=7)"G5_-4!1%16@^@X ,[8DN2]<F6.4Z?O1Q-!P^'' *RS6^W
M0&W$V](TDC6NM23_ &5P!W@ "E%7'[,!AH3W?:?[\!BL!*20,^RN>8S[?A@"
M3U :E./K3K6I.@I3E5-. ID#@"Z:^64+)0E27:D-J2"OX!7'A@"5N6IM!; 4
MMHFJDI)JD9$BO<, 6SQ&DO(=CK4N0PD?=ZB?+7M2:C/ )FYVXR&')*6>4HJ\
MP(%"JG8FG;@ T:P>MA-J8*4/)5YM)I\I\,A@-\JQ%"$1B4E:@ K4NI^L\, '
M_E^$ZM#+B2%-T05 D"J<B0>VN "7K;,)MZ(E+@\Z0*E1 IJ.7VX JD[2T<UP
MN(6U0(2D<:DU!KQKE@$^NQM\MUI>E2$)40#QR!(';_EP#:R-LMR)3JT( %3D
M*@=V T(VHTTH$(!4<R3F*DY\<!E-VZ"E&EJODS(X#.OT8!(S-OO&J0BG#,YB
ME>VO:< ';V^M%24H^%!EX_5@$G>=MN.*5RDGS"AI]8^S $T?;4B.E.I(R_62
M%'C45)Q6DUE@8[:65LJ#H;"DT &D9\<A3M&&%X@(W9%*',0R'-'RT2/KIVX'
M&K6[93(4I/)0VI= LE S.7AEPP.=1LC;ZG$I0H )3PTBAK\1F<#C4.3:7VBG
M,%(["*F@SSPP<0IH3"U)Y:.  U:10D<!V>&&#C4K(,!82A.A)(.2BD%52:9*
M.>"7629_*6/1*XRW8MSMK[JE(CI^Y2K]&O;GF:8C,QON>WI+ER?Y7AO/(ML%
M(-QCLDH+Q('S+3G3PP$*HZ6R[1"5)- I&K,ALCR"IXT3VXK37669H)+#/.</
M**GE)T%=/*D'@2.';@O.HD:MSK*B \T6W%ZB- R^)H._'.WQ,PXU8S((4RZ\
MXL*44TS^6E,O+P[,9=[)S"9:L[<E_P!*IED,OA(42@5-:9@TJ,/Z;',+NP6"
M7MZ6RXTA#L992"@-A6A/&I/9EVXTTMLS7&TQ3ZVV1';4@("]"T EQ-2V%DCR
MZ?E&.D'-TCNOA,IILOJ0WDX*I"  #4H&1I@/+6)H4E:DD'Q309_#C@'#M4]N
MXZ+<]#6B2A?D>:!:"BG]:E-23W'+ &=RVI,9+%SB("9;3WWG+1I*V\JZDI'Q
MSP Z?LAC<#;,QA+T:6I*6WJ*407* E1012E1@!,&&_:UIM$V)(4O3RO5I:*6
M5-J&@A20 DZAE@-]ELS]KN"GF%K9BQW%NLMH24HJKCK'Z:3W8!?"*N=)BWF.
MP$K"0U,<2V!S>.I0I\JCWX!8M6>-<GHLF..4NVAP(2X=:EJ=;/,4=0\V2B!W
M8 SV^VPW&EQTN*2J+)"4LE1)HM:E+)2>/'Z, )BO%QR6R0$K!*D>4&J!\P'>
M:8 ^6I#D!EP)HENE!2BCI(!J1QP&^*XIYI*]8T$9(2*4%32I'>1@!K*DK60&
MPG20*E(J<_[L!N=3J.F@-2,C2F2:\#EV8 .J&%'46V]7>$I'P[.S !T-N,$D
MH3X@)!I4=@X# ;$E2!S$ 57QUIU=N?$4_NP'CC>IMQPI25&F92*9X#9!08Q0
M6]0#A\XK4&H).1X8 ^UCN/\ EP ;E^/V?Y<!J60@T-3_ $^. TN'4,B12I/C
ME\< E+QSF4KE,T46!S.4!FO2<Q7QK@ <R0F=$8F1ET=;2.>WH42% 5(( H>W
M  T28K;(<94EQ:C]Y'-$KJ3YZ%60&K >RHT!G1+C-.-2UH27$$<X%(KE5NH%
M:G  G[U;"PIJ9&D,@#Y^4K2I=>P4RRP!,R&$5DQ9=(JC5;8;<"T()\Q_5R&
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MI'$5' 5P!R64/D&-I<52HTD'RGCVC :_3/ T4 ._(_WX#6[!H*U%,S6G].&
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MR44H#PRX\,L -1:4I2 E*2!P^7OP&A^U"J?(G@?U?[\ '5:"L42D ^%*^/#
M9)LJ,@X,\O\ -\<\ (.WPW0Z?IRKV>'' &4>S#E)XY:NS]HX#=^##Q^H8#Q5
ME!!&?U# '5CA>F<-!P\*8!FMU6Z3)O$YQQLD"N9'B>_C@$F;276P@-94I_0\
M, 13=LK0DJ0S\_S&F9&7?QP )_:VN)^Y&L@Z<@37ZL FV]DZWZ., U)K5/\
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M<!X.744T5[*::_13 9X KD^F^^YM-66NG&O9@/E\K0G3JTZ!ITZ:::#O[:8
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':=V V8#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tv488528_img11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv488528_img11.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!%P#U P$1  (1 0,1 ?_$ ,X   $$ P$! 0
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M-2="U+1N*FN(2A?U;X$B2,)Y1<MZHEDG&0QGW]O?&X@\C,^/XXEDO1'J((%
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M2;-.,1S "H<>&79. +D%6:;9FZRD@%=M\TQ/[1#FH@& *HZ7OZ*AFA09H%6
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MVRQ[C.+-GR? QEY'X,]H\IQ[>'A*(.=#1&ZVH22>$R/AG^.!T(:CQ2I)4%<
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M63GI^6*1!%W?I>CYH T#ZX_/_' $AIO53_%^4P!,[X]RMLWQ.0-N:[<I+^2
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MX4Z1&T-@C=%%'_\ (5 DB7DJ!_G0""LZ@F=CJI?Z-"DSSG(&7PQ9N.ME> Y
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M8K&K?5IOV^-R.)I*ZZA(T,-NA(>2VH3TH3J( G&_[A?<^]OJE&$Y.O\ C3_
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MT/U#*A)?.<>GQ*7,AWY17NA$37ZZ_P .)BE+S_$<S$SGZ3\D;R1TI\QX'Y8
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MI)F.Z/>SCT^74_'K=^[=X7$_B7&U@<2!B,Y1I:D]4S9Z5M]A(;<X T\01.8
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ML<!..IC>0S!7WJ^VQNF^ (("*M24XY)4HS!),4\CF00>M4VAQQ:1+$Z>( X
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FHPC%J+3?<"ZP#,XSG+AP[L8L@]0 H 4 * % "@!0 H 4 * /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>17
<FILENAME>eyen-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 2.0 on 02-Apr-2018 [12:58:23] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:eyen="http://www.eyenoviabio.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="eyen-20171231.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2015To12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2017To03_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>

      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_27_2018">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_06_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2016To09_15_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-09-01</xbrli:startDate>

      <xbrli:endDate>2016-09-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2017To09_27_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-09-01</xbrli:startDate>

      <xbrli:endDate>2017-09-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_15_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-09-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_27_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-09-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_RetainedEarningsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2015_RetainedEarningsMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-01-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:PrivateMedicalEquityIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:PrivateMedicalEquityIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2016To07_31_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-07-01</xbrli:startDate>

      <xbrli:endDate>2016-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_06_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_CuraPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:CuraPartnersMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ExercisePrice698MemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePrice698Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_ExercisePriceOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_ExercisePriceTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_ExercisePriceThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ExercisePriceOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceOneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ExercisePriceTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceTwoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ExercisePriceThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">eyen:ExercisePriceThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-01-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_05_2018_EquityIncentivePlanMemberusgaapPlanNameAxis_MinimumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EquityIncentivePlanMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-01-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn01_05_2018_EquityIncentivePlanMemberusgaapPlanNameAxis_MaximumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EquityIncentivePlanMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-01-05</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P10_01_2016To10_06_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-10-01</xbrli:startDate>

      <xbrli:endDate>2016-10-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn10_06_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-10-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2017To09_27_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-09-01</xbrli:startDate>

      <xbrli:endDate>2017-09-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2017To09_27_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-09-01</xbrli:startDate>

      <xbrli:endDate>2017-09-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To01_08_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-01-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_BeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_BeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:BeneficialOwnerMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2016_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:PrivateMedicalEquityIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:PrivateMedicalEquityIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:PrivateMedicalEquityIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:PrivateMedicalEquityIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:PrivateMedicalEquityIncMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_CuraPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:CuraPartnersMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:ConsultingAgreementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2015To12_31_2015_SenjuPharmaceuticalCoMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:SenjuPharmaceuticalCoMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>

      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_06_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2017To07_07_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>

      <xbrli:endDate>2017-07-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-01-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn09_15_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2016-09-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P09_01_2016To09_15_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-09-01</xbrli:startDate>

      <xbrli:endDate>2016-09-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_27_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2018To12_31_2018_ScenarioPlanMemberusgaapStatementScenarioAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>

      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_SeriesAndSeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">eyen:SeriesAndSeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2018To03_06_2018_OmnibusStockIncentivePlan2018MemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2018-03-01</xbrli:startDate>

      <xbrli:endDate>2018-03-06</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_06_2018_OmnibusStockIncentivePlan2018MemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:OmnibusStockIncentivePlan2018Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2018-03-06</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_NonemployeeGrantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eyen:NonemployeeGrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2016To12_31_2016_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>

      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2017To12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">eyen:VicePresidentOfResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>

      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2017_EquityIncentivePlanMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001682639</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eyen:EquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="acre">
    <xbrli:measure>utr:acre</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="sqft">
    <xbrli:measure>utr:sqft</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <dei:DocumentType contextRef="P01_01_2017To12_31_2017" id="Factid_1">10-K</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2017To12_31_2017" id="Factid_2">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2017To12_31_2017" id="Factid_3">2017-12-31</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2017To12_31_2017" id="Factid_4">2017</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2017To12_31_2017" id="Factid_5">FY</dei:DocumentFiscalPeriodFocus>

  <dei:EntityRegistrantName contextRef="P01_01_2017To12_31_2017" id="Factid_6">EYENOVIA, INC.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2017To12_31_2017" id="Factid_7">0001682639</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2017To12_31_2017" id="Factid_8">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2017To12_31_2017" id="Factid_9">No</dei:EntityWellKnownSeasonedIssuer>

  <dei:EntityVoluntaryFilers contextRef="P01_01_2017To12_31_2017" id="Factid_10">No</dei:EntityVoluntaryFilers>

  <dei:EntityCurrentReportingStatus contextRef="P01_01_2017To12_31_2017" id="Factid_11">No</dei:EntityCurrentReportingStatus>

  <dei:EntityFilerCategory contextRef="P01_01_2017To12_31_2017" id="Factid_12">Smaller Reporting Company</dei:EntityFilerCategory>

  <dei:EntityPublicFloat contextRef="PAsOn06_30_2017" id="Factid_13" unitRef="USD" decimals="0">51000000</dei:EntityPublicFloat>

  <dei:TradingSymbol contextRef="P01_01_2017To12_31_2017" id="Factid_14">EYEN</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn03_27_2018" id="Factid_15" unitRef="shares" decimals="INF">9936771</dei:EntityCommonStockSharesOutstanding>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2017To12_31_2017" id="Factid_16" unitRef="USD" decimals="0">3816732</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2016To12_31_2016" id="Factid_17" unitRef="USD" decimals="0">2966165</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2017To12_31_2017" id="Factid_18" unitRef="USD" decimals="0">1315635</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2016To12_31_2016" id="Factid_19" unitRef="USD" decimals="0">568775</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:OperatingExpenses contextRef="P01_01_2017To12_31_2017" id="Factid_20" unitRef="USD" decimals="0">5132367</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2016To12_31_2016" id="Factid_21" unitRef="USD" decimals="0">3534940</us-gaap:OperatingExpenses>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2017To12_31_2017" id="Factid_22" unitRef="USD" decimals="0">-5132367</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2016To12_31_2016" id="Factid_23" unitRef="USD" decimals="0">-3534940</us-gaap:OperatingIncomeLoss>

  <us-gaap:InvestmentIncomeInterest contextRef="P01_01_2017To12_31_2017" id="Factid_24" unitRef="USD" decimals="0">2380</us-gaap:InvestmentIncomeInterest>

  <us-gaap:InvestmentIncomeInterest contextRef="P01_01_2016To12_31_2016" id="Factid_25" unitRef="USD" decimals="0">1497</us-gaap:InvestmentIncomeInterest>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To12_31_2017" id="Factid_26" unitRef="USD" decimals="0">-5129987</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016" id="Factid_27" unitRef="USD" decimals="0">-3533443</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2017To12_31_2017" id="Factid_28" unitRef="USD_per_Share" decimals="2">-2.19</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2016To12_31_2016" id="Factid_29" unitRef="USD_per_Share" decimals="2">-1.56</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2017To12_31_2017" id="Factid_30" unitRef="shares" decimals="INF">2344712</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2016To12_31_2016" id="Factid_31" unitRef="shares" decimals="INF">2266667</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:Cash contextRef="PAsOn12_31_2017" id="Factid_32" unitRef="USD" decimals="0">5249511</us-gaap:Cash>

  <us-gaap:Cash contextRef="PAsOn12_31_2016" id="Factid_33" unitRef="USD" decimals="0">3387288</us-gaap:Cash>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn12_31_2017" id="Factid_34" unitRef="USD" decimals="0">37149</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="PAsOn12_31_2016" id="Factid_35" unitRef="USD" decimals="0">2335</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2017" id="Factid_36" unitRef="USD" decimals="0">27960</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2016" id="Factid_37" unitRef="USD" decimals="0">43192</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="PAsOn12_31_2017" id="Factid_38" unitRef="USD" decimals="0">328700</us-gaap:DeferredFinanceCostsNoncurrentNet>

  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="PAsOn12_31_2016" id="Factid_39" unitRef="USD" decimals="0">0</us-gaap:DeferredFinanceCostsNoncurrentNet>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn12_31_2017" id="Factid_40" unitRef="USD" decimals="0">246384</us-gaap:AccountsPayableCurrent>

  <us-gaap:AccountsPayableCurrent contextRef="PAsOn12_31_2016" id="Factid_41" unitRef="USD" decimals="0">302031</us-gaap:AccountsPayableCurrent>

  <eyen:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_42" unitRef="USD" decimals="0">306263</eyen:AccruedExpensesAndOtherLiabilitiesCurrent>

  <eyen:AccruedExpensesAndOtherLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_43" unitRef="USD" decimals="0">121703</eyen:AccruedExpensesAndOtherLiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_44" unitRef="USD" decimals="0">552647</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_45" unitRef="USD" decimals="0">423734</us-gaap:LiabilitiesCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2017" id="Factid_46" unitRef="USD" decimals="0">5286660</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2016" id="Factid_47" unitRef="USD" decimals="0">3389623</us-gaap:AssetsCurrent>

  <us-gaap:Assets contextRef="PAsOn12_31_2017" id="Factid_48" unitRef="USD" decimals="0">5643320</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2016" id="Factid_49" unitRef="USD" decimals="0">3432815</us-gaap:Assets>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2017" id="Factid_50" unitRef="USD" decimals="0">24351138</us-gaap:AdditionalPaidInCapital>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2016" id="Factid_51" unitRef="USD" decimals="0">17139651</us-gaap:AdditionalPaidInCapital>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2017" id="Factid_52" unitRef="USD" decimals="0">-19261186</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="PAsOn12_31_2016" id="Factid_53" unitRef="USD" decimals="0">-14131199</us-gaap:RetainedEarningsAccumulatedDeficit>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017" id="Factid_54" unitRef="USD" decimals="0">5090673</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_55" unitRef="USD" decimals="0">3009081</us-gaap:StockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2017" id="Factid_56" unitRef="USD" decimals="0">5643320</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2016" id="Factid_57" unitRef="USD" decimals="0">3432815</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2017" id="Factid_58" unitRef="USD" decimals="0">257</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2016" id="Factid_59" unitRef="USD" decimals="0">227</us-gaap:CommonStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_60" unitRef="USD" decimals="0">92</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_61" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_62" unitRef="USD" decimals="0">79</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_63" unitRef="USD" decimals="0">79</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2017" id="Factid_64" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2017" id="Factid_65" unitRef="shares" decimals="INF">36000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_66" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <eyen:PreferredStockDesignatedShares contextRef="PAsOn12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_67" unitRef="shares" decimals="INF">20000000</eyen:PreferredStockDesignatedShares>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_68" unitRef="shares" decimals="INF">2932431</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_69" unitRef="shares" decimals="INF">3232294</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="PAsOn12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_70" unitRef="USD" decimals="0">10996014</us-gaap:PreferredStockLiquidationPreferenceValue>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_71" unitRef="shares" decimals="INF">2932431</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_72" unitRef="shares" decimals="INF">3232294</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="PAsOn12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_73" unitRef="USD" decimals="0">12121102</us-gaap:PreferredStockLiquidationPreferenceValue>

  <eyen:PreferredStockDesignatedShares contextRef="PAsOn12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_74" unitRef="shares" decimals="INF">5714286</eyen:PreferredStockDesignatedShares>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_75" unitRef="shares" decimals="INF">788827</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="PAsOn12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_76" unitRef="USD" decimals="0">4141338</us-gaap:PreferredStockLiquidationPreferenceValue>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_77" unitRef="shares" decimals="INF">788827</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="PAsOn12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_78" unitRef="USD" decimals="0">4141338</us-gaap:PreferredStockLiquidationPreferenceValue>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_79" unitRef="shares" decimals="INF">788827</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_80" unitRef="shares" decimals="INF">788827</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_81" unitRef="shares" decimals="INF">918983</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_82" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_83" unitRef="USD" decimals="0">6409657</us-gaap:PreferredStockLiquidationPreferenceValue>

  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="PAsOn12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_84" unitRef="USD" decimals="0">0</us-gaap:PreferredStockLiquidationPreferenceValue>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_85" unitRef="shares" decimals="INF">918983</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_86" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2017" id="Factid_87" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2017" id="Factid_88" unitRef="shares" decimals="INF">60000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2017" id="Factid_89" unitRef="shares" decimals="INF">2566530</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2016" id="Factid_90" unitRef="shares" decimals="INF">2266667</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2016" id="Factid_91" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2017" id="Factid_92" unitRef="shares" decimals="INF">2566530</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2016" id="Factid_93" unitRef="shares" decimals="INF">2266667</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To12_31_2017" id="Factid_94" unitRef="USD" decimals="0">431574</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_95" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_96" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_97" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_98" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_99" unitRef="USD" decimals="0">431574</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_100" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_101" unitRef="USD" decimals="0">293</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_102" unitRef="USD" decimals="0">79</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_103" unitRef="USD" decimals="0">92</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_104" unitRef="USD" decimals="0">257</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_105" unitRef="USD" decimals="0">24351138</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_106" unitRef="USD" decimals="0">-19261186</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_107" unitRef="USD" decimals="0">323</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_108" unitRef="USD" decimals="0">79</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_109" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_110" unitRef="USD" decimals="0">227</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_111" unitRef="USD" decimals="0">17139651</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2016_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_112" unitRef="USD" decimals="0">-14131199</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_113" unitRef="shares" decimals="INF">2932431</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_114" unitRef="shares" decimals="INF">788827</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_115" unitRef="shares" decimals="INF">918983</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_116" unitRef="shares" decimals="INF">2566530</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_117" unitRef="shares" decimals="INF">3232294</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_118" unitRef="shares" decimals="INF">788827</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_119" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_120" unitRef="shares" decimals="INF">2266667</us-gaap:SharesOutstanding>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_121" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_122" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_123" unitRef="USD" decimals="0">-3533443</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_124" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_125" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_126" unitRef="USD" decimals="0">-5129987</us-gaap:NetIncomeLoss>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017" id="Factid_127" unitRef="USD" decimals="0">412312</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016" id="Factid_128" unitRef="USD" decimals="0">2690</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_129" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_130" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_131" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_132" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_133" unitRef="USD" decimals="0">412312</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_134" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_135" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_136" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_137" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_138" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_139" unitRef="USD" decimals="0">2690</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="P01_01_2016To12_31_2016_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_140" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015" id="Factid_141" unitRef="USD" decimals="0">2398496</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_142" unitRef="USD" decimals="0">323</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_143" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_144" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_145" unitRef="USD" decimals="0">227</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_146" unitRef="USD" decimals="0">12995702</us-gaap:StockholdersEquity>

  <us-gaap:StockholdersEquity contextRef="PAsOn12_31_2015_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_147" unitRef="USD" decimals="0">-10597756</us-gaap:StockholdersEquity>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2015_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_148" unitRef="shares" decimals="INF">3232294</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2015_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_149" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2015_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_150" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2015_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_151" unitRef="shares" decimals="INF">2266667</us-gaap:SharesOutstanding>

  <us-gaap:DepreciationDepletionAndAmortization contextRef="P01_01_2017To12_31_2017" id="Factid_152" unitRef="USD" decimals="0">25466</us-gaap:DepreciationDepletionAndAmortization>

  <us-gaap:DepreciationDepletionAndAmortization contextRef="P01_01_2016To12_31_2016" id="Factid_153" unitRef="USD" decimals="0">12802</us-gaap:DepreciationDepletionAndAmortization>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2017To12_31_2017" id="Factid_154" unitRef="USD" decimals="0">412312</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2016To12_31_2016" id="Factid_155" unitRef="USD" decimals="0">2690</us-gaap:ShareBasedCompensation>

  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="P01_01_2017To12_31_2017" id="Factid_156" unitRef="USD" decimals="0">-55647</us-gaap:IncreaseDecreaseInAccountsPayable>

  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="P01_01_2016To12_31_2016" id="Factid_157" unitRef="USD" decimals="0">55509</us-gaap:IncreaseDecreaseInAccountsPayable>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2017To12_31_2017" id="Factid_158" unitRef="USD" decimals="0">51560</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2016To12_31_2016" id="Factid_159" unitRef="USD" decimals="0">-51598</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_160" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>

  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_161" unitRef="USD" decimals="0">6409651</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>

  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="P01_01_2016To12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_162" unitRef="USD" decimals="0">4141338</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>

  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="P01_01_2016To12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_163" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_164" unitRef="USD" decimals="0">41958</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_01_2016To12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_165" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P01_01_2017To12_31_2017" id="Factid_166" unitRef="USD" decimals="0">431574</us-gaap:ProceedsFromIssuanceOfWarrants>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P01_01_2016To12_31_2016" id="Factid_167" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfWarrants>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2017To12_31_2017" id="Factid_168" unitRef="USD" decimals="0">1862223</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2016To12_31_2016" id="Factid_169" unitRef="USD" decimals="0">894677</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2016" id="Factid_170" unitRef="USD" decimals="0">3387288</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2015" id="Factid_171" unitRef="USD" decimals="0">2492611</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2017" id="Factid_172" unitRef="USD" decimals="0">5249511</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <eyen:AccrualInitialPublicOfferingCosts contextRef="P01_01_2017To12_31_2017" id="Factid_173" unitRef="USD" decimals="0">133000</eyen:AccrualInitialPublicOfferingCosts>

  <eyen:AccrualInitialPublicOfferingCosts contextRef="P01_01_2016To12_31_2016" id="Factid_174" unitRef="USD" decimals="0">0</eyen:AccrualInitialPublicOfferingCosts>

  <us-gaap:ConversionOfStockAmountIssued1 contextRef="P01_01_2017To12_31_2017" id="Factid_175" unitRef="USD" decimals="0">30</us-gaap:ConversionOfStockAmountIssued1>

  <us-gaap:ConversionOfStockAmountIssued1 contextRef="P01_01_2016To12_31_2016" id="Factid_176" unitRef="USD" decimals="0">0</us-gaap:ConversionOfStockAmountIssued1>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2017To12_31_2017" id="Factid_177" unitRef="USD" decimals="0">-4731110</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="P01_01_2016To12_31_2016" id="Factid_178" unitRef="USD" decimals="0">-3203542</us-gaap:NetCashProvidedByUsedInOperatingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2017To12_31_2017" id="Factid_179" unitRef="USD" decimals="0">6603567</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="P01_01_2016To12_31_2016" id="Factid_180" unitRef="USD" decimals="0">4141338</us-gaap:NetCashProvidedByUsedInFinancingActivities>

  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="P01_01_2017To12_31_2017" id="Factid_181" unitRef="USD" decimals="0">34814</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="P01_01_2016To12_31_2016" id="Factid_182" unitRef="USD" decimals="0">-310498</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2016To12_31_2016" id="Factid_183" unitRef="USD" decimals="0">-43119</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="P01_01_2017To12_31_2017" id="Factid_184" unitRef="USD" decimals="0">-10234</us-gaap:NetCashProvidedByUsedInInvestingActivities>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2017To12_31_2017" id="Factid_185" unitRef="USD" decimals="0">10234</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2016To12_31_2016" id="Factid_186" unitRef="USD" decimals="0">43119</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_187">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; Note 1 &amp;#150; Business Organization and Nature of Operations&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt;Eyenovia, Inc. (&amp;#8220;Eyenovia&amp;#8221; or the &amp;#8220;Company&amp;#8221;) was organized as a corporation under the laws of the State of Florida on March&amp;#160;12, 2014 under the name, PGP Holdings V, Inc. On May&amp;#160;5, 2014, PGP Holdings V, Inc. changed its name to Eyenovia, Inc. On October&amp;#160;6, 2014, Eyenovia, Inc. reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt;Eyenovia is a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-doses (6&amp;#150;8 &amp;#181;L) of active pharmaceutical ingredients (or &amp;#8220;micro-therapeutics&amp;#8221;) topically to the eye. This disruptive micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers), that routinely overdoses or under-doses the topical administration of ophthalmic therapeutics.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt;Effective January 8, 2018, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&amp;#8217;s issued and outstanding common stock and preferred stock (the &amp;#8220;Reverse Split&amp;#8221;). The number of authorized shares remains unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise indicated.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>

  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_188">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Cash&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2017 and 2016, the Company had no cash equivalents.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. On December 31, 2017 and 2016, the Company had cash balances in excess of FDIC insurance limits of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,999,511&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,137,288&lt;/font&gt;, respectively.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>

  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_189">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Property and Equipment, Net&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>

  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_190">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Impairment of Long-lived Assets&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the years ended December 31, 2017 and 2016.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>

  <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="P01_01_2017To12_31_2017" id="Factid_191">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#8217; equity.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>

  <us-gaap:DerivativesPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_192">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Convertible Instruments&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; If the instrument is determined to be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the market price of the Company&amp;#8217;s common stock as of the commitment date to the effective conversion price of the instrument.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DerivativesPolicyTextBlock>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_193">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Income Taxes&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&amp;#8220;temporary differences&amp;#8221;) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&amp;#8217;s financial statements as of December 31, 2017 and 2016. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company&amp;#8217;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of operations.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>

  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2017To12_31_2017" id="Factid_194">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Research and Development&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>

  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_195">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,684,416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;786,667&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series A Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;2,932,431&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;3,232,294&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series A-2 Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;788,827&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;788,827&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series B Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;918,983&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Total potentially dilutive shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;6,386,532&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;4,807,787&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>

  <eyen:WorkingCapitalAmount contextRef="PAsOn12_31_2017" id="Factid_196" unitRef="USD" decimals="0">4734013</eyen:WorkingCapitalAmount>

  <us-gaap:CashUninsuredAmount contextRef="PAsOn12_31_2017" id="Factid_197" unitRef="USD" decimals="0">4999511</us-gaap:CashUninsuredAmount>

  <us-gaap:CashUninsuredAmount contextRef="PAsOn12_31_2016" id="Factid_198" unitRef="USD" decimals="0">3137288</us-gaap:CashUninsuredAmount>

  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="P01_01_2018To01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_199" unitRef="USD" decimals="-5">24500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>

  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_200">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; As of December 31, 2017 and 2016, prepaid expenses and other current assets consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Prepaid research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;28,932&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Prepaid patent expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,833&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Prepaid insurance expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;383&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Total prepaid expenses and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;37,149&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>

  <eyen:PrepaidResearchAndDevelopmentExpenses contextRef="PAsOn12_31_2017" id="Factid_201" unitRef="USD" decimals="0">28932</eyen:PrepaidResearchAndDevelopmentExpenses>

  <eyen:PrepaidResearchAndDevelopmentExpenses contextRef="PAsOn12_31_2016" id="Factid_202" unitRef="USD" decimals="0">0</eyen:PrepaidResearchAndDevelopmentExpenses>

  <us-gaap:PrepaidInsurance contextRef="PAsOn12_31_2017" id="Factid_203" unitRef="USD" decimals="0">383</us-gaap:PrepaidInsurance>

  <us-gaap:PrepaidInsurance contextRef="PAsOn12_31_2016" id="Factid_204" unitRef="USD" decimals="0">2335</us-gaap:PrepaidInsurance>

  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_205">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; Note 4 &amp;#150; Property and Equipment, Net&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;As of December 31, 2017 and 2016, property and equipment consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34,979&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;24,745&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;40,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;40,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;74,979&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;64,745&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Less: accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(47,019)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(21,553)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;27,960&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;43,192&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Depreciation and amortization expense was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;25,466&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;12,802&lt;/font&gt; for the years ended December 31, 2017 and 2016, respectively, which is included within research and development expenses in the statements of operations.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>

  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_206">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; As of December 31, 2017 and 2016, property and equipment consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34,979&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;24,745&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;40,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;40,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;74,979&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;64,745&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Less: accumulated depreciation and amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(47,019)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(21,553)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;27,960&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;43,192&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2017" id="Factid_207" unitRef="USD" decimals="0">74979</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2016" id="Factid_208" unitRef="USD" decimals="0">64745</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2017" id="Factid_209" unitRef="USD" decimals="0">47019</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="PAsOn12_31_2016" id="Factid_210" unitRef="USD" decimals="0">21553</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>

  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_211">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; Note 5 &amp;#150; Accrued Expenses and Other Current Liabilities&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;As of December 31, 2017 and 2016, accrued expenses and other current liabilities consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;120,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;61,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued legal expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;37,597&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued rent expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,590&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued professional services&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;41,831&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued offering costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;133,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,977&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,516&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Total accrued expenses and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;306,263&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;121,703&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>

  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_212">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; As of December 31, 2017 and 2016, accrued expenses and other current liabilities consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;120,455&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;61,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued legal expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;37,597&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued rent expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;18,590&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued professional services&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;41,831&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Accrued offering costs&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;133,000&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;10,977&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4,516&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Total accrued expenses and other current liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;306,263&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;121,703&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>

  <eyen:AccruedResearchAndDevelopmentExpensesCurrent contextRef="PAsOn12_31_2017" id="Factid_213" unitRef="USD" decimals="0">120455</eyen:AccruedResearchAndDevelopmentExpensesCurrent>

  <eyen:AccruedResearchAndDevelopmentExpensesCurrent contextRef="PAsOn12_31_2016" id="Factid_214" unitRef="USD" decimals="0">61000</eyen:AccruedResearchAndDevelopmentExpensesCurrent>

  <us-gaap:AccruedRentCurrent contextRef="PAsOn12_31_2017" id="Factid_215" unitRef="USD" decimals="0">0</us-gaap:AccruedRentCurrent>

  <us-gaap:AccruedRentCurrent contextRef="PAsOn12_31_2016" id="Factid_216" unitRef="USD" decimals="0">18590</us-gaap:AccruedRentCurrent>

  <us-gaap:AccruedProfessionalFeesCurrent contextRef="PAsOn12_31_2017" id="Factid_217" unitRef="USD" decimals="0">41831</us-gaap:AccruedProfessionalFeesCurrent>

  <us-gaap:AccruedProfessionalFeesCurrent contextRef="PAsOn12_31_2016" id="Factid_218" unitRef="USD" decimals="0">0</us-gaap:AccruedProfessionalFeesCurrent>

  <eyen:AccruedOfferingCosts contextRef="PAsOn12_31_2017" id="Factid_219" unitRef="USD" decimals="0">133000</eyen:AccruedOfferingCosts>

  <eyen:AccruedOfferingCosts contextRef="PAsOn12_31_2016" id="Factid_220" unitRef="USD" decimals="0">0</eyen:AccruedOfferingCosts>

  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2017" id="Factid_221" unitRef="USD" decimals="0">10977</us-gaap:OtherAccruedLiabilitiesCurrent>

  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="PAsOn12_31_2016" id="Factid_222" unitRef="USD" decimals="0">4516</us-gaap:OtherAccruedLiabilitiesCurrent>

  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_223">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; Future minimum payments under this operating lease agreement are as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 40%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%"&gt; &lt;div&gt;For&amp;#160;the&amp;#160;Year&amp;#160;Ending&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="20%" colspan="2"&gt; &lt;div&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;33,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;33,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="PAsOn12_31_2017" id="Factid_224" unitRef="USD" decimals="0">33108</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>

  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="PAsOn12_31_2017" id="Factid_225" unitRef="USD" decimals="0">33108</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>

  <us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="P09_01_2016To09_15_2016" id="Factid_226" unitRef="USD" decimals="0">3895</us-gaap:OperatingLeasesRentExpenseMinimumRentals>

  <us-gaap:LeaseExpirationDate1 contextRef="P09_01_2016To09_15_2016" id="Factid_227">2018-09-14</us-gaap:LeaseExpirationDate1>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P01_01_2017To12_31_2017" id="Factid_228" unitRef="USD" decimals="0">45678</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:OperatingLeasesRentExpenseNet contextRef="P01_01_2016To12_31_2016" id="Factid_229" unitRef="USD" decimals="0">18590</us-gaap:OperatingLeasesRentExpenseNet>

  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="P01_01_2017To12_31_2017" id="Factid_230">P2Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2017To12_31_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_231" unitRef="USD" decimals="0">329400</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2016To12_31_2016_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_232" unitRef="USD" decimals="0">398400</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <eyen:MinorityInterestOwnershipPercentageInCompany contextRef="PAsOn12_31_2017" id="Factid_233" unitRef="pure" decimals="2">0.05</eyen:MinorityInterestOwnershipPercentageInCompany>

  <eyen:OfficeSpaceExpenses contextRef="P07_01_2016To07_31_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_234" unitRef="USD" decimals="0">3000</eyen:OfficeSpaceExpenses>

  <eyen:ConsultingAgreementPaymentPermonth contextRef="P07_01_2017To07_06_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_CuraPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_235" unitRef="USD" decimals="0">9567</eyen:ConsultingAgreementPaymentPermonth>

  <eyen:ConsultingAgreementPaymentPerhour contextRef="P07_01_2017To07_06_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_CuraPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_236" unitRef="USD" decimals="0">250</eyen:ConsultingAgreementPaymentPerhour>

  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_237">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; Note 6 &amp;#150; Income Taxes&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The income tax (provision) benefit consists of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;For&amp;#160;The&amp;#160;Years&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Federal:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Current&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Deferred&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;235,473&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,287,931&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;State and local:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Current&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Deferred&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;80,301&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;151,521&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;315,774&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,439,452&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(315,774)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,439,452)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Income tax (provision) benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A reconciliation of the statutory federal income tax rate to the Company&amp;#8217;s effective tax rate is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;For&amp;#160;The&amp;#160;Years&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Tax benefit at federal statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;State income taxes, net of federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Incremental research and development credits&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Prior period adjustments and other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(8.1)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Effect of tax rate changes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(30.0)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(6.2)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(40.7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Effective income tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Deferred Tax Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,588,641&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,742,397&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;347,977&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;333,066&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Research &amp;#38; development tax credits&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;526,134&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;201,840&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;364,508&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;234,183&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Gross deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,827,260&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,511,486&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3,827,260)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3,511,486)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Deferred tax assets, net of valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Changes in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(315,774)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,439,452)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company&amp;#8217;s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; At December 31, 2017 and 2016, the Company estimates that it has approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11,000,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7,200,000&lt;/font&gt;, respectively, of federal net operating losses that may be available to offset future taxable income. The net operating loss carry forwards, if not utilized, will expire from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2034 to 2037&lt;/font&gt; for federal purposes. At December 31, 2017, the Company estimates that it has approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,000,000&lt;/font&gt; of New York State net operating losses that may be available to offset future taxable income. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company&amp;#8217;s net operating loss carry forwards could become subject to annual limitations if there are greater than 50% ownership changes.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company files income tax returns in the U.S. federal jurisdiction, the State of New York and the state of Florida (where the Company filed its final return in 2015), which remain subject to examination by the various taxing authorities beginning with the tax year ended December 31, 2014.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Tax Cuts and Jobs Act (the "Act") was enacted in December 2017. Among other things, the primary provision of Tax Reform impacting the Company is the reduction to the U.S. corporate income tax rate from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 35&lt;/font&gt;% to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 21&lt;/font&gt;%. The change in tax law required the Company to remeasure existing net deferred tax assets using the lower rate in the period of enactment resulting in an income tax expense of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.5&lt;/font&gt; million which is fully offset by the corresponding tax benefit of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.5&lt;/font&gt; million from the reduction in the valuation allowance in the year ended December 31, 2017. There were no specific impacts of Tax Reform that could not be reasonably estimated which the Company accounted for under the prior tax law. However, further analysis of the estimates and further guidance on the application of the law could result in additional revisions during the allowable one-year measurement period, as outlined in Staff Accounting Bulletin No. 118.&amp;#160;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>

  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_238">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; A reconciliation of the statutory federal income tax rate to the Company&amp;#8217;s effective tax rate is as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;For&amp;#160;The&amp;#160;Years&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Tax benefit at federal statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;34.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;State income taxes, net of federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;4.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Incremental research and development credits&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;6.3&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Prior period adjustments and other&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(8.1)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Effect of tax rate changes&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(30.0)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(6.2)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(40.7)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Effective income tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;0.0&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>

  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_239">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"&gt; The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Deferred Tax Assets:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,588,641&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,742,397&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Stock-based compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;347,977&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;333,066&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Research &amp;#38; development tax credits&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;526,134&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;201,840&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;364,508&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;234,183&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Gross deferred tax assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,827,260&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;3,511,486&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3,827,260)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(3,511,486)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Deferred tax assets, net of valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Changes in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(315,774)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,439,452)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>

  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="P01_01_2017To12_31_2017" id="Factid_240" unitRef="USD" decimals="0">0</us-gaap:CurrentFederalTaxExpenseBenefit>

  <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_241" unitRef="USD" decimals="0">0</us-gaap:CurrentFederalTaxExpenseBenefit>

  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="P01_01_2017To12_31_2017" id="Factid_242" unitRef="USD" decimals="0">235473</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>

  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_243" unitRef="USD" decimals="0">1287931</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>

  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="P01_01_2017To12_31_2017" id="Factid_244" unitRef="USD" decimals="0">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>

  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_245" unitRef="USD" decimals="0">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>

  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="P01_01_2017To12_31_2017" id="Factid_246" unitRef="USD" decimals="0">80301</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>

  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_247" unitRef="USD" decimals="0">151521</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>

  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="P01_01_2017To12_31_2017" id="Factid_248" unitRef="USD" decimals="0">315774</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>

  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="P01_01_2016To12_31_2016" id="Factid_249" unitRef="USD" decimals="0">1439452</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2017To12_31_2017" id="Factid_250" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2016To12_31_2016" id="Factid_251" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2017To12_31_2017" id="Factid_252" unitRef="pure" decimals="3">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2016To12_31_2016" id="Factid_253" unitRef="pure" decimals="3">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="P01_01_2017To12_31_2017" id="Factid_254" unitRef="pure" decimals="3">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="P01_01_2016To12_31_2016" id="Factid_255" unitRef="pure" decimals="3">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="P01_01_2017To12_31_2017" id="Factid_256" unitRef="pure" decimals="3">0.063</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>

  <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="P01_01_2016To12_31_2016" id="Factid_257" unitRef="pure" decimals="3">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2017To12_31_2017" id="Factid_258" unitRef="pure" decimals="3">-0.062</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2016To12_31_2016" id="Factid_259" unitRef="pure" decimals="3">-0.407</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P01_01_2017To12_31_2017" id="Factid_260" unitRef="pure" decimals="1">0.0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="P01_01_2016To12_31_2016" id="Factid_261" unitRef="pure" decimals="1">0.0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn12_31_2017" id="Factid_262" unitRef="USD" decimals="0">2588641</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn12_31_2016" id="Factid_263" unitRef="USD" decimals="0">2742397</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="PAsOn12_31_2017" id="Factid_264" unitRef="USD" decimals="0">347977</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="PAsOn12_31_2016" id="Factid_265" unitRef="USD" decimals="0">333066</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>

  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="PAsOn12_31_2017" id="Factid_266" unitRef="USD" decimals="0">526134</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>

  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="PAsOn12_31_2016" id="Factid_267" unitRef="USD" decimals="0">201840</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>

  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="PAsOn12_31_2017" id="Factid_268" unitRef="USD" decimals="0">364508</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>

  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="PAsOn12_31_2016" id="Factid_269" unitRef="USD" decimals="0">234183</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn12_31_2017" id="Factid_270" unitRef="USD" decimals="0">3827260</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn12_31_2016" id="Factid_271" unitRef="USD" decimals="0">3511486</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2017" id="Factid_272" unitRef="USD" decimals="0">3827260</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2016" id="Factid_273" unitRef="USD" decimals="0">3511486</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsNet contextRef="PAsOn12_31_2017" id="Factid_274" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>

  <us-gaap:DeferredTaxAssetsNet contextRef="PAsOn12_31_2016" id="Factid_275" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>

  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_276">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; For&amp;#160;the&amp;#160;Year&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Expected term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.32 - 10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.95 - 2.39&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.53% - 1.83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;130&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;131&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_277">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; A summary of the option activity during the year ended December 31, 2017 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;786,669&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;897,747&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,684,416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.68&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;8.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4,361,825&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;920,383&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.39&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7.6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;883,675&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <eyen:ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_278">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The following table presents information related to stock options as of December 31, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&amp;#160;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&amp;#160;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.24&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;760,001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7.2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;760,001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;897,747&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;152,465&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;26,668&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;8.8&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,917&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,684,416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7.6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;920,383&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eyen:ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2016" id="Factid_279" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2017To12_31_2017" id="Factid_280" unitRef="shares" decimals="INF">61875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2017To12_31_2017" id="Factid_281" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2017" id="Factid_282" unitRef="shares" decimals="INF">61875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <eyen:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber contextRef="P01_01_2017To12_31_2017" id="Factid_283" unitRef="shares" decimals="INF">61875</eyen:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber>

  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017" id="Factid_284" unitRef="USD_per_Share" decimals="2">6.98</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice>

  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017" id="Factid_285" unitRef="USD_per_Share" decimals="0">0</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice>

  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017" id="Factid_286" unitRef="USD_per_Share" decimals="2">6.98</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice>

  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice contextRef="PAsOn12_31_2016" id="Factid_287" unitRef="USD_per_Share" decimals="0">0</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice>

  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice contextRef="PAsOn12_31_2017" id="Factid_288" unitRef="USD_per_Share" decimals="2">6.98</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice>

  <eyen:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms contextRef="P01_01_2017To12_31_2017" id="Factid_289">P9Y8M12D</eyen:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="P01_01_2017To12_31_2017" id="Factid_290">P9Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="PAsOn12_31_2017" id="Factid_291" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>

  <eyen:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue contextRef="P01_01_2017To12_31_2017" id="Factid_292" unitRef="USD" decimals="0">0</eyen:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue>

  <eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017_ExercisePrice698MemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_293" unitRef="USD_per_Share" decimals="2">6.98</eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice>

  <eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants contextRef="P01_01_2017To12_31_2017" id="Factid_294" unitRef="shares" decimals="INF">61875</eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants>

  <eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants contextRef="P01_01_2017To12_31_2017_ExercisePrice698MemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_295" unitRef="shares" decimals="INF">61875</eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants>

  <eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife contextRef="P01_01_2017To12_31_2017" id="Factid_296">P9Y8M12D</eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife>

  <eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife contextRef="P01_01_2017To12_31_2017_ExercisePrice698MemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_297">P9Y8M12D</eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife>

  <eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants contextRef="P01_01_2017To12_31_2017" id="Factid_298" unitRef="shares" decimals="INF">61875</eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants>

  <eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants contextRef="P01_01_2017To12_31_2017_ExercisePrice698MemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_299" unitRef="shares" decimals="INF">61875</eyen:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2016To12_31_2016" id="Factid_300">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2017To12_31_2017" id="Factid_301" unitRef="pure" decimals="1">1.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="P01_01_2016To12_31_2016" id="Factid_302" unitRef="pure" decimals="2">1.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P01_01_2017To12_31_2017" id="Factid_303" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="P01_01_2016To12_31_2016" id="Factid_304" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="P01_01_2017To12_31_2017" id="Factid_305" unitRef="pure" decimals="4">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="P01_01_2017To12_31_2017" id="Factid_306" unitRef="pure" decimals="4">0.0239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="P01_01_2016To12_31_2016" id="Factid_307" unitRef="pure" decimals="4">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="P01_01_2016To12_31_2016" id="Factid_308" unitRef="pure" decimals="4">0.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2016" id="Factid_309" unitRef="shares" decimals="INF">786669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P01_01_2017To12_31_2017" id="Factid_310" unitRef="shares" decimals="INF">897747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2017To12_31_2017" id="Factid_311" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2017" id="Factid_312" unitRef="shares" decimals="INF">1684416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2017" id="Factid_313" unitRef="shares" decimals="INF">920383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017" id="Factid_314" unitRef="USD_per_Share" decimals="2">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2017To12_31_2017" id="Factid_315" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2016" id="Factid_316" unitRef="USD_per_Share" decimals="2">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2017" id="Factid_317" unitRef="USD_per_Share" decimals="2">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2017" id="Factid_318" unitRef="USD_per_Share" decimals="2">1.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017" id="Factid_319">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2017To12_31_2017" id="Factid_320">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn12_31_2017" id="Factid_321" unitRef="USD" decimals="0">883675</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="PAsOn12_31_2017_ExercisePriceOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_322" unitRef="USD_per_Share" decimals="2">1.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="PAsOn12_31_2017_ExercisePriceTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_323" unitRef="USD_per_Share" decimals="2">1.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="PAsOn12_31_2017_ExercisePriceThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_324" unitRef="USD_per_Share" decimals="2">5.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017" id="Factid_325" unitRef="shares" decimals="INF">1684416</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_ExercisePriceOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_326" unitRef="shares" decimals="INF">760001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_ExercisePriceTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_327" unitRef="shares" decimals="INF">897747</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="PAsOn12_31_2017_ExercisePriceThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_328" unitRef="shares" decimals="INF">26668</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017" id="Factid_329">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_ExercisePriceOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_330">P7Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_ExercisePriceTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_331">P9Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2017To12_31_2017_ExercisePriceThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_332">P8Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017" id="Factid_333" unitRef="shares" decimals="INF">920383</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_ExercisePriceOneMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_334" unitRef="shares" decimals="INF">760001</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_ExercisePriceTwoMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_335" unitRef="shares" decimals="INF">152465</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="PAsOn12_31_2017_ExercisePriceThreeMemberusgaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" id="Factid_336" unitRef="shares" decimals="INF">7917</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>

  <eyen:PreferredStockDesignatedShares contextRef="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_337" unitRef="shares" decimals="INF">10000000</eyen:PreferredStockDesignatedShares>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_338" unitRef="shares" decimals="INF">90000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_339" unitRef="shares" decimals="INF">6000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="PAsOn01_05_2018_EquityIncentivePlanMemberusgaapPlanNameAxis_MinimumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_340" unitRef="shares" decimals="INF">1733333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="PAsOn01_05_2018_EquityIncentivePlanMemberusgaapPlanNameAxis_MaximumMemberusgaapRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_341" unitRef="shares" decimals="INF">1866667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P10_01_2016To10_06_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_342" unitRef="shares" decimals="INF">788827</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn10_06_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_343" unitRef="USD_per_Share" decimals="2">5.25</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="P10_01_2016To10_06_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_344" unitRef="USD" decimals="0">4141338</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>

  <eyen:PreferredStockSharesNotParticipatingInFinancings contextRef="P09_01_2017To09_27_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_345" unitRef="shares" decimals="INF">299863</eyen:PreferredStockSharesNotParticipatingInFinancings>

  <eyen:PreferredStockProrataAllotmentPecentage contextRef="P09_01_2017To09_27_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_346" unitRef="pure" decimals="2">0.75</eyen:PreferredStockProrataAllotmentPecentage>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_347" unitRef="shares" decimals="INF">918983</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_348" unitRef="USD_per_Share" decimals="2">6.98</us-gaap:SharesIssuedPricePerShare>

  <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_349">The Series B Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series B Convertible Preferred Stock conversion price shall be reduced on a weighted average basis. Each share of Series B Convertible Preferred Stock shall automatically be converted into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters&#39; discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.</us-gaap:ConvertiblePreferredStockTermsOfConversion>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn09_27_2017" id="Factid_350" unitRef="shares" decimals="INF">61875</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="PAsOn09_27_2017" id="Factid_351" unitRef="USD_per_Share" decimals="2">6.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>

  <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="P09_01_2017To09_27_2017" id="Factid_352" unitRef="USD" decimals="0">431574</us-gaap:ProceedsFromIssuanceOfWarrants>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2017To12_31_2017" id="Factid_353" unitRef="USD_per_Share" decimals="2">1.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2016To12_31_2016" id="Factid_354" unitRef="USD_per_Share" decimals="2">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="P01_01_2017To12_31_2017" id="Factid_355" unitRef="USD" decimals="0">412312</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 contextRef="P01_01_2016To12_31_2016" id="Factid_356" unitRef="USD" decimals="0">2690</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="PAsOn12_31_2017" id="Factid_357" unitRef="USD" decimals="0">1327224</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>

  <us-gaap:SharesIssuedPricePerShare contextRef="PAsOn01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_358" unitRef="USD_per_Share" decimals="2">10.00</us-gaap:SharesIssuedPricePerShare>

  <eyen:LiquidityAndFinancialConditionPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_359">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Liquidity and Financial Condition&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company incurred net losses of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,129,987&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,533,443&lt;/font&gt; for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, the Company&amp;#8217;s working capital and accumulated deficit were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,734,013&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19,261,186&lt;/font&gt;, respectively. The Company has not yet generated revenues or achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Subsequent to December 31, 2017, the Company raised aggregate net proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;24.5&lt;/font&gt; million in connection with its initial public offering (&amp;#8220;IPO&amp;#8221;). See Note 10 &amp;#150; Subsequent Events for additional details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company believes its current cash on hand is sufficient to meet its operating and capital requirements for at least the next fifteen months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. The Company&amp;#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&amp;#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&amp;#8217;s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eyen:LiquidityAndFinancialConditionPolicyTextBlock>

  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_360">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The income tax (provision) benefit consists of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;For&amp;#160;The&amp;#160;Years&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Federal:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Current&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Deferred&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;235,473&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,287,931&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;State and local:&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Current&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Deferred&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;80,301&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;151,521&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;315,774&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;1,439,452&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(315,774)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;(1,439,452)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Income tax (provision) benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016" id="Factid_361" unitRef="USD" decimals="0">4141338</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To12_31_2017" id="Factid_362" unitRef="USD" decimals="0">6367693</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_363" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_364" unitRef="USD" decimals="0">79</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_365" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_366" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_367" unitRef="USD" decimals="0">4141259</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2016To12_31_2016_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_368" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_369" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_370" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_371" unitRef="USD" decimals="0">92</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_372" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_373" unitRef="USD" decimals="0">6367601</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_374" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2016To12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_375" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2016To12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_376" unitRef="shares" decimals="INF">788827</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2016To12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_377" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2016To12_31_2016_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_378" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2017To12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_379" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_380" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_381" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017" id="Factid_382" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_383" unitRef="USD" decimals="0">-30</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_384" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_385" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_386" unitRef="USD" decimals="0">30</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_AdditionalPaidInCapitalMemberusgaapStatementClassOfStockAxis" id="Factid_387" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_RetainedEarningsMemberusgaapStatementClassOfStockAxis" id="Factid_388" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_389" unitRef="shares" decimals="INF">-299863</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_390" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_391" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="P01_01_2017To12_31_2017_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_392" unitRef="shares" decimals="INF">299863</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>

  <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="P01_01_2017To12_31_2017" id="Factid_393" unitRef="USD" decimals="0">195700</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>

  <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering contextRef="P01_01_2016To12_31_2016" id="Factid_394" unitRef="USD" decimals="0">0</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>

  <dei:EntityIncorporationStateCountryName contextRef="P01_01_2017To12_31_2017" id="Factid_395">Florida</dei:EntityIncorporationStateCountryName>

  <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2017To12_31_2017" id="Factid_396">2014-03-12</dei:EntityIncorporationDateOfIncorporation>

  <us-gaap:StockholdersEquityReverseStockSplit contextRef="P01_01_2018To01_08_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_397">1-for-3.75</us-gaap:StockholdersEquityReverseStockSplit>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2017To12_31_2017_BeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_398" unitRef="USD" decimals="0">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2016To12_31_2016_BeneficialOwnerMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_399" unitRef="USD" decimals="0">366209</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_400" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_401" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2016To12_31_2016_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_402" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_403" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_404" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_405" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>

  <us-gaap:TaxCreditCarryforwardLimitationsOnUse contextRef="P01_01_2017To12_31_2017" id="Factid_406">In accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#39;s net operating loss carry forwards could become subject to annual limitations if there are greater than 50% ownership changes.</us-gaap:TaxCreditCarryforwardLimitationsOnUse>

  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_407">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Note 7 &amp;#150; Commitments and Contingencies&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Operating Leases&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On September 15, 2016, the Company entered into a lease agreement to lease &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 953&lt;/font&gt; square feet of space located in Reno, NV with respect to its research and development activities. The monthly base rent is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,895&lt;/font&gt; per month over the term of the lease. The lease expires on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; September 14, 2018&lt;/font&gt; and is subject to an extension at the option of the Company at a fixed rental rate for an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2&lt;/font&gt;-year period. The Company&amp;#8217;s rent expense amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;45,678&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,590&lt;/font&gt; for the years ended December 31, 2017 and 2016, respectively. See Note 8 &amp;#151; Related Party Transactions.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Future minimum payments under this operating lease agreement are as follows:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 40%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%"&gt; &lt;div&gt;For&amp;#160;the&amp;#160;Year&amp;#160;Ending&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="20%" colspan="2"&gt; &lt;div&gt;Amount&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;33,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"&gt; &lt;div&gt;33,108&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Litigations, Claims and Assessments&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company, its Chief Executive Officer and members of its Board of Directors are named as defendants in a legal proceeding filed in the United States District Court for the District of New Jersey on September 2, 2014 that has not yet been fully resolved in connection with the Company&amp;#8217;s Asset Purchase Agreement with Corinthian Ophthalmic, Inc. (&amp;#8220;Corinthian&amp;#8221;). A shareholder of Corinthian, alleging a fraudulent transfer, is seeking to recover the purchase price of its Corinthian shares and other damages in aggregate amount of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.1&lt;/font&gt; million.&amp;#160;The parties are not close to agreement on a settlement, and although further discussions may occur, the parties are prepared to proceed to trial. The court conducted a pretrial conference on January 22, 2018 and entered a final pretrial order on January 23, 2018. The order provided, among other things, for a final pretrial conference to be conducted on August 15, 2018 to address objections to expert witnesses&amp;#8217; opinions and testimony, with objections to be submitted by July 18, 2018 and responses by August 1, 2018. Trial briefs, requests for jury instructions, and proposed voir dire questions are due on August 30, 2018. The trial is scheduled for September 10, 2018. The Company is indemnified by Corinthian and Corinthian&amp;#8217;s applicable insurance policy provides coverage of&#32;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt; million, such that the Company does not expect to incur a material loss as a result of this litigation and, as a result, did not record a loss contingency as of December 31, 2017 or 2016, respectively.&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>

  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_408">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Note 9 &amp;#150; Stockholders&amp;#8217; Equity&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"&gt;&lt;u&gt;Reverse Stock Split&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Effective January&amp;#160;8, 2018, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&amp;#8217;s issued and outstanding common stock and preferred stock (the &amp;#8220;Reverse Split&amp;#8221;). The number of authorized shares remains unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise indicated.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Authorized Capital&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; As of December 31, 2017, the Company was authorized to issue &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 60,000,000&lt;/font&gt; shares of common stock, par value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt; per share, and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 36,000,000&lt;/font&gt; shares of preferred stock, par value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.0001&lt;/font&gt; per share. The holders of the Company&amp;#8217;s common stock are entitled to one vote per share. As of December 31, 2017, the preferred stock was designated as follows: &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 20,000,000&lt;/font&gt; shares designated as Series&amp;#160;A Convertible Preferred Stock; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 5,714,286&lt;/font&gt; shares designated as Series&amp;#160;A-2 Convertible Preferred Stock; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 10,000,000&lt;/font&gt; shares designated as Series&amp;#160;B Convertible Preferred Stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On January 29, 2018, in connection with its IPO and the conversion of all then existing preferred stock into common stock, the Company filed its Third Amended and Restated Certificate of Incorporation (the &amp;#8220;Third Amendment&amp;#8221;) with the Secretary of State of the State of Delaware, effective the same day. Pursuant to the Third Amendment, the Company is authorized to issue &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 90,000,000&lt;/font&gt; shares of common stock and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 6,000,000&lt;/font&gt; shares of preferred stock. The holders of the Company&amp;#8217;s common stock are entitled to one vote per share. No shares of preferred stock were designated. Pursuant to the Third Amendment, the Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;2014 Equity Incentive Plan&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company&amp;#8217;s 2014 Equity Incentive Plan (&amp;#8220;2014 Plan&amp;#8221;) provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock&amp;#160;units to employees, directors and consultants of the Company and its affiliates.&amp;#160;The 2014 Plan became effective on December&amp;#160;14, 2014 and shall terminate on the tenth (10th) anniversary of the effective date. The 2014 Plan requires the exercise price of stock options to be greater than or equal to the fair value of the Company&amp;#8217;s common stock on the date of grant. As of December&amp;#160;31, 2017, there were 48,917 shares available for future issuance under the 2014 Plan.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On January 5, 2018, the Company&amp;#8217;s Board of Directors and shareholders approved an amendment to the Company&amp;#8217;s 2014 Plan to increase the number of shares of common stock authorized under the 2014 Plan from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,733,333&lt;/font&gt; shares to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 1,866,667&lt;/font&gt; shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Series A and Series A-2 Convertible Preferred Stock&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;strong&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On October&amp;#160;6, 2016, the Company sold an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 788,827&lt;/font&gt; shares of Series&amp;#160;A-2 Convertible Preferred Stock to investors at a price of&#32;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.25&lt;/font&gt; per share for aggregate proceeds of&#32;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,141,338&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; On July 6, 2017, the Company&amp;#8217;s Board of Directors adopted, and the Company&amp;#8217;s stockholders approved, the Second Amendment to the Company&amp;#8217;s Certificate of Incorporation (the &amp;#8220;Second Amendment&amp;#8221;). Pursuant to the Second Amendment, in the event that any holder of shares of Series A Convertible Preferred Stock or Series A-2 Convertible Preferred Stock (collectively, the &amp;#8220;Series A/A-2 Preferred Stock&amp;#8221;) does not participate in a subsequent financing (as defined in the Second Amendment) by purchasing in the aggregate, in such subsequent financing, at least &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 75&lt;/font&gt;% of such holder&amp;#8217;s pro rata amount, then each share of Series A/A-2 Preferred Stock held by such holder shall automatically be converted into common stock concurrently with the consummation of such subsequent financing. Such conversion is referred to as a &amp;#8220;Special Mandatory Conversion.&amp;#8221;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On September 27, 2017, in connection with the sale of Series B Convertible Preferred Stock, holders of an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 299,863&lt;/font&gt; shares of Series A Convertible Preferred Stock did not participate in such financing by purchasing at least &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 75&lt;/font&gt;% of such holder&amp;#8217;s pro rata amount. As a result, the Special Mandatory Conversion of the Series A/A-2 Preferred Stock was triggered and, accordingly, such shares of Series A Convertible Preferred stock were automatically converted into an aggregate of 299,863 shares of common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The preferred stock did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders&amp;#8217; equity on the balance sheet. While the embedded conversion option (&amp;#8220;ECO&amp;#8221;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the preferred stock did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company&amp;#8217;s common stock as of the commitment date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The Series&amp;#160;A and Series&amp;#160;A-2 Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price shall be reduced on a weighted average basis. Each share of preferred stock shall automatically be converted into shares of common stock at the then effective conversion price: (i)&amp;#160;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters&amp;#8217; discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.&lt;/font&gt; See Note 10 &amp;#150; Subsequent Events for additional details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Series B Convertible Preferred Stock&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; During the year ended December 31, 2017, the Company sold an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 918,983&lt;/font&gt; shares of its Series B Convertible Preferred Stock to investors at a price of&#32;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.98&lt;/font&gt; per share for aggregate gross proceeds of&#32;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,409,651&lt;/font&gt;. The Company incurred $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;41,958&lt;/font&gt; of legal costs in connection with the sale, such that the aggregate net proceeds from the sale were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,367,693&lt;/font&gt;.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On November 9, 2017, the Board adopted resolutions ratifying each of the issuances of Series B Convertible Preferred Stock, which were then approved by the Company&amp;#8217;s shareholders. On November 13, 2017, the Company filed a certificate of validation with the Delaware Secretary of State in respect of such ratifications, such that, as of that date, the Series B Convertible Preferred Stock was duly authorized, validly issued, fully paid and nonassessable.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The Series B Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series B Convertible Preferred Stock conversion price shall be reduced on a weighted average basis. Each share of Series B Convertible Preferred Stock shall automatically be converted into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters' discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Series B Convertible Preferred did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders&amp;#8217; equity on the balance sheet. While the embedded conversion option (&amp;#8220;ECO&amp;#8221;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company&amp;#8217;s common stock as of the commitment date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; See Note 10 &amp;#150; Subsequent Events for additional details.&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Stock Warrants&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On September 27, 2017, the Company issued a warrant to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 61,875&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.98&lt;/font&gt; per share to an investor for cash consideration of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;431,574&lt;/font&gt;, which was included within additional paid-in capital on the balance sheet as of December 31, 2017. The warrant is exercisable any time through September 27, 2027. The warrant was sold to an investor for the amount of the investment in excess of what was permitted to be purchased of Series B Convertible Preferred Stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of the warrant activity during the year ended December 31, 2017 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The following table presents information related to warrants as of December 31, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&amp;#160;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&amp;#160;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Stock Options&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt; For&amp;#160;the&amp;#160;Year&amp;#160;Ended&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="6"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Expected term (years)&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.32 - 10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;10.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Risk free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.95 - 2.39&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.53% - 1.83&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;130&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;131&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Expected dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;0.00&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued to non-employees is usually the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &amp;#8220;simplified&amp;#8221; method to develop an estimate of the expected term of &amp;#8220;plain vanilla&amp;#8221; employee option grants. The Company does not currently have a trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The weighted average estimated grant date fair value of the stock options granted for the year ended December 31, 2017 and 2016 was approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.77&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.16&lt;/font&gt; per share, respectively.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company recorded stock-based compensation expense related to stock options of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;412,312&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,690&lt;/font&gt; during the year ended December 31, 2017 and 2016, respectively. As of December 31, 2017, there was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,327,224&lt;/font&gt; of unrecognized stock-based compensation expense, of which, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;377,816&lt;/font&gt; related to non-employee grants, which will be recognized over a weighted average period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2.4&lt;/font&gt; years. Subsequent to December 31, 2017, the Company closed on its IPO at an offering price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.00&lt;/font&gt; per share and as of March 27, 2018, the Company&amp;#8217;s shares closed at $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9.20&lt;/font&gt; per share. The Company&amp;#8217;s stock-based compensation expense related to non-employee grants that is recognized subsequent to December 31, 2017 will be materially impacted as a result of the increase in stock price subsequent to December 31, 2017.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;A summary of the option activity during the year ended December 31, 2017 is presented below:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;786,669&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.37&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;897,747&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,684,416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.68&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;8.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;4,361,825&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;920,383&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.39&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7.6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;883,675&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table presents information related to stock options as of December 31, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&amp;#160;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&amp;#160;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.24&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;760,001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7.2&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;760,001&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1.95&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;897,747&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.5&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;152,465&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;5.25&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;26,668&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;8.8&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7,917&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;1,684,416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;7.6&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;920,383&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>

  <eyen:ProceedsOfStockIssuedDuringPeriodGross contextRef="P01_01_2017To12_31_2017" id="Factid_409" unitRef="USD" decimals="0">6409651</eyen:ProceedsOfStockIssuedDuringPeriodGross>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2017To12_31_2017" id="Factid_410" unitRef="USD" decimals="0">41958</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:UseOfEstimates contextRef="P01_01_2017To12_31_2017" id="Factid_411">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Use of Estimates&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&amp;#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; establishment of&lt;/font&gt; valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&amp;#8217;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&amp;#8217;s estimates and could cause actual results to differ from those estimates.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Summary of Significant Accounting Policies&amp;#160;&amp;#151; Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&amp;#8217;s common stock.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2017To12_31_2017" id="Factid_412">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 &amp;#8220;Fair Value Measurements and Disclosures&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.&lt;/font&gt;&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Level 1&amp;#160;&amp;#151; quoted prices in active markets for identical assets or liabilities;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Level 2&amp;#160;&amp;#151; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Level 3&amp;#160;&amp;#151; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The carrying amounts of the Company&amp;#8217;s financial instruments, such as cash, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>

  <eyen:WarrantsOutstandingAndExercisableExercisePriceTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_413">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following table presents information related to warrants as of December 31, 2017:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&amp;#160;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&amp;#160;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&amp;#160;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eyen:WarrantsOutstandingAndExercisableExercisePriceTableTextBlock>

  <eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_414">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Note 3 &amp;#150; Prepaid Expenses and Other Current Assets&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;As of December 31, 2017 and 2016, prepaid expenses and other current assets consisted of the following:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Prepaid research and development expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;28,932&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Prepaid patent expense&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;7,833&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Prepaid insurance expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;383&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"&gt; &lt;div&gt;Total prepaid expenses and other current assets&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;37,149&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"&gt; &lt;div&gt;2,335&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eyen:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock>

  <eyen:ScheduleOfWarrantsOutstandingTableTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_415">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;A summary of the warrant activity during the year ended December 31, 2017 is presented below:&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Weighted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Remaining&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Aggregate&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Number&amp;#160;of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercise&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Intrinsic&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;In&amp;#160;Years&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Value&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Outstanding December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;Exercisable December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;6.98&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;9.7&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;$&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</eyen:ScheduleOfWarrantsOutstandingTableTextBlock>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_416" unitRef="USD" decimals="0">293</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2016_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_417" unitRef="USD" decimals="0">323</us-gaap:PreferredStockValue>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2017To12_31_2017" id="Factid_418" unitRef="shares" decimals="INF">6386532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016" id="Factid_419" unitRef="shares" decimals="INF">4807787</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_420" unitRef="shares" decimals="INF">786667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_421" unitRef="shares" decimals="INF">3232294</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_422" unitRef="shares" decimals="INF">788827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_423" unitRef="shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2017To12_31_2017_EmployeeStockOptionMemberusgaapOptionIndexedToIssuersEquityTypeAxis" id="Factid_424" unitRef="shares" decimals="INF">1684416</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2017To12_31_2017_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_425" unitRef="shares" decimals="INF">2932431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2017To12_31_2017_SeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_426" unitRef="shares" decimals="INF">788827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2017To12_31_2017_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_427" unitRef="shares" decimals="INF">918983</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2017To12_31_2017_MinimumMemberusgaapRangeAxis" id="Factid_428">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis" id="Factid_429">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2017_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_430" unitRef="USD" decimals="0">40000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2016_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_431" unitRef="USD" decimals="0">40000</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2017_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_432" unitRef="USD" decimals="0">34979</us-gaap:PropertyPlantAndEquipmentGross>

  <us-gaap:PropertyPlantAndEquipmentGross contextRef="PAsOn12_31_2016_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" id="Factid_433" unitRef="USD" decimals="0">24745</us-gaap:PropertyPlantAndEquipmentGross>

  <eyen:AccruedLegalExpensesCurrent contextRef="PAsOn12_31_2017" id="Factid_434" unitRef="USD" decimals="0">0</eyen:AccruedLegalExpensesCurrent>

  <eyen:AccruedLegalExpensesCurrent contextRef="PAsOn12_31_2016" id="Factid_435" unitRef="USD" decimals="0">37597</eyen:AccruedLegalExpensesCurrent>

  <eyen:AccruedExpensesAndOtherLiabilitiesCurrents contextRef="PAsOn12_31_2017" id="Factid_436" unitRef="USD" decimals="0">306263</eyen:AccruedExpensesAndOtherLiabilitiesCurrents>

  <eyen:AccruedExpensesAndOtherLiabilitiesCurrents contextRef="PAsOn12_31_2016" id="Factid_437" unitRef="USD" decimals="0">121703</eyen:AccruedExpensesAndOtherLiabilitiesCurrents>

  <eyen:IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance contextRef="P01_01_2016To12_31_2016" id="Factid_438" unitRef="USD" decimals="0">1439452</eyen:IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance>

  <eyen:IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance contextRef="P01_01_2017To12_31_2017" id="Factid_439" unitRef="USD" decimals="0">315774</eyen:IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance>

  <us-gaap:LossContingencyDamagesSoughtValue contextRef="P01_01_2017To12_31_2017" id="Factid_440" unitRef="USD" decimals="-5">1100000</us-gaap:LossContingencyDamagesSoughtValue>

  <us-gaap:MalpracticeLossContingencyInsuranceRecoveries contextRef="P01_01_2017To12_31_2017" id="Factid_441" unitRef="USD" decimals="-6">10000000</us-gaap:MalpracticeLossContingencyInsuranceRecoveries>

  <us-gaap:NetRentableArea contextRef="PAsOn09_15_2016" id="Factid_442" unitRef="acre" decimals="0">953</us-gaap:NetRentableArea>

  <eyen:ConsultingFee contextRef="P01_01_2017To12_31_2017_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_443" unitRef="USD" decimals="0">33200</eyen:ConsultingFee>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2017To12_31_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_444" unitRef="USD" decimals="0">176344</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2016To12_31_2016_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_445" unitRef="USD" decimals="0">318720</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2017To12_31_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_446" unitRef="USD" decimals="0">152656</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2016To12_31_2016_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis_PrivateMedicalEquityIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_447" unitRef="USD" decimals="0">79680</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="P01_01_2017To12_31_2017_ConsultingAgreementMemberusgaapRelatedPartyTransactionAxis_CuraPartnersMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" id="Factid_448" unitRef="USD" decimals="0">85835</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>

  <us-gaap:LeaseAndRentalExpense contextRef="P01_01_2017To12_31_2017_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_449" unitRef="USD" decimals="0">36000</us-gaap:LeaseAndRentalExpense>

  <us-gaap:LeaseAndRentalExpense contextRef="P01_01_2016To12_31_2016_ChiefExecutiveOfficerMemberusgaapTitleOfIndividualAxis" id="Factid_450" unitRef="USD" decimals="0">18000</us-gaap:LeaseAndRentalExpense>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="P01_01_2017To12_31_2017" id="Factid_451" unitRef="USD" decimals="0">4361825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>

  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_452">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Note 2 &amp;#150; Summary of Significant Accounting Policies&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Liquidity and Financial Condition&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company incurred net losses of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,129,987&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,533,443&lt;/font&gt; for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, the Company&amp;#8217;s working capital and accumulated deficit were $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,734,013&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19,261,186&lt;/font&gt;, respectively. The Company has not yet generated revenues or achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Subsequent to December 31, 2017, the Company raised aggregate net proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;24.5&lt;/font&gt; million in connection with its initial public offering (&amp;#8220;IPO&amp;#8221;). See Note 10 &amp;#150; Subsequent Events for additional details.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company believes its current cash on hand is sufficient to meet its operating and capital requirements for at least the next fifteen months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. The Company&amp;#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&amp;#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&amp;#8217;s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Use of Estimates&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&amp;#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; establishment of&lt;/font&gt; valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&amp;#8217;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&amp;#8217;s estimates and could cause actual results to differ from those estimates.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Summary of Significant Accounting Policies&amp;#160;&amp;#151; Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&amp;#8217;s common stock.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Cash&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2017 and 2016, the Company had no cash equivalents.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. On December 31, 2017 and 2016, the Company had cash balances in excess of FDIC insurance limits of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;4,999,511&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,137,288&lt;/font&gt;, respectively.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Property and Equipment, Net&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2&lt;/font&gt; to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt; years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;u&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Deferred Offering Costs&lt;/font&gt;&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company&amp;#8217;s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. As of December 31, 2017 and 2016, there were deferred offering costs in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;328,700&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;, respectively. Upon the closing of the IPO, the deferred offering costs will be offset against the proceeds of the IPO.&lt;/font&gt;&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Impairment of Long-lived Assets&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the years ended December 31, 2017 and 2016.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Preferred Stock&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&amp;#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&amp;#8217; equity.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Convertible Instruments&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; If the instrument is determined to be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the market price of the Company&amp;#8217;s common stock as of the commitment date to the effective conversion price of the instrument.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;font style="FONT-SIZE: 10pt"&gt;The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 &amp;#8220;Fair Value Measurements and Disclosures&amp;#8221; (&amp;#8220;ASC 820&amp;#8221;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.&lt;/font&gt;&lt;/div&gt; &amp;#160; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Level 1&amp;#160;&amp;#151; quoted prices in active markets for identical assets or liabilities;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Level 2&amp;#160;&amp;#151; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Level 3&amp;#160;&amp;#151; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The carrying amounts of the Company&amp;#8217;s financial instruments, such as cash, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Income Taxes&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&amp;#8220;temporary differences&amp;#8221;) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&amp;#8217;s financial statements as of December 31, 2017 and 2016. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company&amp;#8217;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of operations.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Research and Development&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Stock-Based Compensation&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option, the Company issues new shares of common stock out of its authorized shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; During the year ended December 31, 2016, the fair value of the Company&amp;#8217;s common stock was based on an analysis completed by management that considered the cash sales prices of the convertible preferred stock as well as the relative characteristics, rights and privileges of the convertible preferred stock as compared to the common stock. During the year ended December 31, 2017, the Company obtained a third-party 409A valuation of its common stock, which was also considered in management&amp;#8217;s estimation of the value of the equity instruments issued during that period. This third-party valuation was done in accordance with the guidance outlined in the American Institute of Certified Public Accountants&amp;#8217; Accounting and Valuation Guide, &lt;i&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/i&gt;. The estimates used by management are considered highly complex and subjective. Subsequent to the IPO, the shares began trading on January 24, 2018, which is the date the use of such estimates is no longer necessary to determine the fair value of the common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The independent analysis utilized the Backsolve method since this method is generally considered the most reliable and is recommended by the American Institute of Certified Public Accountants&amp;#8217; Accounting and Valuation Guide,&amp;#160;&lt;i&gt;Valuation of Privately Held Company Equity Securities Issued as Compensation&lt;/i&gt;. In addition, the method utilizes the economics from a direct transaction in our securities in determining the fair market value. This method utilizes the Black Scholes option pricing model which allocated a probability weighted equity value to the Company&amp;#8217;s Series A- 2 preferred stock. The Series A-2 preferred stock was utilized since it included new investors, was considered at arms&amp;#8217; length and closed in the fourth quarter of 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The March 2017 independent appraisal utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Establishment of total enterprise or equity value;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Analysis of equity rights for each class of security;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Selection of appropriate model for valuation purposes;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Determination of key valuation inputs; and&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Computation of the fair value of the subject security.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Under the OPM, it was determined the Company&amp;#8217;s common stock had an allocated per share value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.23&lt;/font&gt; per share. As a private company, the analysis provided for a discount for lack of marketability of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% resulting in a fair market value of the Company&amp;#8217;s common stock of&#32;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.95&lt;/font&gt; per share as of March 2017 based upon the independent appraisal. This price represents the same exercise price of the stock options the Company granted in July 2017 as management determined no material events or conditions occurred at the Company that would have a material effect on this per share price.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;u&gt;Net Loss Per Common Share&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,684,416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;786,667&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series A Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;2,932,431&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;3,232,294&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series A-2 Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;788,827&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;788,827&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series B Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;918,983&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Total potentially dilutive shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;6,386,532&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;4,807,787&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Subsequent Events&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.&lt;/div&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In February 2016, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02, &amp;#8220;Leases (Topic 842)&amp;#8221; (&amp;#8220;ASU 2016-02&amp;#8221;). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In August 2016, the FASB issued ASU 2016-15, &amp;#8220;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments,&amp;#8221; (&amp;#8220;ASU 2016-15&amp;#8221;). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. We will require adoption on a retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating ASU 2016-15 and its impact on its financial position, results of operations, and cash flows.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In May 2017, the FASB issued ASU No. 2017-09, &amp;#8220;Compensation&amp;#151;Stock Compensation (Topic 718): Scope of Modification Accounting&amp;#8221; (&amp;#8220;ASU 2017-09&amp;#8221;). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending December 15, 2018 for share-based payment awards modified on or after the adoption date. The Company is currently evaluating ASU 2017-09 and its impact on its financial position, results of operations, and cash flows.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In July 2017, the FASB issued ASU No. 2017-11, &amp;#8220;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&amp;#8221; (&amp;#8220;ASU 2017-11&amp;#8221;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating ASU 2017-11 and its impact on its financial position, results of operations, and cash flows.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;u&gt;Recently Adopted Accounting Pronouncements&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In March 2016, the FASB issued ASU No. 2016-09, &amp;#8220;Compensation &amp;#150; Stock Compensation (Topic 718)&amp;#8221; (&amp;#8220;ASU 2016-09&amp;#8221;). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of this standard did not have a material impact on the Company&amp;#8217;s financial position, results of operations and cash flows.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>

  <us-gaap:DeferredChargesPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_453">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt; &lt;u&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Deferred Offering Costs&lt;/font&gt;&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company&amp;#8217;s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. As of December 31, 2017 and 2016, there were deferred offering costs in the amount of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;328,700&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt;, respectively. Upon the closing of the IPO, the deferred offering costs will be offset against the proceeds of the IPO.&lt;/font&gt;&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredChargesPolicyTextBlock>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2017To12_31_2017" id="Factid_454">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;Stock-Based Compensation&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option, the Company issues new shares of common stock out of its authorized shares.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; During the year ended December 31, 2016, the fair value of the Company&amp;#8217;s common stock was based on an analysis completed by management that considered the cash sales prices of the convertible preferred stock as well as the relative characteristics, rights and privileges of the convertible preferred stock as compared to the common stock. During the year ended December 31, 2017, the Company obtained a third-party 409A valuation of its common stock, which was also considered in management&amp;#8217;s estimation of the value of the equity instruments issued during that period. This third-party valuation was done in accordance with the guidance outlined in the American Institute of Certified Public Accountants&amp;#8217; Accounting and Valuation Guide, &lt;i&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation&lt;/i&gt;. The estimates used by management are considered highly complex and subjective. Subsequent to the IPO, the shares began trading on January 24, 2018, which is the date the use of such estimates is no longer necessary to determine the fair value of the common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The independent analysis utilized the Backsolve method since this method is generally considered the most reliable and is recommended by the American Institute of Certified Public Accountants&amp;#8217; Accounting and Valuation Guide,&amp;#160;&lt;i&gt;Valuation of Privately Held Company Equity Securities Issued as Compensation&lt;/i&gt;. In addition, the method utilizes the economics from a direct transaction in our securities in determining the fair market value. This method utilizes the Black Scholes option pricing model which allocated a probability weighted equity value to the Company&amp;#8217;s Series A- 2 preferred stock. The Series A-2 preferred stock was utilized since it included new investors, was considered at arms&amp;#8217; length and closed in the fourth quarter of 2016.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The March 2017 independent appraisal utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Establishment of total enterprise or equity value;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Analysis of equity rights for each class of security;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Selection of appropriate model for valuation purposes;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Determination of key valuation inputs; and&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.5in"&gt;&lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#8901;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div&gt;Computation of the fair value of the subject security.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Under the OPM, it was determined the Company&amp;#8217;s common stock had an allocated per share value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3.23&lt;/font&gt; per share. As a private company, the analysis provided for a discount for lack of marketability of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 40&lt;/font&gt;% resulting in a fair market value of the Company&amp;#8217;s common stock of&#32;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.95&lt;/font&gt; per share as of March 2017 based upon the independent appraisal. This price represents the same exercise price of the stock options the Company granted in July 2017 as management determined no material events or conditions occurred at the Company that would have a material effect on this per share price.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_455">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;u&gt;Subsequent Events&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_456">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In February 2016, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02, &amp;#8220;Leases (Topic 842)&amp;#8221; (&amp;#8220;ASU 2016-02&amp;#8221;). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In August 2016, the FASB issued ASU 2016-15, &amp;#8220;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments,&amp;#8221; (&amp;#8220;ASU 2016-15&amp;#8221;). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. We will require adoption on a retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating ASU 2016-15 and its impact on its financial position, results of operations, and cash flows.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In May 2017, the FASB issued ASU No. 2017-09, &amp;#8220;Compensation&amp;#151;Stock Compensation (Topic 718): Scope of Modification Accounting&amp;#8221; (&amp;#8220;ASU 2017-09&amp;#8221;). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending December 15, 2018 for share-based payment awards modified on or after the adoption date. The Company is currently evaluating ASU 2017-09 and its impact on its financial position, results of operations, and cash flows.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In July 2017, the FASB issued ASU No. 2017-11, &amp;#8220;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&amp;#8221; (&amp;#8220;ASU 2017-11&amp;#8221;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating ASU 2017-11 and its impact on its financial position, results of operations, and cash flows.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;u&gt;Recently Adopted Accounting Pronouncements&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; In March 2016, the FASB issued ASU No. 2016-09, &amp;#8220;Compensation &amp;#150; Stock Compensation (Topic 718)&amp;#8221; (&amp;#8220;ASU 2016-09&amp;#8221;). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of this standard did not have a material impact on the Company&amp;#8217;s financial position, results of operations and cash flows.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_457">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Note 8 &amp;#150; Related Party Transactions&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; The Company&amp;#8217;s Chief Executive Officer as well as a member of its Board of Directors are both partners in Private Medical Equity, Inc. (&amp;#8220;PME&amp;#8221;). The Company and PME are parties to a consulting agreement dated November 4, 2014 that provides for the payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;33,200&lt;/font&gt; per month to PME in consulting fees for general management and strategy services. Any time spent by PME in excess of the specified amount is billed separately. During the years ended December 31, 2017 and 2016, the Company incurred $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;329,400&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;398,400&lt;/font&gt;, respectively, related to the agreement, of which, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;176,344&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;318,720&lt;/font&gt;, respectively, was included within research and development expenses and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;152,656&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;79,680&lt;/font&gt;, respectively, was included within general and administrative expenses on the condensed statements of operations. On August 1, 2017, the agreement was terminated and the Company&amp;#8217;s Chief Executive Officer was employed full time by the Company. The&amp;#160;Board member now bills the Company through a separate consulting agreement dated July 6, 2017 that is discussed below.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; A company that beneficially owns greater than &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;% of the Company&amp;#8217;s common stock has a consulting agreement with the Company for research and development services. During the years ended December 31, 2017 and 2016, the Company recognized $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;366,209&lt;/font&gt;, respectively, related to the agreement, which was included within research and development expenses on the statements of operations.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Since July 2016, the Company pays $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,000&lt;/font&gt; per month to a company controlled by a member of its Board of Directors for office space in New York, New York for its Chief Executive Officer. During the years ended December 31, 2017 and 2016, the Company recorded rent expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;36,000&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,000&lt;/font&gt;, respectively, related to the office space.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; A company in which a member of the Company&amp;#8217;s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment&amp;#160;of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,567&lt;/font&gt; per month, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;250&lt;/font&gt; per hour for any additional work, for advisory services performed by such director. During the year ended December 31, 2017, the Company incurred $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;85,835&lt;/font&gt; related to the agreement which was included within general and administrative expenses on the statement of operations.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On July 6, 2017, the Company entered into an engagement letter with its Vice President of Research and Development (&amp;#8220;VP of R&amp;#38;D&amp;#8221;). Pursuant to the terms of the engagement letter, starting on August 1, 2017, the VP of R&amp;#38;D was to provide service to the Company as a non-employee on a part-time basis in exchange for $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,167&lt;/font&gt; per month and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;175&lt;/font&gt; per hour for any additional work. On July 7, 2017, the VP of R&amp;#38;D was granted options to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 100,264&lt;/font&gt; shares of common stock at an exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1.95&lt;/font&gt; per share that vest in equal monthly installments over &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;36&lt;/font&gt; months starting from the date of grant. The options had a grant date fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;173,900&lt;/font&gt;. On August 16, 2017, the VP of R&amp;#38;D changed from a non-employee to an employee of the Company but remained employed on a part-time basis at the same compensation rate. Subsequent to December 31, 2017, the VP of R&amp;#38;D&amp;#8217;s salary was increased to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;165,000&lt;/font&gt; per year in connection with the increase from two (2) to three (3) days of work per week. The following are related party transactions involving the VP of R&amp;#38;D:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;The VP of R&amp;#38;D owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 953&lt;/font&gt; square feet of space located in Reno, NV with respect to its research and development activities. The monthly base rent is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,895&lt;/font&gt; per month over the term of the lease and the security deposit is $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,895&lt;/font&gt;. The lease expires on &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;September 14, 2018&lt;/font&gt; and is subject to an extension at the option of the Company at a fixed rental rate for an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2&lt;/font&gt;-year period. The Company made $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;40,000&lt;/font&gt; of leasehold improvements related to this lease which are included on the balance sheet.&amp;#160;The Company&amp;#8217;s rent expense amounted to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;45,678&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,590&lt;/font&gt; for the years ended December 31, 2017 and 2016, respectively.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr style="VERTICAL-ALIGN: top"&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="WIDTH: 0.25in"&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;&lt;font style="FONT-FAMILY:Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="CLEAR:both;CLEAR: both"&gt;The VP of R&amp;#38;D is the sole owner and President of a company that performs contract engineering services for the Company. During the years ended December 31, 2017 and 2016, the Company recognized research and development expense of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,155,500&lt;/font&gt; and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,427,958&lt;/font&gt;, respectively, related to services provided by such vendor. As of December 31, 2017, the Company had a liability of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;94,998&lt;/font&gt; to the vendor and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;9,906&lt;/font&gt; related to expenses incurred by the VP of R&amp;#38;D.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; During 2015, the Company entered into a license agreement with Senju Pharmaceutical Co., Lt. (&amp;#8220;Senju&amp;#8221;) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its micro-dose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the micro-dose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;%) royalties for the term of the license agreement. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents.&lt;/font&gt; As of the date of filing, there had been no commercial sales of a micro-dose product candidate in Asia such that no royalties had been earned. Senju is owned by the family of a member of the Company&amp;#8217;s Board of Directors and both beneficially own greater than &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;% of the Company&amp;#8217;s common stock.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="P01_01_2018To01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_458" unitRef="USD" decimals="-5">2800000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>

  <us-gaap:DeferredOfferingCosts contextRef="PAsOn12_31_2017" id="Factid_459" unitRef="USD" decimals="0">328700</us-gaap:DeferredOfferingCosts>

  <us-gaap:DeferredOfferingCosts contextRef="PAsOn12_31_2016" id="Factid_460" unitRef="USD" decimals="0">0</us-gaap:DeferredOfferingCosts>

  <us-gaap:SharePrice contextRef="PAsOn03_31_2017" id="Factid_461" unitRef="USD_per_Share" decimals="2">3.23</us-gaap:SharePrice>

  <us-gaap:FairValueInputsDiscountForLackOfMarketability contextRef="P03_01_2017To03_31_2017" id="Factid_462" unitRef="pure" decimals="1">0.4</us-gaap:FairValueInputsDiscountForLackOfMarketability>

  <eyen:SharePriceAtFairValue contextRef="PAsOn03_31_2017" id="Factid_463" unitRef="USD_per_Share" decimals="2">1.95</eyen:SharePriceAtFairValue>

  <eyen:PreferredStockSharesNotParticipatingInFinancings contextRef="P09_01_2017To09_27_2017_SeriesConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_464" unitRef="shares" decimals="INF">299863</eyen:PreferredStockSharesNotParticipatingInFinancings>

  <eyen:PrepaidPatentExpense contextRef="PAsOn12_31_2017" id="Factid_465" unitRef="USD" decimals="0">7833</eyen:PrepaidPatentExpense>

  <eyen:GrossProceedsFromIssuanceOfConvertiblePreferredStock contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_466" unitRef="USD" decimals="0">6409651</eyen:GrossProceedsFromIssuanceOfConvertiblePreferredStock>

  <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="P01_01_2017To12_31_2017" id="Factid_467" unitRef="pure" decimals="3">-0.081</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes contextRef="P01_01_2016To12_31_2016" id="Factid_468" unitRef="pure" decimals="1">0.0</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="P01_01_2017To12_31_2017" id="Factid_469" unitRef="pure" decimals="2">-0.30</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="P01_01_2016To12_31_2016" id="Factid_470" unitRef="pure" decimals="1">0.0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2018To01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_471" unitRef="shares" decimals="INF">2730000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <eyen:GrossProceedsOfStockValueIssuedDuringPeriod contextRef="P01_01_2018To01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_472" unitRef="USD" decimals="-5">27300000</eyen:GrossProceedsOfStockValueIssuedDuringPeriod>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2017" id="Factid_473" unitRef="USD" decimals="0">11000000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2016" id="Factid_474" unitRef="USD" decimals="0">7200000</us-gaap:OperatingLossCarryforwards>

  <eyen:NetProceedsFromIssuanceOfCommonStock contextRef="P01_01_2018To01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_475" unitRef="USD" decimals="-5">24500000</eyen:NetProceedsFromIssuanceOfCommonStock>

  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="P01_01_2017To12_31_2017" id="Factid_476" unitRef="USD" decimals="-5">1500000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>

  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2017To12_31_2017" id="Factid_477" unitRef="USD" decimals="-5">1500000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <eyen:LicenseAgreementExpiryPeriodDescription contextRef="P01_01_2015To12_31_2015_SenjuPharmaceuticalCoMemberusgaapRelatedPartyTransactionAxis" id="Factid_478">The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents.</eyen:LicenseAgreementExpiryPeriodDescription>

  <eyen:RelatedPartiesOwnershipInterestPercentage contextRef="P01_01_2015To12_31_2015" id="Factid_479" unitRef="pure" decimals="2">0.05</eyen:RelatedPartiesOwnershipInterestPercentage>

  <eyen:OfficersCompensationPerMonth contextRef="P07_01_2017To07_06_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_480" unitRef="USD" decimals="0">9167</eyen:OfficersCompensationPerMonth>

  <eyen:OfficersCompensationPerHour contextRef="P07_01_2017To07_06_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_481" unitRef="USD" decimals="0">175</eyen:OfficersCompensationPerHour>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="P07_01_2017To07_07_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_482" unitRef="shares" decimals="INF">100264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P07_01_2017To07_07_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_483" unitRef="USD_per_Share" decimals="2">1.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P07_01_2017To07_07_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_484">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P07_01_2017To07_07_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_485" unitRef="USD_per_Share" decimals="0">173900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:OfficersCompensation contextRef="P01_01_2018To01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_486" unitRef="USD" decimals="0">165000</us-gaap:OfficersCompensation>

  <us-gaap:NetRentableArea contextRef="PAsOn09_15_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_487" unitRef="sqft" decimals="0">953</us-gaap:NetRentableArea>

  <eyen:LeaseMonthlyBaseRent contextRef="P09_01_2016To09_15_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_488" unitRef="USD" decimals="0">3895</eyen:LeaseMonthlyBaseRent>

  <eyen:LesseeOperatingLeaseExpiryDate contextRef="P09_01_2016To09_15_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_489">2018-09-14</eyen:LesseeOperatingLeaseExpiryDate>

  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="P09_01_2016To09_15_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_490">P2Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>

  <us-gaap:OperatingLeaseExpense contextRef="P01_01_2017To12_31_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_491" unitRef="USD" decimals="0">45678</us-gaap:OperatingLeaseExpense>

  <us-gaap:OperatingLeaseExpense contextRef="P01_01_2016To12_31_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_492" unitRef="USD" decimals="0">18590</us-gaap:OperatingLeaseExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2017To12_31_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_493" unitRef="USD" decimals="0">1155500</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2016To12_31_2016_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_494" unitRef="USD" decimals="0">1427958</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="PAsOn12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_495" unitRef="USD" decimals="0">94998</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>

  <eyen:RoyaltyIncomePercentage contextRef="P01_01_2015To12_31_2015_SenjuPharmaceuticalCoMemberusgaapRelatedPartyTransactionAxis" id="Factid_496" unitRef="pure" decimals="2">0.05</eyen:RoyaltyIncomePercentage>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2017To12_31_2017" id="Factid_497">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

  <us-gaap:SharePrice contextRef="PAsOn03_27_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_498" unitRef="USD_per_Share" decimals="2">9.20</us-gaap:SharePrice>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2017To12_31_2017_MaximumMemberusgaapRangeAxis" id="Factid_499" unitRef="pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2018To12_31_2018_ScenarioPlanMemberusgaapStatementScenarioAxis" id="Factid_500" unitRef="pure" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="P01_01_2017To12_31_2017_SeriesAndSeriesA2ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_501">The SeriesA and SeriesA-2 Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price shall be reduced on a weighted average basis. Each share of preferred stock shall automatically be converted into shares of common stock at the then effective conversion price: (i)immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.</us-gaap:ConvertiblePreferredStockTermsOfConversion>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2017_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="Factid_502" unitRef="USD" decimals="0">2000000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_503">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Note 10 &amp;#150; Subsequent Events&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Initial Public Offering&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On January 29, 2018, the Company consummated its IPO of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 2,730,000&lt;/font&gt; shares of its common stock at an offering price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10.00&lt;/font&gt; per share, generating $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;27.3&lt;/font&gt; million and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;24.5&lt;/font&gt; million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.8&lt;/font&gt; million, a portion of which is included within deferred offering costs on the balance sheet as of December 31, 2017. &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;Conversion of Preferred Stock&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; Immediately prior to the closing of the IPO on January 29, 2018, all outstanding shares of preferred stock were automatically converted into an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 4,640,241&lt;/font&gt; shares of the Company&amp;#8217;s common stock.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;u&gt;2018 Omnibus Stock Incentive Plan&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; On March 6, 2018, the Company&amp;#8217;s Board of Directors approved the 2018 Omnibus Stock Incentive Plan (&amp;#8220;2018 Plan&amp;#8221;). The 2018 Plan provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock&amp;#160;units to employees, directors and consultants of the Company and its affiliates. The 2018 Plan will be approved and adopted by the Company upon receipt of stockholder approval and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;shall terminate on the tenth (10th) anniversary of the effective date&lt;/font&gt;. The 2018 Plan requires the exercise price of stock options to be greater than or equal to the fair value of the Company&amp;#8217;s common stock on the date of grant. There are &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; 750,000&lt;/font&gt; shares of common stock authorized under the 2018 Plan.&lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="P03_01_2018To03_06_2018_OmnibusStockIncentivePlan2018MemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_504">shall terminate on the tenth (10th) anniversary of the effective date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>

  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="PAsOn01_29_2018_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_505" unitRef="shares" decimals="INF">4640241</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="PAsOn03_06_2018_OmnibusStockIncentivePlan2018MemberusgaapPlanNameAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" id="Factid_506" unitRef="shares" decimals="INF">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>

  <eyen:OperatingLossCarryforwardsExpirationTerm contextRef="P01_01_2017To12_31_2017" id="Factid_507">2034 to 2037</eyen:OperatingLossCarryforwardsExpirationTerm>

  <eyen:NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="P01_01_2017To12_31_2017_SeriesBConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_508" unitRef="USD" decimals="0">6367693</eyen:NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock>

  <us-gaap:SecurityDeposit contextRef="PAsOn12_31_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_509" unitRef="USD" decimals="0">3895</us-gaap:SecurityDeposit>

  <us-gaap:LeaseholdImprovementsGross contextRef="PAsOn12_31_2017_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_510" unitRef="USD" decimals="0">40000</us-gaap:LeaseholdImprovementsGross>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2016" id="Factid_511" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2017" id="Factid_512" unitRef="USD" xsi:nil="true" />

  <eyen:PreferredStockProrataAllotmentPecentage contextRef="P07_01_2017To07_06_2017" id="Factid_513" unitRef="pure" decimals="2">0.75</eyen:PreferredStockProrataAllotmentPecentage>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="PAsOn12_31_2017_NonemployeeGrantsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_514" unitRef="USD" decimals="0">377816</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>

  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum contextRef="P01_01_2017To12_31_2017" id="Factid_515">P5Y3M25D</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum>

  <eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum contextRef="P01_01_2017To12_31_2017" id="Factid_516">P10Y</eyen:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2017To12_31_2017_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_517" unitRef="shares" decimals="INF">61875</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2016To12_31_2016_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_518" unitRef="shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:CostsAndExpensesRelatedParty contextRef="P01_01_2017To12_31_2017_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis_VicePresidentOfResearchAndDevelopmentMemberusgaapRelatedPartyTransactionAxis" id="Factid_519" unitRef="USD" decimals="0">9906</us-gaap:CostsAndExpensesRelatedParty>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2017To12_31_2017" id="Factid_520">&lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &lt;u&gt;Net Loss Per Common Share&lt;/u&gt;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"&gt; Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt; &lt;/font&gt;The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"&gt; &amp;#160;&lt;/div&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt; &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"&gt; &lt;div&gt;December&amp;#160;31,&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2017&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"&gt; &lt;div&gt;2016&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Options&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;1,684,416&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;786,667&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;61,875&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series A Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;2,932,431&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;3,232,294&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series A-2 Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;788,827&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;788,827&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Series B Convertible Preferred Stock&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;918,983&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="HEIGHT: 12px"&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"&gt; &lt;div&gt;Total potentially dilutive shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;6,386,532&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"&gt; &lt;div&gt;4,807,787&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"&gt; &lt;div&gt;&amp;#160;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt; &lt;/div&gt; &lt;/div&gt;&lt;table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="PAsOn12_31_2017_EquityIncentivePlanMemberusgaapPlanNameAxis" id="Factid_521" unitRef="shares" decimals="INF">48917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#Factid_362" xlink:type="locator" xlink:label="loc_1" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_1">Includes gross proceeds of $6,409,651, less issuance costs of $41,958.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_369" xlink:type="locator" xlink:label="loc_3" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_370" xlink:type="locator" xlink:label="loc_4" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_371" xlink:type="locator" xlink:label="loc_5" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_372" xlink:type="locator" xlink:label="loc_6" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_373" xlink:type="locator" xlink:label="loc_7" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_374" xlink:type="locator" xlink:label="loc_8" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_379" xlink:type="locator" xlink:label="loc_9" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_380" xlink:type="locator" xlink:label="loc_10" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_347" xlink:type="locator" xlink:label="loc_11" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_381" xlink:type="locator" xlink:label="loc_12" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
  </link:footnoteLink>
</xbrli:xbrl>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>eyen-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2018 [12:58:23] {PM} EST - www.datatracks.com -->
<schema targetNamespace="http://www.eyenoviabio.com/20171231" elementFormDefault="qualified" xmlns:eyen="http://www.eyenoviabio.com/20171231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.eyenoviabio.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>101 - Document - Document And Entity Information</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>102 - Statement - Balance Sheets</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>103 - Statement - Balance Sheets (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementsOfOperations" id="StatementsOfOperations">
        <link:definition>104 - Statement - Statements of Operations</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
        <link:definition>105 - Statement - Statements of Changes in Stockholders&#8217; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquityParenthetical" id="StatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>106 - Statement - Statements of Changes in Stockholders&#8217; Equity (Parenthetical)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>107 - Statement - Statements of Cash Flows</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperations" id="BusinessOrganizationAndNatureOfOperations">
        <link:definition>108 - Disclosure - Business Organization and Nature of Operations</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>109 - Disclosure - Summary of Significant Accounting Policies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
        <link:definition>110 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
        <link:definition>111 - Disclosure - Property and Equipment, Net</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>112 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>113 - Disclosure - Income Taxes</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>114 - Disclosure - Commitments and Contingencies</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>115 - Disclosure - Related Party Transactions</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>116 - Disclosure - Stockholders&#8217; Equity</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>117 - Disclosure - Subsequent Events</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>118 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>119 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>120 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
        <link:definition>121 - Disclosure - Property and Equipment, Net (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>122 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <link:definition>123 - Disclosure - Income Taxes (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
        <link:definition>124 - Disclosure - Commitments and Contingencies (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <link:definition>125 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperationsDetailsTextual" id="BusinessOrganizationAndNatureOfOperationsDetailsTextual">
        <link:definition>126 - Disclosure - Business Organization and Nature of Operations (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>127 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
        <link:definition>128 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>129 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetDetails">
        <link:definition>130 - Disclosure - Property and Equipment, Net (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetailsTextual" id="PropertyAndEquipmentNetDetailsTextual">
        <link:definition>131 - Disclosure - Property and Equipment, Net (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>132 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
        <link:definition>133 - Disclosure - Income Taxes (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
        <link:definition>134 - Disclosure - Income Taxes (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
        <link:definition>135 - Disclosure - Income Taxes (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
        <link:definition>136 - Disclosure - Income Taxes (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <link:definition>137 - Disclosure - Commitments and Contingencies (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
        <link:definition>138 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
        <link:definition>139 - Disclosure - Related Party Transactions (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
        <link:definition>140 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
        <link:definition>141 - Disclosure - Stockholders&#8217; Equity (Details 1)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
        <link:definition>142 - Disclosure - Stockholders&#8217; Equity (Details 2)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
        <link:definition>143 - Disclosure - Stockholders&#8217; Equity (Details 3)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
        <link:definition>144 - Disclosure - Stockholders&#8217; Equity (Details 4)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
        <link:definition>145 - Disclosure - Stockholders&#8217; Equity (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:roleType roleURI="http://www.eyenoviabio.com/role/SubsequentEventsDetailsTextual" id="SubsequentEventsDetailsTextual">
        <link:definition>146 - Disclosure - Subsequent Events (Details Textual)</link:definition>

        <link:usedOn>link:presentationLink</link:usedOn>

        <link:usedOn>link:definitionLink</link:usedOn>

        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>

      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />

      <link:linkbaseRef xlink:type="simple" xlink:href="eyen-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>

  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />

  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />

  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />

  <import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />

  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />

  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />

  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />

  <import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />

  <element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_DocumentAndEntityInformationAbstract" />

  <element name="SeriesConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SeriesConvertiblePreferredStockMember" />

  <element name="SeriesA2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SeriesA2ConvertiblePreferredStockMember" />

  <element name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SeriesBConvertiblePreferredStockMember" />

  <element name="AccrualInitialPublicOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="eyen_AccrualInitialPublicOfferingCosts" />

  <element name="AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="eyen_AccruedExpensesAndOtherLiabilitiesCurrent" />

  <element name="PreferredStockDesignatedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="eyen_PreferredStockDesignatedShares" />

  <element name="LiquidityAndFinancialConditionPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_LiquidityAndFinancialConditionPolicyTextBlock" />

  <element name="WorkingCapitalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_WorkingCapitalAmount" />

  <element name="PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />

  <element name="PrepaidResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_PrepaidResearchAndDevelopmentExpenses" />

  <element name="PrepaidPatentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_PrepaidPatentExpense" />

  <element name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="eyen_AccruedResearchAndDevelopmentExpensesCurrent" />

  <element name="AccruedLegalExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="eyen_AccruedLegalExpensesCurrent" />

  <element name="AccruedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="eyen_AccruedOfferingCosts" />

  <element name="IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" />

  <element name="OperatingLossCarryforwardsExpirationTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_OperatingLossCarryforwardsExpirationTerm" />

  <element name="ConsultingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_ConsultingFee" />

  <element name="OfficeSpaceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_OfficeSpaceExpenses" />

  <element name="ConsultingAgreementPaymentPermonth" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_ConsultingAgreementPaymentPermonth" />

  <element name="ScheduleOfWarrantsOutstandingTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ScheduleOfWarrantsOutstandingTableTextBlock" />

  <element name="WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" />

  <element name="AccruedExpensesAndOtherLiabilitiesCurrents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="eyen_AccruedExpensesAndOtherLiabilitiesCurrents" />

  <element name="CuraPartnersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_CuraPartnersMember" />

  <element name="PrivateMedicalEquityIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_PrivateMedicalEquityIncMember" />

  <element name="MinorityInterestOwnershipPercentageInCompany" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="eyen_MinorityInterestOwnershipPercentageInCompany" />

  <element name="ConsultingAgreementPaymentPerhour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_ConsultingAgreementPaymentPerhour" />

  <element name="ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" />

  <element name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" />

  <element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" />

  <element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" />

  <element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" />

  <element name="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" />

  <element name="ExercisePrice698Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ExercisePrice698Member" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" />

  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" />

  <element name="ExercisePriceOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ExercisePriceOneMember" />

  <element name="ExercisePriceTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ExercisePriceTwoMember" />

  <element name="ExercisePriceThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ExercisePriceThreeMember" />

  <element name="EquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_EquityIncentivePlanMember" />

  <element name="PreferredStockSharesNotParticipatingInFinancings" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_PreferredStockSharesNotParticipatingInFinancings" />

  <element name="PreferredStockProrataAllotmentPecentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_PreferredStockProrataAllotmentPecentage" />

  <element name="SeriesAndSeriesA2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" />

  <element name="ProceedsOfStockIssuedDuringPeriodGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_ProceedsOfStockIssuedDuringPeriodGross" />

  <element name="ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_ConsultingAgreementMember" />

  <element name="NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />

  <element name="SharePriceAtFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="eyen_SharePriceAtFairValue" />

  <element name="GrossProceedsFromIssuanceOfConvertiblePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" />

  <element name="GrossProceedsOfStockValueIssuedDuringPeriod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="credit" substitutionGroup="xbrli:item" id="eyen_GrossProceedsOfStockValueIssuedDuringPeriod" />

  <element name="NetProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_NetProceedsFromIssuanceOfCommonStock" />

  <element name="VicePresidentOfResearchAndDevelopmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_VicePresidentOfResearchAndDevelopmentMember" />

  <element name="OfficersCompensationPerMonth" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_OfficersCompensationPerMonth" />

  <element name="OfficersCompensationPerHour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_OfficersCompensationPerHour" />

  <element name="LeaseMonthlyBaseRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" xbrli:balance="debit" substitutionGroup="xbrli:item" id="eyen_LeaseMonthlyBaseRent" />

  <element name="LesseeOperatingLeaseExpiryDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_LesseeOperatingLeaseExpiryDate" />

  <element name="RoyaltyIncomePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_RoyaltyIncomePercentage" />

  <element name="LicenseAgreementExpiryPeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_LicenseAgreementExpiryPeriodDescription" />

  <element name="SenjuPharmaceuticalCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_SenjuPharmaceuticalCoMember" />

  <element name="OmnibusStockIncentivePlan2018Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_OmnibusStockIncentivePlan2018Member" />

  <element name="RelatedPartiesOwnershipInterestPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_RelatedPartiesOwnershipInterestPercentage" />

  <element name="NonemployeeGrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="eyen_NonemployeeGrantsMember" />
</schema>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>eyen-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2018 [12:58:23] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#BalanceSheets" roleURI="http://www.eyenoviabio.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PropertyAndEquipmentNet" roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNet" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxes" roleURI="http://www.eyenoviabio.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails1" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails2" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails2" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StockholdersEquity" />

  <calculationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="20" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="40" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" use="optional" order="60" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" use="optional" order="10" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="30" weight="-1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" use="optional" order="30" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrent" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrent" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="40" weight="1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" use="optional" order="20" weight="-1" />
  </calculationLink>

  <calculationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="10" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="20" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" use="optional" order="30" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" use="optional" order="40" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" use="optional" order="50" weight="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="60" weight="1" />
  </calculationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>eyen-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2018 [12:58:23] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#DocumentAndEntityInformation" roleURI="http://www.eyenoviabio.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#BalanceSheets" roleURI="http://www.eyenoviabio.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#BalanceSheetsParenthetical" roleURI="http://www.eyenoviabio.com/role/BalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PropertyAndEquipmentNetDetailsTextual" roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails1" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails2" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails2" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.eyenoviabio.com/role/RelatedPartyTransactionsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails1" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails1" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails2" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails2" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails3" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails3" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails4" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails4" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.eyenoviabio.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#BusinessOrganizationAndNatureOfOperationsDetailsTextual" roleURI="http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperationsDetailsTextual" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />

  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_20" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_21" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_21" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_21_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_21_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_14" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_15" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_16" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_16" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_17" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityPublicFloat_17" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_18" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_18" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_19" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_19" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_24" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_StatementTable_24" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_25" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_24" xlink:to="loc_us-gaap_StatementClassOfStockAxis_25" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_26" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25" xlink:to="loc_us-gaap_ClassOfStockDomain_26" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_26_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25" xlink:to="loc_us-gaap_ClassOfStockDomain_26_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_28" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_OperatingExpensesAbstract_28" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_29" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_29" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_30" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_30" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_31" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28" xlink:to="loc_us-gaap_OperatingExpenses_31" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_32" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_OperatingIncomeLoss_32" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_34" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33" xlink:to="loc_us-gaap_InvestmentIncomeInterest_34" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_35" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_NetIncomeLoss_35" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_36" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_36" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_37" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_36" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_37" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_38" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_38" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_39" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_38" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_39" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_42" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StatementTable_42" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_44" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43" xlink:to="loc_us-gaap_ClassOfStockDomain_44" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_44_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43" xlink:to="loc_us-gaap_ClassOfStockDomain_44_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember_46" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_eyen_SeriesConvertiblePreferredStockMember_46" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_47" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_47" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_48" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_48" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_255" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_CommonStockMember_255" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_256" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_256" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_257" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_RetainedEarningsMember_257" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_51" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockholdersEquity_51" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_52" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_SharesOutstanding_52" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_262" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_262" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_260" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_260" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_543" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_543" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_544" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_544" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_545" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_545" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_546" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_546" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_261" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_NetIncomeLoss_261" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_61" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_58" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_StatementTable_58" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_59" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_59" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_60" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59" xlink:to="loc_us-gaap_ClassOfStockDomain_60" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_60_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59" xlink:to="loc_us-gaap_ClassOfStockDomain_60_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_79" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_60" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_79" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_80" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_60" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_80" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_63" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" xlink:to="loc_us-gaap_NetIncomeLoss_63" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_65" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_65" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_66" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" xlink:to="loc_us-gaap_ShareBasedCompensation_66" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_69" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_69" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_70" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_70" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_73" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_73" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_556" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_556" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_77" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_77" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_76" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_76" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_81" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_81" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_83" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_83" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_86" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_86" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccrualInitialPublicOfferingCosts" xlink:label="loc_eyen_AccrualInitialPublicOfferingCosts_87" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_86" xlink:to="loc_eyen_AccrualInitialPublicOfferingCosts_87" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_88" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_86" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_88" use="optional" order="30" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StatementTable_92" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_93" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_us-gaap_StatementClassOfStockAxis_93" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_94" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93" xlink:to="loc_us-gaap_ClassOfStockDomain_94" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_94_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93" xlink:to="loc_us-gaap_ClassOfStockDomain_94_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember_95" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_94" xlink:to="loc_eyen_SeriesConvertiblePreferredStockMember_95" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_96" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_94" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_96" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_97" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_94" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_97" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_99" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AssetsAbstract_99" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_100" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_99" xlink:to="loc_us-gaap_AssetsCurrentAbstract_100" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_101" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_100" xlink:to="loc_us-gaap_Cash_101" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_102" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_100" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_102" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_103" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_100" xlink:to="loc_us-gaap_AssetsCurrent_103" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_104" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_104" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_105" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_99" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_105" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_106" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_99" xlink:to="loc_us-gaap_Assets_106" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_107" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_107" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_108" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_107" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_108" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_109" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_108" xlink:to="loc_us-gaap_AccountsPayableCurrent_109" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrent_110" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_108" xlink:to="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrent_110" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_111" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_108" xlink:to="loc_us-gaap_LiabilitiesCurrent_111" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_112" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_CommitmentsAndContingencies_112" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_113" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityAbstract_113" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_114" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_PreferredStockValue_114" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_115" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_CommonStockValue_115" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_116" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_AdditionalPaidInCapital_116" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_117" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_117" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_118" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_StockholdersEquity_118" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_119" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_119" use="optional" order="28" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_124" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_121" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_StatementTable_121" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_122" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_121" xlink:to="loc_us-gaap_StatementClassOfStockAxis_122" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_123" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_122" xlink:to="loc_us-gaap_ClassOfStockDomain_123" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_123_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_122" xlink:to="loc_us-gaap_ClassOfStockDomain_123_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember_125" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_123" xlink:to="loc_eyen_SeriesConvertiblePreferredStockMember_125" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_126" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_123" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_126" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_127" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_123" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_127" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_129" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_129" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_130" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_130" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockDesignatedShares" xlink:label="loc_eyen_PreferredStockDesignatedShares_131" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_eyen_PreferredStockDesignatedShares_131" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_132" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockSharesIssued_132" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_133" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_133" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_134" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_134" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_135" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_135" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_136" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_136" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_137" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_CommonStockSharesIssued_137" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_138" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_138" use="optional" order="17" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_590" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_162" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_StatementTable_162" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_163" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_162" xlink:to="loc_us-gaap_StatementClassOfStockAxis_163" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_164" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163" xlink:to="loc_us-gaap_ClassOfStockDomain_164" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_164_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163" xlink:to="loc_us-gaap_ClassOfStockDomain_164_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_165" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_162" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_165" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_167" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_165" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_167" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_167_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_165" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_167_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_168" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_167" xlink:to="loc_us-gaap_SubsequentEventMember_168" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_166" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_162" xlink:to="loc_us-gaap_RangeAxis_166" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_591" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_166" xlink:to="loc_us-gaap_RangeMember_591" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_591_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_166" xlink:to="loc_us-gaap_RangeMember_591_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_592" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_591" xlink:to="loc_us-gaap_MinimumMember_592" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_593" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_591" xlink:to="loc_us-gaap_MaximumMember_593" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_WorkingCapitalAmount" xlink:label="loc_eyen_WorkingCapitalAmount_174" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_eyen_WorkingCapitalAmount_174" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_176" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_176" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_177" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_CashUninsuredAmount_177" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_566" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_NetIncomeLoss_566" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_589" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_589" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_615" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_DeferredOfferingCosts_615" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_616" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_SharePrice_616" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountForLackOfMarketability" xlink:label="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability_617" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability_617" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharePriceAtFairValue" xlink:label="loc_eyen_SharePriceAtFairValue_618" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_eyen_SharePriceAtFairValue_618" use="optional" order="23" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_676" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_181" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_676" xlink:to="loc_us-gaap_StatementTable_181" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_182" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_181" xlink:to="loc_us-gaap_StatementClassOfStockAxis_182" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_183" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_182" xlink:to="loc_us-gaap_ClassOfStockDomain_183" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_183_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_182" xlink:to="loc_us-gaap_ClassOfStockDomain_183_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_185" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_183" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_185" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_188" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_183" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_188" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_186" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_183" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_186" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_184" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_181" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_184" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_586" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_184" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_586" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_586_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_184" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_586_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_587" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_586" xlink:to="loc_us-gaap_EmployeeStockOptionMember_587" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_585" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_181" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_585" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_677" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_585" xlink:to="loc_us-gaap_EquityComponentDomain_677" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_677_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_585" xlink:to="loc_us-gaap_EquityComponentDomain_677_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_678" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_677" xlink:to="loc_us-gaap_WarrantMember_678" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_584" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_676" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_584" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_596" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_216" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_596" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_216" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_217" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_596" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_217" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_373" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_596" xlink:to="loc_us-gaap_StatementTable_373" use="optional" order="3" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_374" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_373" xlink:to="loc_us-gaap_StatementClassOfStockAxis_374" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_375" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_374" xlink:to="loc_us-gaap_ClassOfStockDomain_375" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_375_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_374" xlink:to="loc_us-gaap_ClassOfStockDomain_375_default" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_376" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_373" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_376" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_599" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597" xlink:to="loc_us-gaap_EquipmentMember_599" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_598" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_598" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_218" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_596" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_218" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_372" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_220" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_220" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_369" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_StatementTable_369" use="optional" order="2" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_370" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_369" xlink:to="loc_us-gaap_StatementClassOfStockAxis_370" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371_default" use="optional" order="5" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_414" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_240" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_240" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_241" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_240" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_241" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_242" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_240" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_242" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_243" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_243" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_415" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_243" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_415" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_244" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_243" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_244" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_250" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_250" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_416" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_416" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_411" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_StatementTable_411" use="optional" order="9" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_412" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_411" xlink:to="loc_us-gaap_StatementClassOfStockAxis_412" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_412" xlink:to="loc_us-gaap_ClassOfStockDomain_413" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_412" xlink:to="loc_us-gaap_ClassOfStockDomain_413_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_247" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_247" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_381" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_eyen_AccruedResearchAndDevelopmentExpensesCurrent_232" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_eyen_AccruedResearchAndDevelopmentExpensesCurrent_232" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedLegalExpensesCurrent" xlink:label="loc_eyen_AccruedLegalExpensesCurrent_233" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_eyen_AccruedLegalExpensesCurrent_233" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_234" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_us-gaap_AccruedRentCurrent_234" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_235" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_235" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedOfferingCosts" xlink:label="loc_eyen_AccruedOfferingCosts_236" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_eyen_AccruedOfferingCosts_236" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_237" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_237" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_378" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_us-gaap_StatementTable_378" use="optional" order="7" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_379" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_378" xlink:to="loc_us-gaap_StatementClassOfStockAxis_379" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_380" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_379" xlink:to="loc_us-gaap_ClassOfStockDomain_380" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_380_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_379" xlink:to="loc_us-gaap_ClassOfStockDomain_380_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrents" xlink:label="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrents_382" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrents_382" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_420" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_271" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_271" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_272" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_272" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_273" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_273" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_621" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_621" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_622" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_622" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_417" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_StatementTable_417" use="optional" order="6" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_418" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_417" xlink:to="loc_us-gaap_StatementClassOfStockAxis_418" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_419" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_418" xlink:to="loc_us-gaap_ClassOfStockDomain_419" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_419_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_418" xlink:to="loc_us-gaap_ClassOfStockDomain_419_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_274" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_274" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_275" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_275" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_424" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_421" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_424" xlink:to="loc_us-gaap_StatementTable_421" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_422" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_421" xlink:to="loc_us-gaap_StatementClassOfStockAxis_422" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_423" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_422" xlink:to="loc_us-gaap_ClassOfStockDomain_423" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_423_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_422" xlink:to="loc_us-gaap_ClassOfStockDomain_423_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_424" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_281" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_281" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_282" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_282" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_283" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_283" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_284" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_284" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_285" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_285" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_286" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_286" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_287" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_287" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_288" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_288" use="optional" order="13" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_680" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_291" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_OperatingLossCarryforwards_291" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OperatingLossCarryforwardsExpirationTerm" xlink:label="loc_eyen_OperatingLossCarryforwardsExpirationTerm_292" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_eyen_OperatingLossCarryforwardsExpirationTerm_292" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_425" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_StatementTable_425" use="optional" order="3" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_626" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_425" xlink:to="loc_us-gaap_StatementScenarioAxis_626" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_660" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_626" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_660" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_660_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_626" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_660_default" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_661" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_660" xlink:to="loc_us-gaap_ScenarioPlanMember_661" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_656" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_425" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_656" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_658" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_656" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_658" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_658_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_656" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_658_default" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_659" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_658" xlink:to="loc_us-gaap_DomesticCountryMember_659" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_657" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_425" xlink:to="loc_us-gaap_RangeAxis_657" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_681" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_657" xlink:to="loc_us-gaap_RangeMember_681" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_681_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_657" xlink:to="loc_us-gaap_RangeMember_681_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_682" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_681" xlink:to="loc_us-gaap_MaximumMember_682" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_430" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_430" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_631" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_631" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_632" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_632" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_633" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_633" use="optional" order="19" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_386" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_300" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_386" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_300" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_301" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_386" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_301" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_383" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_386" xlink:to="loc_us-gaap_StatementTable_383" use="optional" order="3" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_384" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_383" xlink:to="loc_us-gaap_StatementClassOfStockAxis_384" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_385" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_384" xlink:to="loc_us-gaap_ClassOfStockDomain_385" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_385_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_384" xlink:to="loc_us-gaap_ClassOfStockDomain_385_default" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_303" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_NetRentableArea_303" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_304" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_304" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_306" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_LeaseExpirationDate1_306" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_307" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_307" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_308" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_308" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_309" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_309" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xlink:label="loc_us-gaap_MalpracticeLossContingencyInsuranceRecoveries_310" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_MalpracticeLossContingencyInsuranceRecoveries_310" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_387" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_StatementTable_387" use="optional" order="8" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_388" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_387" xlink:to="loc_us-gaap_StatementClassOfStockAxis_388" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_389" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_388" xlink:to="loc_us-gaap_ClassOfStockDomain_389" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_389_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_388" xlink:to="loc_us-gaap_ClassOfStockDomain_389_default" use="optional" order="11" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/RelatedPartyTransactionsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_635" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingFee" xlink:label="loc_eyen_ConsultingFee_316" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_ConsultingFee_316" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_317" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_317" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficeSpaceExpenses" xlink:label="loc_eyen_OfficeSpaceExpenses_318" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_OfficeSpaceExpenses_318" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_319" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_LeaseAndRentalExpense_319" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="loc_eyen_ConsultingAgreementPaymentPermonth_320" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_ConsultingAgreementPaymentPermonth_320" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_StatementTable_393" use="optional" order="6" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_394" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_StatementClassOfStockAxis_394" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_395" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_394" xlink:to="loc_us-gaap_ClassOfStockDomain_395" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_395_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_394" xlink:to="loc_us-gaap_ClassOfStockDomain_395_default" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_396" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_396" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_398" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_396" xlink:to="loc_us-gaap_RelatedPartyDomain_398" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_398_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_396" xlink:to="loc_us-gaap_RelatedPartyDomain_398_default" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_CuraPartnersMember" xlink:label="loc_eyen_CuraPartnersMember_399" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_398" xlink:to="loc_eyen_CuraPartnersMember_399" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrivateMedicalEquityIncMember" xlink:label="loc_eyen_PrivateMedicalEquityIncMember_400" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_398" xlink:to="loc_eyen_PrivateMedicalEquityIncMember_400" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="loc_us-gaap_BeneficialOwnerMember_604" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_398" xlink:to="loc_us-gaap_BeneficialOwnerMember_604" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_397" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_TitleOfIndividualAxis_397" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_408" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_397" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_408" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_408_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_397" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_408_default" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_409" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_408" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_409" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_407" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_407" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_569" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_407" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_569" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_569_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_407" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_569_default" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_570" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_569" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_570" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_603" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_569" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_603" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_568" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_568" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_601" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_568" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_601" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_601_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_568" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_601_default" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementMember" xlink:label="loc_eyen_ConsultingAgreementMember_602" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_601" xlink:to="loc_eyen_ConsultingAgreementMember_602" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="loc_eyen_VicePresidentOfResearchAndDevelopmentMember_634" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_601" xlink:to="loc_eyen_VicePresidentOfResearchAndDevelopmentMember_634" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="loc_eyen_SenjuPharmaceuticalCoMember_654" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_601" xlink:to="loc_eyen_SenjuPharmaceuticalCoMember_654" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_600" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_600" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_636" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_600" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_636" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_636_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_600" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_636_default" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_637" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_636" xlink:to="loc_us-gaap_SubsequentEventMember_637" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_402" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_402" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_MinorityInterestOwnershipPercentageInCompany" xlink:label="loc_eyen_MinorityInterestOwnershipPercentageInCompany_404" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_MinorityInterestOwnershipPercentageInCompany_404" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="loc_eyen_ConsultingAgreementPaymentPerhour_405" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_ConsultingAgreementPaymentPerhour_405" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficersCompensationPerMonth" xlink:label="loc_eyen_OfficersCompensationPerMonth_638" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_OfficersCompensationPerMonth_638" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficersCompensationPerHour" xlink:label="loc_eyen_OfficersCompensationPerHour_639" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_OfficersCompensationPerHour_639" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_640" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_640" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_641" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_641" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_642" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_642" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_643" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_643" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_644" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_OfficersCompensation_644" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_645" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_NetRentableArea_645" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="loc_eyen_LeaseMonthlyBaseRent_646" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_LeaseMonthlyBaseRent_646" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LesseeOperatingLeaseExpiryDate" xlink:label="loc_eyen_LesseeOperatingLeaseExpiryDate_647" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_LesseeOperatingLeaseExpiryDate_647" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_648" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_648" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_649" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_OperatingLeaseExpense_649" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_650" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_650" use="optional" order="50" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_679" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_679" use="optional" order="51" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_RoyaltyIncomePercentage" xlink:label="loc_eyen_RoyaltyIncomePercentage_651" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_RoyaltyIncomePercentage_651" use="optional" order="52" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LicenseAgreementExpiryPeriodDescription" xlink:label="loc_eyen_LicenseAgreementExpiryPeriodDescription_652" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_LicenseAgreementExpiryPeriodDescription_652" use="optional" order="53" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_RelatedPartiesOwnershipInterestPercentage" xlink:label="loc_eyen_RelatedPartiesOwnershipInterestPercentage_653" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_RelatedPartiesOwnershipInterestPercentage_653" use="optional" order="54" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_668" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_SecurityDeposit_668" use="optional" order="55" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_669" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_669" use="optional" order="56" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_438" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_337" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_337" use="optional" order="1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_338" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_338" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_339" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_339" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_340" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_340" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_341" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_341" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_342" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_342" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice_350" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice_350" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_344" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_344" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_351" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_351" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_439" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_439" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_435" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_StatementTable_435" use="optional" order="11" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_436" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_435" xlink:to="loc_us-gaap_StatementClassOfStockAxis_436" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_437" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_436" xlink:to="loc_us-gaap_ClassOfStockDomain_437" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_437_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_436" xlink:to="loc_us-gaap_ClassOfStockDomain_437_default" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_352" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_352" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue_440" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue_440" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_449" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_441" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_us-gaap_StatementTable_441" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_442" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_441" xlink:to="loc_us-gaap_StatementClassOfStockAxis_442" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_443" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_442" xlink:to="loc_us-gaap_ClassOfStockDomain_443" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_443_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_442" xlink:to="loc_us-gaap_ClassOfStockDomain_443_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_444" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_441" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_444" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_450" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_444" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_450" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_450_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_444" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_450_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePrice698Member" xlink:label="loc_eyen_ExercisePrice698Member_451" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_450" xlink:to="loc_eyen_ExercisePrice698Member_451" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice_445" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice_445" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants_446" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants_446" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife_447" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife_447" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants_448" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants_448" use="optional" order="12" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_457" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_453" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_StatementTable_453" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_454" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_StatementClassOfStockAxis_454" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_455" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_454" xlink:to="loc_us-gaap_ClassOfStockDomain_455" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_455_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_454" xlink:to="loc_us-gaap_ClassOfStockDomain_455_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_456" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_RangeAxis_456" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_458" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_456" xlink:to="loc_us-gaap_RangeMember_458" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_458_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_456" xlink:to="loc_us-gaap_RangeMember_458_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum_673" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum_673" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum_674" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum_674" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_461" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_461" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_462" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_462" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_463" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_463" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_464" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_464" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_465" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_465" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_470" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_467" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_StatementTable_467" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_468" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_467" xlink:to="loc_us-gaap_StatementClassOfStockAxis_468" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_469" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_468" xlink:to="loc_us-gaap_ClassOfStockDomain_469" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_469_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_468" xlink:to="loc_us-gaap_ClassOfStockDomain_469_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_471" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_471" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_472" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_472" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_473" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_473" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_475" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_475" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_476" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_476" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_477" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_477" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_478" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_478" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_480" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_480" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_481" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_481" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_482" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_482" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_606" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_606" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_483" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_483" use="optional" order="16" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_490" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_486" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_StatementTable_486" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_487" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_486" xlink:to="loc_us-gaap_StatementClassOfStockAxis_487" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_488" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_487" xlink:to="loc_us-gaap_ClassOfStockDomain_488" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_488_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_487" xlink:to="loc_us-gaap_ClassOfStockDomain_488_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_489" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_486" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_489" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_489" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_489" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceOneMember" xlink:label="loc_eyen_ExercisePriceOneMember_492" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" xlink:to="loc_eyen_ExercisePriceOneMember_492" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceTwoMember" xlink:label="loc_eyen_ExercisePriceTwoMember_493" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" xlink:to="loc_eyen_ExercisePriceTwoMember_493" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceThreeMember" xlink:label="loc_eyen_ExercisePriceThreeMember_494" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" xlink:to="loc_eyen_ExercisePriceThreeMember_494" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_495" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_495" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_496" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_496" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_497" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_497" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_498" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_498" use="optional" order="14" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_663" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_358" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_StatementTable_358" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_359" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_358" xlink:to="loc_us-gaap_StatementClassOfStockAxis_359" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_360" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_359" xlink:to="loc_us-gaap_ClassOfStockDomain_360" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_360_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_359" xlink:to="loc_us-gaap_ClassOfStockDomain_360_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_361" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_358" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_361" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_540" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_361" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_540" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_540_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_361" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_540_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_541" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_540" xlink:to="loc_us-gaap_SubsequentEventMember_541" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_362" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_358" xlink:to="loc_us-gaap_PlanNameAxis_362" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_664" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_362" xlink:to="loc_us-gaap_PlanNameDomain_664" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_664_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_362" xlink:to="loc_us-gaap_PlanNameDomain_664_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="loc_eyen_OmnibusStockIncentivePlan2018Member_665" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_664" xlink:to="loc_eyen_OmnibusStockIncentivePlan2018Member_665" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_365" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_365" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_367" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_367" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="loc_eyen_GrossProceedsOfStockValueIssuedDuringPeriod_623" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_eyen_GrossProceedsOfStockValueIssuedDuringPeriod_623" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_624" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_624" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_eyen_NetProceedsFromIssuanceOfCommonStock_625" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_eyen_NetProceedsFromIssuanceOfCommonStock_625" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_662" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_662" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_667" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_667" use="optional" order="20" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_501" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_StatementTable_501" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_502" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_StatementClassOfStockAxis_502" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_502" xlink:to="loc_us-gaap_ClassOfStockDomain_503" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_502" xlink:to="loc_us-gaap_ClassOfStockDomain_503_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember_509" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_eyen_SeriesConvertiblePreferredStockMember_509" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_510" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_510" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_511" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_511" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_580" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_580" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_504" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_504" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_514" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_504" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_514" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_514_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_504" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_514_default" use="optional" order="11" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_515" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_514" xlink:to="loc_us-gaap_SubsequentEventMember_515" use="optional" order="12" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_513" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_PlanNameAxis_513" use="optional" order="13" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_517" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_513" xlink:to="loc_us-gaap_PlanNameDomain_517" use="optional" order="14" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_517_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_513" xlink:to="loc_us-gaap_PlanNameDomain_517_default" use="optional" order="15" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_EquityIncentivePlanMember" xlink:label="loc_eyen_EquityIncentivePlanMember_518" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_517" xlink:to="loc_eyen_EquityIncentivePlanMember_518" use="optional" order="16" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_516" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_RangeAxis_516" use="optional" order="17" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_577" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_516" xlink:to="loc_us-gaap_RangeMember_577" use="optional" order="18" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_577_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_516" xlink:to="loc_us-gaap_RangeMember_577_default" use="optional" order="19" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_578" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_577" xlink:to="loc_us-gaap_MaximumMember_578" use="optional" order="20" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_579" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_577" xlink:to="loc_us-gaap_MinimumMember_579" use="optional" order="21" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_576" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_576" use="optional" order="22" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_576" xlink:to="loc_us-gaap_RelatedPartyDomain_671" use="optional" order="23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_576" xlink:to="loc_us-gaap_RelatedPartyDomain_671_default" use="optional" order="24" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NonemployeeGrantsMember" xlink:label="loc_eyen_NonemployeeGrantsMember_672" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_671" xlink:to="loc_eyen_NonemployeeGrantsMember_672" use="optional" order="25" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_505" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_505" use="optional" order="26" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_506" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_506" use="optional" order="27" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_507" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_507" use="optional" order="28" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_508" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_508" use="optional" order="29" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockDesignatedShares" xlink:label="loc_eyen_PreferredStockDesignatedShares_512" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_PreferredStockDesignatedShares_512" use="optional" order="30" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_521" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_521" use="optional" order="31" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_522" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_522" use="optional" order="32" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_523" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_523" use="optional" order="33" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_524" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_524" use="optional" order="34" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_525" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_525" use="optional" order="35" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockSharesNotParticipatingInFinancings" xlink:label="loc_eyen_PreferredStockSharesNotParticipatingInFinancings_526" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_PreferredStockSharesNotParticipatingInFinancings_526" use="optional" order="36" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockProrataAllotmentPecentage" xlink:label="loc_eyen_PreferredStockProrataAllotmentPecentage_527" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_PreferredStockProrataAllotmentPecentage_527" use="optional" order="37" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_528" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_528" use="optional" order="38" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_529" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_529" use="optional" order="39" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_532" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_532" use="optional" order="40" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_533" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_533" use="optional" order="41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_534" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_534" use="optional" order="42" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536" use="optional" order="43" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_537" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_537" use="optional" order="44" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_538" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_538" use="optional" order="45" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_539" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_539" use="optional" order="46" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_571" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_571" use="optional" order="47" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock_613" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock_613" use="optional" order="48" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock_619" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock_619" use="optional" order="49" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_655" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_SharePrice_655" use="optional" order="50" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_552" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_549" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_552" xlink:to="loc_us-gaap_StatementTable_549" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_550" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_549" xlink:to="loc_us-gaap_StatementClassOfStockAxis_550" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_551" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_550" xlink:to="loc_us-gaap_ClassOfStockDomain_551" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_551_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_550" xlink:to="loc_us-gaap_ClassOfStockDomain_551_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="loc_eyen_ProceedsOfStockIssuedDuringPeriodGross_581" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_552" xlink:to="loc_eyen_ProceedsOfStockIssuedDuringPeriodGross_581" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_582" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_552" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_582" use="optional" order="6" />
  </definitionLink>

  <definitionLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperationsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_572" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_559" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_572" xlink:to="loc_us-gaap_StatementTable_559" use="optional" order="1" xbrldt:contextElement="segment" xbrldt:closed="true" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_560" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_559" xlink:to="loc_us-gaap_StatementClassOfStockAxis_560" use="optional" order="2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_561" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_560" xlink:to="loc_us-gaap_ClassOfStockDomain_561" use="optional" order="3" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_561_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_560" xlink:to="loc_us-gaap_ClassOfStockDomain_561_default" use="optional" order="4" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_562" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_559" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_562" use="optional" order="5" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_573" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_562" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_573" use="optional" order="6" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_573_default" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_562" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_573_default" use="optional" order="7" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_574" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_573" xlink:to="loc_us-gaap_SubsequentEventMember_574" use="optional" order="8" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationStateCountryName" xlink:label="loc_dei_EntityIncorporationStateCountryName_563" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572" xlink:to="loc_dei_EntityIncorporationStateCountryName_563" use="optional" order="9" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_564" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_564" use="optional" order="10" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_565" />

    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_572" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_565" use="optional" order="11" />
  </definitionLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>eyen-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2018 [12:58:23] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />

  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />

  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_DocumentAndEntityInformationAbstract" xlink:label="loc_eyen_DocumentAndEntityInformationAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_DocumentAndEntityInformationAbstract" xlink:to="lab_eyen_DocumentAndEntityInformationAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss From Operations</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net Loss Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">- Basic and Diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Weighted Average Number of Common Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">- Basic and Diluted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders&#39; Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SeriesConvertiblePreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SeriesConvertiblePreferredStockMember" xlink:to="lab_eyen_SeriesConvertiblePreferredStockMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SeriesA2ConvertiblePreferredStockMember" xml:lang="en-US">Series A2 Convertible Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_SeriesA2ConvertiblePreferredStockMember" xml:lang="en-US">Series A-2 Convertible Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SeriesA2ConvertiblePreferredStockMember" xlink:to="lab_eyen_SeriesA2ConvertiblePreferredStockMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SeriesBConvertiblePreferredStockMember" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SeriesBConvertiblePreferredStockMember" xlink:to="lab_eyen_SeriesBConvertiblePreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders&#39; Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accrued expenses and other current liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used In Investing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xml:lang="en-US">Payments for Repurchase of Initial Public Offering</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xml:lang="en-US">Payment of initial public offering costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from sale of Convertible Preferred Stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of Series B Convertible Preferred Stock issuance costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from sale of warrant</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net Increase in Cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash - Beginning of Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash - End of Period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental Disclosure of Non-Cash Financing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccrualInitialPublicOfferingCosts" xlink:label="loc_eyen_AccrualInitialPublicOfferingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_AccrualInitialPublicOfferingCosts" xml:lang="en-US">Accrual initial public offering costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_AccrualInitialPublicOfferingCosts" xml:lang="en-US">Accrual of intitial public offering costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_AccrualInitialPublicOfferingCosts" xml:lang="en-US">Amount of accrual initial public offering costs.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_AccrualInitialPublicOfferingCosts" xlink:to="lab_eyen_AccrualInitialPublicOfferingCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of Stock, Amount Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of convertible preferred stock into common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Total prepaid expenses and other current assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xml:lang="en-US">Deferred offering costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xml:lang="en-US">Accrued expenses and other liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xml:lang="en-US">Accrued expenses and other current liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="lab_eyen_AccruedExpensesAndOtherLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 7)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity Attributable to Parent [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders&#39; Equity:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.0001 par value, 60,000,000 shares authorized as of December 31, 2017 (see Note 9), 2,566,530 and 2,266,667 shares issued and outstanding as of December 31, 2017 and 2016, respectively</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders&#39; Equity</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockDesignatedShares" xlink:label="loc_eyen_PreferredStockDesignatedShares" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_PreferredStockDesignatedShares" xml:lang="en-US">Preferred Stock Designated Shares</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_PreferredStockDesignatedShares" xml:lang="en-US">The number of designated preferred stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_PreferredStockDesignatedShares" xlink:to="lab_eyen_PreferredStockDesignatedShares" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LiquidityAndFinancialConditionPolicyTextBlock" xlink:label="loc_eyen_LiquidityAndFinancialConditionPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_LiquidityAndFinancialConditionPolicyTextBlock" xml:lang="en-US">Liquidity and Financial Condition [Policy Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_LiquidityAndFinancialConditionPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for liquidity and financial condition.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_LiquidityAndFinancialConditionPolicyTextBlock" xlink:to="lab_eyen_LiquidityAndFinancialConditionPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xml:lang="en-US">Stockholders&#39; Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="lab_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis" xlink:to="lab_us-gaap_RangeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_WorkingCapitalAmount" xlink:label="loc_eyen_WorkingCapitalAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_WorkingCapitalAmount" xml:lang="en-US">Working capital, Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_WorkingCapitalAmount" xml:lang="en-US">The increase in amount of working capital.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_WorkingCapitalAmount" xlink:to="lab_eyen_WorkingCapitalAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashUninsuredAmount" xml:lang="en-US">Cash, Uninsured Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="loc_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xml:lang="en-US">Prepaid Expenses and Other Current Assets Disclosure [Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xml:lang="en-US">The entire disclosure of prepaid expenses and other current assets.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="lab_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="loc_eyen_PrepaidResearchAndDevelopmentExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_PrepaidResearchAndDevelopmentExpenses" xml:lang="en-US">Prepaid research and development expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_PrepaidResearchAndDevelopmentExpenses" xml:lang="en-US">Prepaid research and development expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_PrepaidResearchAndDevelopmentExpenses" xml:lang="en-US">Amount of asset related to consideration paid in advance for research and development expenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_PrepaidResearchAndDevelopmentExpenses" xlink:to="lab_eyen_PrepaidResearchAndDevelopmentExpenses" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrepaidPatentExpense" xlink:label="loc_eyen_PrepaidPatentExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_PrepaidPatentExpense" xml:lang="en-US">Prepaid Patent Expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_PrepaidPatentExpense" xml:lang="en-US">Prepaid patent expense</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_PrepaidPatentExpense" xml:lang="en-US">Amount of asset related to consideration paid in advance for patent expenses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_PrepaidPatentExpense" xlink:to="lab_eyen_PrepaidPatentExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid Insurance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid insurance expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation and amortization</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_eyen_AccruedResearchAndDevelopmentExpensesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_AccruedResearchAndDevelopmentExpensesCurrent" xml:lang="en-US">Accrued research and development expenses, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_AccruedResearchAndDevelopmentExpensesCurrent" xml:lang="en-US">Accrued research and development expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_AccruedResearchAndDevelopmentExpensesCurrent" xml:lang="en-US">Amount of accrued research and development expenses paid by the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="lab_eyen_AccruedResearchAndDevelopmentExpensesCurrent" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedLegalExpensesCurrent" xlink:label="loc_eyen_AccruedLegalExpensesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_AccruedLegalExpensesCurrent" xml:lang="en-US">Accrued legal expenses, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_AccruedLegalExpensesCurrent" xml:lang="en-US">Accrued legal expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_AccruedLegalExpensesCurrent" xml:lang="en-US">Amount of accrued legal expenses paid by the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_AccruedLegalExpensesCurrent" xlink:to="lab_eyen_AccruedLegalExpensesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedRentCurrent" xml:lang="en-US">Accrued Rent, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedRentCurrent" xml:lang="en-US">Accrued rent expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrent" xlink:to="lab_us-gaap_AccruedRentCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional services</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedOfferingCosts" xlink:label="loc_eyen_AccruedOfferingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_AccruedOfferingCosts" xml:lang="en-US">Accrued offering costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_AccruedOfferingCosts" xml:lang="en-US">Accrued offering costs</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_AccruedOfferingCosts" xml:lang="en-US">Amount of accrued offering costs paid by the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_AccruedOfferingCosts" xlink:to="lab_eyen_AccruedOfferingCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Federal:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">State and local:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xml:lang="en-US">Income Tax Expense Benefit Before Adjustments for Change in Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xml:lang="en-US">Income Tax Expense Benefit Before Adjustments for Change in Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xml:lang="en-US">Represents the income tax expense (benefit) before change in valuation allowance.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:to="lab_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Change in valuation allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Changes in valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-In Capital [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US">Issuance of warrant</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance convertible preferred stock, net of issuance costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance convertible preferred stock, net of issuance costs (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of Series A convertible preferred stock into common stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Tax benefit at federal statutory rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income taxes, net of federal benefit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Incremental research and development credits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xml:lang="en-US">Prior period adjustments and other</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effect of tax rate changes</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock-based compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Research &#38; development tax credits</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangible assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Gross deferred tax assets</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OperatingLossCarryforwardsExpirationTerm" xlink:label="loc_eyen_OperatingLossCarryforwardsExpirationTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_OperatingLossCarryforwardsExpirationTerm" xml:lang="en-US">Operating loss carryforwards expiration term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_OperatingLossCarryforwardsExpirationTerm" xml:lang="en-US">The expiry term of carryforward operating losses.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_OperatingLossCarryforwardsExpirationTerm" xlink:to="lab_eyen_OperatingLossCarryforwardsExpirationTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">2018</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetRentableArea" xml:lang="en-US">Net Rentable Area</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetRentableArea" xlink:to="lab_us-gaap_NetRentableArea" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseMinimumRentals" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xml:lang="en-US">Loss Contingency, Damages Sought, Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xlink:label="loc_us-gaap_MalpracticeLossContingencyInsuranceRecoveries" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xml:lang="en-US">Malpractice Loss Contingency, Insurance Recoveries</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xlink:to="lab_us-gaap_MalpracticeLossContingencyInsuranceRecoveries" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingFee" xlink:label="loc_eyen_ConsultingFee" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ConsultingFee" xml:lang="en-US">Consulting Fee</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ConsultingFee" xml:lang="en-US">Amount of expenses related to consulting fees.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ConsultingFee" xlink:to="lab_eyen_ConsultingFee" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficeSpaceExpenses" xlink:label="loc_eyen_OfficeSpaceExpenses" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_OfficeSpaceExpenses" xml:lang="en-US">Office space expenses</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_OfficeSpaceExpenses" xml:lang="en-US">Amount of expenses incurred for office space.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_OfficeSpaceExpenses" xlink:to="lab_eyen_OfficeSpaceExpenses" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="loc_eyen_ConsultingAgreementPaymentPermonth" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ConsultingAgreementPaymentPermonth" xml:lang="en-US">Consulting agreement payment, Permonth</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ConsultingAgreementPaymentPermonth" xml:lang="en-US">It represents monthly consulting fee expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ConsultingAgreementPaymentPermonth" xlink:to="lab_eyen_ConsultingAgreementPaymentPermonth" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders&#39; Equity Note Disclosure [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_eyen_ScheduleOfWarrantsOutstandingTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ScheduleOfWarrantsOutstandingTableTextBlock" xml:lang="en-US">Schedule Of Warrants Outstanding [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ScheduleOfWarrantsOutstandingTableTextBlock" xml:lang="en-US">The tabular disclosure of warrants outstanding.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:to="lab_eyen_ScheduleOfWarrantsOutstandingTableTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" xlink:label="loc_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" xml:lang="en-US">Warrants Outstanding And Exercisable Exercise Price [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" xml:lang="en-US">The tabular disclosure of warrants outstanding and exercisable exercise price.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" xlink:to="lab_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Warrants, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Number of Warrants, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of Warrants, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Number of Warrants, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xml:lang="en-US">Number of Warrants, Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xml:lang="en-US">The number of shares into which fully or partially vested other than option awards outstanding as of the balance sheet date can be currently converted under the plan.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:to="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Non Vested Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xml:lang="en-US">The weighted average exercise price of nonvested awards on equity-based plans excluding option plans.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:to="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xml:lang="en-US">The weighted average exercise price of granted awards on equity-based plans excluding option plans.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:to="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" xml:lang="en-US">The weighted average exercise price of forfeited awards on equity-based plans excluding option plans.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" xlink:to="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Exercisable Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">The weighted average exercise price of exercisable awards on equity-based plans excluding option plans.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Life In Years, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrents" xlink:label="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrents" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_AccruedExpensesAndOtherLiabilitiesCurrents" xml:lang="en-US">Accrued expenses and other liabilities, Currents</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_AccruedExpensesAndOtherLiabilitiesCurrents" xml:lang="en-US">Total accrued expenses and other current liabilities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_AccruedExpensesAndOtherLiabilitiesCurrents" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrents" xlink:to="lab_eyen_AccruedExpensesAndOtherLiabilitiesCurrents" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis" xlink:to="lab_us-gaap_TitleOfIndividualAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_CuraPartnersMember" xlink:label="loc_eyen_CuraPartnersMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_CuraPartnersMember" xml:lang="en-US">Cura Partners [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_CuraPartnersMember" xlink:to="lab_eyen_CuraPartnersMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrivateMedicalEquityIncMember" xlink:label="loc_eyen_PrivateMedicalEquityIncMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_PrivateMedicalEquityIncMember" xml:lang="en-US">Private Medical Equity, Inc. [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_PrivateMedicalEquityIncMember" xlink:to="lab_eyen_PrivateMedicalEquityIncMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_MinorityInterestOwnershipPercentageInCompany" xlink:label="loc_eyen_MinorityInterestOwnershipPercentageInCompany" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_MinorityInterestOwnershipPercentageInCompany" xml:lang="en-US">Minority Interest Ownership Percentage In Company</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_MinorityInterestOwnershipPercentageInCompany" xml:lang="en-US">The minority interest ownership percentage in company.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_MinorityInterestOwnershipPercentageInCompany" xlink:to="lab_eyen_MinorityInterestOwnershipPercentageInCompany" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="loc_eyen_ConsultingAgreementPaymentPerhour" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ConsultingAgreementPaymentPerhour" xml:lang="en-US">Consulting agreement payment, Perhour</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ConsultingAgreementPaymentPerhour" xml:lang="en-US">It represents hourly consulting fee expenses</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ConsultingAgreementPaymentPerhour" xlink:to="lab_eyen_ConsultingAgreementPaymentPerhour" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_us-gaap_ChiefExecutiveOfficerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax (provision) benefit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xml:lang="en-US">Tax Credit Carryforward, Limitations on Use</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:to="lab_us-gaap_TaxCreditCarryforwardLimitationsOnUse" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:label="loc_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xml:lang="en-US">Schedule Of Share Based Compensation Shares Outstanding Under Stock Option Plans By Exercise Price Range [Table Text Block]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xml:lang="en-US">The tabular disclosure of share based compensation shares outstanding under stock option plans by exercise price range.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:to="lab_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Remaining Contractual Terms</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted Average Remaining Life In Years, Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xml:lang="en-US">Weighted average remaining contractual term for equity-based awards excluding options which are exercisable.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:to="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Aggregated Intrinsic Vallue</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" xml:lang="en-US">The aggregate intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" xlink:to="lab_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Warrants, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" xml:lang="en-US">Warrants Outstanding, Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" xml:lang="en-US">The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock warrants which are in the customized range of exercise prices.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" xlink:to="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" xml:lang="en-US">Warrants Outstanding, Outstanding Number of Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" xml:lang="en-US">The number of shares reserved for issuance pertaining to the outstanding stock warrants as of the balance sheet date for all option plans in the customized range of exercise prices.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" xlink:to="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Life</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" xml:lang="en-US">Warrants Exercisable, Weighted Average Remaining Life In Years</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" xml:lang="en-US">The weighted remaining life of the all outstanding stock warrants which are in the customized range of exercise prices.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" xlink:to="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" xml:lang="en-US">Warrants Exercisable, Exercisable Number of Warrants</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" xml:lang="en-US">The number of shares reserved for issuance pertaining to the outstanding exercisable stock warrants as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" xlink:to="lab_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePrice698Member" xlink:label="loc_eyen_ExercisePrice698Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ExercisePrice698Member" xml:lang="en-US">Exercise Price 6.98 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ExercisePrice698Member" xlink:to="lab_eyen_ExercisePrice698Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember" xlink:to="lab_us-gaap_RangeMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Minimum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" xml:lang="en-US">Expected term, Minimum (years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" xml:lang="en-US">The minimum expected term of share-based compensation awards, in &#39;PnYnMnDTnHnMnS&#39; format, for example, &#39;P1Y5M13D&#39; represents the reported fact of one year, five months, and thirteen days.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" xlink:to="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Term Maximum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" xml:lang="en-US">Expected term, Maximum (years)</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" xml:lang="en-US">The maximum expected term of share-based compensation awards, in &#39;PnYnMnDTnHnMnS&#39; format, for example, &#39;P1Y5M13D&#39; represents the reported fact of one year, five months, and thirteen days.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" xlink:to="lab_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (years)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk free interest rate, Minimum</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk free interest rate, Maximum</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Options, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Options, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Life In Years, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Life In Years, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceOneMember" xlink:label="loc_eyen_ExercisePriceOneMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ExercisePriceOneMember" xml:lang="en-US">Exercise Price One [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_ExercisePriceOneMember" xml:lang="en-US">Exercise Price 1.24 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ExercisePriceOneMember" xlink:to="lab_eyen_ExercisePriceOneMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceTwoMember" xlink:label="loc_eyen_ExercisePriceTwoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ExercisePriceTwoMember" xml:lang="en-US">Exercise Price Two [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_ExercisePriceTwoMember" xml:lang="en-US">Exercise Price 1.95 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ExercisePriceTwoMember" xlink:to="lab_eyen_ExercisePriceTwoMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceThreeMember" xlink:label="loc_eyen_ExercisePriceThreeMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ExercisePriceThreeMember" xml:lang="en-US">Exercise Price Three [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_ExercisePriceThreeMember" xml:lang="en-US">Exercise Price 5.25 [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ExercisePriceThreeMember" xlink:to="lab_eyen_ExercisePriceThreeMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US">Options Outstanding, Exercise Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US">Options Outstanding, Outstanding Number of Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Life In Years</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US">Options Exercisable, Exercisable Number of Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_EquityIncentivePlanMember" xlink:label="loc_eyen_EquityIncentivePlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_EquityIncentivePlanMember" xml:lang="en-US">Equity Incentive Plan [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_EquityIncentivePlanMember" xml:lang="en-US">2014 Equity Incentive Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_EquityIncentivePlanMember" xlink:to="lab_eyen_EquityIncentivePlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockSharesNotParticipatingInFinancings" xlink:label="loc_eyen_PreferredStockSharesNotParticipatingInFinancings" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_PreferredStockSharesNotParticipatingInFinancings" xml:lang="en-US">Preferred Stock, Shares Not Participating in Financings</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_PreferredStockSharesNotParticipatingInFinancings" xml:lang="en-US">Represents the number of preferred stock not participating in financing.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_PreferredStockSharesNotParticipatingInFinancings" xlink:to="lab_eyen_PreferredStockSharesNotParticipatingInFinancings" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockProrataAllotmentPecentage" xlink:label="loc_eyen_PreferredStockProrataAllotmentPecentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_PreferredStockProrataAllotmentPecentage" xml:lang="en-US">Preferred stock, prorata allotment, Pecentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_PreferredStockProrataAllotmentPecentage" xml:lang="en-US">Percentage of prorata allotment of preferred stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_PreferredStockProrataAllotmentPecentage" xlink:to="lab_eyen_PreferredStockProrataAllotmentPecentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockTermsOfConversion" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of Series A convertible preferred stock into common stock (in shares)</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationStateCountryName" xlink:label="loc_dei_EntityIncorporationStateCountryName" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryName" xml:lang="en-US">Entity Incorporation, State Country Name</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryName" xlink:to="lab_dei_EntityIncorporationStateCountryName" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders&#39; Equity, Reverse Stock Split</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_us-gaap_StockholdersEquityReverseStockSplit" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xml:lang="en-US">Deferred Tax Assets:</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember" xlink:to="lab_us-gaap_MaximumMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember" xlink:to="lab_us-gaap_MinimumMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xml:lang="en-US">Series A And Series A2 Convertible Preferred Stock [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xlink:to="lab_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="loc_eyen_ProceedsOfStockIssuedDuringPeriodGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ProceedsOfStockIssuedDuringPeriodGross" xml:lang="en-US">Proceeds Of Stock Issued During Period Gross</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_ProceedsOfStockIssuedDuringPeriodGross" xml:lang="en-US">It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity&#39;s common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:to="lab_eyen_ProceedsOfStockIssuedDuringPeriodGross" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer&#39;s Equity, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementMember" xlink:label="loc_eyen_ConsultingAgreementMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_ConsultingAgreementMember" xml:lang="en-US">Consulting Agreement [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_ConsultingAgreementMember" xlink:to="lab_eyen_ConsultingAgreementMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="loc_us-gaap_BeneficialOwnerMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BeneficialOwnerMember" xml:lang="en-US">Beneficial Owner [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BeneficialOwnerMember" xlink:to="lab_us-gaap_BeneficialOwnerMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Net Proceeds From Issuance Of Preferred Stock And Preference Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">It represents the net proceeds from issuance of preferred stock and preference stock which takes precedence over common stockholders in the event of liquidation.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountForLackOfMarketability" xlink:label="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsDiscountForLackOfMarketability" xml:lang="en-US">Fair Value Inputs, Discount for Lack of Marketability</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability" xlink:to="lab_us-gaap_FairValueInputsDiscountForLackOfMarketability" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharePriceAtFairValue" xlink:label="loc_eyen_SharePriceAtFairValue" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SharePriceAtFairValue" xml:lang="en-US">Share Price, at Fair Value</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_SharePriceAtFairValue" xml:lang="en-US">The share price at fair value.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SharePriceAtFairValue" xlink:to="lab_eyen_SharePriceAtFairValue" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Gross Proceeds From Issuance Of Convertible Preferred Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">It represents the gross proceeds from issuance of convertible preferred stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective income tax rate</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="loc_eyen_GrossProceedsOfStockValueIssuedDuringPeriod" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xml:lang="en-US">Gross Proceeds of Stock Value Issued During Period</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xml:lang="en-US">Equity impact of the value of new stock issued during the period.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:to="lab_eyen_GrossProceedsOfStockValueIssuedDuringPeriod" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_eyen_NetProceedsFromIssuanceOfCommonStock" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_NetProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Net Proceeds from Issuance of Common Stock</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_NetProceedsFromIssuanceOfCommonStock" xml:lang="en-US">The cash inflow from issuance of common stock.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_NetProceedsFromIssuanceOfCommonStock" xlink:to="lab_eyen_NetProceedsFromIssuanceOfCommonStock" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="loc_eyen_VicePresidentOfResearchAndDevelopmentMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_VicePresidentOfResearchAndDevelopmentMember" xml:lang="en-US">Vice President of Research and Development [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:to="lab_eyen_VicePresidentOfResearchAndDevelopmentMember" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficersCompensationPerMonth" xlink:label="loc_eyen_OfficersCompensationPerMonth" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_OfficersCompensationPerMonth" xml:lang="en-US">Officers Compensation per Month</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_OfficersCompensationPerMonth" xml:lang="en-US">Expenditures for salaries of officers per month agreed to pay.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_OfficersCompensationPerMonth" xlink:to="lab_eyen_OfficersCompensationPerMonth" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficersCompensationPerHour" xlink:label="loc_eyen_OfficersCompensationPerHour" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_OfficersCompensationPerHour" xml:lang="en-US">Officers Compensation per Hour</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_OfficersCompensationPerHour" xml:lang="en-US">Expenditures for salaries of officers per hour agreed to pay on additional work provided.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_OfficersCompensationPerHour" xlink:to="lab_eyen_OfficersCompensationPerHour" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OfficersCompensation" xml:lang="en-US">Officers&#39; Compensation</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficersCompensation" xlink:to="lab_us-gaap_OfficersCompensation" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="loc_eyen_LeaseMonthlyBaseRent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_LeaseMonthlyBaseRent" xml:lang="en-US">Lease, Monthly Base Rent</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_LeaseMonthlyBaseRent" xml:lang="en-US">The base rent per month for lease.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_LeaseMonthlyBaseRent" xlink:to="lab_eyen_LeaseMonthlyBaseRent" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LesseeOperatingLeaseExpiryDate" xlink:label="loc_eyen_LesseeOperatingLeaseExpiryDate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_LesseeOperatingLeaseExpiryDate" xml:lang="en-US">Lessee, Operating Lease, Expiry date</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_LesseeOperatingLeaseExpiryDate" xml:lang="en-US">Expiry date of lessees operating lease contract.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_LesseeOperatingLeaseExpiryDate" xlink:to="lab_eyen_LesseeOperatingLeaseExpiryDate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseExpense" xml:lang="en-US">Operating Lease, Expense</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to Related Parties</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Costs and Expenses, Related Party</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Related to expenses incurred</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_RoyaltyIncomePercentage" xlink:label="loc_eyen_RoyaltyIncomePercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_RoyaltyIncomePercentage" xml:lang="en-US">Royalty Income, Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_RoyaltyIncomePercentage" xml:lang="en-US">The royalty income expressed as percentage.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_RoyaltyIncomePercentage" xlink:to="lab_eyen_RoyaltyIncomePercentage" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LicenseAgreementExpiryPeriodDescription" xlink:label="loc_eyen_LicenseAgreementExpiryPeriodDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_LicenseAgreementExpiryPeriodDescription" xml:lang="en-US">License Agreement, Expiry Period, Description</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_LicenseAgreementExpiryPeriodDescription" xml:lang="en-US">The description of expiry period of license agreement.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_LicenseAgreementExpiryPeriodDescription" xlink:to="lab_eyen_LicenseAgreementExpiryPeriodDescription" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="loc_eyen_SenjuPharmaceuticalCoMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_SenjuPharmaceuticalCoMember" xml:lang="en-US">Senju Pharmaceutical Co [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_SenjuPharmaceuticalCoMember" xlink:to="lab_eyen_SenjuPharmaceuticalCoMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioPlanMember" xml:lang="en-US">Scenario, Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioPlanMember" xlink:to="lab_us-gaap_ScenarioPlanMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="loc_eyen_OmnibusStockIncentivePlan2018Member" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_OmnibusStockIncentivePlan2018Member" xml:lang="en-US">Omnibus Stock Incentive Plan 2018 [Member]</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_eyen_OmnibusStockIncentivePlan2018Member" xml:lang="en-US">2018 Omnibus Stock Incentive Plan [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_OmnibusStockIncentivePlan2018Member" xlink:to="lab_eyen_OmnibusStockIncentivePlan2018Member" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_RelatedPartiesOwnershipInterestPercentage" xlink:label="loc_eyen_RelatedPartiesOwnershipInterestPercentage" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_RelatedPartiesOwnershipInterestPercentage" xml:lang="en-US">Related Parties, Ownership Interest Percentage</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_eyen_RelatedPartiesOwnershipInterestPercentage" xml:lang="en-US">The ownership interest percentage held by related parties in the entity.</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_RelatedPartiesOwnershipInterestPercentage" xlink:to="lab_eyen_RelatedPartiesOwnershipInterestPercentage" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NonemployeeGrantsMember" xlink:label="loc_eyen_NonemployeeGrantsMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_eyen_NonemployeeGrantsMember" xml:lang="en-US">Non-Employee Grants [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eyen_NonemployeeGrantsMember" xlink:to="lab_eyen_NonemployeeGrantsMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividends</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" />

    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xml:lang="en-US">Leasehold Improvements, Gross</label>

    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" />
  </labelLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>eyen-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.9 on 02-Apr-2018 [12:58:23] {PM} EST - www.datatracks.com -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#DocumentAndEntityInformation" roleURI="http://www.eyenoviabio.com/role/DocumentAndEntityInformation" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssets" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PropertyAndEquipmentNet" roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNet" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#AccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilities" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxes" roleURI="http://www.eyenoviabio.com/role/IncomeTaxes" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#CommitmentsAndContingencies" roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingencies" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#RelatedPartyTransactions" roleURI="http://www.eyenoviabio.com/role/RelatedPartyTransactions" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SubsequentEvents" roleURI="http://www.eyenoviabio.com/role/SubsequentEvents" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesTables" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#BalanceSheets" roleURI="http://www.eyenoviabio.com/role/BalanceSheets" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PropertyAndEquipmentNetTables" roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetTables" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesTables" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesTables" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#CommitmentsAndContingenciesTables" roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesTables" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityTables" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityTables" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#BusinessOrganizationAndNatureOfOperationsDetailsTextual" roleURI="http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperationsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#BalanceSheetsParenthetical" roleURI="http://www.eyenoviabio.com/role/BalanceSheetsParenthetical" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PropertyAndEquipmentNetDetails" roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#PropertyAndEquipmentNetDetailsTextual" roleURI="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails1" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails1" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetails2" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetails2" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.eyenoviabio.com/role/IncomeTaxesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.eyenoviabio.com/role/RelatedPartyTransactionsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfOperations" roleURI="http://www.eyenoviabio.com/role/StatementsOfOperations" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails1" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails1" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails2" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails2" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails3" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails3" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetails4" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetails4" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.eyenoviabio.com/role/StockholdersEquityDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SubsequentEventsDetailsTextual" roleURI="http://www.eyenoviabio.com/role/SubsequentEventsDetailsTextual" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfChangesInStockholdersEquity" roleURI="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquity" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquityParenthetical" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#StatementsOfCashFlows" roleURI="http://www.eyenoviabio.com/role/StatementsOfCashFlows" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#BusinessOrganizationAndNatureOfOperations" roleURI="http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperations" />

  <roleRef xlink:type="simple" xlink:href="eyen-20171231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPolicies" />

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_DocumentAndEntityInformationAbstract" xlink:label="loc_eyen_DocumentAndEntityInformationAbstract_2" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eyen_DocumentAndEntityInformationAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_20" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_21" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_21" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_4" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_4" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentType_5" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_AmendmentFlag_6" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentPeriodEndDate_7" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_8" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalYearFocus_8" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_10" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityRegistrantName_10" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_11" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCentralIndexKey_11" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_12" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_CurrentFiscalYearEndDate_12" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_13" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_13" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_14" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityVoluntaryFilers_14" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_15" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCurrentReportingStatus_15" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_16" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityFilerCategory_16" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_17" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityPublicFloat_17" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_18" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_TradingSymbol_18" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_19" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_19" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_198" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="loc_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_199" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_198" xlink:to="loc_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_199" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PropertyAndEquipmentNet">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_210" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_211" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_210" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_211" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_224" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_225" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_224" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_225" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_251" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_252" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_251" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_252" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_293" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_294" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_293" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_294" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_313" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_314" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_313" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_314" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_328" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_329" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_328" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_329" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_355" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_356" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_355" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_356" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_146" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LiquidityAndFinancialConditionPolicyTextBlock" xlink:label="loc_eyen_LiquidityAndFinancialConditionPolicyTextBlock_542" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_eyen_LiquidityAndFinancialConditionPolicyTextBlock_542" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_147" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_UseOfEstimates_147" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_148" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_148" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_149" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_149" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_607" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_607" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_150" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_150" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_151" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_151" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_152" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_152" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_153" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_153" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_154" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_154" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_155" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_155" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_156" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_156" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_157" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_157" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_158" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_158" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_159" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_146" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_159" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_193" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_194" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_193" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_194" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_91" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_92" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_91" xlink:to="loc_us-gaap_StatementTable_92" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_93" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_us-gaap_StatementClassOfStockAxis_93" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_94" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_93" xlink:to="loc_us-gaap_ClassOfStockDomain_94" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember_95" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_94" xlink:to="loc_eyen_SeriesConvertiblePreferredStockMember_95" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_96" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_94" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_96" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_97" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_94" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_97" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_98" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_92" xlink:to="loc_us-gaap_StatementLineItems_98" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_99" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_AssetsAbstract_99" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_100" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99" xlink:to="loc_us-gaap_AssetsCurrentAbstract_100" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_101" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_100" xlink:to="loc_us-gaap_Cash_101" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_102" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_100" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_102" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_103" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_100" xlink:to="loc_us-gaap_AssetsCurrent_103" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_104" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_104" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_105" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_105" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_106" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99" xlink:to="loc_us-gaap_Assets_106" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_107" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_107" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_108" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_107" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_108" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_109" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_108" xlink:to="loc_us-gaap_AccountsPayableCurrent_109" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrent_110" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_108" xlink:to="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrent_110" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_111" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_108" xlink:to="loc_us-gaap_LiabilitiesCurrent_111" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_112" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_CommitmentsAndContingencies_112" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_113" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_StockholdersEquityAbstract_113" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_114" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_PreferredStockValue_114" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_115" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_CommonStockValue_115" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_116" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_AdditionalPaidInCapital_116" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_117" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_117" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_118" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_113" xlink:to="loc_us-gaap_StockholdersEquity_118" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_119" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_119" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_200" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_202" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_200" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_202" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_212" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_213" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_212" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_213" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_226" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_227" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_226" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_227" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_248" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_249" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_248" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_249" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_254" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_248" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_254" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_289" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_248" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_289" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_295" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_296" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_295" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_296" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_330" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ScheduleOfWarrantsOutstandingTableTextBlock" xlink:label="loc_eyen_ScheduleOfWarrantsOutstandingTableTextBlock_331" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_330" xlink:to="loc_eyen_ScheduleOfWarrantsOutstandingTableTextBlock_331" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock" xlink:label="loc_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock_332" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_330" xlink:to="loc_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock_332" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_431" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_330" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_431" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_432" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_330" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_432" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock" xlink:label="loc_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock_433" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_330" xlink:to="loc_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock_433" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperationsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_558" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_559" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_558" xlink:to="loc_us-gaap_StatementTable_559" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_560" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_559" xlink:to="loc_us-gaap_StatementClassOfStockAxis_560" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_561" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_560" xlink:to="loc_us-gaap_ClassOfStockDomain_561" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_562" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_559" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_562" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_573" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_562" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_573" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_574" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_573" xlink:to="loc_us-gaap_SubsequentEventMember_574" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_572" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_559" xlink:to="loc_us-gaap_StatementLineItems_572" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationStateCountryName" xlink:label="loc_dei_EntityIncorporationStateCountryName_563" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572" xlink:to="loc_dei_EntityIncorporationStateCountryName_563" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_564" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_564" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_565" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_572" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_565" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_180" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_181" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_180" xlink:to="loc_us-gaap_StatementTable_181" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_182" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_181" xlink:to="loc_us-gaap_StatementClassOfStockAxis_182" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_183" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_182" xlink:to="loc_us-gaap_ClassOfStockDomain_183" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_185" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_183" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_185" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_188" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_183" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_188" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_186" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_183" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_186" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_184" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_181" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_184" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_586" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_184" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_586" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_587" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_586" xlink:to="loc_us-gaap_EmployeeStockOptionMember_587" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_585" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_181" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_585" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_677" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_585" xlink:to="loc_us-gaap_EquityComponentDomain_677" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_678" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_677" xlink:to="loc_us-gaap_WarrantMember_678" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_676" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_181" xlink:to="loc_us-gaap_StatementLineItems_676" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_584" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_676" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_584" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_161" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_162" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_161" xlink:to="loc_us-gaap_StatementTable_162" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_163" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_162" xlink:to="loc_us-gaap_StatementClassOfStockAxis_163" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_164" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_163" xlink:to="loc_us-gaap_ClassOfStockDomain_164" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_165" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_162" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_165" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_167" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_165" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_167" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_168" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_167" xlink:to="loc_us-gaap_SubsequentEventMember_168" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_166" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_162" xlink:to="loc_us-gaap_RangeAxis_166" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_591" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_166" xlink:to="loc_us-gaap_RangeMember_591" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_592" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_591" xlink:to="loc_us-gaap_MinimumMember_592" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_593" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_591" xlink:to="loc_us-gaap_MaximumMember_593" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_590" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_162" xlink:to="loc_us-gaap_StatementLineItems_590" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_WorkingCapitalAmount" xlink:label="loc_eyen_WorkingCapitalAmount_174" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_eyen_WorkingCapitalAmount_174" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_176" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_176" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_177" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_CashUninsuredAmount_177" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_566" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_NetIncomeLoss_566" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_589" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_589" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_615" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_DeferredOfferingCosts_615" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_616" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_SharePrice_616" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountForLackOfMarketability" xlink:label="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability_617" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_us-gaap_FairValueInputsDiscountForLackOfMarketability_617" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharePriceAtFairValue" xlink:label="loc_eyen_SharePriceAtFairValue_618" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_590" xlink:to="loc_eyen_SharePriceAtFairValue_618" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_201" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrepaidResearchAndDevelopmentExpenses" xlink:label="loc_eyen_PrepaidResearchAndDevelopmentExpenses_203" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_201" xlink:to="loc_eyen_PrepaidResearchAndDevelopmentExpenses_203" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrepaidPatentExpense" xlink:label="loc_eyen_PrepaidPatentExpense_620" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_201" xlink:to="loc_eyen_PrepaidPatentExpense_620" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_204" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_201" xlink:to="loc_us-gaap_PrepaidInsurance_204" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_205" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsAbstract_201" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_205" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BalanceSheetsParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_120" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_121" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_120" xlink:to="loc_us-gaap_StatementTable_121" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_122" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_121" xlink:to="loc_us-gaap_StatementClassOfStockAxis_122" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_123" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_122" xlink:to="loc_us-gaap_ClassOfStockDomain_123" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember_125" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_123" xlink:to="loc_eyen_SeriesConvertiblePreferredStockMember_125" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_126" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_123" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_126" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_127" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_123" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_127" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_124" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_121" xlink:to="loc_us-gaap_StatementLineItems_124" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_129" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_129" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_130" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_130" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockDesignatedShares" xlink:label="loc_eyen_PreferredStockDesignatedShares_131" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_eyen_PreferredStockDesignatedShares_131" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_132" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockSharesIssued_132" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_133" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_133" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_134" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_134" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_135" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_135" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_136" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_136" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_137" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_CommonStockSharesIssued_137" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_138" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_124" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_138" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_214" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_373" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_214" xlink:to="loc_us-gaap_StatementTable_373" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_374" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_373" xlink:to="loc_us-gaap_StatementClassOfStockAxis_374" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_375" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_374" xlink:to="loc_us-gaap_ClassOfStockDomain_375" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_376" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_373" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_376" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_376" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_599" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597" xlink:to="loc_us-gaap_EquipmentMember_599" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_598" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_597" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_598" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_596" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_373" xlink:to="loc_us-gaap_StatementLineItems_596" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_216" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_596" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_216" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_217" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_596" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_217" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_218" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_596" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_218" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_219" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_369" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_219" xlink:to="loc_us-gaap_StatementTable_369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_370" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_369" xlink:to="loc_us-gaap_StatementClassOfStockAxis_370" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_371" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_370" xlink:to="loc_us-gaap_ClassOfStockDomain_371" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_372" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_369" xlink:to="loc_us-gaap_StatementLineItems_372" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_220" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_372" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_220" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_231" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_378" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_231" xlink:to="loc_us-gaap_StatementTable_378" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_379" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_378" xlink:to="loc_us-gaap_StatementClassOfStockAxis_379" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_380" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_379" xlink:to="loc_us-gaap_ClassOfStockDomain_380" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_381" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_378" xlink:to="loc_us-gaap_StatementLineItems_381" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="loc_eyen_AccruedResearchAndDevelopmentExpensesCurrent_232" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_eyen_AccruedResearchAndDevelopmentExpensesCurrent_232" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedLegalExpensesCurrent" xlink:label="loc_eyen_AccruedLegalExpensesCurrent_233" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_eyen_AccruedLegalExpensesCurrent_233" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_234" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_us-gaap_AccruedRentCurrent_234" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_235" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_235" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedOfferingCosts" xlink:label="loc_eyen_AccruedOfferingCosts_236" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_eyen_AccruedOfferingCosts_236" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_237" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_237" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccruedExpensesAndOtherLiabilitiesCurrents" xlink:label="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrents_382" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_381" xlink:to="loc_eyen_AccruedExpensesAndOtherLiabilitiesCurrents_382" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_239" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_411" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_239" xlink:to="loc_us-gaap_StatementTable_411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_412" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411" xlink:to="loc_us-gaap_StatementClassOfStockAxis_412" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_413" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_412" xlink:to="loc_us-gaap_ClassOfStockDomain_413" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_414" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_411" xlink:to="loc_us-gaap_StatementLineItems_414" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_240" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_240" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_241" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_240" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_241" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_242" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_240" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_242" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_243" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_243" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_415" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_243" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_415" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_244" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_243" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_244" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance" xlink:label="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_250" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance_250" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_416" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_416" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_247" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_414" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_247" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_270" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_417" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_270" xlink:to="loc_us-gaap_StatementTable_417" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_418" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_417" xlink:to="loc_us-gaap_StatementClassOfStockAxis_418" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_419" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_418" xlink:to="loc_us-gaap_ClassOfStockDomain_419" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_420" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_417" xlink:to="loc_us-gaap_StatementLineItems_420" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_271" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_271" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_272" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_272" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_273" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_273" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_621" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_621" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_622" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_622" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_274" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_274" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_275" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_420" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_275" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_280" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_421" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_280" xlink:to="loc_us-gaap_StatementTable_421" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_422" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_421" xlink:to="loc_us-gaap_StatementClassOfStockAxis_422" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_423" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_422" xlink:to="loc_us-gaap_ClassOfStockDomain_423" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_424" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_421" xlink:to="loc_us-gaap_StatementLineItems_424" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_424" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_281" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_281" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_282" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_282" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_283" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_283" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_284" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_284" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_285" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_285" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_286" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_286" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_287" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_287" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_288" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_575" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_288" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/IncomeTaxesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_290" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_425" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_290" xlink:to="loc_us-gaap_StatementTable_425" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_626" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_425" xlink:to="loc_us-gaap_StatementScenarioAxis_626" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_660" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_626" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_660" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="loc_us-gaap_ScenarioPlanMember_661" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_660" xlink:to="loc_us-gaap_ScenarioPlanMember_661" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_656" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_425" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_656" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_658" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_656" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_658" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_659" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_658" xlink:to="loc_us-gaap_DomesticCountryMember_659" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_657" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_425" xlink:to="loc_us-gaap_RangeAxis_657" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_681" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_657" xlink:to="loc_us-gaap_RangeMember_681" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_682" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_681" xlink:to="loc_us-gaap_MaximumMember_682" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_680" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_425" xlink:to="loc_us-gaap_StatementLineItems_680" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_291" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_OperatingLossCarryforwards_291" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OperatingLossCarryforwardsExpirationTerm" xlink:label="loc_eyen_OperatingLossCarryforwardsExpirationTerm_292" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_eyen_OperatingLossCarryforwardsExpirationTerm_292" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLimitationsOnUse" xlink:label="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_430" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_TaxCreditCarryforwardLimitationsOnUse_430" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_631" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_631" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_632" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_632" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_633" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_680" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_633" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_299" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_383" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_299" xlink:to="loc_us-gaap_StatementTable_383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_384" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_383" xlink:to="loc_us-gaap_StatementClassOfStockAxis_384" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_385" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_384" xlink:to="loc_us-gaap_ClassOfStockDomain_385" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_386" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_383" xlink:to="loc_us-gaap_StatementLineItems_386" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_300" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_386" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_300" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_301" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_386" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_301" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_302" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_387" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_302" xlink:to="loc_us-gaap_StatementTable_387" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_388" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_387" xlink:to="loc_us-gaap_StatementClassOfStockAxis_388" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_389" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_388" xlink:to="loc_us-gaap_ClassOfStockDomain_389" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_390" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_387" xlink:to="loc_us-gaap_StatementLineItems_390" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_303" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_NetRentableArea_303" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_304" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_304" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_306" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_LeaseExpirationDate1_306" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_307" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_307" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_308" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_308" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_309" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_309" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MalpracticeLossContingencyInsuranceRecoveries" xlink:label="loc_us-gaap_MalpracticeLossContingencyInsuranceRecoveries_310" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_390" xlink:to="loc_us-gaap_MalpracticeLossContingencyInsuranceRecoveries_310" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/RelatedPartyTransactionsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_315" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_393" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_315" xlink:to="loc_us-gaap_StatementTable_393" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_394" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_StatementClassOfStockAxis_394" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_395" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_394" xlink:to="loc_us-gaap_ClassOfStockDomain_395" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_396" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_396" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_398" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_396" xlink:to="loc_us-gaap_RelatedPartyDomain_398" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_CuraPartnersMember" xlink:label="loc_eyen_CuraPartnersMember_399" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_398" xlink:to="loc_eyen_CuraPartnersMember_399" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PrivateMedicalEquityIncMember" xlink:label="loc_eyen_PrivateMedicalEquityIncMember_400" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_398" xlink:to="loc_eyen_PrivateMedicalEquityIncMember_400" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BeneficialOwnerMember" xlink:label="loc_us-gaap_BeneficialOwnerMember_604" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_398" xlink:to="loc_us-gaap_BeneficialOwnerMember_604" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_397" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_TitleOfIndividualAxis_397" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_408" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_397" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_408" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_409" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_408" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_409" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_407" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_407" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_569" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_407" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_569" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_570" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_569" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_570" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_603" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_569" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_603" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_568" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_568" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_601" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_568" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_601" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementMember" xlink:label="loc_eyen_ConsultingAgreementMember_602" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_601" xlink:to="loc_eyen_ConsultingAgreementMember_602" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_VicePresidentOfResearchAndDevelopmentMember" xlink:label="loc_eyen_VicePresidentOfResearchAndDevelopmentMember_634" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_601" xlink:to="loc_eyen_VicePresidentOfResearchAndDevelopmentMember_634" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SenjuPharmaceuticalCoMember" xlink:label="loc_eyen_SenjuPharmaceuticalCoMember_654" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_601" xlink:to="loc_eyen_SenjuPharmaceuticalCoMember_654" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_600" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_600" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_636" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_600" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_636" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_637" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_636" xlink:to="loc_us-gaap_SubsequentEventMember_637" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_635" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_393" xlink:to="loc_us-gaap_StatementLineItems_635" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingFee" xlink:label="loc_eyen_ConsultingFee_316" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_ConsultingFee_316" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_317" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_317" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficeSpaceExpenses" xlink:label="loc_eyen_OfficeSpaceExpenses_318" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_OfficeSpaceExpenses_318" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_319" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_LeaseAndRentalExpense_319" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementPaymentPermonth" xlink:label="loc_eyen_ConsultingAgreementPaymentPermonth_320" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_ConsultingAgreementPaymentPermonth_320" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_402" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_402" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_MinorityInterestOwnershipPercentageInCompany" xlink:label="loc_eyen_MinorityInterestOwnershipPercentageInCompany_404" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_MinorityInterestOwnershipPercentageInCompany_404" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ConsultingAgreementPaymentPerhour" xlink:label="loc_eyen_ConsultingAgreementPaymentPerhour_405" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_ConsultingAgreementPaymentPerhour_405" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficersCompensationPerMonth" xlink:label="loc_eyen_OfficersCompensationPerMonth_638" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_OfficersCompensationPerMonth_638" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OfficersCompensationPerHour" xlink:label="loc_eyen_OfficersCompensationPerHour_639" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_OfficersCompensationPerHour_639" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_640" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_640" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_641" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_641" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_642" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_642" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_643" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_643" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_644" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_OfficersCompensation_644" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetRentableArea" xlink:label="loc_us-gaap_NetRentableArea_645" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_NetRentableArea_645" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LeaseMonthlyBaseRent" xlink:label="loc_eyen_LeaseMonthlyBaseRent_646" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_LeaseMonthlyBaseRent_646" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LesseeOperatingLeaseExpiryDate" xlink:label="loc_eyen_LesseeOperatingLeaseExpiryDate_647" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_LesseeOperatingLeaseExpiryDate_647" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_648" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_648" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaap_OperatingLeaseExpense_649" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_OperatingLeaseExpense_649" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_650" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_650" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_679" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_679" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_RoyaltyIncomePercentage" xlink:label="loc_eyen_RoyaltyIncomePercentage_651" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_RoyaltyIncomePercentage_651" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_LicenseAgreementExpiryPeriodDescription" xlink:label="loc_eyen_LicenseAgreementExpiryPeriodDescription_652" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_LicenseAgreementExpiryPeriodDescription_652" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_RelatedPartiesOwnershipInterestPercentage" xlink:label="loc_eyen_RelatedPartiesOwnershipInterestPercentage_653" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_eyen_RelatedPartiesOwnershipInterestPercentage_653" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_668" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_SecurityDeposit_668" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_669" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_635" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_669" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_23" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_24" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_23" xlink:to="loc_us-gaap_StatementTable_24" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_25" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_24" xlink:to="loc_us-gaap_StatementClassOfStockAxis_25" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_26" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_25" xlink:to="loc_us-gaap_ClassOfStockDomain_26" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_24" xlink:to="loc_us-gaap_StatementLineItems_27" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_28" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_OperatingExpensesAbstract_28" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_29" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_29" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_30" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_30" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_31" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_28" xlink:to="loc_us-gaap_OperatingExpenses_31" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_32" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_OperatingIncomeLoss_32" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_34" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_33" xlink:to="loc_us-gaap_InvestmentIncomeInterest_34" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_35" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_NetIncomeLoss_35" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_36" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_36" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_37" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_36" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_37" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_38" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_38" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_39" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_38" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_39" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_336" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_435" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_336" xlink:to="loc_us-gaap_StatementTable_435" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_436" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_435" xlink:to="loc_us-gaap_StatementClassOfStockAxis_436" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_437" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_436" xlink:to="loc_us-gaap_ClassOfStockDomain_437" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_438" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_435" xlink:to="loc_us-gaap_StatementLineItems_438" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_337" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_337" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_338" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_338" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_339" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_339" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_434" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_434" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_340" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber_340" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_341" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_341" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_342" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice_342" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice_350" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice_350" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_343" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice_343" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_344" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice_344" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_351" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_351" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_439" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms_439" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_352" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_352" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue" xlink:label="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue_440" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_438" xlink:to="loc_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue_440" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_345" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_441" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_345" xlink:to="loc_us-gaap_StatementTable_441" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_442" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_441" xlink:to="loc_us-gaap_StatementClassOfStockAxis_442" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_443" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_442" xlink:to="loc_us-gaap_ClassOfStockDomain_443" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_444" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_441" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_444" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_450" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_444" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_450" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePrice698Member" xlink:label="loc_eyen_ExercisePrice698Member_451" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_450" xlink:to="loc_eyen_ExercisePrice698Member_451" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_449" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_441" xlink:to="loc_us-gaap_StatementLineItems_449" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice_445" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice_445" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants_446" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants_446" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife_447" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife_447" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants" xlink:label="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants_448" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_449" xlink:to="loc_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants_448" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_452" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_453" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_452" xlink:to="loc_us-gaap_StatementTable_453" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_454" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_StatementClassOfStockAxis_454" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_455" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_454" xlink:to="loc_us-gaap_ClassOfStockDomain_455" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_456" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_RangeAxis_456" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_458" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_456" xlink:to="loc_us-gaap_RangeMember_458" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_457" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_453" xlink:to="loc_us-gaap_StatementLineItems_457" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum_673" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum_673" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum" xlink:label="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum_674" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum_674" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_461" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_461" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_462" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_462" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_463" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_463" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_464" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_464" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_465" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_457" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_465" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_466" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_467" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_466" xlink:to="loc_us-gaap_StatementTable_467" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_468" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_467" xlink:to="loc_us-gaap_StatementClassOfStockAxis_468" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_469" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_468" xlink:to="loc_us-gaap_ClassOfStockDomain_469" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_470" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_467" xlink:to="loc_us-gaap_StatementLineItems_470" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_471" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_471" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_472" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_472" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_473" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_473" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_474" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_474" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_475" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_475" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_476" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_476" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_477" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_477" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_478" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_478" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_479" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_479" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_480" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_480" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_481" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_481" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_482" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_482" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_606" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_606" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_483" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_470" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_483" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_485" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_486" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_485" xlink:to="loc_us-gaap_StatementTable_486" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_487" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_486" xlink:to="loc_us-gaap_StatementClassOfStockAxis_487" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_488" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_487" xlink:to="loc_us-gaap_ClassOfStockDomain_488" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_489" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_486" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_489" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_489" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceOneMember" xlink:label="loc_eyen_ExercisePriceOneMember_492" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" xlink:to="loc_eyen_ExercisePriceOneMember_492" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceTwoMember" xlink:label="loc_eyen_ExercisePriceTwoMember_493" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" xlink:to="loc_eyen_ExercisePriceTwoMember_493" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ExercisePriceThreeMember" xlink:label="loc_eyen_ExercisePriceThreeMember_494" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_491" xlink:to="loc_eyen_ExercisePriceThreeMember_494" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_490" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_486" xlink:to="loc_us-gaap_StatementLineItems_490" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_495" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_495" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_496" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_496" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_497" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_497" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_498" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_490" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_498" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StockholdersEquityDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_500" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_501" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_500" xlink:to="loc_us-gaap_StatementTable_501" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_502" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_StatementClassOfStockAxis_502" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_503" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_502" xlink:to="loc_us-gaap_ClassOfStockDomain_503" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember_509" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_eyen_SeriesConvertiblePreferredStockMember_509" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_510" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_510" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_511" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_511" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_580" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_503" xlink:to="loc_eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember_580" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_504" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_504" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_514" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_504" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_514" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_515" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_514" xlink:to="loc_us-gaap_SubsequentEventMember_515" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_513" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_PlanNameAxis_513" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_517" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_513" xlink:to="loc_us-gaap_PlanNameDomain_517" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_EquityIncentivePlanMember" xlink:label="loc_eyen_EquityIncentivePlanMember_518" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_517" xlink:to="loc_eyen_EquityIncentivePlanMember_518" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_516" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_RangeAxis_516" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_577" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_516" xlink:to="loc_us-gaap_RangeMember_577" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_578" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_577" xlink:to="loc_us-gaap_MaximumMember_578" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_579" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_577" xlink:to="loc_us-gaap_MinimumMember_579" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_576" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_576" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_671" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_576" xlink:to="loc_us-gaap_RelatedPartyDomain_671" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NonemployeeGrantsMember" xlink:label="loc_eyen_NonemployeeGrantsMember_672" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_671" xlink:to="loc_eyen_NonemployeeGrantsMember_672" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_670" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_501" xlink:to="loc_us-gaap_StatementLineItems_670" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_505" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_505" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_506" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_506" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_507" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_507" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_508" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_508" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockDesignatedShares" xlink:label="loc_eyen_PreferredStockDesignatedShares_512" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_PreferredStockDesignatedShares_512" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_521" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_521" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_522" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_522" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_523" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_523" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_524" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_524" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_525" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_525" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockSharesNotParticipatingInFinancings" xlink:label="loc_eyen_PreferredStockSharesNotParticipatingInFinancings_526" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_PreferredStockSharesNotParticipatingInFinancings_526" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_PreferredStockProrataAllotmentPecentage" xlink:label="loc_eyen_PreferredStockProrataAllotmentPecentage_527" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_PreferredStockProrataAllotmentPecentage_527" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_528" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_528" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_529" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_529" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_532" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_532" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_533" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_533" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_534" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_534" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_536" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_537" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1_537" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_538" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_538" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_539" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_539" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_571" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_571" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock_613" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock_613" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock_619" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock_619" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_655" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_670" xlink:to="loc_us-gaap_SharePrice_655" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SubsequentEventsDetailsTextual">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_357" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_358" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_357" xlink:to="loc_us-gaap_StatementTable_358" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_359" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_358" xlink:to="loc_us-gaap_StatementClassOfStockAxis_359" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_360" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_359" xlink:to="loc_us-gaap_ClassOfStockDomain_360" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_361" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_358" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_361" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_540" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_361" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_540" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_541" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_540" xlink:to="loc_us-gaap_SubsequentEventMember_541" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_362" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_358" xlink:to="loc_us-gaap_PlanNameAxis_362" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_664" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_362" xlink:to="loc_us-gaap_PlanNameDomain_664" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_OmnibusStockIncentivePlan2018Member" xlink:label="loc_eyen_OmnibusStockIncentivePlan2018Member_665" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_664" xlink:to="loc_eyen_OmnibusStockIncentivePlan2018Member_665" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_663" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_358" xlink:to="loc_us-gaap_StatementLineItems_663" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_365" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_365" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_367" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_367" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_GrossProceedsOfStockValueIssuedDuringPeriod" xlink:label="loc_eyen_GrossProceedsOfStockValueIssuedDuringPeriod_623" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_eyen_GrossProceedsOfStockValueIssuedDuringPeriod_623" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_624" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_624" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_NetProceedsFromIssuanceOfCommonStock" xlink:label="loc_eyen_NetProceedsFromIssuanceOfCommonStock_625" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_eyen_NetProceedsFromIssuanceOfCommonStock_625" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_662" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_662" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_666" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_667" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_663" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_667" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_41" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_42" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_41" xlink:to="loc_us-gaap_StatementTable_42" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_44" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43" xlink:to="loc_us-gaap_ClassOfStockDomain_44" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesConvertiblePreferredStockMember_46" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_eyen_SeriesConvertiblePreferredStockMember_46" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_47" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_47" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_48" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_48" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_255" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_CommonStockMember_255" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_256" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_256" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_257" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_RetainedEarningsMember_257" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_55" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_us-gaap_StatementLineItems_55" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_51" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockholdersEquity_51" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_52" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_SharesOutstanding_52" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_262" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_262" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_260" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_260" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_543" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_543" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_544" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_544" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_545" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_545" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_546" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_546" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_261" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_NetIncomeLoss_261" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_265" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_StockholdersEquity_265" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_266" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_55" xlink:to="loc_us-gaap_SharesOutstanding_266" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquityParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_548" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_549" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_548" xlink:to="loc_us-gaap_StatementTable_549" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_550" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_549" xlink:to="loc_us-gaap_StatementClassOfStockAxis_550" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_551" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_550" xlink:to="loc_us-gaap_ClassOfStockDomain_551" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_552" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_549" xlink:to="loc_us-gaap_StatementLineItems_552" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_ProceedsOfStockIssuedDuringPeriodGross" xlink:label="loc_eyen_ProceedsOfStockIssuedDuringPeriodGross_581" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_552" xlink:to="loc_eyen_ProceedsOfStockIssuedDuringPeriodGross_581" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_582" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_552" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_582" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/StatementsOfCashFlows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_57" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_58" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_57" xlink:to="loc_us-gaap_StatementTable_58" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_59" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_58" xlink:to="loc_us-gaap_StatementClassOfStockAxis_59" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_60" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_59" xlink:to="loc_us-gaap_ClassOfStockDomain_60" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesA2ConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesA2ConvertiblePreferredStockMember_79" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_60" xlink:to="loc_eyen_SeriesA2ConvertiblePreferredStockMember_79" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_SeriesBConvertiblePreferredStockMember" xlink:label="loc_eyen_SeriesBConvertiblePreferredStockMember_80" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_60" xlink:to="loc_eyen_SeriesBConvertiblePreferredStockMember_80" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_61" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_58" xlink:to="loc_us-gaap_StatementLineItems_61" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_63" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" xlink:to="loc_us-gaap_NetIncomeLoss_63" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_65" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_65" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_66" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" xlink:to="loc_us-gaap_ShareBasedCompensation_66" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_64" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_68" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_69" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_69" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_70" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_67" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_70" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_62" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_73" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_73" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_74" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_556" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_556" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_77" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_77" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_76" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_76" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_81" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_81" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_75" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_83" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_83" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_85" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_85" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_86" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_61" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_86" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="eyen-20171231.xsd#eyen_AccrualInitialPublicOfferingCosts" xlink:label="loc_eyen_AccrualInitialPublicOfferingCosts_87" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_86" xlink:to="loc_eyen_AccrualInitialPublicOfferingCosts_87" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_88" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_86" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_88" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_140" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_141" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_140" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_141" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>

  <presentationLink xlink:type="extended" xlink:role="http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_144" />

    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_145" />

    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_144" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_145" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</linkbase>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761467856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 27, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EYENOVIA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001682639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EYEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,936,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767438000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 5,249,511<span></span>
</td>
<td class="nump">$ 3,387,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">37,149<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">5,286,660<span></span>
</td>
<td class="nump">3,389,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">27,960<span></span>
</td>
<td class="nump">43,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred offering costs</a></td>
<td class="nump">328,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">5,643,320<span></span>
</td>
<td class="nump">3,432,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">246,384<span></span>
</td>
<td class="nump">302,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">306,263<span></span>
</td>
<td class="nump">121,703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">552,647<span></span>
</td>
<td class="nump">423,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 60,000,000 shares authorized as of December 31, 2017 (see Note 9), 2,566,530 and 2,266,667 shares issued and outstanding as of December 31, 2017 and 2016, respectively</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">24,351,138<span></span>
</td>
<td class="nump">17,139,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(19,261,186)<span></span>
</td>
<td class="num">(14,131,199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">5,090,673<span></span>
</td>
<td class="nump">3,009,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">5,643,320<span></span>
</td>
<td class="nump">3,432,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765563184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">2,566,530<span></span>
</td>
<td class="nump">2,266,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">2,566,530<span></span>
</td>
<td class="nump">2,266,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockDesignatedShares', window );">Preferred Stock Designated Shares</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">2,932,431<span></span>
</td>
<td class="nump">3,232,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">2,932,431<span></span>
</td>
<td class="nump">3,232,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock, Liquidation Preference, Value</a></td>
<td class="nump">$ 10,996,014<span></span>
</td>
<td class="nump">$ 12,121,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockDesignatedShares', window );">Preferred Stock Designated Shares</a></td>
<td class="nump">5,714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">788,827<span></span>
</td>
<td class="nump">788,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">788,827<span></span>
</td>
<td class="nump">788,827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock, Liquidation Preference, Value</a></td>
<td class="nump">$ 4,141,338<span></span>
</td>
<td class="nump">$ 4,141,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockDesignatedShares', window );">Preferred Stock Designated Shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">918,983<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">918,983<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred Stock, Liquidation Preference, Value</a></td>
<td class="nump">$ 6,409,657<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PreferredStockDesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of designated preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PreferredStockDesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767530592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 3,816,732<span></span>
</td>
<td class="nump">$ 2,966,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,315,635<span></span>
</td>
<td class="nump">568,775<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">5,132,367<span></span>
</td>
<td class="nump">3,534,940<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss From Operations</a></td>
<td class="num">(5,132,367)<span></span>
</td>
<td class="num">(3,534,940)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,380<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (5,129,987)<span></span>
</td>
<td class="num">$ (3,533,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">- Basic and Diluted</a></td>
<td class="num">$ (2.19)<span></span>
</td>
<td class="num">$ (1.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted Average Number of Common Shares Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">- Basic and Diluted</a></td>
<td class="nump">2,344,712<span></span>
</td>
<td class="nump">2,266,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761291856">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series A-2 Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series B Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-In Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,398,496<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 12,995,702<span></span>
</td>
<td class="num">$ (10,597,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,232,294<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,266,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,690<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance convertible preferred stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,141,338<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,141,259<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">788,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,533,443)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,533,443)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,009,081<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">17,139,651<span></span>
</td>
<td class="num">(14,131,199)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,232,294<span></span>
</td>
<td class="nump">788,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,266,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrant</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">431,574<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">431,574<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">412,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">412,312<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance convertible preferred stock, net of issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,367,693<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,367,601<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">918,983<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A convertible preferred stock into common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (30)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A convertible preferred stock into common stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(299,863)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">299,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,129,987)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,129,987)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,090,673<span></span>
</td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 24,351,138<span></span>
</td>
<td class="num">$ (19,261,186)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,932,431<span></span>
</td>
<td class="nump">788,827<span></span>
</td>
<td class="nump">918,983<span></span>
</td>
<td class="nump">2,566,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes gross proceeds of $6,409,651, less issuance costs of $41,958.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79512289&amp;loc=d3e4724-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758180000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Changes in Stockholders&#8217; Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ProceedsOfStockIssuedDuringPeriodGross', window );">Proceeds Of Stock Issued During Period Gross</a></td>
<td class="nump">$ 6,409,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</a></td>
<td class="nump">$ 41,958<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ProceedsOfStockIssuedDuringPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ProceedsOfStockIssuedDuringPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768057968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,129,987)<span></span>
</td>
<td class="num">$ (3,533,443)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">25,466<span></span>
</td>
<td class="nump">12,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">412,312<span></span>
</td>
<td class="nump">2,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(34,814)<span></span>
</td>
<td class="nump">310,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(55,647)<span></span>
</td>
<td class="nump">55,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">51,560<span></span>
</td>
<td class="num">(51,598)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
<td class="num">(4,731,110)<span></span>
</td>
<td class="num">(3,203,542)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(10,234)<span></span>
</td>
<td class="num">(43,119)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used In Investing Activities</a></td>
<td class="num">(10,234)<span></span>
</td>
<td class="num">(43,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payment of initial public offering costs</a></td>
<td class="num">(195,700)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from sale of warrant</a></td>
<td class="nump">431,574<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
<td class="nump">6,603,567<span></span>
</td>
<td class="nump">4,141,338<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net Increase in Cash</a></td>
<td class="nump">1,862,223<span></span>
</td>
<td class="nump">894,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash - Beginning of Period</a></td>
<td class="nump">3,387,288<span></span>
</td>
<td class="nump">2,492,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash - End of Period</a></td>
<td class="nump">5,249,511<span></span>
</td>
<td class="nump">3,387,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccrualInitialPublicOfferingCosts', window );">Accrual of intitial public offering costs</a></td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from sale of Convertible Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,141,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from sale of Convertible Preferred Stock</a></td>
<td class="nump">6,409,651<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of Series B Convertible Preferred Stock issuance costs</a></td>
<td class="num">$ (41,958)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccrualInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrual initial public offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccrualInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758147536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> Note 1 &#150; Business Organization and Nature of Operations</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">Eyenovia, Inc. (&#8220;Eyenovia&#8221; or the &#8220;Company&#8221;) was organized as a corporation under the laws of the State of Florida on March&#160;12, 2014 under the name, PGP Holdings V, Inc. On May&#160;5, 2014, PGP Holdings V, Inc. changed its name to Eyenovia, Inc. On October&#160;6, 2014, Eyenovia, Inc. reincorporated in the State of Delaware by merging into Eyenovia, Inc., a Delaware corporation.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">Eyenovia is a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-doses (6&#150;8 &#181;L) of active pharmaceutical ingredients (or &#8220;micro-therapeutics&#8221;) topically to the eye. This disruptive micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers), that routinely overdoses or under-doses the topical administration of ophthalmic therapeutics.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal">Effective January 8, 2018, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&#8217;s issued and outstanding common stock and preferred stock (the &#8220;Reverse Split&#8221;). The number of authorized shares remains unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise indicated.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908615136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Note 2 &#150; Summary of Significant Accounting Policies</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Liquidity and Financial Condition</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company incurred net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,129,987</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,533,443</font> for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, the Company&#8217;s working capital and accumulated deficit were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,734,013</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,261,186</font>, respectively. The Company has not yet generated revenues or achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Subsequent to December 31, 2017, the Company raised aggregate net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24.5</font> million in connection with its initial public offering (&#8220;IPO&#8221;). See Note 10 &#150; Subsequent Events for additional details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company believes its current cash on hand is sufficient to meet its operating and capital requirements for at least the next fifteen months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. The Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#8217;s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> establishment of</font> valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&#8217;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&#8217;s estimates and could cause actual results to differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Summary of Significant Accounting Policies&#160;&#151; Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&#8217;s common stock.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2017 and 2016, the Company had no cash equivalents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. On December 31, 2017 and 2016, the Company had cash balances in excess of FDIC insurance limits of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,999,511</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,137,288</font>, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Property and Equipment, Net</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Deferred Offering Costs</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company&#8217;s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. As of December 31, 2017 and 2016, there were deferred offering costs in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">328,700</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, respectively. Upon the closing of the IPO, the deferred offering costs will be offset against the proceeds of the IPO.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Impairment of Long-lived Assets</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the years ended December 31, 2017 and 2016.</font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Preferred Stock</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#8217; equity.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Convertible Instruments</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#8220;ASC&#8221;). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> If the instrument is determined to be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the market price of the Company&#8217;s common stock as of the commitment date to the effective conversion price of the instrument.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Fair Value of Financial Instruments</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</font></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 1&#160;&#151; quoted prices in active markets for identical assets or liabilities;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 2&#160;&#151; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 3&#160;&#151; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The carrying amounts of the Company&#8217;s financial instruments, such as cash, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&#8220;temporary differences&#8221;) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s financial statements as of December 31, 2017 and 2016. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company&#8217;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of operations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Stock-Based Compensation</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option, the Company issues new shares of common stock out of its authorized shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the year ended December 31, 2016, the fair value of the Company&#8217;s common stock was based on an analysis completed by management that considered the cash sales prices of the convertible preferred stock as well as the relative characteristics, rights and privileges of the convertible preferred stock as compared to the common stock. During the year ended December 31, 2017, the Company obtained a third-party 409A valuation of its common stock, which was also considered in management&#8217;s estimation of the value of the equity instruments issued during that period. This third-party valuation was done in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, <i>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</i>. The estimates used by management are considered highly complex and subjective. Subsequent to the IPO, the shares began trading on January 24, 2018, which is the date the use of such estimates is no longer necessary to determine the fair value of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The independent analysis utilized the Backsolve method since this method is generally considered the most reliable and is recommended by the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<i>Valuation of Privately Held Company Equity Securities Issued as Compensation</i>. In addition, the method utilizes the economics from a direct transaction in our securities in determining the fair market value. This method utilizes the Black Scholes option pricing model which allocated a probability weighted equity value to the Company&#8217;s Series A- 2 preferred stock. The Series A-2 preferred stock was utilized since it included new investors, was considered at arms&#8217; length and closed in the fourth quarter of 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The March 2017 independent appraisal utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Establishment of total enterprise or equity value;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Analysis of equity rights for each class of security;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Selection of appropriate model for valuation purposes;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Determination of key valuation inputs; and</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Computation of the fair value of the subject security.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Under the OPM, it was determined the Company&#8217;s common stock had an allocated per share value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.23</font> per share. As a private company, the analysis provided for a discount for lack of marketability of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% resulting in a fair market value of the Company&#8217;s common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.95</font> per share as of March 2017 based upon the independent appraisal. This price represents the same exercise price of the stock options the Company granted in July 2017 as management determined no material events or conditions occurred at the Company that would have a material effect on this per share price.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Net Loss Per Common Share</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,684,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>786,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="59%"> <div>Warrant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series A Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>2,932,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>3,232,294</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series A-2 Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>788,827</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>788,827</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series B Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>918,983</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total potentially dilutive shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>6,386,532</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>4,807,787</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Subsequent Events</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recently Issued Accounting Pronouncements</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In February 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments,&#8221; (&#8220;ASU 2016-15&#8221;). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. We will require adoption on a retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating ASU 2016-15 and its impact on its financial position, results of operations, and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In May 2017, the FASB issued ASU No. 2017-09, &#8220;Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting&#8221; (&#8220;ASU 2017-09&#8221;). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending December 15, 2018 for share-based payment awards modified on or after the adoption date. The Company is currently evaluating ASU 2017-09 and its impact on its financial position, results of operations, and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In July 2017, the FASB issued ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&#8221; (&#8220;ASU 2017-11&#8221;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating ASU 2017-11 and its impact on its financial position, results of operations, and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Recently Adopted Accounting Pronouncements</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In March 2016, the FASB issued ASU No. 2016-09, &#8220;Compensation &#150; Stock Compensation (Topic 718)&#8221; (&#8220;ASU 2016-09&#8221;). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of this standard did not have a material impact on the Company&#8217;s financial position, results of operations and cash flows.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758147536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Note 3 &#150; Prepaid Expenses and Other Current Assets</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of December 31, 2017 and 2016, prepaid expenses and other current assets consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Prepaid research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,932</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"> <div>Prepaid patent expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>7,833</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Prepaid insurance expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Total prepaid expenses and other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>37,149</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6625456032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> Note 4 &#150; Property and Equipment, Net</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of December 31, 2017 and 2016, property and equipment consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34,979</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>24,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>74,979</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>64,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Less: accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(47,019)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(21,553)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>27,960</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>43,192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Depreciation and amortization expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,466</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,802</font> for the years ended December 31, 2017 and 2016, respectively, which is included within research and development expenses in the statements of operations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6925867440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> Note 5 &#150; Accrued Expenses and Other Current Liabilities</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of December 31, 2017 and 2016, accrued expenses and other current liabilities consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>120,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>61,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued legal expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,597</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued rent expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,590</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued professional services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>41,831</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued offering costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>133,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,516</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Total accrued expenses and other current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>306,263</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>121,703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6909948512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> Note 6 &#150; Income Taxes&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The income tax (provision) benefit consists of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>For&#160;The&#160;Years&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Federal:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Deferred</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>235,473</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,287,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>State and local:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Deferred</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>80,301</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>151,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>315,774</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,439,452</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(315,774)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,439,452)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Income tax (provision) benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>For&#160;The&#160;Years&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Tax benefit at federal statutory rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>State income taxes, net of federal benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Incremental research and development credits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"> <div>Prior period adjustments and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(8.1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"> <div>Effect of tax rate changes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(30.0)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(6.2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(40.7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Effective income tax rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Deferred Tax Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Net operating loss carryforwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,588,641</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,742,397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>347,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>333,066</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Research &#38; development tax credits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>526,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>201,840</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>364,508</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>234,183</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Gross deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,827,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,511,486</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,827,260)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,511,486)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Deferred tax assets, net of valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Changes in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(315,774)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,439,452)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company assesses the likelihood that deferred tax assets will be realized. To the extent that realization is not likely, a valuation allowance is established. Based upon the Company&#8217;s history of losses since inception, management believes that it is more likely than not that future benefits of deferred tax assets will not be realized.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> At December 31, 2017 and 2016, the Company estimates that it has approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">11,000,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">7,200,000</font>, respectively, of federal net operating losses that may be available to offset future taxable income. The net operating loss carry forwards, if not utilized, will expire from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2034 to 2037</font> for federal purposes. At December 31, 2017, the Company estimates that it has approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,000,000</font> of New York State net operating losses that may be available to offset future taxable income. In accordance with Section 382 of the Internal Revenue Code, the usage of the Company&#8217;s net operating loss carry forwards could become subject to annual limitations if there are greater than 50% ownership changes.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company files income tax returns in the U.S. federal jurisdiction, the State of New York and the state of Florida (where the Company filed its final return in 2015), which remain subject to examination by the various taxing authorities beginning with the tax year ended December 31, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Tax Cuts and Jobs Act (the "Act") was enacted in December 2017. Among other things, the primary provision of Tax Reform impacting the Company is the reduction to the U.S. corporate income tax rate from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 21</font>%. The change in tax law required the Company to remeasure existing net deferred tax assets using the lower rate in the period of enactment resulting in an income tax expense of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million which is fully offset by the corresponding tax benefit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million from the reduction in the valuation allowance in the year ended December 31, 2017. There were no specific impacts of Tax Reform that could not be reasonably estimated which the Company accounted for under the prior tax law. However, further analysis of the estimates and further guidance on the application of the law could result in additional revisions during the allowable one-year measurement period, as outlined in Staff Accounting Bulletin No. 118.&#160;</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913665344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Note 7 &#150; Commitments and Contingencies</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Operating Leases</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On September 15, 2016, the Company entered into a lease agreement to lease <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 953</font> square feet of space located in Reno, NV with respect to its research and development activities. The monthly base rent is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,895</font> per month over the term of the lease. The lease expires on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> September 14, 2018</font> and is subject to an extension at the option of the Company at a fixed rental rate for an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2</font>-year period. The Company&#8217;s rent expense amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,678</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,590</font> for the years ended December 31, 2017 and 2016, respectively. See Note 8 &#151; Related Party Transactions.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Future minimum payments under this operating lease agreement are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 40%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%"> <div>For&#160;the&#160;Year&#160;Ending</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="20%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>33,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>33,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Litigations, Claims and Assessments</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company, its Chief Executive Officer and members of its Board of Directors are named as defendants in a legal proceeding filed in the United States District Court for the District of New Jersey on September 2, 2014 that has not yet been fully resolved in connection with the Company&#8217;s Asset Purchase Agreement with Corinthian Ophthalmic, Inc. (&#8220;Corinthian&#8221;). A shareholder of Corinthian, alleging a fraudulent transfer, is seeking to recover the purchase price of its Corinthian shares and other damages in aggregate amount of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.1</font> million.&#160;The parties are not close to agreement on a settlement, and although further discussions may occur, the parties are prepared to proceed to trial. The court conducted a pretrial conference on January 22, 2018 and entered a final pretrial order on January 23, 2018. The order provided, among other things, for a final pretrial conference to be conducted on August 15, 2018 to address objections to expert witnesses&#8217; opinions and testimony, with objections to be submitted by July 18, 2018 and responses by August 1, 2018. Trial briefs, requests for jury instructions, and proposed voir dire questions are due on August 30, 2018. The trial is scheduled for September 10, 2018. The Company is indemnified by Corinthian and Corinthian&#8217;s applicable insurance policy provides coverage of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font> million, such that the Company does not expect to incur a material loss as a result of this litigation and, as a result, did not record a loss contingency as of December 31, 2017 or 2016, respectively.</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6913383680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Note 8 &#150; Related Party Transactions</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company&#8217;s Chief Executive Officer as well as a member of its Board of Directors are both partners in Private Medical Equity, Inc. (&#8220;PME&#8221;). The Company and PME are parties to a consulting agreement dated November 4, 2014 that provides for the payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,200</font> per month to PME in consulting fees for general management and strategy services. Any time spent by PME in excess of the specified amount is billed separately. During the years ended December 31, 2017 and 2016, the Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">329,400</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">398,400</font>, respectively, related to the agreement, of which, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">176,344</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">318,720</font>, respectively, was included within research and development expenses and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">152,656</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">79,680</font>, respectively, was included within general and administrative expenses on the condensed statements of operations. On August 1, 2017, the agreement was terminated and the Company&#8217;s Chief Executive Officer was employed full time by the Company. The&#160;Board member now bills the Company through a separate consulting agreement dated July 6, 2017 that is discussed below.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> A company that beneficially owns greater than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>% of the Company&#8217;s common stock has a consulting agreement with the Company for research and development services. During the years ended December 31, 2017 and 2016, the Company recognized $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">366,209</font>, respectively, related to the agreement, which was included within research and development expenses on the statements of operations.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Since July 2016, the Company pays $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font> per month to a company controlled by a member of its Board of Directors for office space in New York, New York for its Chief Executive Officer. During the years ended December 31, 2017 and 2016, the Company recorded rent expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,000</font>, respectively, related to the office space.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> A company in which a member of the Company&#8217;s Board of Directors is part owner is a party to a consulting agreement with the Company dated July 6, 2017 that provides for the payment&#160;of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,567</font> per month, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250</font> per hour for any additional work, for advisory services performed by such director. During the year ended December 31, 2017, the Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">85,835</font> related to the agreement which was included within general and administrative expenses on the statement of operations.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On July 6, 2017, the Company entered into an engagement letter with its Vice President of Research and Development (&#8220;VP of R&#38;D&#8221;). Pursuant to the terms of the engagement letter, starting on August 1, 2017, the VP of R&#38;D was to provide service to the Company as a non-employee on a part-time basis in exchange for $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,167</font> per month and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">175</font> per hour for any additional work. On July 7, 2017, the VP of R&#38;D was granted options to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,264</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.95</font> per share that vest in equal monthly installments over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">36</font> months starting from the date of grant. The options had a grant date fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">173,900</font>. On August 16, 2017, the VP of R&#38;D changed from a non-employee to an employee of the Company but remained employed on a part-time basis at the same compensation rate. Subsequent to December 31, 2017, the VP of R&#38;D&#8217;s salary was increased to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">165,000</font> per year in connection with the increase from two (2) to three (3) days of work per week. The following are related party transactions involving the VP of R&#38;D:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both">The VP of R&#38;D owns a company that entered into a lease agreement with the Company on September 15, 2016 to lease <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 953</font> square feet of space located in Reno, NV with respect to its research and development activities. The monthly base rent is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,895</font> per month over the term of the lease and the security deposit is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,895</font>. The lease expires on <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">September 14, 2018</font> and is subject to an extension at the option of the Company at a fixed rental rate for an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2</font>-year period. The Company made $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font> of leasehold improvements related to this lease which are included on the balance sheet.&#160;The Company&#8217;s rent expense amounted to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">45,678</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,590</font> for the years ended December 31, 2017 and 2016, respectively.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-FAMILY:Symbol">&#183;</font></div> </td> <td> <div style="CLEAR:both;CLEAR: both">The VP of R&#38;D is the sole owner and President of a company that performs contract engineering services for the Company. During the years ended December 31, 2017 and 2016, the Company recognized research and development expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,155,500</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,427,958</font>, respectively, related to services provided by such vendor. As of December 31, 2017, the Company had a liability of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">94,998</font> to the vendor and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,906</font> related to expenses incurred by the VP of R&#38;D.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During 2015, the Company entered into a license agreement with Senju Pharmaceutical Co., Lt. (&#8220;Senju&#8221;) whereby the Company agreed to grant to Senju an exclusive, royalty-bearing license for its micro-dose product candidates for Asia to sublicense, develop, make, have made, manufacture, use, import, market, sell, and otherwise distribute the micro-dose product candidates. In consideration for the license, Senju agreed to pay to Eyenovia five percent (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>%) royalties for the term of the license agreement. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents.</font> As of the date of filing, there had been no commercial sales of a micro-dose product candidate in Asia such that no royalties had been earned. Senju is owned by the family of a member of the Company&#8217;s Board of Directors and both beneficially own greater than <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font>% of the Company&#8217;s common stock.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6910203584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Note 9 &#150; Stockholders&#8217; Equity</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal" align="justify"><u>Reverse Stock Split</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Effective January&#160;8, 2018, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-3.75 reverse split of the Company&#8217;s issued and outstanding common stock and preferred stock (the &#8220;Reverse Split&#8221;). The number of authorized shares remains unchanged. All share and per share information has been retroactively adjusted to reflect the Reverse Split for all periods presented, unless otherwise indicated.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Authorized Capital</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> As of December 31, 2017, the Company was authorized to issue <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000,000</font> shares of common stock, par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> per share, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 36,000,000</font> shares of preferred stock, par value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.0001</font> per share. The holders of the Company&#8217;s common stock are entitled to one vote per share. As of December 31, 2017, the preferred stock was designated as follows: <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20,000,000</font> shares designated as Series&#160;A Convertible Preferred Stock; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 5,714,286</font> shares designated as Series&#160;A-2 Convertible Preferred Stock; and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10,000,000</font> shares designated as Series&#160;B Convertible Preferred Stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On January 29, 2018, in connection with its IPO and the conversion of all then existing preferred stock into common stock, the Company filed its Third Amended and Restated Certificate of Incorporation (the &#8220;Third Amendment&#8221;) with the Secretary of State of the State of Delaware, effective the same day. Pursuant to the Third Amendment, the Company is authorized to issue <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 90,000,000</font> shares of common stock and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000,000</font> shares of preferred stock. The holders of the Company&#8217;s common stock are entitled to one vote per share. No shares of preferred stock were designated. Pursuant to the Third Amendment, the Board of Directors is empowered, without stockholder approval, to issue preferred stock with dividend, liquidation, redemption, voting or other rights.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>2014 Equity Incentive Plan</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company&#8217;s 2014 Equity Incentive Plan (&#8220;2014 Plan&#8221;) provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock&#160;units to employees, directors and consultants of the Company and its affiliates.&#160;The 2014 Plan became effective on December&#160;14, 2014 and shall terminate on the tenth (10th) anniversary of the effective date. The 2014 Plan requires the exercise price of stock options to be greater than or equal to the fair value of the Company&#8217;s common stock on the date of grant. As of December&#160;31, 2017, there were 48,917 shares available for future issuance under the 2014 Plan.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On January 5, 2018, the Company&#8217;s Board of Directors and shareholders approved an amendment to the Company&#8217;s 2014 Plan to increase the number of shares of common stock authorized under the 2014 Plan from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,733,333</font> shares to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,866,667</font> shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Series A and Series A-2 Convertible Preferred Stock</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <strong><i>&#160;</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On October&#160;6, 2016, the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 788,827</font> shares of Series&#160;A-2 Convertible Preferred Stock to investors at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.25</font> per share for aggregate proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,141,338</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> On July 6, 2017, the Company&#8217;s Board of Directors adopted, and the Company&#8217;s stockholders approved, the Second Amendment to the Company&#8217;s Certificate of Incorporation (the &#8220;Second Amendment&#8221;). Pursuant to the Second Amendment, in the event that any holder of shares of Series A Convertible Preferred Stock or Series A-2 Convertible Preferred Stock (collectively, the &#8220;Series A/A-2 Preferred Stock&#8221;) does not participate in a subsequent financing (as defined in the Second Amendment) by purchasing in the aggregate, in such subsequent financing, at least <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 75</font>% of such holder&#8217;s pro rata amount, then each share of Series A/A-2 Preferred Stock held by such holder shall automatically be converted into common stock concurrently with the consummation of such subsequent financing. Such conversion is referred to as a &#8220;Special Mandatory Conversion.&#8221;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On September 27, 2017, in connection with the sale of Series B Convertible Preferred Stock, holders of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 299,863</font> shares of Series A Convertible Preferred Stock did not participate in such financing by purchasing at least <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 75</font>% of such holder&#8217;s pro rata amount. As a result, the Special Mandatory Conversion of the Series A/A-2 Preferred Stock was triggered and, accordingly, such shares of Series A Convertible Preferred stock were automatically converted into an aggregate of 299,863 shares of common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The preferred stock did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders&#8217; equity on the balance sheet. While the embedded conversion option (&#8220;ECO&#8221;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the preferred stock did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company&#8217;s common stock as of the commitment date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Series&#160;A and Series&#160;A-2 Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price shall be reduced on a weighted average basis. Each share of preferred stock shall automatically be converted into shares of common stock at the then effective conversion price: (i)&#160;immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters&#8217; discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.</font> See Note 10 &#150; Subsequent Events for additional details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Series B Convertible Preferred Stock</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> During the year ended December 31, 2017, the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 918,983</font> shares of its Series B Convertible Preferred Stock to investors at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.98</font> per share for aggregate gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,409,651</font>. The Company incurred $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">41,958</font> of legal costs in connection with the sale, such that the aggregate net proceeds from the sale were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6,367,693</font>.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On November 9, 2017, the Board adopted resolutions ratifying each of the issuances of Series B Convertible Preferred Stock, which were then approved by the Company&#8217;s shareholders. On November 13, 2017, the Company filed a certificate of validation with the Delaware Secretary of State in respect of such ratifications, such that, as of that date, the Series B Convertible Preferred Stock was duly authorized, validly issued, fully paid and nonassessable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Series B Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series B Convertible Preferred Stock conversion price shall be reduced on a weighted average basis. Each share of Series B Convertible Preferred Stock shall automatically be converted into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters' discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Series B Convertible Preferred did not contain a redemption provision and an overall analysis of its features performed by the Company determined that it was more akin to equity and therefore, has been classified within stockholders&#8217; equity on the balance sheet. While the embedded conversion option (&#8220;ECO&#8221;) was subject to an anti-dilution price adjustment, since the ECO was clearly and closely related to the equity host, it was not required to be bifurcated and accounted for as a derivative liability under ASC 815. The Company determined that the Series B Convertible Preferred did not contain a beneficial conversion feature, since the conversion price exceeded the estimated fair value of the Company&#8217;s common stock as of the commitment date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> See Note 10 &#150; Subsequent Events for additional details.</div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Stock Warrants</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On September 27, 2017, the Company issued a warrant to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 61,875</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.98</font> per share to an investor for cash consideration of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">431,574</font>, which was included within additional paid-in capital on the balance sheet as of December 31, 2017. The warrant is exercisable any time through September 27, 2027. The warrant was sold to an investor for the amount of the investment in excess of what was permitted to be purchased of Series B Convertible Preferred Stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the warrant activity during the year ended December 31, 2017 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Outstanding January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">6.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Outstanding December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">6.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">9.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Exercisable December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">6.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">9.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table presents information related to warrants as of December 31, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"> <div style="CLEAR:both;CLEAR: both">Warrants&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"> <div style="CLEAR:both;CLEAR: both">Warrants&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">6.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">9.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">9.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Stock Options</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For&#160;the&#160;Year&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="6"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div style="CLEAR:both;CLEAR: both">Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">5.32 - 10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">1.95 - 2.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">1.53% - 1.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div style="CLEAR:both;CLEAR: both">Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company has computed the fair value of stock options granted using the Black-Scholes option pricing model. Option forfeitures are accounted for at the time of occurrence. The expected term used for options issued to non-employees is usually the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the &#8220;simplified&#8221; method to develop an estimate of the expected term of &#8220;plain vanilla&#8221; employee option grants. The Company does not currently have a trading history to support its historical volatility calculations. Accordingly, the Company is utilizing an expected volatility figure based on a review of the historical volatility of three comparable entities over a period of time equivalent to the expected life of the instrument being valued. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The weighted average estimated grant date fair value of the stock options granted for the year ended December 31, 2017 and 2016 was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.77</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.16</font> per share, respectively.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company recorded stock-based compensation expense related to stock options of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">412,312</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,690</font> during the year ended December 31, 2017 and 2016, respectively. As of December 31, 2017, there was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,327,224</font> of unrecognized stock-based compensation expense, of which, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">377,816</font> related to non-employee grants, which will be recognized over a weighted average period of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.4</font> years. Subsequent to December 31, 2017, the Company closed on its IPO at an offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.00</font> per share and as of March 27, 2018, the Company&#8217;s shares closed at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9.20</font> per share. The Company&#8217;s stock-based compensation expense related to non-employee grants that is recognized subsequent to December 31, 2017 will be materially impacted as a result of the increase in stock price subsequent to December 31, 2017.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the option activity during the year ended December 31, 2017 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Outstanding January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">786,669</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">897,747</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Outstanding December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,684,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">8.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">4,361,825</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Exercisable December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">920,383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">7.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">883,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents information related to stock options as of December 31, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"> <div style="CLEAR:both;CLEAR: both">Options&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"> <div style="CLEAR:both;CLEAR: both">Options&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">1.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">760,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">7.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">760,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">1.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">897,747</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">9.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">152,465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">5.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">26,668</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">8.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">7,917</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">1,684,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">7.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">920,383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758178768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: bold 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Note 10 &#150; Subsequent Events</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Initial Public Offering</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On January 29, 2018, the Company consummated its IPO of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,730,000</font> shares of its common stock at an offering price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10.00</font> per share, generating $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">27.3</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24.5</font> million in gross and net proceeds, respectively. Underwriting discounts, commissions and other offering expenses were approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.8</font> million, a portion of which is included within deferred offering costs on the balance sheet as of December 31, 2017. <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Conversion of Preferred Stock</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Immediately prior to the closing of the IPO on January 29, 2018, all outstanding shares of preferred stock were automatically converted into an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 4,640,241</font> shares of the Company&#8217;s common stock.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>2018 Omnibus Stock Incentive Plan</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> On March 6, 2018, the Company&#8217;s Board of Directors approved the 2018 Omnibus Stock Incentive Plan (&#8220;2018 Plan&#8221;). The 2018 Plan provides for the issuance of incentive stock options, nonstatutory stock options, rights to purchase common stock, stock appreciation rights, restricted stock and restricted stock&#160;units to employees, directors and consultants of the Company and its affiliates. The 2018 Plan will be approved and adopted by the Company upon receipt of stockholder approval and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">shall terminate on the tenth (10th) anniversary of the effective date</font>. The 2018 Plan requires the exercise price of stock options to be greater than or equal to the fair value of the Company&#8217;s common stock on the date of grant. There are <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 750,000</font> shares of common stock authorized under the 2018 Plan.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756166288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LiquidityAndFinancialConditionPolicyTextBlock', window );">Liquidity and Financial Condition [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u>Liquidity and Financial Condition</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company incurred net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,129,987</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,533,443</font> for the years ended December 31, 2017 and 2016, respectively. At December 31, 2017, the Company&#8217;s working capital and accumulated deficit were $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,734,013</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,261,186</font>, respectively. The Company has not yet generated revenues or achieved profitability and it is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Subsequent to December 31, 2017, the Company raised aggregate net proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24.5</font> million in connection with its initial public offering (&#8220;IPO&#8221;). See Note 10 &#150; Subsequent Events for additional details.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company believes its current cash on hand is sufficient to meet its operating and capital requirements for at least the next fifteen months from the date these financial statements are issued. Thereafter, the Company may need to raise further capital, through the sale of additional equity or debt securities, to support its future operations. The Company&#8217;s operating needs include the planned costs to operate its business, including amounts required to fund working capital and capital expenditures. The Company&#8217;s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company&#8217;s ability to successfully commercialize its products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives and take additional measures to reduce costs in order to conserve its cash.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> establishment of</font> valuation allowances for deferred tax assets, stock-based compensation, the recoverability and useful lives of long-lived assets and the recovery of deferred costs. Certain of the Company&#8217;s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company&#8217;s estimates and could cause actual results to differ from those estimates.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Summary of Significant Accounting Policies&#160;&#151; Stock-Based Compensation for additional discussion of the use of estimates in estimating the fair value of the Company&#8217;s common stock.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <u>Cash</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents in the financial statements. As of December 31, 2017 and 2016, the Company had no cash equivalents.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company has cash deposits in several financial institutions which, at times, may be in excess of Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. The Company has not experienced losses in such accounts and periodically evaluates the creditworthiness of its financial institutions. On December 31, 2017 and 2016, the Company had cash balances in excess of FDIC insurance limits of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,999,511</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,137,288</font>, respectively.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <u>Property and Equipment, Net</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Property and equipment are stated at cost, net of accumulated depreciation, which is recorded commencing at the in-service date using the straight-line method at rates sufficient to charge the cost of depreciable assets to operations over their estimated useful lives, which range from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5</font> years. Leasehold improvements are amortized over the lesser of (a) the useful life of the asset; or (b) the remaining lease term. Maintenance and repairs are charged to operations as incurred. The Company capitalizes costs attributable to the betterment of property and equipment when such betterment extends the useful life of the assets.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Charges, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Deferred Offering Costs</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with the Company&#8217;s IPO as well as other private equity offerings are capitalized as non-current assets on the balance sheet. As of December 31, 2017 and 2016, there were deferred offering costs in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">328,700</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0</font>, respectively. Upon the closing of the IPO, the deferred offering costs will be offset against the proceeds of the IPO.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <u>Impairment of Long-lived Assets</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. An impairment would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. The Company did not record any impairment losses during the years ended December 31, 2017 and 2016.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <u>Preferred Stock</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company applies the accounting standards for distinguishing liabilities from equity when determining the classification and measurement of its preferred stock. Preferred shares subject to mandatory redemption are classified as liability instruments and are measured at fair value. Conditionally redeemable preferred shares (including preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, preferred shares are classified as stockholders&#8217; equity.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <u>Convertible Instruments</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification (&#8220;ASC&#8221;). The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. Embedded conversion options and any related freestanding instruments are recorded as a discount to the host instrument.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> If the instrument is determined to be a derivative liability, the Company then evaluates for the existence of a beneficial conversion feature by comparing the market price of the Company&#8217;s common stock as of the commitment date to the effective conversion price of the instrument.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820 &#8220;Fair Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.</font></div> &#160; <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 1&#160;&#151; quoted prices in active markets for identical assets or liabilities;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 2&#160;&#151; quoted prices for similar assets and liabilities in active markets or inputs that are observable; and</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Level 3&#160;&#151; inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The carrying amounts of the Company&#8217;s financial instruments, such as cash, accounts payable, accrued expenses and other current liabilities approximate fair values due to the short-term nature of these instruments.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <u>Income Taxes</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (&#8220;temporary differences&#8221;) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company utilizes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s financial statements as of December 31, 2017 and 2016. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company&#8217;s policy is to classify assessments, if any, for tax-related interest as interest expense and penalties as general and administrative expenses in the statements of operations.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> <u>Research and Development</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> Research and development expenses are charged to operations as incurred. The Company records prepaid expenses on its balance sheet for the payment of research and development expenses in advance of services being provided.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <u><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-Based Compensation</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Awards granted to directors are treated on the same basis as awards granted to employees. Upon the exercise of an option, the Company issues new shares of common stock out of its authorized shares.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> During the year ended December 31, 2016, the fair value of the Company&#8217;s common stock was based on an analysis completed by management that considered the cash sales prices of the convertible preferred stock as well as the relative characteristics, rights and privileges of the convertible preferred stock as compared to the common stock. During the year ended December 31, 2017, the Company obtained a third-party 409A valuation of its common stock, which was also considered in management&#8217;s estimation of the value of the equity instruments issued during that period. This third-party valuation was done in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, <i>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</i>. The estimates used by management are considered highly complex and subjective. Subsequent to the IPO, the shares began trading on January 24, 2018, which is the date the use of such estimates is no longer necessary to determine the fair value of the common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The independent analysis utilized the Backsolve method since this method is generally considered the most reliable and is recommended by the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide,&#160;<i>Valuation of Privately Held Company Equity Securities Issued as Compensation</i>. In addition, the method utilizes the economics from a direct transaction in our securities in determining the fair market value. This method utilizes the Black Scholes option pricing model which allocated a probability weighted equity value to the Company&#8217;s Series A- 2 preferred stock. The Series A-2 preferred stock was utilized since it included new investors, was considered at arms&#8217; length and closed in the fourth quarter of 2016.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 20pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The March 2017 independent appraisal utilized the option pricing method, or OPM, as the most reliable method with the following steps being applied:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Establishment of total enterprise or equity value;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Analysis of equity rights for each class of security;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Selection of appropriate model for valuation purposes;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Determination of key valuation inputs; and</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.75in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.5in"></td> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Symbol">&#8901;</font></div> </td> <td> <div>Computation of the fair value of the subject security.</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Under the OPM, it was determined the Company&#8217;s common stock had an allocated per share value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.23</font> per share. As a private company, the analysis provided for a discount for lack of marketability of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 40</font>% resulting in a fair market value of the Company&#8217;s common stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.95</font> per share as of March 2017 based upon the independent appraisal. This price represents the same exercise price of the stock options the Company granted in July 2017 as management determined no material events or conditions occurred at the Company that would have a material effect on this per share price.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Net Loss Per Common Share</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,684,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>786,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="59%"> <div>Warrant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series A Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>2,932,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>3,232,294</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series A-2 Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>788,827</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>788,827</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series B Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>918,983</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total potentially dilutive shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>6,386,532</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>4,807,787</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Subsequent Events</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The Company has evaluated subsequent events through the date which the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Recently Issued Accounting Pronouncements</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In February 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, &#8220;Leases (Topic 842)&#8221; (&#8220;ASU 2016-02&#8221;). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating ASU 2016-02 and its impact on its financial position, results of operations, and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In August 2016, the FASB issued ASU 2016-15, &#8220;Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments,&#8221; (&#8220;ASU 2016-15&#8221;). The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. We will require adoption on a retrospective basis unless it is impracticable to apply, in which case we would be required to apply the amendments prospectively as of the earliest date practicable. The Company is currently evaluating ASU 2016-15 and its impact on its financial position, results of operations, and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In May 2017, the FASB issued ASU No. 2017-09, &#8220;Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting&#8221; (&#8220;ASU 2017-09&#8221;). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods for our fiscal year ending December 15, 2018 for share-based payment awards modified on or after the adoption date. The Company is currently evaluating ASU 2017-09 and its impact on its financial position, results of operations, and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In July 2017, the FASB issued ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&#8221; (&#8220;ASU 2017-11&#8221;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share ("EPS") reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating ASU 2017-11 and its impact on its financial position, results of operations, and cash flows.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Recently Adopted Accounting Pronouncements</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In March 2016, the FASB issued ASU No. 2016-09, &#8220;Compensation &#150; Stock Compensation (Topic 718)&#8221; (&#8220;ASU 2016-09&#8221;). ASU 2016-09 requires an entity to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2017, with early adoption permitted. The adoption of this standard did not have a material impact on the Company&#8217;s financial position, results of operations and cash flows.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LiquidityAndFinancialConditionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for liquidity and financial condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LiquidityAndFinancialConditionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84234895&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6403650&amp;loc=d3e20905-112640<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761397936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="9%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Options</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>1,684,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>786,667</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="59%"> <div>Warrant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 6px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series A Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>2,932,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>3,232,294</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series A-2 Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>788,827</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>788,827</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Series B Convertible Preferred Stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>918,983</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="8%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total potentially dilutive shares</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>6,386,532</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="8%"> <div>4,807,787</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6925688544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> As of December 31, 2017 and 2016, prepaid expenses and other current assets consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Prepaid research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>28,932</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"> <div>Prepaid patent expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>7,833</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Prepaid insurance expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Total prepaid expenses and other current assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>37,149</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>2,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758022672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> As of December 31, 2017 and 2016, property and equipment consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34,979</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>24,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>40,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>74,979</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>64,745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Less: accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(47,019)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(21,553)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Property and equipment, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>27,960</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>43,192</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6703677168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> As of December 31, 2017 and 2016, accrued expenses and other current liabilities consisted of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued research and development expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>120,455</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>61,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued legal expenses</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>37,597</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued rent expense</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>18,590</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued professional services</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>41,831</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Accrued offering costs</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>133,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,516</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Total accrued expenses and other current liabilities</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>306,263</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>121,703</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6925649168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The income tax (provision) benefit consists of the following:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>For&#160;The&#160;Years&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Federal:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Deferred</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>235,473</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,287,931</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>State and local:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Current</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Deferred</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>80,301</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>151,521</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>315,774</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1,439,452</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(315,774)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,439,452)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Income tax (provision) benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> A reconciliation of the statutory federal income tax rate to the Company&#8217;s effective tax rate is as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.25in; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>For&#160;The&#160;Years&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Tax benefit at federal statutory rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>34.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>State income taxes, net of federal benefit</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Incremental research and development credits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>6.3</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"> <div>Prior period adjustments and other</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(8.1)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="49%"> <div>Effect of tax rate changes</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>(30.0)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Change in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(6.2)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(40.7)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Effective income tax rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>0.0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>%</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> The tax effects of temporary differences that give rise to deferred tax assets and liabilities are presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="5"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Deferred Tax Assets:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Net operating loss carryforwards</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,588,641</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,742,397</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Stock-based compensation</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>347,977</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>333,066</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Research &#38; development tax credits</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>526,134</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>201,840</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Intangible assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>364,508</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>234,183</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Gross deferred tax assets</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,827,260</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>3,511,486</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,827,260)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(3,511,486)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Deferred tax assets, net of valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="49%"> <div>Changes in valuation allowance</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(315,774)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(1,439,452)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911879280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: bold 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px; font-size-adjust: none; font-stretch: normal"> Future minimum payments under this operating lease agreement are as follows:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 40%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%"> <div>For&#160;the&#160;Year&#160;Ending</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="19%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%"> <div>December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="20%" colspan="2"> <div>Amount</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="18%"> <div>2018</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>33,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="18%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="19%"> <div>33,108</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597618656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ScheduleOfWarrantsOutstandingTableTextBlock', window );">Schedule Of Warrants Outstanding [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">A summary of the warrant activity during the year ended December 31, 2017 is presented below:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Outstanding January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">6.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Outstanding December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">6.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">9.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="37%"> <div style="CLEAR:both;CLEAR: both">Exercisable December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">6.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">9.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="11%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock', window );">Warrants Outstanding And Exercisable Exercise Price [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table presents information related to warrants as of December 31, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"> <div style="CLEAR:both;CLEAR: both">Warrants&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"> <div style="CLEAR:both;CLEAR: both">Warrants&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">6.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">9.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">9.7</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">61,875</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> In applying the Black-Scholes option pricing model to stock options granted, the Company used the following approximate assumptions:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> For&#160;the&#160;Year&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="18%" colspan="6"> <div style="CLEAR:both;CLEAR: both">December&#160;31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="40%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="8%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div style="CLEAR:both;CLEAR: both">Expected term (years)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">5.32 - 10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">10.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div style="CLEAR:both;CLEAR: both">Risk free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">1.95 - 2.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">1.53% - 1.83</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div style="CLEAR:both;CLEAR: both">Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">130</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">131</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div style="CLEAR:both;CLEAR: both">Expected dividends</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="7%"> <div style="CLEAR:both;CLEAR: both">0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> A summary of the option activity during the year ended December 31, 2017 is presented below:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Aggregate</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Intrinsic</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Outstanding January 1, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">786,669</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.37</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">897,747</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Outstanding December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1,684,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.68</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">8.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">4,361,825</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="43%"> <div style="CLEAR:both;CLEAR: both">Exercisable December 31, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">920,383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">1.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">7.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="12%"> <div style="CLEAR:both;CLEAR: both">883,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock', window );">Schedule Of Share Based Compensation Shares Outstanding Under Stock Option Plans By Exercise Price Range [Table Text Block]</a></td>
<td class="text"><div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size:10pt;; font-size-adjust: none; font-stretch: normal"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> The following table presents information related to stock options as of December 31, 2017:</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif; font-size-adjust: none; font-stretch: normal"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 60%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"> <div style="CLEAR:both;CLEAR: both">Options&#160;Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="29%" colspan="5"> <div style="CLEAR:both;CLEAR: both">Options&#160;Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Outstanding</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercisable</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Remaining&#160;Life</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number&#160;of</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">In&#160;Years</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="14%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Options</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">1.24</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">760,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">7.2</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">760,001</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">1.95</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">897,747</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">9.5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">152,465</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">5.25</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">26,668</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">8.8</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">7,917</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">1,684,416</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">7.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="13%"> <div style="CLEAR:both;CLEAR: both">920,383</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of share based compensation shares outstanding under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ScheduleOfShareBasedCompensationSharesOutstandingUnderStockOptionPlansByExercisePriceRangeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ScheduleOfWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ScheduleOfWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of warrants outstanding and exercisable exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_WarrantsOutstandingAndExercisableExercisePriceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758150736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Organization and Nature of Operations (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryName', window );">Entity Incorporation, State Country Name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Florida<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity Incorporation, Date of Incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 12,  2014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">1-for-3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State or Country Name where an entity is incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755944400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">6,386,532<span></span>
</td>
<td class="nump">4,807,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">61,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,684,416<span></span>
</td>
<td class="nump">786,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">2,932,431<span></span>
</td>
<td class="nump">3,232,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember', window );">Series A-2 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">788,827<span></span>
</td>
<td class="nump">788,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">918,983<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765662800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 29, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 27, 2018</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_WorkingCapitalAmount', window );">Working capital, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,734,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,261,186)<span></span>
</td>
<td class="num">$ (14,131,199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash, Uninsured Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,999,511<span></span>
</td>
<td class="nump">3,137,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,129,987)<span></span>
</td>
<td class="num">(3,533,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountForLackOfMarketability', window );">Fair Value Inputs, Discount for Lack of Marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharePriceAtFairValue', window );">Share Price, at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SharePriceAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The share price at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SharePriceAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_WorkingCapitalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in amount of working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_WorkingCapitalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountForLackOfMarketability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to the discount rate used to measure fair value for lack of ability to convert business interests into cash quickly.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountForLackOfMarketability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757588000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidResearchAndDevelopmentExpenses', window );">Prepaid research and development expenses</a></td>
<td class="nump">$ 28,932<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PrepaidPatentExpense', window );">Prepaid patent expense</a></td>
<td class="nump">7,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expenses</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">2,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 37,149<span></span>
</td>
<td class="nump">$ 2,335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidPatentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for patent expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidPatentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PrepaidResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PrepaidResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756429216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 74,979<span></span>
</td>
<td class="nump">$ 64,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(47,019)<span></span>
</td>
<td class="num">(21,553)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">27,960<span></span>
</td>
<td class="nump">43,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">34,979<span></span>
</td>
<td class="nump">24,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6925830160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="nump">$ 25,466<span></span>
</td>
<td class="nump">$ 12,802<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755965232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">$ 120,455<span></span>
</td>
<td class="nump">$ 61,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedLegalExpensesCurrent', window );">Accrued legal expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">37,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">41,831<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedOfferingCosts', window );">Accrued offering costs</a></td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">10,977<span></span>
</td>
<td class="nump">4,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrents', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 306,263<span></span>
</td>
<td class="nump">$ 121,703<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedExpensesAndOtherLiabilitiesCurrents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedExpensesAndOtherLiabilitiesCurrents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedLegalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued legal expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedLegalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued offering costs paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development expenses paid by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657674048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Federal:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">235,473<span></span>
</td>
<td class="nump">1,287,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State and local:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">80,301<span></span>
</td>
<td class="nump">151,521<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance', window );">Income Tax Expense Benefit Before Adjustments for Change in Valuation Allowance</a></td>
<td class="nump">315,774<span></span>
</td>
<td class="nump">1,439,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="num">(315,774)<span></span>
</td>
<td class="num">(1,439,452)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (provision) benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the income tax expense (benefit) before change in valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_IncomeTaxExpenseBenefitBeforeAdjustmentsForChangeInValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6925817664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax benefit at federal statutory rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Incremental research and development credits</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior period adjustments and other</a></td>
<td class="num">(8.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effect of tax rate changes</a></td>
<td class="num">(30.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(6.20%)<span></span>
</td>
<td class="num">(40.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756292208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 2,588,641<span></span>
</td>
<td class="nump">$ 2,742,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">347,977<span></span>
</td>
<td class="nump">333,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research &amp; development tax credits</a></td>
<td class="nump">526,134<span></span>
</td>
<td class="nump">201,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">364,508<span></span>
</td>
<td class="nump">234,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">3,827,260<span></span>
</td>
<td class="nump">3,511,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(3,827,260)<span></span>
</td>
<td class="num">(3,511,486)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Changes in valuation allowance</a></td>
<td class="nump">$ 315,774<span></span>
</td>
<td class="nump">$ 1,439,452<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6767770432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OperatingLossCarryforwardsExpirationTerm', window );">Operating loss carryforwards expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2034 to 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse', window );">Tax Credit Carryforward, Limitations on Use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In accordance with Section 382 of the Internal Revenue Code, the usage of the Company's net operating loss carry forwards could become subject to annual limitations if there are greater than 50% ownership changes.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OperatingLossCarryforwardsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiry term of carryforward operating losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OperatingLossCarryforwardsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the limitation related to use of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649351744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 33,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating Leases, Future Minimum Payments Due</a></td>
<td class="nump">$ 33,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6754957344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2016 </div>
<div>USD ($) </div>
<div>a</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | a</a></td>
<td class="nump">953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Operating Leases, Rent Expense, Minimum Rentals</a></td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">Sep. 14,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,678<span></span>
</td>
<td class="nump">$ 18,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MalpracticeLossContingencyInsuranceRecoveries', window );">Malpractice Loss Contingency, Insurance Recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeLossContingencyInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of insurance recoveries recognized from insurance and similar arrangements for reimbursement and payment of malpractice claims recognized during an accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68060100&amp;loc=d3e8578-115644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeLossContingencyInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77910348&amp;loc=d3e34039-112682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770336960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 07, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 29, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 15, 2016 </div>
<div>USD ($) </div>
<div>a </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,816,732<span></span>
</td>
<td class="nump">$ 2,966,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_MinorityInterestOwnershipPercentageInCompany', window );">Minority Interest Ownership Percentage In Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">897,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | a</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RelatedPartiesOwnershipInterestPercentage', window );">Related Parties, Ownership Interest Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember', window );">Vice President of Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,155,500<span></span>
</td>
<td class="nump">$ 1,427,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OfficersCompensationPerMonth', window );">Officers Compensation per Month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OfficersCompensationPerHour', window );">Officers Compensation per Hour</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares</a></td>
<td class="nump">100,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 173,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LeaseMonthlyBaseRent', window );">Lease, Monthly Base Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LesseeOperatingLeaseExpiryDate', window );">Lessee, Operating Lease, Expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 14,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lessee, Operating Lease, Renewal Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,678<span></span>
</td>
<td class="nump">18,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold Improvements, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember', window );">Vice President of Research and Development [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Officers' Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember', window );">Senju Pharmaceutical Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_RoyaltyIncomePercentage', window );">Royalty Income, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_LicenseAgreementExpiryPeriodDescription', window );">License Agreement, Expiry Period, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The agreement shall continue in full force and effect, on a country-by-country basis, until the latest to occur of: (i) the tenth (10th) anniversary of the first commercial sale of a micro-dose product candidate in Asia; or (ii) the expiration of the licensed patents.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Vice President of Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Related to expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_OfficeSpaceExpenses', window );">Office space expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating Leases, Rent Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember', window );">Cura Partners [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ConsultingAgreementPaymentPermonth', window );">Consulting agreement payment, Permonth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ConsultingAgreementPaymentPerhour', window );">Consulting agreement payment, Perhour</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember', window );">Cura Partners [Member] | General and Administrative Expense [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_PrivateMedicalEquityIncMember', window );">Private Medical Equity, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ConsultingFee', window );">Consulting Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_PrivateMedicalEquityIncMember', window );">Private Medical Equity, Inc. [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,400<span></span>
</td>
<td class="nump">398,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_PrivateMedicalEquityIncMember', window );">Private Medical Equity, Inc. [Member] | Research and Development Expense [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,344<span></span>
</td>
<td class="nump">318,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_PrivateMedicalEquityIncMember', window );">Private Medical Equity, Inc. [Member] | General and Administrative Expense [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,656<span></span>
</td>
<td class="nump">79,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember', window );">Beneficial Owner [Member] | Research and Development Expense [Member] | Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 366,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ConsultingAgreementPaymentPerhour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents hourly consulting fee expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ConsultingAgreementPaymentPerhour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ConsultingAgreementPaymentPermonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents monthly consulting fee expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ConsultingAgreementPaymentPermonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ConsultingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ConsultingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LeaseMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The base rent per month for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LeaseMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LesseeOperatingLeaseExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date of lessees operating lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LesseeOperatingLeaseExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_LicenseAgreementExpiryPeriodDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of expiry period of license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_LicenseAgreementExpiryPeriodDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_MinorityInterestOwnershipPercentageInCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minority interest ownership percentage in company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_MinorityInterestOwnershipPercentageInCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OfficeSpaceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred for office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OfficeSpaceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OfficersCompensationPerHour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers per hour agreed to pay on additional work provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OfficersCompensationPerHour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_OfficersCompensationPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers per month agreed to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_OfficersCompensationPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RelatedPartiesOwnershipInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ownership interest percentage held by related parties in the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RelatedPartiesOwnershipInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_RoyaltyIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The royalty income expressed as percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_RoyaltyIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_VicePresidentOfResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_SenjuPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_CuraPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=eyen_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=eyen_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_PrivateMedicalEquityIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_PrivateMedicalEquityIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_BeneficialOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657316672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Outstanding | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted | shares</a></td>
<td class="nump">61,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Outstanding | shares</a></td>
<td class="nump">61,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber', window );">Number of Warrants, Exercisable | shares</a></td>
<td class="nump">61,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">6.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / shares</a></td>
<td class="nump">6.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 6.98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life In Years, Outstanding</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Life In Years, Exercisable</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of exercisable awards on equity-based plans excluding option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of forfeited awards on equity-based plans excluding option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of granted awards on equity-based plans excluding option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of nonvested awards on equity-based plans excluding option plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonVestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate intrinsic value of equity-based compensation awards not vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableAggregatedIntrinsicVallue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested other than option awards outstanding as of the balance sheet date can be currently converted under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options which are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761606976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details 1)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants', window );">Warrants Outstanding, Outstanding Number of Warrants</a></td>
<td class="nump">61,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife', window );">Warrants Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants', window );">Warrants Exercisable, Exercisable Number of Warrants</a></td>
<td class="nump">61,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice698Member', window );">Exercise Price 6.98 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice', window );">Warrants Outstanding, Exercise Price | $ / shares</a></td>
<td class="nump">$ 6.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants', window );">Warrants Outstanding, Outstanding Number of Warrants</a></td>
<td class="nump">61,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife', window );">Warrants Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">9 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants', window );">Warrants Exercisable, Exercisable Number of Warrants</a></td>
<td class="nump">61,875<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock warrants as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock warrants as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted remaining life of the all outstanding stock warrants which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock warrants which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingWarrantsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice698Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePrice698Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757125792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details 2)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum', window );">Expected term, Minimum (years)</a></td>
<td class="text">5 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum', window );">Expected term, Maximum (years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, Minimum</a></td>
<td class="nump">1.95%<span></span>
</td>
<td class="nump">1.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, Maximum</a></td>
<td class="nump">2.39%<span></span>
</td>
<td class="nump">1.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="nump">131.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756576320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details 3)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding | shares</a></td>
<td class="nump">786,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted | shares</a></td>
<td class="nump">897,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding | shares</a></td>
<td class="nump">1,684,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable | shares</a></td>
<td class="nump">920,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / shares</a></td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">1.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding | $ / shares</a></td>
<td class="nump">1.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable | $ / shares</a></td>
<td class="nump">$ 1.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life In Years, Outstanding</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life In Years, Exercisable</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 4,361,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 883,675<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6756974656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details 4)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">1,684,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">920,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember', window );">Exercise Price 1.24 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">760,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">760,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember', window );">Exercise Price 1.95 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">897,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">9 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">152,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember', window );">Exercise Price 5.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Outstanding Number of Options</a></td>
<td class="nump">26,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Life In Years</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Exercisable Number of Options</a></td>
<td class="nump">7,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=eyen_ExercisePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768442368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th"><div>Jul. 06, 2017</div></th>
<th class="th"><div>Oct. 06, 2016</div></th>
<th class="th"><div>Jan. 29, 2018</div></th>
<th class="th"><div>Sep. 27, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 27, 2018</div></th>
<th class="th"><div>Jan. 05, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockProrataAllotmentPecentage', window );">Preferred stock, prorata allotment, Pecentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 431,574<span></span>
</td>
<td class="nump">$ 431,574<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.77<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,327,224<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_NonemployeeGrantsMember', window );">Non-Employee Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 377,816<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eyen_EquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,917<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' Equity, Reverse Stock Split</a></td>
<td class="text">1-for-3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2014 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,866,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2014 Equity Incentive Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockDesignatedShares', window );">Preferred Stock Designated Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockSharesNotParticipatingInFinancings', window );">Preferred Stock, Shares Not Participating in Financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockProrataAllotmentPecentage', window );">Preferred stock, prorata allotment, Pecentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember', window );">Series A2 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockDesignatedShares', window );">Preferred Stock Designated Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,714,286<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">788,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from Issuance of Preferred Stock and Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,141,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockDesignatedShares', window );">Preferred Stock Designated Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918,983<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_PreferredStockSharesNotParticipatingInFinancings', window );">Preferred Stock, Shares Not Participating in Financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Series B Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis, subject to certain adjustments. In the event of any issuances by the Company for less than the in-force conversion price, the Series B Convertible Preferred Stock conversion price shall be reduced on a weighted average basis. Each share of Series B Convertible Preferred Stock shall automatically be converted into shares of common stock at the then effective conversion price: (i) immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters' discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,958<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net Proceeds From Issuance Of Preferred Stock And Preference Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,367,693<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross Proceeds From Issuance Of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,409,651<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember', window );">Series A And Series A2 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The SeriesA and SeriesA-2 Convertible Preferred Stock is convertible, at the option of the holder, at any time into shares of common stock on a one-for-one basis. In the event of any issuances by the Company for less than the in-force conversion price, the preferred stock conversion price shall be reduced on a weighted average basis. Each share of preferred stock shall automatically be converted into shares of common stock at the then effective conversion price: (i)immediately prior to the closing of a firm commitment underwritten initial public offering provided that (A) the aggregate offering price, net of underwriters discounts and expenses, is at least $2.00 per share of common stock and (B) the aggregate proceeds of such offering are not less than $20,000,000; or (ii) the date specified by written consent or agreement of the holders of at least 75% of the then outstanding shares of preferred stock.<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes gross proceeds of $6,409,651, less issuance costs of $41,958.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the gross proceeds from issuance of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_GrossProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents the net proceeds from issuance of preferred stock and preference stock which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PreferredStockDesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of designated preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PreferredStockDesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PreferredStockProrataAllotmentPecentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of prorata allotment of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PreferredStockProrataAllotmentPecentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_PreferredStockSharesNotParticipatingInFinancings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of preferred stock not participating in financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_PreferredStockSharesNotParticipatingInFinancings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21538-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized and expensed compensation cost from equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_NonemployeeGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eyen_NonemployeeGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=eyen_SeriesAndSeriesA2ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6926459056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 06, 2018</div></th>
<th class="th"><div>Jan. 29, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of Financing and Stock Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod', window );">Gross Proceeds of Stock Value Issued During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,730,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eyen_NetProceedsFromIssuanceOfCommonStock', window );">Net Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,640,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">2018 Omnibus Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Share-based Compensation Arrangement by Share-based Payment Award, Description</a></td>
<td class="text">shall terminate on the tenth (10th) anniversary of the effective date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_GrossProceedsOfStockValueIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_GrossProceedsOfStockValueIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eyen_NetProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eyen_NetProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eyen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General descriptive information regarding an arrangement under which employees and directors receive: (a) awards of equity shares, equity share options, or other equity instruments; or (b) the entity incurs liabilities to them: (1) in amounts based, at least in part, on the price of the entity's shares or other equity instruments; or (2) that require or may require settlement by issuance of the entity's shares. Such an arrangement is usually provided to employees and directors to compensate them, provide performance incentives to them, and to attract or retain their services. May also include pertinent information particular to a plan that is not elsewhere specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eyen_OmnibusStockIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M'WX781^LV[I_;'P65"W\N@OU!5!+ P04    "  @B(),F5R<(Q &  "<)P
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MHJM,NH[B;5]UH:'T6_T#4$L#!!0    ( ""(@DP'9JNTK0,   01   8
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M+85 GX3FA'3($)@T!<M3T/58\/60\E9)28\DT4I*QUEJD4M?+C0G4DQ#AH&
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M,W?<G=[+3R>#/<R_.23G'SY6_P-02P,$%     @ ((B"3*-$,^ * P  -@T
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ME!GF>BSZIMU/%.^&"TDRWHK6_P!02P,$%     @ ((B"3/8%F^J_!   \A@
M !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6R-F6%OHS@0AO]*E.]9L,$&
M5VFD;1(@TIU4[>GN/M/$;:*%D 7:[/W[,X32,#/!Z8<&R#/VS(NQ7YSYN2A_
M5GNMZ\GO/#M6C]-]79\>'*?:[G6>5M^*DSZ:;UZ+,D]K<UJ^.=6IU.FN#<HS
MA[NN=/+T<)PNYNVUYW(Q+][K['#4S^6D>L_SM/SO26?%^7'*II\7?AS>]G5S
MP5G,3^F;_DO7?Y^>2W/F]*WL#KD^5H?B."GUZ^/T.WO8<+<):(E_#OI<71U/
MFE)>BN)G<[+9/4[=)B.=Z6W=-)&:CP^]U%G6M&3R^-4U.NW[; *OCS];C]KB
M33$O::671?;O85?O'Z?A=++3K^E[5O\HSHGN"A+325?]'_I#9P9O,C%];(NL
M:O]/MN]57>1=*R:5//U]^3P<V\]SU_YG&!W NP#>!P1L-,#K KP^@/'1 +\+
M\/L 7XX&B"Y ? 6$HP&R"Y#W]A!T 4$?P,=K"+N L _PQGM078#ZZD&U0^1R
M_]H!L4KK=#$OB_.DO(SI4]H\.NQ!F2&W;2ZV(ZS]SHR)RES]6 3AW/EHVNF0
MY07AUX@:(BN,"#9$U@3B#9&(0/PA$F,D=(=(0B @EPV!\!YQC%Z]:)P4C;?Q
M_G4\J&5Y062+'%N$>RKTE03*8<[CH*TU9D#-D96(B7QX )3##.-*B<#E0#\,
MSI@K5! (2<OHD3)Z6$9POU<71 SEX5P!;HTY*)&5B#'!N31_ 5V33];DXYH$
M&!H^[D<JD,S*M]W1M96(K$1L)9)[DMU@R*4U$Z1F FL&'I.E0#WXS&>>!^:J
ME;#*A@DXFT761F(KD= )<P'ZVF#NAG22E$YBZ<!3O9*V@;_&1!"&(9P>(FM#
M\1@Q*"8@BPEP,7 M"E /,T]XGN^#.7,56 >"E8BL1&PE$IPP?'CN*&F@74AJ
M%V+MP%!;AG@N=5WEPM5Q%=ZQ)&$&/448@>IA J]).&D6,$])Z"\V&)PU,P1C
M2M$Z*E)'A71$4[.Z<TW"'/E880SJA(G1A8FYM--S<6E Q&7'#*8MCXD +LL=
M-_9XV9'(CL1V)+DSYPW!W9B=V VKS.QK>\<,YWWN,0X%Q!P2T(I$=B2V(\F=
M.6]&FQH*2-MF1OAFL- _$8SB4&2.$I&>#*2"BP"S^N*U'8D(!*84VYM);F7M
MHK<3#-[2F?;5C##6 =09,["H%;-ZYK4=B0A$L5#!-Z9XM*EAV;3U9MA[PQ&Q
M9&-6M:L:F^*9A^JVNV\[$A,(["FQ9[P918;*T0:<80<.5[,5PTYU9MX.0PFM
M 0$B::Q(3""@MV%AM#UFA#]&VQO8M<Y$\^*+G'1'CDXG5B2R([$=28BLT;"X
MH["AB+0M9]B7*[3N82<LC+>4 9J2,<CA4[HF(&0O"0;/RD1G CI,"O(]P1A\
MN=P0Y(PI+AD+;^Q[,-JL,^S6T<80PX;6"&4R0QMK&"1])L'1\S#1L9!2>+?F
M%&BDAQMHM!GEA!D%=^^)8N#(=:[V.7-=OK4;Y]5D6[P?ZV;;Z>IJOSG_U&X_
MH^OJ(6&*^,;D\9!<]O.=KRXNOP;\F99OAV,U>2GJNLC;?=37HJBU2=_]9A3<
MZW37GV3ZM6X. W-<7G;A+R=U<>I^87#ZGSD6_P-02P,$%     @ ((B"3)PC
M6!+' 0  _ ,  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6QU4]MNG# 0
M_17+'Q #83?+"I"RJ:I6:J55JJ;/7A@NBB_4-DOZ]_6%4+2A+]@S/F?.&3/.
M)ZE>=0=@T!MG0A>X,V8X$J*K#CC5=W( 84\:J3@U-E0MT8,"6GL29R2)HCWA
MM!>XS'WNK,I<CH;U LX*Z9%SJOZ<@,FIP#%^3SSW;6=<@I3Y0%OX >;G<%8V
M(DN5NN<@="\%4M 4^#$^GE*']X"7'B:]VB/7R47*5Q=\K0L<.4/ H#*N K7+
M%9Z ,5?(VO@]U\2+I".N]^_5/_O>;2\7JN%)LE]];;H"'S"JH:$C,\]R^@)S
M/SN,YN:_P168A3LG5J.23/LOJD9M))^K6"N<OH6U%WZ=PLE#,M.V"<E,2!9"
M$GH)0M[Y)VIHF2LY(17N?J#N%\?'Q-Y-Y9+^*OR9-:]M]EIFAYQ<79T9<@J0
M9 6)%P2QQ1>%9$OAE'R@9]DV_W[3X;WGIVOY*+JQ&#![CQ$>LT^C;+_[C]%T
M4RC=$(IOA-(/0FF<[0XW,F1U^QQ4Z^=.HTJ.PL_\*KN,]J/_W>0?/+R+[U2U
MO=#H(HV= ?^G&BD-6#/1G1VVSC[%)6#0&+=]L'L5!C($1@[S6R/+@R__ E!+
M P04    "  @B(),!;DLA1\$   1$P  &    'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;)68V8[C-A!%?T70>X]4Q452PS;0=A D0 (T)DCRK+;I!:/%D>3V
MY.]#+>.1645/Y\62Z,OB+2Y'%!?7NOG2'HWI@J]E4;7+\-AUY^<H:K='4^;M
MI_IL*OO/OF[*O+./S2%JSXW)=T.ELH@PCG54YJ<J7"V&LM=FM:@O77&JS&L3
MM)>RS)M_UZ:HK\L0PF\%GT^'8]<71*O%.3^8/TSWY_FUL4_1+<KN5)JJ/=55
MT)C],GR!YXW0?85!\=?)7-O9?="G\E;77_J'7W?+,.X=F<)LNSY$;B_O9F.*
MHH]D??PS!0UO;?85Y_??HO\\)&^3><M;LZF+OT^[[K@,TS#8F7U^*;K/]?47
M,R6DPF#*_C?S;@HK[YW8-K9UT0Z_P?;2=G4Y1;%6ROSK>#U5P_4Z_I/HJ1I?
M :<*>*L CRN(J8+X7D$.R8_.AE1_RKM\M6CJ:]",HW7.^TD!S\)VYK8O'/IN
M^,]FV]K2]Q7$N(C>^T"39CUJ<*ZY*2(;_=8$<DVLD51W&MA0A?"T(-@DQ%!?
MW"4A^ "2#2"' '(6($V=3A@E>I!4@^1) 699FCC),$*AA)#2XTBQCA23DN0#
M:#: )BE!K)R<1HV:644EM782HBK =#9)[LPDK)F$]J_K)2&M2$ ![E2A,M19
MS'M)62\IT[.:#Y"Q 3*2C)!.,AEQ^21D"HYL0V7"CG*6\FX@YE=P3/S(V%W!
M,36DE);NW&5T2JDX\QCR( 6H(7 - 6T(E(Y=/U1F5YWR]A +H!= 9BTDKB.D
M3<E$   QQ2@%QD))SYH GEK 8<N7&<\MH.""V6A-F4GJUT+>G;0;3B=M!_A&
MGP<7*&K)[<+U)/JQ)4;WR!*/0M"TH\'S@@$>8$ )!BZ;UD#A] 292F(R@ZC0
M@S#@&08I8T>X=E**5 $J(9U,=3XW/!"!$A%<UJV!PDYKNV@T81 52I @A&=I
M((]%I%@$<%\Z2'D'J49$IR\WC##-I$X2CR>>C$C)"*!=3Y1Y-O<$W1W)AA&B
MS%#[IC;R=$2&CN#2$2GSE&U, ;BFJ-!U?V^*9R,R; 1?")Z-R+ 17#8B99Z=
M:3%9L8S.LT:0QR(R6$07BTAQ)X@3JO$YX6F(=&>H/%M3Y&&(R<?WV\@##"G
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M0N6#^05M.Z[9Z'C332^(S<\X_P=02P,$%     @ ((B"3/+:^>BW 0  T@,
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M\6<SC=ED.-W//X@LW[C\ U!+ P04    "  @B(),L\ 63;<!  #2 P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6QM4VUOVR 0_BN('U 2XK119%MJ
M6E6;M$E1IVV?B7U^48'S ,?=OQ]@UW4[?P'NN.>YYXXC'="\V ; D5<EM<UH
MXUQW9,P6#2AA;[ #[6\J-$HX;YJ:V<Z *"-(2<8WFUNF1*MIGD;?V>0I]DZV
M&LZ&V%XI8?Z>0.*0T2U]<SRW=>."@^5I)VKX >YG=S;>8C-+V2K0MD5-#%09
MO=\>3TF(CP&_6ACLXDQ")1?$EV!\+3.Z"8) 0N$"@_#;%1Y RD#D9?R9..F<
M,@"7YS?VIUB[K^4B+#R@_-V6KLGH@9(2*M%+]XS#%YCJV5,R%?\-KB!]>%#B
M<Q0H;5Q)T5N':F+Q4I1X'?=6QWT8;_;)!%L'\ G 9\ AYF%CHJC\43B1IP8'
M8L;>=R(\\?;(?6^*X(RMB'=>O/7>:[[=[5-V#413S&F,X<N8.8)Y]CD%7TMQ
MXO_!^3I\MZIP%^&[#PIOUPF258(D$B0?".X^E;@6<_B4A"UZJL#4<9HL*;#7
M<9(7WGE@[WE\D_?P<=J_"U.WVI(+.O^RL?\5H@,O97/C1ZCQ'VPV)%0N'._\
MV8QC-AH.N^D'L?D;Y_\ 4$L#!!0    ( ""(@DR-27S8L@$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;&U3VVZ<,!#]%<L?$(.7I.T*D+*)
MHE9JI56JIL]>&,"*+]0V2_KWM0U+R887/#/,.7-F/,Y';5YM!^#0FQ3*%KAS
MKM\38JL.)+,WN@?E_S3:2.:\:UIB>P.LCB I"$V2.R(95[C,8^QHREP/3G %
M1X/L("4S?P\@]%C@%%\"S[SM7 B0,N]9"S_!_>J/QGMD8:FY!&6Y5LA 4^#[
M='_(0GY,>.$PVI6-0B<GK5^#\ZTN<!($@8#*!0;FCS,\@!"!R,OX,W/BI60
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M=',O<VAE970Q.2YX;6QM4VUOFS 0_BN6?T"=.+3K(D!J.DV;M$I1IZV?'3C
MJLTQVX3VW\\VA-&,+_CN>)[G7GQ.!S2OM@%PY$VKUF:T<:[;,V:+!K2P-]A!
MZ_]4:+1PWC4ULYT!44:25HQO-G=,"]G2/(VQH\E3[)V2+1P-L;W6PKP?0.&0
MT2V]!)YEW;@08'G:B1I^@OO5'8WWV*Q22@VME=@2 U5&'[;[0Q+P$?!;PF 7
M-@F=G!!?@_.]S.@F% 0*"A<4A#_.\ A*!2%?QI])D\XI W%I7]2_QMY]+R=A
MX1'5BRQ=D]%[2DJH1*_<,P[?8.KGEI*I^1]P!N7AH1*?HT!EXY<4O76H)Q5?
MBA9OXRG;> Z3_H6V3N 3@5\1V)@H5OY%.)&G!@=BQMEW(ESQ=L_];(H0C*.(
M_WSQUD?/^?9SDK)S$)HPAQ'#EY@9P;SZG(*OI3CP_^A\G;Y;K7 7Z;ME=GZ_
M+I"L"B11(/G0XNU5BVN8NZLD;#%3#::.VV1)@7T;-WD1G1?V@<<[^0<?M_U)
MF%JVEIS0^9N-\Z\0'?A2-C=^A1K_P&9'0>6"^<G;9ERST7'832^(S<\X_PM0
M2P,$%     @ ((B"3)71K5ZS 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL=5-M;YLP$/XKEG] G9!T;2- :EI5F[1)4:=UGQTXP*I?F&U"
M]^]W-H31E'[!=\?S//?B<]H;^^H: $_>E-0NHXWW[8XQ5S2@N+LR+6C\4QFK
MN$?7ULRU%G@924JR9+7ZPA07FN9IC!ULGIK.2Z'A8(GKE.+V[QZDZ3.ZIN?
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MH_%XLW'^E3$>L)35%:Y0@P]L<B14/I@W:-MAS0;'FW9\06QZQOD_4$L#!!0
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M\65C_QMC/*"4W16.4(<?;#$D-#X</^/93F,V&=[T\P]BRS<N_P)02P,$%
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MR\;^UX@.?"K)C1^AUG^PQ5!0NW#\Y,]F&K/)<-C//X@MW[CX"U!+ P04
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MVKCMP>[5/#"S8>2PO 5D?9"*/U!+ P04    "  @B(),8WT>W;,!  #2 P
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MKHR_B1.ETGNOJT8L_9.4[7,0B.)$:R*>6$L;]>; >$VDFO)C(%I.R=XDU54
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M#XQ)JA2&3TK;277R85+1@]3#5(UYU\ZZB61MWZJ#X?_"ZB]02P,$%     @
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M!K73,-X3J9;\AL3(@=2&U%,4!4&*>M(-?I&9VH47&;M+V@UPX9ZX]SWA?\Y
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MJ#FW'[A=2#;.;Q=:'M#B+U!+ P04    "  AB(),=*KLP1<"  !*!@  &0
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MT+T42$%31(_)[I ZO <\]S#IU1XY)2<I7YSQI2ZBV!4$#"KC(E"[G.$ C+E
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MV89RYEQ1'1(^Z-)J_<3,!J-G9::9GHNQT8Z&XOWTAH#Y(2O_ %!+ P04
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MH'P"Q$*>7I)?Y<&D*(LBP(G(, :4QFEHE(9&CH<&.'22)T<48A+@3&4(0$9
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MTZ9I!$A-JVF3-BGJM.VS T>PZA=F.Z'[]SO;%+$J'_8%^\[/R]UA5Y.QKVX
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M\O)>-V416FF[4F2_#I^;;?^Y#^U_AN$ '@+X,4"<#Q A0!P#.#L;($. O#1
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MM=046 T7> 1"-)/R\6LF=1=-G;B>O[)_-,6K8@Y8P",C/]NC;$HW<YTCG/!
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M\(0"HI0N%"P,%P(,5 (4[FI(1,D"!RX$&*@$"(><7L0F"Y=2ACE9VG-P1<!
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MG]$.36P'<ARDR.T6!9YORR1#LOZNN(DRN=!T#=Y&E<!XAVCKO!3B*LH\554
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M0'8V&#L$6EWA$<%&U@E+0R$0OT1<\W )TB7Z(PA^M!CF,BYW@1D!?$EY:TP
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MH=YS'TP"5X-IUWD*&B=[N^*-,GMVB*V>HCUJT0<U]D4]F*6BK&L*LX/Y2S8
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M#=[I ((A:^Q6,<AEVP"8C?=<&C11$G2@_BJG88-.R;)#E9(S&VY:4ZK\FT/
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M@ .@WZVSY&I;ZLK]")]W6L5I^M#(";7 2N#"GGF<2**Y%TEDPECXZ]\#BYS
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M>TQFG(XV59J>;=?<*PZ_W8+PR242K#1.QR27GXY9_8,*L5KI>:YWY?6H9\-
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MZ-XQ#=0Q7 CS[*2_,%CN*E?L F79Q%.Z!.5G@_GQT^!R"8O M;QQH\<LD^C
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MC,:XU' ^[F,!=<""Q"E8- ()9=*? [D;AP.0(G\J<+5M4!JA(@)<H8^58P=
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MIO2@67_0C!XD0R#CD)^$L.9K+8!KX7LM &SABRV ;.&;+0!MX:LM@&WANRT
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MDRO*VAWC6I7-7TD^M5X>YK/NS\79-U!+ 0(4 Q0    ( ""(@DP?(\\#P
M !,"   +              "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M ""(@DQF\PM@@@   +$    0              "  >D   !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ ((B"3,)X'T'N    *P(  !$
M ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ ((B"3)E<G",0
M!@  G"<  !,              ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    "  @B(),4GY! JD"   &"@  &               @ 'W"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ ((B"3 =FJ[2M
M P  !!$  !@              ( !U@L  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( ""(@DRC1#/@"@,  #8-   8              "
M ;D/  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  @B(),
MXH_E +$"   A"0  &               @ 'Y$@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ ((B"3/8%F^J_!   \A@  !@
M     ( !X!4  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M ""(@DR<(U@2QP$  /P#   8              "  =4:  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    "  @B(),!;DLA1\$   1$P  &
M            @ '2'   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ ((B"3$5&AS>R 0  T@,  !@              ( !)R$  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ""(@DSRVOGHMP$  -(#
M   8              "  0\C  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    "  @B(),^WS_.;8!  #2 P  &0              @ '\)
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ""(@DRSP!9-
MMP$  -(#   9              "  >DF  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ ((B"3(U)?-BR 0  T@,  !D
M ( !UR@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  @
MB(),$<#UZ[8!  #2 P  &0              @ ' *@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ""(@DRDG:\PN $  -(#   9
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M970Q."YX;6Q02P$"% ,4    "  @B(),:%P\![,!  #2 P  &0
M    @ $)-P  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M ""(@DR5T:U>LP$  -(#   9              "  ?,X  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ ((B"3"4CS\.W 0  T@,  !D
M             ( !W3H  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    "  @B(),.$_,T[<!  #2 P  &0              @ '+/   >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ""(@DS;D"9+TP$
M )P$   9              "  ;D^  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ ((B"3&-]'MVS 0  T@,  !D              ( !
MPT   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  @B(),
M> 9H"^D!  !F!0  &0              @ &M0@  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( ""(@DR1>),7P $  '<$   9
M      "  <U$  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ ((B"3$1LEEYU @  .P@  !D              ( !Q$8  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  @B(),=KSL:@$#   N"P
M&0              @ %P20  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( ""(@DR);\B\\0$  $P%   9              "  :A,  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ (8B"3'2J[,$7
M @  2@8  !D              ( !T$X  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    "  AB(),Q+3%+=,!   E!   &0
M@ $>40  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "&(
M@DR<)C<U- (  -0&   9              "  2A3  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ (8B"3$(IK$1G @  \@<  !D
M         ( !DU4  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    "  AB(),&,&#M#@"  !7!P  &0              @ $Q6   >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "&(@DP4KU$KC0(  %@(
M   9              "  :!:  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ (8B"3)GHMLQU @  J @  !D              ( !9%T
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  AB(),"K%=
MA:8!  "" P  &0              @ $08   >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( "&(@DS@%NV)2 (   @'   9
M  "  >UA  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M(8B"3)BE',S(!   KQ@  !D              ( !;&0  'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    "  AB(),]>S,1V@"  #'"   &0
M            @ %K:0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( "&(@DS@+*"^$ (  #\&   9              "  0IL  !X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ (8B"3'#2Q-TK @
MZP8  !D              ( !46X  'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    "  AB(),:Y+O5Y$"  #>"   &0              @ &S
M<   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "&(@DRF
MJRQWFP(  !4*   9              "  7MS  !X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ (8B"3%9V;W])!0  \QL  !D
M     ( !378  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
M"  AB(),]%#_U24"  "%!@  &0              @ '->P  >&PO=V]R:W-H
M965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( "&(@DRLB.+;.5,  %)+ 0 4
M              "  2E^  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0
M   ( "&(@DS6WQY*3 (  ( +   -              "  931  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ (8B"3)YUFU># P  6!X   \
M ( !"]0  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "&(@DPE&CD\Q $
M $\<   :              "  ;O7  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( "&(@DRT9AABNP$  &0<   3              "
M ;?9  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     W #< \PX  */;
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>108</ContextCount>
  <ElementCount>252</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>102 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>103 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>104 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>105 - Statement - Statements of Changes in Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>106 - Statement - Statements of Changes in Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Changes in Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>107 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>108 - Disclosure - Business Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperations</Role>
      <ShortName>Business Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>109 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>110 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>111 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>112 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>115 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>116 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>118 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>119 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>120 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>121 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>122 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>123 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/IncomeTaxes</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>124 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>125 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/StockholdersEquity</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>126 - Disclosure - Business Organization and Nature of Operations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperationsDetailsTextual</Role>
      <ShortName>Business Organization and Nature of Operations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/BusinessOrganizationAndNatureOfOperations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>127 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>128 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>129 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>130 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>131 - Disclosure - Property and Equipment, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/PropertyAndEquipmentNetDetailsTextual</Role>
      <ShortName>Property and Equipment, Net (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>132 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>133 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/IncomeTaxesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>134 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/IncomeTaxesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>135 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/IncomeTaxesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>136 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/IncomeTaxesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>137 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>138 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>139 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>140 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>141 - Disclosure - Stockholders??? Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders??? Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/StockholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>142 - Disclosure - Stockholders??? Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders??? Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/StockholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>143 - Disclosure - Stockholders??? Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StockholdersEquityDetails3</Role>
      <ShortName>Stockholders??? Equity (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>144 - Disclosure - Stockholders??? Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StockholdersEquityDetails4</Role>
      <ShortName>Stockholders??? Equity (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>145 - Disclosure - Stockholders??? Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders??? Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/StockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="eyen-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>146 - Disclosure - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyenoviabio.com/role/SubsequentEventsDetailsTextual</Role>
      <ShortName>Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.eyenoviabio.com/role/SubsequentEvents</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>eyen-20171231.xml</File>
    <File>eyen-20171231.xsd</File>
    <File>eyen-20171231_cal.xml</File>
    <File>eyen-20171231_def.xml</File>
    <File>eyen-20171231_lab.xml</File>
    <File>eyen-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001144204-18-018682-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-18-018682-xbrl.zip
M4$L#!!0    ( "&(@DPCLWX;V>   (SP#0 1    97EE;BTR,#$W,3(S,2YX
M;6SLO7ESXT:R+_K_B9CO4%=G/&Y'4&HL)$%*=M]@:VGKC%I22+(]?B]>=$!
M480- C062?2-^]U?5@$@ 1 $01(@"F1-C&V*Q)*9]<NM*BOKQ__]/C;1*W9<
MP[9^.A)/A".$+<W6#>OEIZ-?GJZ.>T?H?W_ZQW_]^+^.C]$7;&%'];".GJ?H
M0O74)T?5_G2C^Y%T(B#XCR =#R;.L22(/?3_BM)IIW<JR?\?^C_W7_\ONGQ\
M0L?H[>WM1(?[/7K_B6:/T?%Q]);/J@MO@.?\Y_/##3Q3#'][?W9,XY3\&P'1
MEGN*IQAH'GG>Y/3C1_)(\H7]:JC/ADV>^1$H4$1)%H_"&TS#^C-Q WG8B>V\
MP)6"_)'\_ POCRXGO^K&[(;XQ=V/P8^S2Q<>_2;3:\5^O_^1_CJ[U#6R+H2'
MBA__\_7F41OAL7IL6*ZG6EJ"%B.']O3UAFNW)5')NR.X(KI!QQ,':V1PE][3
M_Z@ZFF.;^./\XNAVS?8MSYDFA>5B[>3%?OT8_DC'XU@0C^<CHOF. WA;=E_X
M:\:-.C:R[X$?R.7MY.7X71ME7T]^R7B^8;UBU\N^)?B-W"0G;[)40W.S[Z$_
M9;S'-;3L&^ '<KF8NMR;.$NNAU\R;O#=XQ=5G<SN&:KN,QW/\(<,DM[-'-3\
MYR8&9=]S<L "OQZ!WB+T(X'_J4N!_8"'B*K#J3>=X)^.7&,\,0EJZ7<C!P]_
M.B)J?!SI[LF["R#[" \*S,.Y;7GXW4./6// YE#3 *\(C(,6_F@ B.\%\1O\
M'Y[3>;)%Z9L<? Y(FMV!+<_PIN%WLV\-G7P_-+"#*-DXP68D\O/K?Q]]$D!O
MNSVI*_=__)B^.7K5Q]2[$A1,L&/8>IH"T&;' Q.+/Q&BR0 )8O2<^6_1HV+L
MZ/.;1 E&=?YR/;PE3E+LY=%7H0S#9^<*MAL3;+>)@NUN(MAN]8)58H)5FBA8
M91/!*M4)5IX+%CXW6[#R!H*%FRH1[,"]LT"@DD($VFN(0(-8R2.2Z1')2,KL
M\>$OY4FF65"+22:%F;(ET_TF"\V53/=8%BJ0C*#$S!1\[C9)0FDSI6QBIHAL
MJ[#__7G$ I_%3I,CEOX&$0O<)':J%*Q"!1OX@:8B=GW!TIOF[J-LQ]HTI,:,
M9 IR9;N/ID$MZ3[ZU84<C<O'$IA)Q/]52::1F-F)9)HR.1*33*<$R9!II0MC
MC"TZB;UZ8BF)IF^/\'3L?CZWK5?L>,:SB>\=/,2.@_5'S];^_(K'S]CQ73+=
M]NB!?X W>>>FZKIW0WK!X-UP=RSYM"?$+X2HV?O"'W0@Y'UB&IKA!4P@/1+3
M3T?A!.)I#DMD(N^TF'A^_)CYPKD$/F91V@RUZG*(-!8BN_))(40&$L=('D96
MRN<0[ @'21-!LF-+PB&2!Q$6 ;)C*\(!TC2 5&=!LA<>.5":!!2FUU_S\,7#
MF<:$,XW%&$^]&Y)Z-Q!AY_9X;%L'#J;HD@5A<.CD0&>@ZP:9;%;->]70KZUS
M=6)XJLEAE"L8#JD<2#U@3S4LK%^JCF58+R['4K9$.(@RIHZX*V/#E>U^5HC[
M(M9]41V8X,Z$-6=2QWPQ]PK,>84=+29UN5=HCE?8&2:X5V#8*^Q@D2BQ[8][
M!T:\0R,V-B:APYT+V\ZE@9#BOHDUW]1 $/&ZAZ;6/30)7[SNH9EU#TW"&*][
M:&+= V,(2^X1X]ZQ2=ZQY*UR:P"$N[?&N+?Z0,+]4T/\4QT0X3.+;,PLUC'V
M?&J0[:G!.C#!Y_98F]O;"0IF"6[OR28?^O3SMT?_V<5_^4#NY2O\*P&&Y$]/
MTPEN.!26,;3D@EJSU]XFV2N]2>K/7UY]U;[E^J8'6C-X<3#5LSB$'K )[]?O
M@?;IDZ-:KDJ[@A"I?[MWC%?X\2O6#4TU+__R04[7EE;@=O?S-/Y+LT&Y#H\T
MILV5VW*PEDA;C)BEXU^3UC!6&+QTL9]K#=<:=K2&L9G260//+FW@.=.:D8&'
ME^]8\SWC%=\-AX:&G3CPGPS/A.^O+=UX-71?-9N-\27LS%+9Y>*H#T;KMRNE
M-U4+HT0?V&V,[[GOJ.0'"SLNM[@K+.ZBL [=S++6SC<[I >3XFB&B\%C:KC;
M[R52PI'J8'JRS+D]GL"(J$3D]%MWX'LCVS'^QOHOEHX=FF??3<CO]Z9*<))X
M\(-JO30]G:Q"&!2XV4/ 0^J,O34)4=U9F*.U7K3.AJ"6Z;.=;>E*\/ST9G/8
MU0N[V1 <$NQ&$-1PX-4,O/D@[!GTBH2'W.'6#L :'"[+X6$1U')_73MJ:_#7
MC4<M=_<,X+8.=\\R<NDY,KR<@,5R@N0!??&Z@++/$0+KU0G&?[:P1@A]Q42_
MXA@@?]^J8RJG;U\-RQC[X\1$>J1[!P6DN%0BH[-,CB7/H<]M7?158E3*?5O3
M%$:H[."M#15&?><*PY["Q$>%*TSI"B,*L1H:(5S&Y;L_&[<])E4J( J;5)P(
MU2R%TFE6CJW&8BO9N2<.DC(G1#-/:>5;L)JU!2N=3+-T7&TNPCC &K%5F&E\
M)?> "#T^:<-:2%W2'A"AM[M9ZL_8PD,0BFK>O5G)BMSB18/;E&4^8!>KCC8:
M *OX%9OVA-Q]^4ZF@1,SYI >VF,\,R@WMJ;.2P:;BNA*ZB!+)"2S0C2Z)Q,[
MY9*5.^ASVE="B,_WY^QHX3: VP!N PYE?TZV#;@<3TQ[BG%L?36N>,$WUY:.
MW['^9%^[KH\=-YBW;7Y<68R[Z.JEHN( 6]WPCV>_J8QEN5@XG%;W]N-PRH)3
MIE@XG/**M;C[:ZK[8S7'RCSGE]LKUMU?D^#$W1_S[J\9<,JKYFLN8#8OD..0
MR*U7VR](%"L!.R1(I#8NWF#5Q2/;U*_'$\=^I38XT4+CWK'A/=Z4%.YY TLG
MH2.=?_N\!]%Q(>:BBW-$54M!S<X.2.08:2Q&=G1HGO)M)A6.BRQ<I,2SW_:"
M8X%Y+.S@&,5DR,G;(^ZT/6+9T&$YHF6\ RZO@-@)XDND;??5&0TO@V#5(+#9
MW)<;!&X0]MP@-&-A> N#\ 5;V%%-D/Q 'QN6X7J.2K:WKJ?$/"KF)J%<DU (
MESQ*J"9*X$:!&P5N%'BD4')K^I+LR@%9@D9VN#](]6<U)DBI/S_@A.T#3EB%
M42JTY#!B&T:L!B.=&(S(T=+6'_[]2'7&JH9!=A#LGML%PY'F@FFUS\V12TUX
MZFR"IT[UQW<ESUWZ%?3NWL$N';F[8?:L(L?7Z1IRJL\-,G6.40IO"L<;QUMX
MTPZZZ&S>^IA#=)<0W82T ^D65,F)T;31;?^;V FR$H[U!IOC1$F?T#\6JVCT
M.NM^UZ7=[SAP]@ XZ;QW_6YX*;Q5/PO'\;8O>&O&=!W'V[[@C;%YO=36F3+*
M 3E8=U0V=T JM+.M0X(<=E3F'6]9RF&3ATC(L<['56P7ZL5\+^! PY8*CTL?
MNS)3[>B"AD,@FYW9SPM2:-8,1CU]>"R='Q.QE*7X,1&%!<73A(RP[0(B#=<S
MM'/;MSQGNABH/:GOX0&'32_%7,9/]'NF*/8L4($@9;ZX((>+I[UO=V/+>/9=
MJBR)0Z[(KW%,) X,.Z0P)^-,L )".^SE GF3Y0*YNB.8.. YX*LRV2GD5M>B
MA$^1\,F(M0!S:ULX;(CZ!23E;5B_OW=865YXOT1B>P:3)>GG;ZI#>,[,+8/=
M2.0$=) 0R*79N%C!5G190B \A\Q9:N+081 ZC*T:+;$Z?/6H-&SRU:,#L<(9
MO0L+'O7>7'"7<S1[V2BI*E[S+2,8:W>D@F:DAFV,5==W\*>0"WI)]+CHM_@K
MR-.6//^7QXLE#S=<NRV)RBE<L?FSOP'#WQX)@:FWT"U5."U.<NNM/\:.ZME.
M&B:%28L+//W$C!=>8,L>&U;^*U>).OW.Q8=&O\8X+R!#55L07?1:WW-.R<\;
MCH[[U]#+>3+Y><,G3_RE-(=:X!>D^L?_=7Q\:5)OAAXQ]1O'Q\&E.C9.+VS-
M'X?30RC4HP<\7!IL'%'RKH@#TK^)1Y]$X?C?/WY,/RGBBGP_@"]U\L.5J;ZL
M_0KIZ--0-5T<O"/QK/A+HI??4^-P&?B)M5\F'R6LT-('9[WYRG UU?P=W.X5
M?..N_>YV\.[D6U,/7?[>@+S-WMPY^G3U>]9[8P^-O_F2&O<'_$*WD5L><2EK
MO[1[].GR]\O;NU^O!RUT?7M^$A"0]>S%=Y\#B8YJTB-M_HVG:[]<27K=I0^.
MO_G<=YS$B&P*LM[1I^,XPI8]>)'MW[!I_MNRWZQ'4'A(F?3@*)^U*>@??;JU
MXVPO>? B!;_:IF]!Y#:],DSLK \U44B_.O7$C+$.Q/. )[9#FBF0V'P#D(MB
M^LW9#UXD@!)V#@/R8COK0TT$ _8X5DUX!IJ]"I&<5[6F<7(2KUFDXMY_AC#L
MRK15+TD#79OI?I.%C'?+1XCX 7HAB5*0CC4#B'%_.H*!Z(@"_5^<BMAKXC1
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ME] AQX0LYS@-J.NI.P4J];"E5D]26E+WH',DK@]<'V;ZT!'%5KM7V_0^"_K
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MZ3ES.SW[AOT@L.J>W@QE0D5W\Y;7N[ON=<FU[.4Q5P.N!EP-#EH-&(D6^)0
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M"M3^>%1^%LC/*;W.58G7N::*FS+&-?A('C4ZVKKBF3D!B(?.?^^[(Z(>H "
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M2>7&&')SL0_\<W/!?.C1\%J$+2%&*PHYJ@ZA:F7;B9&P:H5CA6-EE;BNK;G
M?L>JPU'#4<,M#!O3*^QT$JFW&R>CQT5M+*CUU[W$$ZF]@; .I9D("]SO7GT8
M/2^<93U2ND)+$$3FP<15B:L2ZZIT(C$/)*Y&7(U85R/ND9J11VV7<>Y3HE2B
M)#;)A/J\SP/;W%>@ (PZEEHUH==76DJ;]XEDFWNN##M1ACX_#XIQ[KDB["8^
MZDBM=I<K _/Y1)WGJ+.53Y0HB?7UI7-2W_EE#4B^-UWP;KR*5"R?/=4FJ=OJ
MUG=,;J/TZ;"UY0!TH7?"%8$[%NY8REDF:?7K.Q*E >K$2%*SC[,!3<G\ZX]
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MJ&1A_5)U+'(HQR8<]Y@=Y(3SJ<* ]QO%>KD&7!$:Q7RI]EO)#[OZ$C/,;V?
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M:KGD%;85%A&Y5XX]CGWM_F9XH_@MA<Q64(JD 2+OWBSLQ-E=\GKW\S3^"Y$
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M_?5/=P,@0>IBV98L2L+6)K%E"D0W^MZ-[G5"UK+[@TX1-& 4\6(KO",5QBS
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M;L)<67_A4:?6G--]2R08*2^8(4T6Y<4;V4;;;K0;(.:+':",Q-T0*+DA@F6
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M1H);#;O3:Q<VE<7.1$]U/_5R2TF3FQ@C.L(PL6A!-==*6M1'5!@*ZOSQ(KY
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MJ+@8?E8Z]RR (TU)B=(A39_AYC2-FV/<G)7<'*1 ZS?%C1D16AH5&L_GJ:"
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MS:^AH0V\FX/1!-X:1E@B)$Z<;F9B5EPXNC+_.(.,V87HD 5HL?9RM:R)N!V
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MWRK=AUQD<RPQ.9[@KQ52#26;XW6FFZQ!-(CO48AN[R3115!@_"(54F<D*G%
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MTS<Y]VTOW5*WN*5N?>F6GKH;:N1Q2=G*F2W46_.QTFT4M_ G:+<_:2%],TW
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MUUA*LEV@!W""E\T_<N)\!@B+ TH26[/)H 4YE@W"N=SN;G>ZO?Z\\)0&P4O
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MLM$$V= $5>XU1M08T3$:T2&,1A$,41=THPDP^/_WT!Z]!^U9_QF@5G.O3_I
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M1#0_4P<\N?Q.%OK!&Y"8GRY2/N^3=*Z-#-%VI^YSAG-K\]$G++V.RJ!29>(
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MFY(-*&)2CG9#2GGQOF8/09HE?I1=^ MLK1)]ZO5<WCB<<('"0*Z3'W=)Q#%
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M^R]^\B><;(OJ%K*B'D;]@"HZ=Z2H =!>>3@L4?%U<$VS5_FP*[+P8Q"4@M=
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M33ZQAR#B'K!//G0WJV%X;T=,())H5+/$+DE.?]T(>ZJI(<';$TM-[>JLBTL
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M.>HY=6'4BX M-"QGHBH^M3<@&G!!:].I3XIR>[%GCBA]0&L!GXH27%@#$)Q
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M@AB-#WY%,1Q]_Z(U%LM"Z*<LV:=ED#^>Q0G.1:&JH*T#R/3Y%4"E;HA82Q\
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M=S%[M87$BML!O!C2VWVQP4 N,8KZ1Z505)]3HY*0NWQ18(*(U_"6.#1ZI%*
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MT/(A3K.<]DQ6A+@H+QX DG?Q[A*3(26KIEM\GL))=9 .O94XH@^[6#*4K_>
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M[62^=2IAC67_U8O7?_2R_FX/-N+ZNP+,S 7@ZX?, ,"-U@X!W.19@0#2U#L
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MHKZ3++W'Q,A) -KF% X1BXL-^WLQ (1&W&#2B?7HSDC"+E8;Q-T8;D5S# J
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MV&HMUE.GY7Y!*!*\IJ7R'%[0WGZ5= '?@G+&=4./CMZEJN]5!%?KW1YH?@X
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M\GH1A"3A63S,;[T!1F>,$I4L)!P*,?MBUMM&L>;<D><XH<$HZF_DVJZB)M[
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MF98C]2I'$AB]"))U_G3D 2Y7@)!P75R]"*S=)O&,D'E*XSPTQ\>/9N0R"K+
M#V]7W\)@=K, *" &@2(H]P%RPW4<4=('37@=!,$L>'G]].DK:#\M-3V71D\9
M7X,L<'B)M*CF N&0ZI9OZ)IDQ1L"5W$JLJPJWWD39"X$)2(9$#@4NN7]X;[%
M]C4EBU5X%2Q$$52%UMX$QV,7VDNT&C".$KCE4-J\X['9=_+7,@6T,[_WI@,'
M;3,!% ZU;CF>\I2:O+JIZ.2[_0B0.[@XU\?/8<XMO].%'R2T+C>8AL^KXG%:
M:CY<Q,F5/_OC9O'%3_Z @T7^V([HD6ZM?D!^#EI9#2!R,B?VY=[B70_=*O)Q
MM@7%\X@P/P9T.")MZBX1 0X.2PX]$W.K\,"ZQ2HEMWMY8;U!*B!G@JQ_\ YX
M GU\@E\\(R\DC'/;;"-DWH11:@S#1>&Y5Q<M8TII(#64)-C);?DUC%M82K;#
MEI!;^=:;#E'X[TUPR0!F*/L/PYWH-<A+ZBBA[C#YFK/]% 2'(@C0E&0Q+D.9
M@(@X9@IHO1\VW&K6K4%B*$Z@AC1!#M50*F%&2\1=63.13OR0ZOO]$P%\M[F$
MGT@6S.Q<A-@:KJ4'"&[C-,AU2&X1J33W!D/W:KD-4600J8M7$A\OH7J_)K&3
ML3Y$D7?$(DM"*QO*^S6)" 2!XE@C88H31>/ L7M-0ECBJU6!+VD1K"$*.X='
M"\O'HXX+YS-P>ZK;-D3A?=<F5A$9BKIM0H9/6A$L:PU20.%=U^97#5@?;D.T
MS1@=#%$X(QJ83C4,?;@H4555.%K>)#G<>1YBV!0<$#L=%#H @6%-<<BIY'H9
ME+'UX0I&%6_Q0.CQ*GN*D^"O-Y>%5 GJ#;W!"(6/N0WY;$QV+V_P0P*E@9^1
M-'B,J-(6$ 3! 4$K@(O+N2&D4!E0+VYPL!0U+QVH.V.+1B 97*Z-QK.UC*<7
M5=)8($L/.&O276H),L+E^FC,^0ZH7MP9J2*]"OY<K5\$+OZ!1#/"RX/1[0*D
MALL\;Z *,G2]N$5R&B^7],VR9F:[0FN0%0H?FIXF* /KQYV1-[0:YKJ@%<@&
MA7^M,>EL0+VX2[*#4FKE<5J 3% XV5J27 ;3BYLF.PC5C#M1,Y .UF17':IW
M$'5PJ63O::_%_9GRU9EKDEG-=.7<Z%%*<Y6T]8:#L76/M69&QPC'6^.*LE5*
MYQCQGQIWZRQL-IUCA*Q*0HDLW72.$;]2@EN'WK;I'"-DA1#83"FG<XSX]0_<
M.KARE[,3E;>=%%J#J'"=8:2S61E4'RIC<L$JU<A4:.U-CE <;Y19U52*.M(^
MU-#<@I._XE3]$D2 (K*LS!:;;":J/F2+7!$_)?3!]<OE<Q*_Y.MA*B59T I$
M@^)$VY)P*<(^9)>T+R[GV$;.P]"/[!".PO^6B&O;B!O"X147R37J-#?G$J8^
ME/:L%&*#<<^"G!?X[Y#D!$6T9E.2!7^MPVT<L0C4P]1/@-!1F'UZBF06?>N$
MEJ-"YR+R2$?T4+OVAFC1N2:-W)'0#"2%PH PM.!L$9E*<<GBS _MW744^\4M
MOO_4M7O\R+J5INL>G^(^>55EJ^8>G_(+ECFU;YMVC^-*X"V1I>\>-U<6PG'W
M.*Z,7C93&NYQ;CZO6^[QMF?FT0&N]%WUN5K#T =?MXI)+Z!7I;DWQ%'!AT<C
MFW1U9.:]VWLV:.&$EZP(K[[955 4W7M[XM2*;>N_TFE*!Y</UP^5:IOQ6WG#
MD7.OFXYP/"<NE:IBH@?_2.C4$FK:DD5Q9F&1I6_)<L\J?S-+]A#7!LAF2MV2
M/>3N>G\S2_80UPE%?:[6,*"LU[$V2\0%,/E%Y[3[@+T+U\&D1E*5TH;P,)?O
M6*.Y(H]^J,<OJPG@19$<JT\G'XVA? L,E22WJ@O;D;1PY.['( ]<";%"=F4X
M#*52U(M 6F/U-HD7)$US.!=$-(O5&H*4<*7*ZK MQ&0H[Z(-\^+56/:>"/=;
MP(<U;4*R_C)@&,J4L#]!BS*TZWWFS;,CGZ#BAB EK*D-@@FJ@LE4!8[N9FC=
M;[>+1#9O%7H ,3IJ'"N#,Y:>8+<4<_'$V8/_PZJ_=CL*^I!+&-.W\Q3\M8)6
M,!N=RS\8#U#X!Z125?+7YF#>_;5UU]EX@&M=+)&EZZ_-H;S[:R,0!"[/ 9LI
M97]M#N?=7TO%ALMGH#Y7:QCZD'EP06#0?KC=G-9VV@F)R"+(3N,H"Z(5G,)N
MGN$SBE0EX-N\4V\XQA6DJ5'.5I"V> VY@^V?:]>F_%H>.Y(0K?_BEB G%$9<
M6Z8YNX4*>$->9_M*LGDH5BQ+8;J32@<@-10V83<JHR.#WOBU\U7Y.)I?P4\8
MWK+:=@V2QF6M*FU<9E C\)X;W;XJ4FFPB8G; Q]XHBBMN1=N:"J"Z(U/?[,B
MJ\A587-3Z08HP'.4ZDB5].6!.%; &?<)6<0).9[_URK-\@O^%W%R^N1'C^0R
MHB5)"S[#,/[.>='37.?><.+0 <PT[J[N1NY_-=I%N)E((*C\ <R-+(Z7](5W
MP8JDVQ40A37D+#"%FJ%L73:\>I':JLKH[U7\91AK&%J@ $(PIDJ!6[XTO1N5
M'/0D+'G@W#NP8QQE**1250Q+\B>)4_YPTV%)%%>%6&3IAR6Y%X7^;F%)7%>#
MV$QIA"6YUX/^9F%)9/=CU>=J#4,?PI+GBP699<$+V6Y/=P#VCLSB:!:$Q7W@
MXTW A IB!0-YK7PL8-] [[ WH@A(\92 K3+&@*.XP+(_56,[GYBOY)GH%F2,
M(G1E7KG$B'L3XE01!?SQ%! %6;JY.-92FW8[!*FB#4JUTR,>UMZ$.E6$<)L$
M<?(O0&]N16)UZ4V'/=WJ^&@-A31=V=\VKLWS"([]N<?3@ 7%[A3DV].]3837
M4)33-7VJN]!3I6A61[\$.P2>:&DGFJ<L! PATBZUD15LUE8T5B<@/CS)&RUU
MB(^O)R5B=Z,=PYY$.P[=BW;@L"&E4E6+=O!-Q+]UM .995<B2SO:P3?:_F;1
MCB$N#P*;*?5HQ_#]$M;:6L!E"ZO/U1J&/D0[=NSV:Z)2+5[4S)L@-E2Y.3AR
M1#T*/.R 79OAT>-5G*:G?I*\+N+DNY_,17-;HQ>P<% 887*6%;5#!K5'A;IV
ML%,;=OVW=<+::;RD_UNP&<W7^6MI_C+VB9^2>?D#6E5'1ZL,_!QP@L(^-*9^
MQF32FZC%CH@NZ4M$,Y)NPS35XH@Z&BCI"B2)PE(UIEU*>'MS]6H'_F]Q//\>
MA"&@O@06H\< #,3BGW2T1M -2!"%#6Q,8Z18>W?7Z@VZY&U!=@.0"@HCV9P&
MO*$RYN*W?I6E71!)*29RB.+"BC$UX$%L[=?']NP?2V*:!V:0#(H\?&/D;S&U
MOIN$9@6P>9EM>(@BA;^I>C3#:^JZT^[)V7H(T.++D!T$ H\<# 2B,+FD4E4,
M!/(M+:<\T%M<]S,2^4D0JP8!R]][TR$*.XI%DH3.71A]"/YM4'V-TF<R"Q8!
MF4MC@-PVWG2*ZX+,+F<<DL6(>A$-7$.D;]M^(<MO)%%@^.UC$ 2*P("$*3&]
M=3A]" QN=ZGC5?84)T'V*EF7V0V\Z<2QA5F$P_Q+CQB(E2[,O"8@%!0G%!%E
MJB27$1D*WMD-[ .^- MFI_1HE;Q*EV;F]R .%#>.Q71QO!-\0(:"7E;YO:-'
M9\F2O/T&8*/P-*FOPK6A&PHVV6=,.@]+7WE3'$D3-2X$A)7';2CB8Y6R+_Z/
M8+E:2DFK? ?P420;[##")HXQ=E,!'!Q^A:MF:8I39&^VJGL4:AA,7:FPRF:C
M!#51DM81BJ65QQF;81D>4V&7ADQS*D_R1WW^XSDH;O\\D&3)(%*K/<@ Q;JK
MQFD#:*9"(U8G\O;Z?!GN5; ,"I[2F^AK*O+I*[7WQB-<B[?2]-: QE$%MUQ,
M^"OM3$<.[A+&@'.4S%%W5\NR UK]@/P<VHI:0.2HB%NN,@GN=DE@[3L'2:-(
M+S:J3,JX.1K6QEFWYT20TW@)6WA>!_PXFA=7WQ\)B,3J^YRB4>GDB&CU W:L
M<V]XCG D]S>0LU(>R8B?R^^6A\#LA?(1C@1]%ED26ME0^I!3TO9"^0A'RKV$
M*3:]/#B]2"%IZ:D=X<BA;S!7:QCZD#?RYM(B?DK2BU4&^]*7(*(QAEO_-=_
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M9K?0M)@7D@3"=Y.T^O%& UPG.R6U: "Q@PL->_9UWY&05K&Z]9/L]0$PIE0
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M[ZE[;VU-43B#68)4"WI/^=E);GKUS02]IRB"-"RRM(/>4V[<YF\6])[BNJG
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MFPK<H>!.NOI6/P0)H(A?[;(B9J\\>E,!),,9L[F_]#*: ?K@A="!2U+J> T
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M24WYK 6=>0>]\5G+4)JZ%XK!H;E^58"FC\W^7 4) 6' 5,E>Z2.'&:RY]#+
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MR\FE^O\!4$L! A0#%     @ (8B"3".S?AO9X   C/ - !$
M ( !     &5Y96XM,C Q-S$R,S$N>&UL4$L! A0#%     @ (8B"3 VUZG0[
M#@  *J<  !$              ( !".$  &5Y96XM,C Q-S$R,S$N>'-D4$L!
M A0#%     @ (8B"3$YWCAN/"   070  !4              ( !<N\  &5Y
M96XM,C Q-S$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( "&(@DP\7D)F+34  "6P
M P 5              "  33X  !E>65N+3(P,3<Q,C,Q7V1E9BYX;6Q02P$"
M% ,4    "  AB(),N,4;=7!.   AD 0 %0              @ &4+0$ 97EE
M;BTR,#$W,3(S,5]L86(N>&UL4$L! A0#%     @ (8B"3/-+"4^S/0  $G@$
M !4              ( !-WP! &5Y96XM,C Q-S$R,S%?<')E+GAM;%!+!08
1    !@ & (H!   =N@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
